<SEC-DOCUMENT>0001144204-18-028920.txt : 20180515
<SEC-HEADER>0001144204-18-028920.hdr.sgml : 20180515
<ACCEPTANCE-DATETIME>20180515162838
ACCESSION NUMBER:		0001144204-18-028920
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180515
DATE AS OF CHANGE:		20180515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		18836974

	BUSINESS ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-839-5200

	MAIL ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv493730_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Mark One)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>x</B></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended <B>March
31, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-37392</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Apollo Medical Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-3837784</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State of Incorporation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRS Employer Identification No.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1668 S. Garfield Avenue, 2<SUP>nd</SUP>
Floor, Alhambra, CA 91801</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(626) 282-0288</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Issuer&rsquo;s telephone number)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name, former address and former
fiscal year, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities Registered Pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each Class</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each Exchange on which Registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock, par value $ 0.001</B>&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The NASDAQ Stock Market LLC</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities Registered Pursuant to Section
12(g) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of class)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days:&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo;, &ldquo;smaller reporting company&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 61%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 39%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp; </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&nbsp; <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 9, 2018, there were 33,334,059 shares of common stock
of the registrant, $0.001 par value per share, legally issued and outstanding (net of 3,039,749 holdback shares).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INDEX TO FORM 10-Q FILING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 80%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#introductory"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Introductory Note</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#introductory"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#note"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Note About Forward-Looking Statements</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#note"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL INFORMATION</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 1.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Condensed Consolidated Financial Statements &ndash; Unaudited</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#balance"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Balance Sheets as of March 31, 2018 and December 31, 2017</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#balance"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#income"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Statements of Income for the Three Months Ended March 31, 2018 and 2017</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#income"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#cashflows"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Statements of Cash Flows for the Three Months Ended March 31, 2018 and 201</U>7</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#cashflows"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#notes"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notes to Condensed Consolidated Financial Statements - Unaudited</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#notes"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 2.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 3.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Quantitative and Qualitative Disclosures about Market Risk</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 4.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Controls and Procedures</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 1.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legal Proceedings</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item1a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 1A.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item1a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Risk Factors</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item1a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 2.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Unregistered Sales of Equity Securities and Use of Proceeds</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 3.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defaults Upon Senior Securities</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 4.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mine Safety Disclosures</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 5.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#part2item5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Information</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#part2item5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item 6.</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><A HREF="#item6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibits</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><A HREF="#item6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="introductory"></A>INTRODUCTORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context
dictates otherwise, references in this Quarterly Report on Form 10-Q (the &ldquo;Report&rdquo;) to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;ApolloMed&rdquo; and similar words are to Apollo Medical Holdings, Inc., a Delaware
corporation, its consolidated subsidiaries and affiliated entities, as appropriate, including variable interest entities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Centers for Medicare &amp; Medicaid Services (&ldquo;CMS&rdquo;) have not reviewed any statements contained in this Quarterly Report
on Form 10-Q describing the participation of APA ACO, Inc. (&ldquo;APAACO&rdquo;) in the next generation accountable care organization
(&ldquo;NGACO&rdquo;) model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trade names and trademarks of ApolloMed and its subsidiaries referred to herein and their respective
logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies,
which are the property of their respective owners. We do not intend our use or display of other companies&rsquo; trade names and/or
trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of ApolloMed&rsquo;s
common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a variable interest entity
of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the condensed consolidated
financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included
in the number of shares of common stock outstanding used to calculate the Company&rsquo;s earnings per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="note"></A>NOTE ABOUT FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This document contains
&ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&nbsp;27A
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section&nbsp;21E of the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;). All statements other than statements of historical fact are &ldquo;forward-looking
statements&rdquo; for purposes of federal and state securities laws, including, but not limited to, any statements about our future
business, financial condition, strategic transactions (including mergers, acquisitions and management services agreements), sources
of revenue, operating results, plans, objectives, expectations and intentions, any projections of earnings, revenue or other financial
items, such as our projected capitation from CMS&nbsp;and our future liquidity; any statements of any plans, targets, strategies
and objectives of management for future operations&nbsp;such as any material opportunities that we believe exist for our company;
any statements concerning anticipated proposed or prospective services, developments, timelines, costs, investments, returns, effects
or results&nbsp;such as our outlook regarding our NGACO, our integration-related costs following the closing of the reverse merger
of Apollo Medical Holdings, Inc. and Network Medical Management, Inc., the expected substantial completion of such integration,
and our strategic transactions, including the prospects of and future investments for our strategic transactions; any statements
regarding management&rsquo;s view of future expectations and prospects for us; any statements about prospective adoption of new
accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance
of our company; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that
are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as &ldquo;anticipate,&rdquo;
&ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;should,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;believe,&rdquo; &ldquo;plan,&rdquo;
&ldquo;envision,&rdquo; &ldquo;intend,&rdquo; &ldquo;continue,&rdquo; &ldquo;target,&rdquo; &ldquo;seek,&rdquo; &ldquo;will,&rdquo;
&ldquo;would,&rdquo; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases
or terminology. Forward-looking statements reflect current views with respect to future events and condition and are based on current
estimates, expectations and assumptions only as of the date of this Quarterly Report on Form 10-Q and therefore are speculative
in nature and subject to change. Although we believe that the expectations reflected in our forward-looking statements are reasonable,
our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and
significant risks and uncertainties that could cause actual condition, outcomes and results to differ materially from those indicated
by such statements. Should one or more of these risks or uncertainties materialize, or should any expectations or assumptions underlying
the relevant forward-looking statements prove incorrect, it could significantly affect our operations and may cause the actual
actions, results, financial condition, performance or achievements of the Company and its subsidiaries and variable interest entities
to be substantially different from any future actions, results, financial condition, performance or achievements, expressed or
implied by any such forward-looking statements, as being expected, anticipated, intended, planned, believed, sought, estimated
or projected on the basis of historical trends.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the key factors
impacting these risks and uncertainties include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
related to our ability, following the consummation of the reverse merger of Apollo Medical Holdings, Inc. and Network Medical
Management, Inc., to successfully integrate operations of the two groups, including realizing the synergies anticipated from the
transaction, which may not be fully realized or may take longer to realize than expected; and our ability to successfully locate
new strategic targets and integrate our operations following mergers, acquisitions or other strategic transactions, including
that the integration may be more costly or more time consuming and complex than anticipated and that synergies anticipated to
be realized may not be fully realized or may take longer to realize than expected;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
dependence on a few key payors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in federal and state programs and policies regarding medical reimbursements and capitated payments for health services we provide;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
success of our focus on our NGACO, to which we have devoted, and intend to continue to devote, considerable effort and resources,
financial and otherwise, including whether we can manage medical costs for patients assigned to us within the capitation received
from CMS and whether we can continue to participate in the All-Inclusive Population-Based Payment (&ldquo;AIPBP&rdquo;) Mechanism
of the NGACO Model as payments thereunder represent a significant part of our total revenues;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our expenses may exceed capitation payments, whether from CMS under the AIPBP Mechanism or health plans,
which could lead to substantial losses, and uncertainty related to the final settlements of such incurred expenses and our actual
earnings (if any) that are generally determined in subsequent periods;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
economic uncertainty;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of emerging and existing competitors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
adverse development in general market, business, economic, labor, regulatory and political conditions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
outbreak or escalation of acts of terrorism or natural disasters;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changing
government programs in which we participate for the provision of health services and on which we are also significantly dependent
in generating revenue;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in laws and regulations and other market-wide developments affecting our industry in general and our operations in particular,
including the impact of any change to applicable laws and regulations relating to trade, monetary and fiscal policies, taxes,
price controls, regulatory approval of new products, registration and licensure, healthcare reform and reimbursements for medical
services from private insurance, on which we are significantly dependent in generating revenue and the impact, including additional
costs, of mandates and other obligations that may be imposed upon us as a result of new or revised federal and state healthcare
laws;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
related to our ability to raise capital as equity or debt to finance our growth and strategic transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to retain key individuals, including members of senior management;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of rigorous competition in the healthcare industry generally;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of any potential future impairment of our assets;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
effectiveness of our compliance and control initiatives;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
related to changes in accounting literature or accounting interpretations; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
fluctuations in the market value of our securities.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a detailed description
of these and other factors that could cause our actual results to differ materially from those expressed in any forward-looking
statement, please see Item 1A entitled &ldquo;Risk Factors,&rdquo; of our most recent Annual Report on Form 10-K for the year ended
December 31, 2017 as filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on April 2, 2018. In light of the
foregoing, investors are advised to carefully read this Quarterly Report on Form 10-Q and our most recent Annual Report on Form
10-K in connection with the important disclaimers set forth above and are urged not to rely on any forward-looking statements in
reaching any conclusions or making any investment decisions about us or our securities. Except as required by law, we do not intend,
and undertake no obligation, to update any statement, whether as a result of the receipt of new information, the occurrence of
future events, the change of circumstances or otherwise. We further do not accept any responsibility for any projections or reports
published by analysts, investors or other third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="part1"></A>PART I FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="item1"></A>ITEM 1. FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="balance"></A>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">103,731,761</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">99,749,199</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Restricted cash &ndash; short-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,028,116</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,005,661</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Fiduciary cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,386,474</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,017,437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Investment in marketable securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,138,477</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,143,095</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Receivables, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,805,123</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20,117,304</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,525,437</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,126,866</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">180,615,388</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">144,159,562</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Noncurrent assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Land, property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,700,034</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,814,306</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99,138,657</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">103,533,558</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">188,933,191</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">189,847,202</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Loans receivable &ndash; related parties</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Loan receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Investments in other entities &ndash; equity method</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,875,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,903,524</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Restricted cash &ndash; long-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">745,293</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">745,235</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,585,850</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,632,406</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total noncurrent assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">340,978,525</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">346,476,231</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">521,593,913</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">490,635,793</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS
(Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities, Mezzanine Equity and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; padding-left: 9pt">Lines of credit</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">5,025,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,110,530</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,279,620</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Incentives payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,900,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Fiduciary accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,386,474</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,017,437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Medical liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">69,110,826</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">63,972,318</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Income taxes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,614,669</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,198,495</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Bank loan, short-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">394,783</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">510,391</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Capital lease obligations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">99,480</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">98,738</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">110,616,762</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,601,999</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Noncurrent liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Deferred tax liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,055,819</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,916,598</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Liability for unissued equity shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,185,025</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,185,025</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Dividends payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Capital lease obligations, net of current portion</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">593,852</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">619,001</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total noncurrent liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">49,834,696</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">44,720,624</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">160,451,458</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">154,322,623</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingencies (Note 11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Mezzanine equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Noncontrolling interest in Allied Pacific of California IPA (&ldquo;APC&rdquo;)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">190,654,312</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">172,129,744</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, par value $0.001; 100,000,000 shares authorized, 32,652,295 and 32,304,876 shares outstanding,
excluding 1,682,110 shares held by APC, at March 31, 2018 and December 31, 2017, respectively (see Note 10)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,653</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,305</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">160,736,190</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">158,181,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Retained earnings</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,897,454</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,734,531</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">165,666,297</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">159,948,028</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Noncontrolling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,821,846</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,235,398</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">170,488,143</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">164,183,426</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities, mezzanine equity and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">521,593,913</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">490,635,793</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="income"></A>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 9pt">Capitation, net</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">85,905,284</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">64,716,133</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Risk pool settlements and incentives</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,986,736</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,137,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Management fee income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,074,572</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,537,110</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Fee-for-service, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,748,109</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,663,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">452,026</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">281,706</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">124,166,727</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">85,336,062</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Cost of services</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84,670,608</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">59,607,514</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,735,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,211,633</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,058,512</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,836,351</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">101,465,018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69,655,498</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Income from operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,701,709</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,680,564</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other income (expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">(Loss) income from equity method investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(28,024</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,227,262</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(85,001</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(811</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">269,818</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">182,285</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative instrument</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,522,222</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,993</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,514</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">244,786</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,932,472</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Income before provision for income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,946,495</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,613,036</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,228,840</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,889,245</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,717,655</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,723,791</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net income attributable to noncontrolling interests</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,557,200</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,374,130</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income attributable to Apollo Medical Holdings, Inc.</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,160,455</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,349,661</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Earnings per share &ndash; basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.07</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.17</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Earnings per share &ndash; diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.06</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.15</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Weighted average shares of common stock outstanding &ndash; basic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,421,467</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,067,954</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average shares of common stock outstanding &ndash; diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">38,098,373</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,445,647</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center; text-indent: -4.5pt">The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center; text-indent: -4.5pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="cashflows"></A>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 9pt">Net income</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">15,717,655</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">11,723,791</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Adjustments to reconcile net income to net cash provided by operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,058,512</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,836,351</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Loss on disposal of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">41,782</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">833,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">321,233</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Unrealized loss from investment in equity securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,550</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Change in fair value of derivative instrument</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,522,222</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Loss (income) from equity method investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,024</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,227,262</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Deferred tax</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,807,407</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,109,535</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(21,087,819</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,410,196</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(398,571</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(428,871</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(59,444</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(54,368</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,169,363</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,350,949</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Incentives payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,600,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,721,645</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Medical liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,138,508</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(257,945</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Income taxes payable</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,416,174</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,267,804</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,735,359</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21,105,648</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Purchases of marketable securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,932</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,301</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Advances to related parties &ndash; loans receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Dividends received from equity method investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Proceeds on sale of investments &ndash; cost method</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(485,121</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(318,821</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(489,053</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,295,122</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS
(Continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-left: 9pt">Repayment of bank loan</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(140,608</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Dividends paid</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,750,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in noncontrolling interest capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(27,500</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Payment of capital lease obligations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(24,407</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(30,980</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Proceeds from exercise of stock options and warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,923,784</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">425,025</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(241,231</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,383,455</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net increase in cash, cash equivalents and restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,005,075</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,427,071</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash, beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">118,500,095</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">54,925,712</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash, end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">122,505,170</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">63,352,783</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosures of cash flow information</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Cash paid for income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,511,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Cash paid for interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">73,610</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">811</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosures of non-cash investing and financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Cashless exercise of stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">43</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Reclassification of stock options exercised to liability for unissued common shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">425,025</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Deferred tax liability adjustment to goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">914,011</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Cumulative effect adjustment for ASC 606 included in accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,600,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Cumulative effect adjustment for ASC 606 included in deferred tax liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,246,098</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Reclassification of fiduciary cash to payable</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">630,963</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">32,485</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation of cash, cash
equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash,
cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">103,731,761</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">63,251,651</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.5pt">Restricted cash &ndash; long-term
    - letters of credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">745,293</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">101,132</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Restricted cash &ndash; short-term - distributions to former NMM shareholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,028,116</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">122,505,170</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,352,783</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="notes"></A>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Business</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Apollo Medical Holdings, Inc. (&ldquo;ApolloMed&rdquo;), entered into an Agreement and Plan of Merger
dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the &ldquo;Merger Agreement&rdquo;) among ApolloMed,
Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (&ldquo;NMM&rdquo;),
and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the &ldquo;Merger&rdquo;).
The Merger closed and became effective on December 8, 2017 (the &ldquo;Closing&rdquo;) (see Note 3). As a result of the Merger,
NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding
common stock of ApolloMed. For accounting purposes, the Merger is treated as a &ldquo;reverse acquisition&rdquo; and NMM is considered
the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM&rsquo;s historical results of
operations replaced ApolloMed&rsquo;s historical results of operations for all periods prior to the Merger, and the results of
operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger.
Effective as of the Closing, ApolloMed&rsquo;s board of directors approved a change in ApolloMed&rsquo;s fiscal year end from March
31 to December 31, to correspond with NMM&rsquo;s fiscal year end prior to the Merger.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined company, following the Merger,
together with its affiliated physician groups and consolidated entities (collectively, the &ldquo;Company&rdquo;) is a physician-centric
integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective
manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid
and health maintenance organizations (&ldquo;HMOs&rdquo;), with a small portion of the Company&rsquo;s revenue coming from non-insured
patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including
patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician
groups and health plans. The Company&rsquo;s physician network consists of primary care physicians, specialist physicians and hospitalists.
The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (&ldquo;AMM&rdquo;),
APA ACO, Inc. (&ldquo;APAACO&rdquo;) and Apollo Care Connect, Inc. (&ldquo;Apollo Care Connect&rdquo;), and their consolidated
entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NMM was formed in 1994 as a management
service organization (&ldquo;MSO&rdquo;) for the purposes of providing management services to medical companies and independent
practice associations (&ldquo;IPAs&rdquo;). The management services cover primarily billing, collection, accounting, administrative,
quality assurance, marketing, compliance and education.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allied Physicians of California IPA, a
Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&ldquo;APC&rdquo;) was incorporated on August&nbsp;17,
1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations
(&ldquo;HMOs&rdquo;) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act
of 1975. Each HMO negotiates a fixed amount per member per month (&ldquo;PMPM&rdquo;) that is to be paid to APC. In return, APC
arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary
care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the
fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is
also minimized by stop-loss provisions in contracts with HMOs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&nbsp;1, 1999, APC entered into
an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered
into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a
variable interest entity (&ldquo;VIE&rdquo;) as NMM is the primary beneficiary with the ability to direct the activities (excluding
clinical decisions) that most significantly affect APC&rsquo;s economic performance through its majority representation of the
APC Joint Planning Board; therefore APC is consolidated by NMM. As of March 31, 2018 and December 31, 2017, APC had an ownership
interest of 4.90% and 4.95% in ApolloMed, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concourse Diagnostic Surgery Center, LLC
(&ldquo;CDSC&rdquo;) was formed on March&nbsp;25, 2010 in the state of California. CDSC is an ambulatory surgery center in City
of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most
advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the
Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $625,000 for a 41.59% ownership in CDSC. Due
to capital stock changes in 2016, APC&rsquo;s ownership percentage in CDSC&rsquo;s capital stock changed to 43.80% and 43.43% on
May&nbsp;31, 2016 and July&nbsp;31, 2016, respectively. CDSC is consolidated as a VIE by APC as it was determined that APC has
a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC also holds a 40% ownership interest
in Pacific Ambulatory Surgery Center, LLC (&ldquo;PASC&rdquo;), a multi-specialty outpatient surgery center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC-LSMA was formed on October&nbsp;15,
2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer
of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds
these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to
receive benefits from all the investments made by APC-LSMA. APC-LSMA&rsquo;s sole function is to act as the nominee shareholder
for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is
the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes:
The IPA line of business of LaSalle Medical Associates (&ldquo;LMA&rdquo;), Pacific Medical Imaging and Oncology Center, Inc. (&ldquo;PMIOC&rdquo;),
Diagnostic Medical Group (&ldquo;DMG&rdquo;) and AHMC International Cancer Center (&ldquo;ICC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICC was formed on September 2, 2010 in
the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations
such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees.
On November&nbsp;15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC 40% of the aggregate issued
and outstanding shares of capital stock of ICC for $400,000 in cash. Certain requirements to complete the investment transaction
was completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC
as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to
receive benefits that could potentially be significant to ICC. The results of operations of ICC from October 31, 2017 to December
31, 2017 were de minimis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universal Care Acquisition Partners, LLC
(&ldquo;UCAP&rdquo;), a 100% owned subsidiary of APC, was formed on June&nbsp;4, 2014, for the purpose of holding the investment
in Universal Care, Inc. (&ldquo;UCI&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APAACO, jointly owned by NMM and AMM, participates
in the next generation accountable care organization model (&ldquo;NGACO Model&rdquo;) of the Centers for Medicare &amp; Medicaid
Services (&ldquo;CMS&rdquo;) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher
levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing
model. In addition to APAACO, NMM and AMM operated three accountable care organizations (&ldquo;ACOs&rdquo;) that participated
in the Medicare Shared Savings Program (&ldquo;MSSP&rdquo;), the goal of which is to improve the quality of patient care and outcomes
through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable
by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including
achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an &ldquo;all or nothing&rdquo;
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2012, ApolloMed formed an ACO, ApolloMed
Accountable Care Organization, Inc. (&ldquo;ApolloMed ACO&rdquo;) to participate in the MSSP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&nbsp;11, 2015, NMM, ACO Acquisition
Corporation, and APCN-ACO, A Medical Professional Corp. (&ldquo;APCN-ACO&rdquo;) entered into a reorganization agreement whereby
ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on
January&nbsp;8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;18, 2016, NMM, ACO Acquisition
Corporation #2, and Allied Physicians ACO, LLC (&ldquo;AP-ACO&rdquo;) entered into a reorganization agreement whereby ACO Acquisition
Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December&nbsp;20,
2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company is transitioning to the
NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. Effective on December 31,
2017, APCN-ACO&rsquo;s MSSP participation agreement with CMS was terminated. Effective on December 31, 2016, AP-ACO&rsquo;s MSSP
participation agreement with CMS was terminated. Effective on December 31, 2017, ApolloMed ACO&rsquo;s MSSP participation agreement
with CMS was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the Merger, ApolloMed
sold to APC-LSMA all the issued and outstanding shares of capital stock of Maverick Medical Group, Inc. (&ldquo;MMG&rdquo;). MMG
has historically been included in the consolidated financial statements filed by ApolloMed.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AMM, a wholly-owned subsidiary of ApolloMed,
manages affiliated medical groups, which consist of ApolloMed Hospitalists (&ldquo;AMH&rdquo;), a hospitalist company, Southern
California Heart Centers (&ldquo;SCHC&rdquo;), Bay Area Hospitalist Associates (&ldquo;BAHA&rdquo;), a medical corporation, ApolloMed
Care Clinic (&ldquo;ACC&rdquo;) and AKM Medical Group, Inc. (&ldquo;AKM&rdquo;). AMH provides hospitalist, intensivist and physician
advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operates a hospitalist,
intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several
skilled nursing facilities. ACC and AKM are no longer active to any material extent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Apollo Care Connect, a wholly-owned subsidiary
of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case
management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic
health records to capture clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ApolloMed also has a controlling interest
in Apollo Palliative Services, LLC (&ldquo;APS&rdquo;), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC
(&ldquo;BCHC&rdquo;) and Holistic Care Home Health Agency, Inc. (&ldquo;HCHHA&rdquo;) and provides palliative care services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ApolloMed also operated Pulmonary Critical
Care Management, Inc. (&ldquo;PCCM&rdquo;) and Verdugo Medical Management, Inc. (&ldquo;VMM&rdquo;), which operated as physician
practice management companies. PCCM and VMM are no longer active to any material extent.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Presentation and Summary of Significant Accounting Policies</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated
balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures
required by accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;). The accompanying
unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017,
have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article
8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial
statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included
in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange
Commission (&ldquo;SEC&rdquo;) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring
adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The
condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary
to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company&rsquo;s
quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the
results that may be expected for the year ending December 31, 2018 or any future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Principles of Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed consolidated balance sheets
as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM&rsquo;s
subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM&rsquo;s consolidated VIE, APC, APC&rsquo;s subsidiary,
UCAP, and APC&rsquo;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three
months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC&rsquo;s subsidiary, UCAP, and APC&rsquo;s consolidated
VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes
ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM&rsquo;s consolidated VIE, APC, APC&rsquo;s
subsidiary, UCAP, and APC&rsquo;s consolidated VIEs, CDSC, APC-LSMA and ICC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All material intercompany balances and
transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the acquisition method
of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value,
to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition
date, and to account for acquisition related costs separately from the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reportable Segments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one reportable
segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered,
physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all
activities in one reportable segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated
financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;Significant
items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible
assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not
reported (&ldquo;IBNR&rdquo;) claims), determination of full-risk and shared-risk revenue and receivable (including constraints,
completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management
evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current
economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be
determined with precision, actual results could differ materially from those estimates and assumptions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts disclosed in prior period
financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect
on the Company&rsquo;s reported revenue, net income, cash flows or total assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s cash and cash equivalents
primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are
both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash in deposit
accounts with several banks, which at times may&nbsp;exceed the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;)&rsquo;s
insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents
and restricted cash. As of March 31, 2018, the Company&rsquo;s deposit accounts with banks exceeded the FDIC&rsquo;s insured limit
by approximately $135.0 million. The Company has not experienced any losses to date and performs ongoing evaluations of these financial
institutions to limit the Company&rsquo;s concentration of risk exposure.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restricted Cash</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At times, APC is required to maintain a
reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from
the date of purchase and interest rates ranging from 0.05% to 0.10%. Restricted cash also consists of cash held as collateral to
secure standby letters of credits as required by certain contracts. As of March 31, 2018 and December 31, 2017, there was $18,028,116
and $18,005,661 included in restricted cash short-term, respectively, in the accompanying condensed consolidated balance sheets.
Approximately $18,000,000 of such restricted cash was related to an amount that, as a result of the Merger between ApolloMed and
NMM (see Note 3), will be held in an escrow account for distribution to former NMM shareholders (see Note 17).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Receivables</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s receivables are comprised
of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable
are recorded and stated at the amount expected to be collected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitation and claims receivable relate
to the health plan&rsquo;s capitation, which is received by the Company in the following month of service. Risk pool and incentive
receivables mainly consist of the Company&rsquo;s full risk pool receivable that is recorded in accordance with Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) ASC 606 (see Note 13). Other receivables
include fee-for-services (&ldquo;FFS&rdquo;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements
from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains reserves for potential
credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts,
customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate
the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain
stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments
are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts are recorded as a receivable when
the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection
is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off
receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As
of March 31, 2018 and December&nbsp;31, 2017, the Company recorded an allowance for doubtful accounts of $763,205 and $407,953,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentrations of Risks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had major payors that contributed
the following percentage of net revenue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">For The Three Months<BR> Ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify">Payor A</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">*</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Payor B</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12.0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24.0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Payor C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11.9</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Payor D</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10.9</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12.7</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; &nbsp;* Less than 10% of total
net revenues</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had major payors that contributed
to the following percentage of receivables before the allowance for doubtful accounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">As of March</FONT><BR>
<FONT STYLE="font-size: 10pt">31, 2018</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">As of December</FONT><BR>
<FONT STYLE="font-size: 10pt">31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 72%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payor D</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payor E</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fair Value Measurements of Financial
Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financial instruments
consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans
receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and
the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance
sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan
receivables &ndash; long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest
at rates that approximate current market rates for debt with similar maturities and credit quality.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, <I>Fair Value Measurement</I>
(&ldquo;ASC 820&rdquo;), applies to all financial assets and financial liabilities that are measured and reported on a fair value
basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements.
ASC&nbsp;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy prioritizes the inputs into
three broad levels as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Level&nbsp;1</I> &mdash;Inputs
are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Level&nbsp;2</I> &mdash;Inputs
include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities
in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest
rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation
or other means (market corroborated inputs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Level&nbsp;3</I> &mdash;Unobservable
inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would
be based on the best information available, including the Company&rsquo;s own data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts and fair values of
the Company&rsquo;s financial instruments as of March 31, 2018 are presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="white-space: nowrap; font: italic 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements</TD><TD NOWRAP STYLE="white-space: nowrap; padding-bottom: 1pt; font: italic 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD NOWRAP STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD NOWRAP STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD NOWRAP STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Money market accounts*</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">42,300,818</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">42,300,818</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Marketable securities &ndash; certificates of deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,061,022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,061,022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Marketable securities &ndash; equity securities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">77,455</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">77,455</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">43,439,295</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">43,439,295</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts and fair values of
the Company&rsquo;s financial instruments as of December&nbsp;31, 2017 are presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: italic 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Money market accounts*</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">41,231,405</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">41,231,405</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Marketable securities &ndash; certificates of deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,057,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,057,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Marketable securities &ndash; equity securities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,005</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,005</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,374,500</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,374,500</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">* <I>Included in cash and
cash equivalents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no Level 3 input measured on
a non-recurring basis for the three months ended March 31, 2018. The following summarizes activity of Level 3 inputs measured
on a recurring basis for the three months ended March 31, 2017:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Derivative<BR> Assets<BR> (Warrants)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2017</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,338,886</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,522,222</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance at March 31, 2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,861,108</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrant derivative
asset of approximately $6.9 million at March&nbsp;31, 2017 was estimated using the Black-Scholes valuation model, using the following
inputs: term of 3.54 &ndash; 4.00 years, risk free rate of 1.62% - 1.71%, no dividends, volatility of 62.3% - 62.4%, share price
of $9.00 per share based on the trading price of ApolloMed&rsquo;s common stock adjusted for a marketability discount, and a 0%
probability of redemption of the warrant shares issued along with the shares of ApolloMed&rsquo;s convertible preferred stock issued
in the financing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in Level 1,
Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31,
2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intangible Assets and Long-Lived
Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets with finite lives include
network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization
and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets with finite lives also
include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to
recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization
and impairment losses and is amortized using the straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangibles and long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&nbsp;not
be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less
than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value.
Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its
finite-lived intangible or long-lived assets during the three months ended March&nbsp;31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill and Indefinite-Lived Intangible
Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the ASC 350, <I>Intangibles &ndash;
Goodwill and Other</I> (&ldquo;ASC 350&rdquo;), goodwill and indefinite-lived intangible assets are reviewed at least annually
for impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At least annually, at the Company&rsquo;s
fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair
value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is
performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised
of (1) provider services, (2) management services, (3) IPA, and (4) ACO.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An impairment loss is recognized if the
implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly.
The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management
believes are appropriate in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At least annually, indefinite-lived intangible
assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible
asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based
on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there
was no impairment of its goodwill during the three months ended March&nbsp;31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investments in Other Entities - Equity
Method</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for certain investments
using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise
significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has
an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation
on the investee&rsquo;s board of directors, are considered in determining whether the equity method of accounting is appropriate.
Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&rsquo;s
share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &ldquo;Income
from equity method investments&rdquo; and also is adjusted by contributions to and distributions from the investee. Equity method
investments are subject to impairment evaluation. No impairment loss was recorded on equity method investments for the three months
ended March&nbsp;31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Medical Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC, APAACO and MMG are responsible for
integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated
care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient
service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as
cost of services expenses in the accompanying consolidated statements of income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An estimate of amounts due to contracted
physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance
sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are
developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical
payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO&rsquo;s NGACO program
is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded
at 100% of the revenue less actual claims processed for or paid to in-network providers (after taking into account the average
discount negotiated with the in-network providers). The Company plans to use the traditional lag models as the claims history matures.
The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex
in nature and may&nbsp;be subject to differing interpretations regarding amounts due for the provision of various services. Such
differing interpretations may&nbsp;not come to light until a substantial period of time has passed following the contract implementation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-09, &ldquo;Revenue from Contracts with Customers (Topic 606)&rdquo;, using the modified retrospective
method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented
in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance
of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company&rsquo;s
contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not
been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue
Recognition for further details.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Federal and state income taxes are computed
at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items
that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine
deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and
liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for
financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance
caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established
when necessary to reduce deferred tax assets to amounts expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses a recognition threshold
of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order
to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine
the actual amount of benefit to recognize in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a stock-based compensation
program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized
as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.
At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject
to the Company&rsquo;s repurchase right (but not obligation) that lapses based on performance of services in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards
granted to persons other than employees and directors under ASC 505-50 <I>Equity-Based Payments to Non-Employees</I>. As such the
fair value of such shares is periodically re-measured using an appropriate valuation model and income or expense is recognized
over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basic and Diluted Earnings Per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic earnings per share (&ldquo;EPS&rdquo;)
is computed by dividing net income attributable to holders of the Company&rsquo;s common stock by the weighted average number of
shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average
number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using
treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The basic EPS for the comparative period
(the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial
statements was calculated by dividing (a) by (b):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income of the legal acquiree (NMM) attributable to holders of the Company&rsquo;s common stock in such period.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The legal acquiree&rsquo;s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Noncontrolling Interests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company consolidates entities in which
the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or
indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests
represent third-party equity ownership interests (including certain VIEs) in the Company&rsquo;s consolidated entities. The amount
of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Mezzanine Equity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to APC&rsquo;s shareholder agreements,
in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective
shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely
within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary
equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&ldquo;Revenue from Contracts with Customers (Topic 606)&rdquo; (&ldquo;ASU 2014-09&rdquo;). ASU 2014-09 and other subsequent revisions
amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this
topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract
revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires
enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers.
Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money
is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies
are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect
adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition,
for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2016, the FASB issued ASU No.
2016-01, &ldquo;Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&rdquo;
(&ldquo;ASU 2016-01&rdquo;). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of
financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value
recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material
impact on the Company&rsquo;s condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU
No. 2016-02, &ldquo;Leases (Topic 842)&rdquo; (&ldquo;ASU 2016-02&rdquo;). Under ASU 2016-02, lessees will be required to recognize
the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a
lessee&rsquo;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset,
which is an asset that represents the lessee&rsquo;s right to use, or control the use of, a specified asset for the lease term.
ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter
of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed
a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial
statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete
the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter
of 2019.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13,
&ldquo;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&rdquo; (&ldquo;ASU
2016-13&rdquo;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting
date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective
for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact
ASU 2016-13 will have on the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2016, the FASB issued ASU No.
2016-15, &ldquo;Statement of Cash Flows (Topic 230) &ndash; Classification of Certain Cash Receipts and Cash Payments&rdquo; (&ldquo;ASU
2016-15&rdquo;). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified
in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing
diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt
extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual
and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU
2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company&rsquo;s condensed consolidated
financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2016, the FASB issued ASU No.
2016-18, &ldquo;Statement of Cash Flows (Topic 230) &ndash; Restricted Cash&rdquo; (&ldquo;ASU 2016-18&rdquo;). The amendments in
ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents,
and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1,
2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to
including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and
end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for
the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, the FASB issued ASU No.
2017-01, &ldquo;Business Combinations (Topic 805): Clarifying the Definition of a Business&rdquo; (&ldquo;ASU 2017-01&rdquo;).
This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value
of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable
assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is
not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process
that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant
could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a
material impact on the Company&rsquo;s condensed consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, the FASB issued ASU No.
2017-04, &ldquo;Intangibles &ndash; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&rdquo; (&ldquo;ASU
2017-04&rdquo;). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of
a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform
a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore,
the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated
to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods
beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing
dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company&rsquo;s
condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued ASU No. 2017-09,
&ldquo;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&rdquo; (&ldquo;ASU 2017-09&rdquo;), to
clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting
in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively
when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018.
The adoption of ASU 2017-09 did not have a material impact on the Company&rsquo;s condensed consolidated financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No. 2017-11,
&ldquo;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815):
(Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral
for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling
Interests with a Scope Exception&rdquo; (&ldquo;ASU 2017-11&rdquo;). The amendments in Part I of this Update change the classification
analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether
certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes
equity classification when assessing whether the instrument is indexed to an entity&rsquo;s own stock. The amendments also clarify
existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including
adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected
as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption
of ASU 2017-11 will have on the Company&rsquo;s condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the exception of the new standards
discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the
Company&rsquo;s financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mergers
and Acquisitions</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2017, (the &ldquo;Effective Time&rdquo;) the merger (the &ldquo;Merger&rdquo;) of ApolloMed&rsquo;s
wholly-owned subsidiary, Apollo Acquisition Corp., with and into Network Medical Management, Inc. as the surviving entity was completed,
in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 21, 2016 (as amended on March
30, 2017 and October 17, 2017), by and among the Company, Merger Sub, NMM and Kenneth Sim, M.D., as the NMM shareholders&rsquo;
representative. As a result of the Merger, NMM now is a wholly-owned subsidiary of ApolloMed and former NMM shareholders own a
majority of the issued and outstanding common stock of the Company. Both companies are considered to be a business under the guidance
outlined in ASC 805, Business Combinations. The combined company operates under the Apollo Medical Holdings name. NMM is the larger
entity in terms of assets, revenues and earnings. In addition, as of the closing of the Merger, the majority of the board of directors
of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed
is considered to be the legal acquirer (and accounting acquiree) whereas NMM is considered to be the accounting acquirer (and legal
acquiree) and, accordingly, the merger transaction is a reverse acquisition. Accordingly, as of the Effective Time, NMM&rsquo;s
historical results of operations replaced ApolloMed&rsquo;s historical results of operations for all periods prior to the Merger,
and the results of operations of both companies will be included in the Company&rsquo;s financial statements for all periods following
the Merger. As of the Effective Time, the Company&rsquo;s board of directors approved a change in the Company&rsquo;s fiscal year
end from March 31 to December 31, to correspond with NMM&rsquo;s fiscal year end prior to the Merger.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, at the
Effective Time, each issued and outstanding share of NMM common stock converted into the right to receive (i) such number of fully
paid and nonassessable shares of ApolloMed&rsquo;s common stock that resulted in the NMM shareholders having a right to receive
an aggregate number of shares of ApolloMed&rsquo;s common stock that represented 82% of the total issued and outstanding shares
of ApolloMed common stock immediately following the Effective Time, with no NMM dissenting shareholder interests as of the Effective
Time (the &ldquo;exchange ratio&rdquo;), plus (ii) an aggregate of 2,566,666 ApolloMed&rsquo;s common stock, with no NMM dissenting
shareholder interests as of the Effective Time, and (iii) common stock warrants to purchase a pro-rata portion of an aggregate
of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share and warrants to purchase an aggregate of 900,000
shares of common stock of ApolloMed at $10.00 per share. At the Effective Time, pre-Merger ApolloMed stockholders held their existing
shares of ApolloMed&rsquo;s common stock. At the Effective Time, ApolloMed held back 10% of the total number of shares of ApolloMed&rsquo;s
common stock issuable to pre-Merger NMM shareholders in the Merger to secure indemnification of ApolloMed and its affiliates under
the Merger Agreement. Separately, indemnification of pre-Merger NMM shareholders under the Merger Agreement was made by the issuance
by ApolloMed to pre-Merger NMM shareholders of new additional shares of common stock (capped at the same number of shares of ApolloMed&rsquo;s
common stock as are subject to the holdback for the indemnification of ApolloMed). These holdback shares will be held for a period
of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which
ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger agreement, by NMM. Half
of these shares will be issued on the first and second anniversary of the Effective Time respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of calculating the exchange
ratio, (A) the aggregate number of shares of ApolloMed common stock held by the NMM shareholders immediately following the Effective
Time excluded (i) any shares of ApolloMed common stock owned by NMM shareholders immediately prior to the Effective Time, (ii)
the Series A warrant and Series B warrant issued by ApolloMed to NMM to purchase ApolloMed common stock (the &ldquo;ApolloMed Warrants&rdquo;)
and (iii) any shares of ApolloMed common stock issued or issuable to NMM shareholders pursuant to the exercise of the ApolloMed
Warrants, and (B) the total number of issued and outstanding shares of ApolloMed common stock immediately following the Effective
Time excluded 520,081 shares of ApolloMed common stock issued or issuable under a Convertible Promissory Note to Alliance Apex,
LLC (&ldquo;Alliance&rdquo;) for $4.99 million and accrued interest pursuant to the Securities Purchase Agreement between ApolloMed
and Alliance dated as of March 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consideration for the transaction was
18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the fair value of NMM&rsquo;s
50% interest in APAACO, an entity that was owned 50% by ApolloMed and 50% by NMM, was remeasured at fair value as of the Effective
Time and added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in
order to obtain control of ApolloMed. The fair value of NMM&rsquo;s noncontrolling interest in APAACO has been estimated to be
$5,129,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total estimated purchase consideration
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left">Equity consideration (1)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">61,092,050</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated fair value of ApolloMed preferred stock held by NMM (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,118,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated fair value of NMM&rsquo;s noncontrolling interest in APAACO (3)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,129,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Estimated fair value of the outstanding ApolloMed stock options (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">187,333</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total estimated purchase consideration</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">85,526,383</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Equity consideration</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Immediately following the Effective
Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The equity consideration, which represents a portion of the
consideration deemed transferred to the pre-Merger ApolloMed stockholders in the Merger, is calculated based on the number of shares
of the combined company that the pre-Merger ApolloMed stockholders would own as of the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders <SUP>(1)</SUP> &nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,109,205</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiplied by the price per share of ApolloMed&rsquo;s common stock <SUP>(2)</SUP> &nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10.00</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">61,092,050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the closing price of ApolloMed&rsquo;s common stock on December 8, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated fair value of ApolloMed&rsquo;s preferred shares held by NMM</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">NMM currently owns all the shares
of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger.&nbsp; As part of the
Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of
the consideration transferred to ApolloMed.&nbsp; The fair value of the Series A preferred stock and Series B preferred stock is
reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A
and Series B preferred stock were valued to be $19,118,000.&nbsp;The valuation methodology was based on an Option
Pricing Method (&ldquo;OPM&rdquo;) which utilized the observable publicly traded common stock price in valuing the Series A preferred
stock and the Series B preferred stock within the context of the capital structure of the Company.&nbsp; OPM assumptions included
an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%.&nbsp; The fair value of the liquidation preference
for the Series A preferred stock and the Series B preferred stock was determined to be&nbsp;$12,745,000 and the fair value of the
conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(3)</I></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated fair value of NMM&rsquo;s 50% share of APA ACO Inc.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Prior to the Merger, APAACO
was owned 50% by ApolloMed and 50% NMM. NMM&rsquo;s noncontrolling interest in APAACO has been remeasured at fair value as of the
closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment
in APAACO in order to obtain control of ApolloMed. The fair value of NMM&rsquo;s noncontrolling interest in APAACO has been estimated
to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the
fair value of this investment prior the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(4)</I></FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Estimated fair value of the ApolloMed outstanding stock options</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The estimated fair value of
the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed
stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated
with the awards. There is no future service requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the acquisition method of accounting,
the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date
fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the
purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG
(see &ldquo;MMG Transaction&rdquo; below), with the excess recorded as goodwill:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets acquired</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">36,367,555</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounts receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,261,588</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,211,028</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">249,193</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property, plant and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,114,332</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">745,220</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Fair value of intangible assets acquired</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,984,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred tax assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,301,972</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">217,241</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total assets acquired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">66,452,129</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities assumed</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8,632,893</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Medical liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">39,353,540</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Line of credit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Convertible note payable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,376,215</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Convertible note payable - related party</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,921,938</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Noncontrolling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,142,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities assumed and noncontrolling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">66,451,586</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net liabilities assumed</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(913,468</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">85,525,840</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is not deductible for tax purposes.
During the three months ended March 31, 2018, the deferred tax assets balance was increased by approximately $0.9 million with
an offset to goodwill as a result of the allocation of transaction costs related to the Merger from ApolloMed to NMM.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase consideration and purchase
price allocation are preliminary and subject to change as more information becomes available, which will be finalized as soon as
practicable within the measurement period of no later than one year following the Effective Time of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>MMG Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital
stock of MMG. MMG has historically been included in the consolidated financial statements filed by ApolloMed. APC-LSMA agreed to
pay $100 in consideration for all the shares of MMG. As the transaction is between related parties, the purchase consideration
of MMG reflected in the purchase price allocation was determined to be the fair value of MMG. MMG and AMM terminated the existing
Management Services Agreement between them (the &ldquo;MMG Management Agreement&rdquo;) and APC-LSMA paid AMM $400,000 as a termination
payment on the Effective Time. APC-LSMA is consolidated by APC which in turn is consolidated by NMM, and as a result, the $400,000
amount is eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Pro Forma Combined Historical Results</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pro forma combined historical results, as if ApolloMed had
been acquired as of January 1, 2017, are estimated as follows (unaudited):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three Months</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Ended</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>March 31, 2017</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">Net revenues</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">98,467,260</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net loss attributable to Apollo Medical Holdings, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(351,982</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Weighted average common shares outstanding:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Basic</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33,601,022</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Earnings per share:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">basic</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(0.01</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Weighted average common shares outstanding:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33,601,022</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Earnings per share:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(0.01</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pro forma information has been prepared
for comparative purposes only and does not purport to be indicative of what would have occurred had the acquisition actually been
made at such date, nor is it necessarily indicative of future operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets, Net</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March&nbsp;31, 2018, the Company&rsquo;s
intangible assets, net, consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Useful</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Gross</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Life</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">March 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Accumulated</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">March 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">(Years)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Amortization</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Indefinite Lived Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 41%; font-size: 10pt; text-align: left; padding-left: 12px">Medicare license</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">N/A</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1,994,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1,994,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Amortized Intangible Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 12px">Network relationships</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">11-15</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,883,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(39,179,025</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,703,975</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 12px">Management contracts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">15</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,832,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,646,843</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,185,157</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 12px">Member relationships</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">12</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,696,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(357,292</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,338,708</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 12px">Patient management platform</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,060,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(137,333</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,922,667</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 12px">Tradename/trademarks</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">20</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,011,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(16,850</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">994,150</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">144,476,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(45,337,343</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">99,138,657</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December&nbsp;31, 2017, the Company&rsquo;s
intangible assets, net, consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Useful</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Gross</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Net</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Life</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">December 31,</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Accumulated</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">December 31,</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">(Years)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Amortization</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 41%"><FONT STYLE="font-size: 10pt">Indefinite Lived Assets:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Medicare license</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,994,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,994,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Amortized Intangible Assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Network relationships</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11-15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">109,883,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(35,842,508</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74,040,492</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Management contracts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22,832,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,014,886</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17,817,114</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Member relationships</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,696,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(46,500</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,649,500</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Patient management platform</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,060,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(34,336</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,025,664</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Tradename/trademarks</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,011,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(4,212</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,006,788</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">144,476,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(40,942,442</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">103,533,558</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Included in depreciation and amortization
on the accompanying consolidated statements of income is amortization expense of $4,394,901 and $4,374,841, (excluding $106,000
amortization expense for exclusivity incentives) for the three months ended March&nbsp;31, 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future amortization expense is estimated
to be as follows for the years ending December&nbsp;31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font: 10pt Times New Roman, Times, Serif; text-align: justify">2018 (remaining nine months)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">12,262,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,480,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,671,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,961,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,448,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Thereafter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,323,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">97,145,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investments
in Other Entities</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Equity Method Investments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>LaSalle Medical Associates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LaSalle Medical Associates (&ldquo;LMA&rdquo;)
was founded by Dr. Albert Arteaga in 1996 and currently operates four neighborhood medical centers employing more than 120 dedicated
healthcare professionals, treating children, adults and seniors in San Bernardino County. LMA&rsquo;s patients are primarily served
by Medi-Cal and they also accept Blue Cross, Blue Shield, Molina, Care 1<SUP>st</SUP>, Health Net and Inland Empire Health Plan.
LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high quality care to more than 245,000
patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered
into a share purchase agreement whereby APC-LSMA invested $5,000,000 for a 25% interest in LMA&rsquo;s IPA line of business. NMM
has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability
to exercise significant influence, but not control over LMA&rsquo;s operations. For the three months ended March&nbsp;31, 2018
and 2017, APC recorded (loss) income from this investment of $(352,792) and $1,311,738, respectively, in the accompanying consolidated
statements of income. The investment balance was $9,099,975 and $9,452,767 at March 31, 2018 and December&nbsp;31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LMA&rsquo;s IPA line of business summarized
balance sheets at March 31, 2018 and December&nbsp;31, 2017 and summarized statements of income for the three months ended March&nbsp;31,
2018 and 2017 are as follows (unaudited):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Balance Sheets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2018<BR> (unaudited)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017 <BR>(unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,064,701</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,065,105</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 9pt">Receivables, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,005,144</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,433,116</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 9pt">Other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,173,110</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,565,606</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 9pt">Loan receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">664,612</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">662,109</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">29,157,567</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,975,936</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Liabilities and Stockholders&rsquo; Equity</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2018<BR> (unaudited)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.5pt">Current liabilities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,946,133</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">20,353,337</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0.5pt">Stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,211,434</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,622,599</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">29,157,567</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,975,936</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Statements of Income</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>March
31, 2018<BR>
(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2017<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.5pt">Revenues</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">52,983,791</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">49,753,004</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; padding-left: 0.5pt">Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,002,458</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,506,050</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.5pt">Net (loss) income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,018,667</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,246,954</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pacific Medical Imaging and Oncology
Center, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PMIOC was incorporated in 2004 in the state
of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high quality
diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography
at their facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&nbsp;2015, APC-LSMA and PMIOC entered
into a share purchase agreement whereby APC-LSMA invested $1,200,000 for a 40% ownership in PMIOC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC and PMIOC have an Ancillary Service
Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary
Service Contract APC paid PMIOC fees of approximately $0.4 million and $0.5 million for the three months ended March&nbsp;31, 2018
and 2017, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to
exercise significant influence, but not control over PMIOC&rsquo;s operations. During the three months ended March&nbsp;31, 2018
and 2017, APC recorded (loss) income from this investment of $(26,025) and $51,080 respectively, in the accompanying consolidated
statements of income and has an investment balance of $1,374,668 and $1,400,693 at March 31, 2018 and December&nbsp;31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 237.3pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Universal Care, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UCI is a privately held health plan that
has been in operation since 1985 in order to help its members through the complexities of the healthcare system. UCI holds a license
under the California Knox-Keene Health Care Services Plan Act (&ldquo;Knox-Keene Act&rdquo;) to operate as a full-service health
plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;10, 2015, UCAP, an entity
solely owned 100% by APC with APC&rsquo;s executives, Dr.&nbsp;Thomas Lam, Dr. Pen Lee and Dr. Kenneth Sim, as designated managers
of UCAP, purchased from UCI 100,000 shares of UCI class A-2 voting common stock (comprising 48.9% of the total outstanding UCI
shares, but 50% of UCI&rsquo;s voting common stock) for $10,000,000. APC accounts for its investment in UCI under the equity method
of accounting as APC has the ability to exercise significant influence, but not control over UCI&rsquo;s operations. During the
three months ended March&nbsp;31, 2018 and 2017, the Company recorded (loss) income from this investment of $(20,202) and $523,301,
respectively, in the accompanying consolidated statements of income and has an investment balance of $8,589,253 and $8,609,455
at March 31, 2018 and December&nbsp;31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, the Company also advanced $5,000,000
to UCI for working capital purposes. The subordinated loan accrues interest at the prime rate plus 1%, or 5.75% and 5.50% as of
March 31, 2018 and December&nbsp;31, 2017, respectively, with interest to be paid monthly. Pursuant to the stock purchase agreement,
the principal repayment schedule is based on certain contingent criteria, and accordingly, the entire note receivable has been
classified as non-current loans receivable - related parties on the consolidated balance sheets in the amount of $5,000,000 as
of March 31, 2018 and December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UCI&rsquo;s balance sheets at March 31,
2018 and December&nbsp;31, 2017 and statements of income for the three months ended March&nbsp;31, 2018 and 2017 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Balance Sheets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>March 31, 2018</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,595,206</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,872,894</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Receivables, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,862,184</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,618,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,870,831</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,021,520</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,259,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,754,470</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,770,157</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,576,621</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">69,357,885</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">58,844,265</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Liabilities and Stockholders&rsquo;
Deficit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>March
31, 2018<BR>
(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Current liabilities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">64,984,078</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">54,421,532</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,044,340</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,051,952</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,670,533</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,629,219</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,357,885</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">58,844,265</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Statements of Income Operations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>March
31, 2018<BR>
(unaudited)</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2017<BR> (unaudited)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif">Revenues</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">72,665,437</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">46,540,892</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72,154,950</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,757,246</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income before provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">510,487</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,783,646</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">551,800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">713,500</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net (loss) income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(41,313</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,070,146</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Diagnostic Medical Group</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;14, 2016, David C.P. Chen M.D.,
Inc., a California professional corporation doing business as Diagnostic Medical Group (&ldquo;DMG&rdquo;), David C.P. Chen M.D.,
individually (collectively &ldquo;Seller&rdquo;) and APC-LSMA, a designated shareholder professional corporation formed on October&nbsp;15,
2012, which is 100% owned by Dr. Thomas Lam (CEO of APC) and is controlled and consolidated by APC who is the primary beneficiary
of this VIE, entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG for total cash consideration
of $1,600,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC accounts for its investment in DMG
under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&rsquo;s
operations. APC recorded income from this investment of $329,042 and $361,644 for the three months ended March 31, 2018 and 2017,
respectively, in the accompanying consolidated statements of operations. The investment balance was $2,176,453 and $1,847,411 at
March 31, 2018 and December&nbsp;31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pacific Ambulatory Surgery Center, LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PASC, a California limited liability company,
is a multi-specialty outpatient surgery center that is certified to participate in the Medicare program and is accredited by the
Accreditation Association for Ambulatory Health Care. PASC has entered into agreements with organizations such as healthcare service
plans, independent physician practice associations, medical groups and other purchasers of healthcare services for the arrangement
of the provision of outpatient surgery center services to subscribers or enrollees of such health plans. On November&nbsp;15, 2016,
PASC and APC, entered into a membership interest purchase agreement whereby PASC sold 40% of its aggregate issued and outstanding
membership interests to APC for total consideration of $800,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the membership interest
purchase agreement, PASC entered into a management services agreement with NMM, which requires the payment of management fees computed
at predetermined percentage (as defined) of PASC revenues. The term of the management services agreement commenced on the effective
date and extend for a period of 60 months thereafter, and may&nbsp;be extended in writing at the sole option of NMM for an additional
period of 60 months following the expiration of the initial term and is automatically renewed for additional consecutive terms
of three years unless terminated by either party. PASC shall not be permitted to terminate the management services agreement for
any reason during the initial term and, if extended, the extended term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC accounts for its investment in PASC
under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PASC&rsquo;s
operations. APC recorded income (loss) from this investment of $41,953 and $(20,501) for the three months ended March 31, 2018
and 2017, respectively, in the accompanying consolidated statements of income and has an investment balance of $635,151 and $593,198
at March 31, 2018 and December&nbsp;31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Equity Method Investment Summary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investments in other entities &ndash; equity
method consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left">Universal Care, Inc.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,589,253</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,609,455</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">LaSalle Medical Associates &ndash; IPA Line of Business</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,099,975</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,452,767</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Diagnostic Medical Group</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,176,453</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,847,411</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Pacific Medical Imaging &amp; Oncology Center, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,374,668</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,400,693</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pacific Ambulatory Surgery Center, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">635,151</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">593,198</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,875,500</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,903,524</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loan
Receivable</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&nbsp;9, 2017, NMM and APC-LSMA
entered into an agreement with Accountable Health Care IPA (&ldquo;Accountable&rdquo;), a California professional medical corporation,
Signal Health Solutions, Inc. (&ldquo;Signal&rdquo;), a California corporation and George M. Jayatilaka, M.D. (&ldquo;Dr.&nbsp;Jay&rdquo;),
individually, whereby concurrent with the execution of the agreement, APC-LSMA extended a line of credit to Dr. Jay in the principal
amount of $10,000,000 (&ldquo;Dr. Jay Loan&rdquo;) to fund the working capital needs of Accountable ($5,000,000 of which was funded
by APC on behalf of APC-LSMA and the other $5,000,000 was funded by NMM to Dr. Jay). Interest on the Dr. Jay Loan accrues at a
rate that is equal to the prime rate plus 1% (5.75% and 5.50% as of March 31, 2018 and December 31, 2017, respectively) and payable
in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date
of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The Dr. Jay
Loan will not be subordinated. The Dr. Jay Loan shall at all times be secured by a first-lien security interest in shares of Accountable
owned by Dr. Jay. The outstanding balance as of both March 31, 2018 and December 31, 2017 was $10,000,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the funding of the Dr.
Jay Loan, Dr. Jay will loan to Accountable the entire proceeds of the Dr. Jay Loan at the same interest rate and maturity date
as the Dr. Jay Loan (&ldquo;Dr.&nbsp;Jay-Accountable Subordinated Loan&rdquo;). Repayment of the Dr. Jay-Accountable Subordinated
Loan will be subordinated to Accountable&rsquo;s creditors in a manner acceptable to the California Department of Managed Health
Care (&ldquo;DMHC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time on or before the date that
is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the
obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountable&rsquo;s capital stock. At
any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three
years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation,
to convert the then outstanding principal amount into Accountable shares based on Accountable&rsquo;s then-current valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to the funding of the Dr. Jay
Loan, to the extent needed by Accountable for working capital needs as determined by APC-LSMA, APC-LSMA will extend an additional
line of credit in the principal amount up to $8,000,000. The funding mechanism, interest rate and maturity date of such additional
line of credit shall be the same as the Dr. Jay Loan and additional collateral security in Accountable&rsquo;s issued and outstanding
shares will be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a condition of funding the Dr. Jay Loan,
Accountable entered into a management service agreement with NMM on October&nbsp;27, 2017, to commence on the termination of the
Accountable&rsquo;s existing management agreement with MedPoint Management to be effective on December&nbsp;1, 2017 and have a
term of ten (10) years from its effective date. NMM will be responsible for managing 100% of all health plan membership assigned
and delegated to Accountable, and all hospital risk pools. The management service agreement requires the payment of IPA management
fees as set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the initial funding of
the Dr. Jay Loan, the Accountable Board of Directors shall be automatically reconstituted to be comprised of two directors, which
will comprise of Dr. Jay and a director appointed by APC-LSMA. Dr. Jay and APC-LSMA will have two and one votes as a director,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on management&rsquo;s assessment,
Accountable is a variable interest entity, however, the Company does not have the power to the direct the activities of Accountable
that most significantly impact its economic performance and as such, the Company is not the primary beneficiary of Accountable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts
Payable and Accrued Expenses</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s accounts payable and
accrued expenses consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,356,677</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,786,381</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Specialty capitation payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">547,307</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Subcontractor IPA risk pool payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,472,985</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,348,376</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,727,238</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,004,215</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">710,106</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,543,524</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,343,341</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,110,530</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,279,620</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Medical
Liabilities</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s medical liabilities
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2018</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December 31, 2017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 72%"><FONT STYLE="font-size: 10pt"><B>Balance, beginning of period</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">63,972,318</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">18,957,465</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Medical liabilities assumed from Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39,353,540</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Claims paid for previous period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(28,633,287</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(23,075,516</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Incurred health care costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44,634,257</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">121,846,375</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Claims paid for current period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(10,805,984</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(92,476,160</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Adjustments</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(56,478</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(633,386</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Balance, end of period</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">69,110,826</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">63,972,318</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bank
Loan, Lines of Credit and Loan Payable &ndash; Related Party</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Bank Loans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2010, ICC borrowed $4,600,000
loan from a financial institution. The loan bears interest based on the Wall Street Journal &ldquo;prime rate&rdquo; or 4.75% and
4.50% per annum as of March 31, 2018 and December 31, 2017, respectively. The loan is collateralized by one if its shareholders
and the medical equipment ICC owns. The loan matures on December 31, 2018. As of March 31, 2018 and December 31, 2017, the balance
outstanding was $394,783 and $510,391, respectively, and is classified as current liabilities. As of March 31, 2018 and December&nbsp;31,
2017, ICC was in compliance with all affirmative and negative covenants contained in the loan agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Lines of Credit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April&nbsp;2012, NMM entered into a
promissory note agreement with a bank, which was amended on April&nbsp;9, 2016 and April 7, 2017 (as amended, the &ldquo;NMM Business
Loan Agreement&rdquo;). The NMM Business Loan Agreement was amended on April 7, 2017 to increase the loan availability from $10,000,000
to $20,000,000. The interest rate is based on the Wall Street Journal &ldquo;prime rate&rdquo; plus 0.125% or 4.875% and 4.675%
as of March&nbsp;31, 2018 and December 31, 2017, respectively. As of December&nbsp;31, 2017, the Company was not in compliance
with certain financial debt covenant requirements contained in the loan agreement for which NMM obtained a waiver through March
31, 2018. As of March 31, 2018, NMM was in compliance with such financial debt covenant requirements. The loan is personally guaranteed
by 14 former shareholders of NMM, 13 of which are also members of former NMM&rsquo;s board of directors, and a Trust held by NMM&rsquo;s
CEO, each of which guarantees is capped at $1,000,000. The loan is collateralized by substantially all assets of NMM. In October
2017, NMM borrowed $5,000,000 on this line of credit to provide to Accountable Health Care IPA (see Note 6). The line of credit
was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018. The amount outstanding as of both
March 31, 2018 and December 31, 2017 was $5,000,000. As of both March 31, 2018 and December 31, 2017, availability under this line
of credit was $8,300,671.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April&nbsp;2012, APC entered into a
promissory note agreement with a bank, which was amended on April&nbsp;22, 2016 and April 7, 2017 (as amended, the &ldquo;APC Business
Loan Agreement&rdquo;). The APC Business Loan Agreement modifies certain terms of the promissory note agreement in order to (i)
increase the original loan availability amount of $2,000,000 to $10,000,000, (ii)&nbsp;extend the maturity date under the promissory
note agreement to April&nbsp;22, 2018, and (iii) add six additional guarantees. The interest rate is based on the Wall Street Journal
&ldquo;prime rate&rdquo; plus 0.125% or 4.875% and 4.675% as of March&nbsp;31, 2018 and December 31, 2017, respectively. As of
March 31, 2018 and December 31, 2017, the Company was not in compliance with certain financial debt covenant requirements contained
in the loan agreement for which APC obtained a waiver from the bank through June 30, 2018. The loan is personally guaranteed by
14 shareholders of APC, 13 of which are also members of APC&rsquo;s board of directors, and a Trust held by NMM&rsquo;s CEO, each
of which guarantees is capped at $1,000,000. The loan is also collateralized by substantially all assets of APC. No amounts were
drawn on this line during the three months ended March 31, 2018 and no amounts were outstanding as of March 31, 2018 and December&nbsp;31,
2017. As of both March 31, 2018 and December 31, 2017, availability under this line of credit was $9,694,984. The line of credit
was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Standby Letters of Credit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 3, 2017, APAACO established an
irrevocable standby letter of credit with a financial institution (through the NMM Business Loan Agreement) for $6,699,329 for
the benefit of CMS. The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional
one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90
days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&rsquo;s notification
of non-renewal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC established irrevocable standby letters
of credit with a financial institution for a total of $305,016 for the benefit of certain health plans. The standby letters of
credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date,
unless notified by the institution in advance of the expiration date that the letter will be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mezzanine
and Stockholders&rsquo; Equity</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the historical NMM share and per share
information has been adjusted to reflect the exchange ratio from the Merger (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Mezzanine</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>APC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the redemption feature (see Note 2)
of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified
as noncontrolling interests in mezzanine or temporary equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Stockholders&rsquo; Equity</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Quarterly Report
on Form 10-Q, 1,000,970 shares, which are net of 3,039,749 holdback shares and are subject to ApolloMed receiving from those former
NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive
their pro rata portion of ApolloMed common stock and warrants.&nbsp; Pending such receipt, such former NMM shareholders have the
right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness
of the Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given
the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares
on the Effective Date of the Merger.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2018, the Company issued 37,593
shares of the Company&rsquo;s common stock to the Company&rsquo;s Chief Operating Officer for prior services rendered. The stock
price on the date of issuance was $16.80, which resulted in the Company recording $631,562 of share-based compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See options and warrants section below
for common stock issued upon exercise of stock options and stock purchase warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s outstanding stock options
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term<BR> (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif">Options outstanding at January&nbsp;1, 2018</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,141,040</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.95</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">5.79</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">19.81</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(129,536</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Options forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Options outstanding at March&nbsp;31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,041,504</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4.09</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.66</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11.86</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Options exercisable at March&nbsp;31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,041,504</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4.09</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.66</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11.86</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended March 31, 2018,
stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to 54,536 shares
of the Company&rsquo;s common stock, which resulted in the Company issuing 43,201 net shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended March 31, 2018,
stock options were exercised for 75,000 shares of the Company&rsquo;s common stock, which resulted in proceeds of approximately
$479,000. The exercise price ranged from $2.10 to $10.00 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outstanding stock options granted to primary
care physicians to purchase shares of APC&rsquo;s common stock consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term<BR> (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif">Options outstanding at January 1, 2018</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">853,800</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.167</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.75</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">508,864</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Options expired/forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Options outstanding at March&nbsp;31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">853,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.167</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">508,864</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Options exercisable at March&nbsp;31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">853,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.167</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">508,864</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price and the estimated fair value of common stock as of March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense related
to option awards granted to primary care physicians to purchase shares of APC&rsquo;s common stock, recognized over their respective
vesting periods, consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: italic 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.5pt">Contracted physicians and other services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">202,382</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">321,233</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining unrecognized share-based
compensation expense of stock option awards granted to primary care physicians to purchase shares of APC&rsquo;s common stock as
of March 31, 2018 was $1,214,292, which is expected to be recognized over the remaining term of 1.50 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s outstanding warrants
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term<BR> (Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif">Warrants outstanding at January&nbsp;1, 2017</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,648,541</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">9.75</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.74</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">14.25</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(191,625</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Warrants expired/forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,250</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding at March&nbsp;31, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,445,666</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.88</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.69</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6.07</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise&nbsp;Price&nbsp;Per</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Remaining</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Per</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Share</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.50</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">24,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.60</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">24,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.50</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,116,111</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.53</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,116,111</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,455,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,455,555</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11.00</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">850,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4.69</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">850,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11.00</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.50 &ndash;11.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,445,666</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.69</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,445,666</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.88</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarter ended March 31,
2018, common stock warrants were exercised for 191,625 shares of the Company&rsquo;s common stock, which resulted in proceeds
of approximately $1.4 million. The exercise price ranged from $4.00 to $10.00 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Treasury Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC owns 1,682,110 shares of ApolloMed&rsquo;s
common stock as of March 31, 2018, which are legally issued and outstanding but excluded from shares of common stock outstanding
in the condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments
and Contingencies</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Laws and regulations governing the Medicare
program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with
all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential
wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government
review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare
and Medi-Cal programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As risk-bearing organizations, APC and
MMG are required to follow regulations of the DMHC, including maintenance of minimum working capital, tangible net equity (&ldquo;TNE&rdquo;),
cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less
non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At March 31, 2018 and
December 31, 2017, APC was in compliance with these regulations. At March 31, 2018 and December 31, 2017, MMG was not in compliance
with these regulations. As a result, the California DMHC required MMG to develop and implement a corrective action plan (&ldquo;CAP&rdquo;)
for such deficiency. The Company has been in communication with the DMHC regarding MMG&rsquo;s business plans that, if implemented,
could result in a significant reduction in the health plan enrollment assigned to MMG. MMG received confirmation from substantially
all of MMG&rsquo;s direct-contracted health plans, that they have moved membership out of MMG effective May 1, 2018. MMG is currently
working with DMHC on providing a CAP plan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the Company&rsquo;s payor and provider
contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical
services. Such differing interpretations may not come to light until a substantial period of time has passed following contract
implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to
reserves are reflected in current operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Litigation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is involved
in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation
is subject to inherent uncertainty and could have a material adverse effect on the Company&rsquo;s financial condition, cash flows
or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On or about March 23, 2018 and April
3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and
Prospect Medical Systems, Inc. (collectively, &ldquo;Prospect&rdquo;) against MMG, ApolloMed and AMM with Judicial
Arbitration Mediation Services (&ldquo;JAMS&rdquo;), arising out of MMG&rsquo;s purported business plans, seeking damages in
excess of $5 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with
Prospect&rsquo;s current and future economic relationships with its health plans and their members. MMG, ApolloMed and AMM
each disputes the allegations and intends to vigorously defend itself in this matter. At this time, it is too early in the
process to assess the probability of the outcome of this matter and/or amount of loss, if any.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Party Transactions</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&nbsp;16, 2015, APC entered
into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid approximately $22,000 and $34,000, respectively, to Advance Diagnostic Surgery Center for services as a
provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, NMM received approximately $4.6 million and $4.5 million, respectively, in management fees from LMA, which is accounted
for under the equity method based on 25% equity ownership interest held by APC in LMA&rsquo;s IPA line of business (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid approximately $0.4 million and $0.5&nbsp;million, respectively, to PMIOC for provider services, which is
accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid approximately $0.7 million and $0.8&nbsp;million, respectively, to AMG, Inc. for services as a provider.
AMG, Inc. shares common ownership with certain board members of APC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2015, ApolloMed entered into
a note receivable with Rob Mikitarian, a minority owner in APS, in the amount of approximately $150,000. The note accrues interest
at 3% per annum and currently due on demand. As of March 31, 2018 and December 31, 2017, the balance of the note was approximately
$150,000 and is included in other receivables in the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, affiliates wholly-owned by
the Company&rsquo;s officers, including Dr. Lam and Dr. Hosseinion, are reported in the accompanying consolidated statement of
income on a consolidated basis, together with the Company&rsquo;s subsidiaries, and therefore, the Company does not separately
disclose transactions between such affiliates and the Company&rsquo;s subsidiaries as related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid approximately $1.6 million and $1.4&nbsp;million, respectively, to DMG for provider services, which is
accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, NMM paid approximately $0.3&nbsp;million to Medical Property Partners (&ldquo;MPP&rdquo;) for office lease. MPP
shares common ownership with certain board members of NMM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid approximately $90,000 to Tag-2 Medical Investment Group, LLC (&ldquo;Tag-2&rdquo;) for office lease. Tag-2
shares common ownership with certain board members of APC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March&nbsp;31,
2018 and 2017, APC paid an aggregate of approximately $9.2 million and $12.8 million, respectively, to shareholders of APC for
provider services, which include approximately $2.3&nbsp;million and $5.4 million, respectively, to shareholders who are also officers
of APC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For loans receivable from related parties,
see Note 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
Recognition</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the adoption of Topic 606, the majority
of what was previously classified as the provision for bad debts in the consolidated statements of income is now reflected as implicit
price concessions and, therefore, included as a reduction to revenues starting in 2018. For changes in credit issues not assessed
at the date of service, the Company will prospectively recognize those amounts in operating expenses in the condensed consolidated
statements of income.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the cumulative effect of initially
applying the new revenue standard is required to be presented as an adjustment to the opening balance of retained earnings. This
cumulative effect amount was determined to be related to the full risk pool arrangements of APC, a variable interest entity (see
Note 1). Therefore, the cumulative net effect of initially applying Topic 606 in the amount of $10,208,000, which is comprised
of $11,600,000 of additional revenue, offset by $1,392,000 in related management fee expense, has been presented as an adjustment
to the opening balance of the mezzanine equity, &ldquo;Noncontrolling interest in Allied Pacific of California IPA.&rdquo; Consequently,
as a result of APC recording additional receivables, NMM recorded a corresponding entry of $1,392,000 to retained earnings to record
the related management fee income. These adjustments were offset by an aggregate adjustment to deferred tax liability of $3,246,098.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of this ASU did not have
a significant impact on the Company&rsquo;s revenue, when comparing the amount of revenue recognized for the three months ended
March 31, 2018 to the revenue that would have been recognized under the prior revenue standard ASC 605, such that comparisons
of revenues and operating profit performance between periods are not affected by the adoption of this ASU.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cumulative effect of changes made
to the Company&rsquo;s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Balance at<BR> December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Adjustments<BR> due to Topic 606</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Balance at <BR> January 1, 2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; padding-left: 9pt">Receivables</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">20,117,304</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">11,600,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">31,717,304</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Liabilities, Mezzanine Equity and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Noncurrent Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Deferred tax liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,916,598</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,246,098</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">28,162,696</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Mezzanine equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Noncontrolling interest in Allied Pacific of California IPA</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">172,129,744</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,351,434</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">179,481,178</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Retained earnings</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,734,531</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,002,468</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,736,999</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as one reportable
segment, the healthcare delivery segment. The Company disaggregates revenue from contracts by service type and by payor. This
level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and
by type of direct contracts. The condensed consolidated statements of income presents disaggregated revenue by service type. The
following table presents disaggregated revenue generated by each payor type:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>March 31, 2018</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(unaudited)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">March 31, 2017 </FONT><BR>
<FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-size: 10pt">Commercial</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">105,350,102</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">83,848,918</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medicare</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18,541,115</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,453,703</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medicaid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">176,350</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Other third parties</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">99,160</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">33,441</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Revenue</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">124,166,727</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">85,336,062</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from the
following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered
by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third party payors (e.g., hospitals); and (v)
individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the
Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.75pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.75pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives a significant
portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare
and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject
to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided and
cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the
applicable regulations or contract terms. The services authorized and provided and related reimbursements are often subject to
interpretation that could result in payments that differ from the Company&rsquo;s estimates. Additionally, updated regulations
and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: justify">Settlements under cost reimbursement
agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are
adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid
programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous
technical provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: justify">Under the new revenue standard,
the Company has elected to apply the following practical expedients and optional exemptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 5pt; text-align: justify; text-indent: 21.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recognize
incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs
are recorded within general and administrative expenses.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 5pt; text-align: justify; text-indent: 21.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recognize
revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly
with the value to the customer of the Company&rsquo;s services completed to date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 5pt; text-align: justify; text-indent: 21.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exemptions
from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year
or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice
for services performed, and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance
obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Use
a portfolio approach for the fee-for-service (FFS) revenue stream to group contracts with similar characteristics and analyze
historical cash collections trends.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
adjustment is made for the effects of a significant financing component as the period between the time of service and time of
payment is typically one year or less.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Nature of Services and Revenue Streams</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue primarily consists of capitation
revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&ldquo;AIPBP&rdquo;) revenue, management
fee income, MSSP surplus revenue and FFS revenue. Revenue is recorded in the period in which services are rendered. The form of
billing and related risk of collection for such services may&nbsp;vary by type of revenue and the customer. The following is a
summary of the principal forms of the Company&rsquo;s billing arrangements and how revenue is recognized for each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Capitation, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Managed care revenues of the Company consist
primarily of capitated fees for medical services provided by the Company under either provider service agreements (each, a &ldquo;PSA&rdquo;)
or capitated arrangements directly made with various managed care providers including HMOs. Capitation revenue under the PSAs
and HMO contracts is prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare
provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments
to prior months&rsquo; capitation, primarily arising from contracted HMOs finalizing of monthly patient eligibility data for additions
or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation
using a &ldquo;Risk Adjustment model,&rdquo; which compensates managed care organizations and providers based on the health status
(acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with
lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using
patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year
and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for
Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the
Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment
are recognized when those changes are communicated by the health plans to the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.65pt 0pt 2pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per member per month (PMPM)
managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation
that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration
of the contract. The transaction price for PMPM contracts is variable as it primarily includes per member per month fees associated
with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for
items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price
using the most likely methodology and amounts are only included in the net transaction price to the extent that it is probable
that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&rsquo;s
net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g.
day or month) and is recognized as revenue in the month in which members are entitled to service.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.65pt 0pt 2pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Risk Pool Settlements and Incentives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APC and APAACO enter into full risk capitation arrangements with certain health plans and local hospitals,
which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional
risk and APC and APAACO is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing
agreement, APC and APAACO generally receives a percentage of the net surplus from the affiliated hospital&rsquo;s risk pools with
HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if
there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely
methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative
revenue will not occur once any uncertainty is resolved. The assumptions for IBNR completion factor and constraint percentages
were used by management in applying the most likely method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under capitated arrangements with certain
HMOs, APC and APAACO participates in one or more shared risk arrangements relating to the provision of institutional services
to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization
of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered
by the health plan, where APC and APAACO is responsible for rendering professional services, but the health plan does not enter
into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits,
if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination
of the HMO contract, any accumulated deficit will be extinguished. Risk pool settlements under arrangements with HMOs are recognized
using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant
reversal of cumulative revenue will not occur once any uncertainty is resolved. Risk pools for the prior contract years are generally
final settled in the third or fourth quarter of the following year. As APAACO does not have sufficient insight into the financial
performance of the shared risk pool with CMS because of unknown factors related to IBNR, risk adjustment factors, stop loss provisions,
etc., an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that
will probably not be reversed in the future and therefore this shared risk pool revenue is considered to be fully constrained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to risk-sharing revenues, the
Company also receives incentives under &ldquo;pay-for-performance&rdquo; programs for quality medical care, based on various criteria.
As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed the quality incentive programs
and commercial generic pharmacy incentive programs to compensate the Company for efforts it takes to improve the quality of services
and for efficient and effective use of pharmacy supplemental benefits provided to the HMO&rsquo;s members. The incentive programs
track specific performance measures and calculate payments to the Company based on the performance measures. Incentives under &ldquo;pay-for-performance&rdquo;
programs are recognized using the most likely methodology. As the Company does not have sufficient insight from the health plans
on the amount and timing of the incentive payments, this revenue is considered to be fully constrained and is only recorded when
such payments are received.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally for the foregoing
arrangements, the final settlement is dependent on each distinct day&rsquo;s performance within the annual measurement period but
cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this
is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e. the contract
year), to the extent the risk of reversal does not exist and the consideration is not constrained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>NGACO AIPBP Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the NGACO Model, CMS grants the Company
a pool of patients to manage (direct care and pay providers) based on a budget established with CMS. The Company is responsible
for managing medical costs for these patients. The patients will receive services from physicians and other medical service providers
that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network
providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable
for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by
in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which
the providers are ultimately paid. Claims from out-of-network providers are processed or paid by CMS and the Company&rsquo;s profits
or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation
with CMS. Pursuant to the Company&rsquo;s risk share agreement with CMS, the Company will be eligible to receive the surplus or
be liable for the deficit according to the budget established by CMS based on the Company&rsquo;s efficiency or lack thereof, respectively,
in managing how the patients assigned to the Company by CMS are served by in-network and out-of-network providers. The Company&rsquo;s
profits or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments
can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes
such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. In accordance with the
guidance in ASC 606-10-55-36 through 55-40 on principal versus agent considerations, the Company records such revenues in the gross
amount of consideration.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also has arrangements for billing
and payment services with the medical providers within the NGACO network. The Company retains certain defined percentages of the
payments made to the providers in exchange for using the Company&rsquo;s billing and payment services. The revenue for this service
is earned as payments are made to medical providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">APAACO and CMS entered into a Next Generation
ACO Model Participation Agreement (the &ldquo;Participation Agreement&rdquo;) with a term of two performance years through December
31, 2018. CMS may offer to renew the Participation Agreement for additional terms of two performance years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For each performance year, the Company
shall submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits
enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent
before voluntarily discontinuing any benefit enhancement during a performance year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For each performance year, CMS shall pay
the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement
for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of
each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement
report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies owed. If CMS
owes the Company shared savings or other monies owed, CMS shall pay the Company in full within 30 days after the date on which
the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared
losses or other monies owed as a result of a final settlement, the Company shall pay CMS in full within 30 days after the relevant
settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of
a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare
debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may
use any applicable debt collection tools available to collect any amounts owed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company participates in the AIPBP track
of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&rsquo;s assigned patients and
pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs
for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As it relates specifically to the Company&rsquo;s
Participation Agreement with CMS, the Company recognizes capitation revenue in the month in which the Company is obligated to provide
services. Also, because the Company&rsquo;s arrangement with CMS is new (became effective in 2017), numerous factors create uncertainty
regarding the risk pool settlement and incentive amounts that the Company is entitled to receive and limited historical data exists
to develop reasonable and reliable estimates. As a result, the Company recognizes revenue from risk pool settlements and incentives
under the arrangement with CMS in the period in which amounts are estimable and collection is reasonably assured. The Company will
continue to evaluate and assess the reliability and reasonableness of data available to it in order develop future estimates, and
will recognize risk pool settlements and incentives revenue based on such estimates only to the extent it is probable that a significant
reversal of cumulative revenue will not occur in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, CMS notified the Company
that it would not be renewed for participation in the AIPBP payment mechanism of the NGACO Model for performance year 2018 due
to certain alleged deficiencies in performance. The Company submitted a reconsideration request. In December 2017, the Company
received the official decision on its reconsideration request that CMS reversed the prior decision against the Company&rsquo;s
continued participation in the AIPBP mechanism. As a result, the Company is eligible for receiving monthly AIPBP payments currently
at a rate of approximately $7.3 million per month from CMS starting February 2018. The Company, however, will need to continue
to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate
in the AIPBP mechanism and/or NGACO Model.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Management Fee Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management fee income encompasses fees
paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company
to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages
of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements
measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may
be subject to achieving quality metrics or fee collections. Such variable supplemental revenues are recognized as revenue in the
period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the
terms of the respective agreement. The Company&rsquo;s MSA revenue also includes revenue sharing payments from the Company&rsquo;s
partners based on their non-medical services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company provides a significant service
of integrating the services selected by the Company&rsquo;s clients into one overall output for which the client has contracted.
Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&rsquo;s performance
obligation is to stand ready to provide services over the contractual period. Also, the Company&rsquo;s performance obligation
forms a series of distinct periods of time over which the Company stands ready to perform. The Company&rsquo;s performance obligation
is satisfied as the Company completes each period&rsquo;s obligations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consideration from management contracts
is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period
to period. The Company has control over pricing. Contractual fees are invoiced to the Company&rsquo;s clients generally monthly
and payment terms are typically due within 30 days. The variable consideration in the Company&rsquo;s management contracts meets
the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed
to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects
to be entitled.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s management contracts
generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the respective contracts.
Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance
obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation
of the transaction price to remaining performance obligations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Medicare Shared Savings Program Surplus
Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company participates in the MSSP, which
is sponsored by CMS. The goal of the MSSP is to improve the quality of patient care and outcomes through a more efficient and coordinated
approach among providers. The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical
services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated
by the ACO participant relative to the ACO participants&rsquo; cost savings benchmark. Revenues earned by the Company are uncertain,
and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and will be
contingent on various factors, including achievement of the minimum savings rate as determined by MSSP for the relevant period.
Such payments are earned and made on an &ldquo;all or nothing&rdquo; basis. The Company considers revenue, if any, under the MSSP,
as contingent upon the realization of program savings as determined solely by CMS, which are subject to significant estimation
risk. Accordingly, they are not recognized as revenue until the amounts are estimable and collection is reasonably assured, which
is generally when notice is received from CMS that cash payments are to be imminently received.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fee-for-Service Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FFS revenue represents revenue earned
under contracts in which the Company bills and collects the professional component of charges for medical services rendered by
the Company&rsquo;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals
and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services
provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and
policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided
are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. The recognition of
net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of
medical charts following a patient visit, the forwarding of such charts to the Company&rsquo;s billing center for medical coding
and entering into the Company&rsquo;s billing system and the verification of each patient&rsquo;s submission or representation
at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the
information known at the time of entering of such information into the Company&rsquo;s billing systems as well as an estimate
of the revenue associated with medical services.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible for confirming
member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial
risk of loss associated with services rendered, as specified within the Company&rsquo;s client contracts. The Company has the ability
to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors
indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consideration from FFS arrangements is
variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all
of which can vary from period to period.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Contract Assets</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, revenues and receivables are
recognized once the Company has satisfied its performance obligation. Accordingly, the Company&rsquo;s contract assets comprise
accounts receivable. Generally, the Company does not have material amounts of other contract assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Contract Liabilities (Deferred Revenue</U>)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract liabilities are recorded when
cash payments are received in advance of the Company&rsquo;s performance, which is generally uncommon. The Company&rsquo;s contract
liability balance was $710,106 and $250,000 as of March 31, 2018 and December 31, 2017, respectively, and is presented within the
&ldquo;Accounts Payable and Accrued Expenses&rdquo; line item of the condensed consolidated balance sheets. None of the amounts
accrued as of December 31, 2017 was recognized as revenue for the three months ended March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the U.S. government
enacted comprehensive tax legislation known as the Tax Cuts and Jobs Act (the &ldquo;TCJA&rdquo;). The TCJA establishes new tax
laws that will take effect in 2018, including, but not limited to (1) a reduction of the U.S. federal corporate tax rate from
a maximum of 35% to 21%; (2) elimination of the corporate alternative minimum tax; (3) a new limitation on deductible interest
expense; (4) limitations on the deductibility of certain executive compensation; (5) changes to the bonus depreciation rules for
fixed asset additions; and (6) limitations on net operating losses generated after December 31, 2017, to 80% of taxable income.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 740, Income Taxes, generally requires
the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity
and significance of the TCJA&rsquo;s provisions, the SEC staff issued Staff Accounting Bulletin 118 (&ldquo;SAB 118&rdquo;), which provides
guidance on accounting for the tax effects of the TCJA. SAB 118 provides a measurement period that should not extend beyond one
year from the TCJA enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company
must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent
that a company&rsquo;s accounting for certain income tax effects of the TCJA is incomplete but it is able to determine a reasonable
estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate
to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws
that were in effect immediately before the enactment of the TCJA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2018 and December 31, 2017,
the Company did not complete its accounting for the tax effects of enactment of the TCJA; however, the Company has made a reasonable
estimate of the effects of the TCJA&rsquo;s change in the federal rate and revalued its deferred tax assets based on the rates
at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable
state tax rate. The Company recorded a decrease in its deferred tax assets and deferred tax liabilities of $6.6 million and $16.3
million, respectively, with a corresponding net adjustment to deferred income tax benefit of $9.7 million,&nbsp;for the year ended
December 31, 2017. The Company&rsquo;s provisional estimates are expected to be adjusted during the measurement period defined
under SAB 118, based upon ongoing analysis of data and tax positions along with the new guidance from regulators and interpretations
of the TCJA. The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability
method, deferred taxes are determined based on the differences between the Company&rsquo;s financial statements and tax bases
of assets and liabilities using enacted tax rates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an interim basis, the Company estimates
what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with
the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the year progresses,
the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant
changes to the Company&rsquo;s estimated effective tax rate. If and when this occurs, the income tax provision (benefit) will be adjusted
during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective
tax rate. These changes, along with adjustments to the Company&rsquo;s deferred taxes and related valuation allowance, may create fluctuations
in the Company&rsquo;s overall effective tax rate from quarter to quarter.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018, due to overall cumulative
losses incurred, prior to the merger with NMM, in recent years, the Company maintained a full valuation allowance against its deferred
tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these
assets is uncertain. The Company&rsquo;s effective tax rate for the three months ended March 31, 2018 differed from the U.S. federal
statutory rate primarily due to state income taxes. As of March 31, 2018, the Company does not have any unrecognized tax benefits
related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized
tax benefits in income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to U.S. federal
income tax as well as income tax in California. The Company and its subsidiaries&rsquo; state and Federal income tax returns are open
to audit under the statute of limitations for the years ended December 31, 2013 through December 31, 2016 and for the years ended
December 31, 2014 through December 31, 2016, respectively. The Company currently does not anticipate material unrecognized tax
benefits within the next 12 months.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Earnings
Per Share</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income per share is calculated
using the weighted average number of shares of the Company&rsquo;s common stock issued and outstanding during a certain period,
and is calculated by dividing net income by the weighted average number of shares of the Company&rsquo;s common stock issued and
outstanding during such period. Diluted net income per share is calculated using the weighted average number of shares of common
stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured
convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, ApolloMed
held back 10% of the shares of its common stock that were issuable to NMM shareholders (&ldquo;Holdback Shares&rdquo;) to secure
indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up
to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed
may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback
Shares are excluded from the computation of basic earnings per share, but included in diluted earnings per share. As of both March
31, 2018 and 2017, APC held 1,682,110 shares of ApolloMed&rsquo;s and NMM&rsquo;s common stock, which are treated as treasury shares
for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share
(see Note 10).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of the earnings per
share computations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-indent: -4.5pt; padding-left: 4.5pt">Earnings per share &ndash; basic</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.07</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.17</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -4.5pt; padding-left: 4.5pt">Earnings per share &ndash; diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.06</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -4.5pt; padding-left: 4.5pt">Weighted average shares of common stock outstanding &ndash; basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,421,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,067,954</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -4.5pt; padding-left: 4.5pt">Weighted average shares of common stock outstanding &ndash; diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,098,373</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">28,445,647</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below is a summary of the shares included in the diluted earnings
per share computations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Three Months Ended March&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif; text-indent: -4.5pt; padding-left: 4.5pt">Weighted average shares of common stock outstanding &ndash; basic</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">32,421,467</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right">25,067,954</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -4.5pt; padding-left: 4.5pt">10% shares held back pursuant to indemnification clause</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,039,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,785,328</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -4.5pt; padding-left: 4.5pt">Stock options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">835,790</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">592,365</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -4.5pt; padding-left: 4.5pt">Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,801,367</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -4.5pt; padding-left: 4.5pt">Weighted average shares of common stock outstanding &ndash; diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,098,373</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">28,445,647</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Variable
                                         Interest Entities (VIEs)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A VIE is defined as a legal entity whose
equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the
following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected
residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to
direct the activities of the VIE that most significantly affect the entity&rsquo;s economic performance and the obligation to absorb
expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s VIEs include APC and
other immaterial entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets recognized as a result of consolidating
these VIEs do not represent additional assets that could be used to satisfy claims against the Company&rsquo;s general assets.
Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on the Company&rsquo;s
general assets; rather, they represent claims against the specific assets of the VIE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates its relationships
with its VIEs on an ongoing basis to ensure that it continues to be the primary beneficiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table includes assets that
can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities,
with the exception of the investments in other entities &ndash; cost method and amounts due to affiliate, which are eliminated
upon consolidation with the NMM, are included in the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>March 31,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><B>2018</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">58,024,188</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">54,686,370</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Restricted cash &ndash; short-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,028,116</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,005,661</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Fiduciary cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,386,474</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,017,437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment in marketable securities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,061,022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,057,090</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Receivables, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,844,184</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,183,483</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,960,737</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,821,328</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">119,304,721</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">92,771,369</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Noncurrent assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Land, property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,201,045</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,167,689</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Intangible assets, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,670,837</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,841,907</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,012,316</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,012,316</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Loans receivable &ndash; related parties</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Loan receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investments in other entities &ndash; equity method</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,875,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,903,524</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investments in other entities &ndash; cost method</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,320,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,320,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Restricted cash &ndash; long-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">745,293</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">745,235</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Other assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,155,114</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,371,664</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total noncurrent assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">175,980,105</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">179,362,335</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">295,284,826</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">272,133,704</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,505,047</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,625,610</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Incentives payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,900,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Fiduciary accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,386,474</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,017,437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Medical liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,212,116</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,186,240</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Income taxes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,229,058</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,463,540</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amount due to affiliate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,061,953</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,889,717</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Bank loan, short-term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">394,783</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">510,391</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Capital lease obligations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">99,480</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">98,738</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">76,788,911</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">79,291,673</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Noncurrent liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Deferred tax liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,406,818</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20,970,766</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Liability for unissued equity shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,185,025</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,185,025</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Capital lease obligations, net of current portion</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">593,852</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">619,001</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total noncurrent liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">29,185,695</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,774,792</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">105,974,606</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">102,066,465</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The assets of the Company&rsquo;s
other consolidated VIEs were not considered significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately $18,000,000 of restricted
cash is related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), was held for distribution
to former NMM shareholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent
                                         Events</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2018, NMM distributed approximately
$10,000,000 to former NMM shareholders, which was previously classified as restricted cash and dividends payable as of March 31,
2018, with $8,000,000 of restricted cash resulting from the Merger continuing to be held for distribution.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2018, APC acquired a 50% membership
interest in a joint venture limited liability company. The joint venture entered into an agreement, effective as of April 10, 2018,
to purchase real property of approximately 109,000 square feet including a building containing approximately 89,000 rentable square
feet situated in the City of Los Angeles, and provided a securing deposit into an escrow account. The transaction is expected to
close on May 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: yellow"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="item2"></A>ITEM 2.&nbsp;&nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following management&rsquo;s discussion
and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto
included in Part I, Item 1, &ldquo;Financial Statements&rdquo; of this Quarterly Report on Form 10-Q. In addition, reference is
made to our audited consolidated financial statements and notes thereto and related Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the year ended December&nbsp;31,
2017, filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on April 2, 2018.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following management&rsquo;s discussion
and analysis contain forward-looking statements that reflect our plans, estimates, and beliefs as discussed in the &ldquo;Forward-Looking
Statements&rdquo; at the beginning of this Quarterly Report on Form 10-Q. Our actual results could differ materially from those
plans, estimates, and beliefs. Factors that could cause or contribute to these differences include those discussed below and elsewhere
in this Quarterly Report on Form 10-Q as well as the factors discussed in Part I, Item 1A, &ldquo;Risk Factors&rdquo; in our most
recent Annual Report on Form 10-K.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We together with
our affiliated physician groups and consolidated entities are a physician-centric integrated population health management company
working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority
of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (&ldquo;HMOs&rdquo;),
with a small portion of our revenue coming from non-insured patients. We provide care coordination services to each major constituent
of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative
sites of inpatient care, physician groups and health plans. Our physician network consists of primary care physicians, specialist
physicians and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&ldquo;ApolloMed&rdquo;) and the following
subsidiaries: Network Medical Management (&ldquo;NMM&rdquo;), Apollo Medical Management, Inc. (&ldquo;AMM&rdquo;), APA ACO, Inc.
(&ldquo;APAACO&rdquo;) and Apollo Care Connect, Inc. (&ldquo;Apollo Care Connect&rdquo;), and their consolidated entities, including
consolidated VIEs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Led by a management
team with over a decade of experience, we have built a company and culture that is focused on physicians providing high-quality
medical care, population health management and care coordination for patients. We believe that we are well-positioned to take advantage
of the growing trends in the U.S. healthcare industry towards value-based and results-oriented healthcare focusing on the triple
aim of patient satisfaction, high-quality care and cost efficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through our next generation
accountable organization (&ldquo;NGACO&rdquo;) model and a network of independent practice associations (&ldquo;IPAs&rdquo;) with
more than 4,000 contracted physicians, which physical groups have agreements with various health plans, hospitals and other HMOs,
we are currently responsible for coordinating the care for over one million patients in California. These covered patients are
comprised of managed care members whose health coverage is provided through their employers or who have acquired health coverage
directly from a health plan or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit
from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques
and clinical protocols to provide high-quality, cost effective care. To implement a patient-centered, physician-centric experience,
we also have other integrated and synergistic operations, including (i) MSOs that provide management and other services to our
affiliated IPAs, (ii) outpatient clinics and (iii) hospitalists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following describes
certain developments from 2017 to date that are important to understanding our overall results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Consummation of Merger</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 8, 2017, ApolloMed completed its business combination with NMM following the satisfaction
or waiver of the conditions set forth in the Agreement and Plan of Merger, dated as of December 21, 2016 (as amended on March 30,
2017 and October 17, 2017), among ApolloMed, Apollo Acquisition Corp. (&ldquo;Merger Sub&rdquo;), NMM and Kenneth Sim, as the shareholders&rsquo;
representative (the &ldquo;Merger Agreement&rdquo;), pursuant to which Merger Sub merged with and into NMM, with NMM surviving
as a wholly owned subsidiary of ApolloMed (the &ldquo;Merger&rdquo;). The combination of ApolloMed and NMM brings together two
complementary healthcare organizations to form one of the nation&rsquo;s largest integrated population health management companies.
As a result of the Merger, NMM now is a wholly-owned subsidiary of ApolloMed and former NMM shareholders own a majority of the
issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a &ldquo;reverse acquisition&rdquo;
and NMM is considered the accounting acquirer. Accordingly, as of the closing of the Merger, NMM&rsquo;s historical results of
operations replaced ApolloMed&rsquo;s historical results of operations for periods prior to the Merger, and the results of operations
of both companies are included in the accompanying condensed consolidated financial statements for periods following the Merger.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each issued and outstanding
share of NMM&rsquo;s common stock was converted into the right to receive such number of shares of ApolloMed&rsquo;s common stock
that results in the former NMM shareholders who did not dissent from the Merger (the &ldquo;former NMM Shareholders&rdquo;) having
a right to receive an aggregate of 30,397,489 shares of ApolloMed&rsquo;s common stock, subject to the 10% holdback as described
below, (A) without taking into account (i) shares of ApolloMed&rsquo;s common stock issuable upon the conversion of the Alliance
Note as described below, and (ii) shares of ApolloMed&rsquo;s common stock issuable upon the exercise of any common stock warrants
issued in connection with the Merger, and (B) without giving effect to shares of ApolloMed&rsquo;s common stock issuable upon payment
of any indemnification obligations under the Merger Agreement. Immediately following the closing of the Merger, ApolloMed&rsquo;s
stockholders prior to the Merger continued to hold an aggregate of 6,109,205 shares of its common stock. In connection with the
Merger, ApolloMed issued to the former NMM Shareholders (i) common stock warrants to purchase an aggregate of 850,000 shares of
ApolloMed&rsquo;s common stock, exercisable at $11.00 per share, and (ii) common stock warrants to purchase an aggregate of 900,000
shares of ApolloMed&rsquo;s common stock, exercisable at $10.00 per share. ApolloMed held back an aggregate of 3,039,749 shares
of ApolloMed&rsquo;s common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed&rsquo;s
common stock issuable to former NMM Shareholders, to secure indemnification rights of ApolloMed and its affiliates under the Merger
Agreement. ApolloMed had previously issued a convertible promissory note (the &ldquo;Alliance Note&rdquo;) to Alliance Apex, LLC
in the principal amount of $4,990,000. Following the closing of the Merger, the Alliance Note and accrued interest automatically
converted into 520,081 shares of ApolloMed&rsquo;s common stock. Immediately prior to the closing of the Merger, NMM made a distribution
to the former NMM Shareholders on a pro-rata basis of its Series A warrant to purchase an aggregate of 1,111,111 shares of ApolloMed&rsquo;s
common stock and its Series B warrant to purchase an aggregate of 555,555 shares of ApolloMed&rsquo;s common stock. Similarly,
if one or more indemnification rights of the former NMM Shareholders are triggered, additional shares of ApolloMed&rsquo;s common
stock (capped at the same number of shares that are subject to the holdback for the indemnification of ApolloMed and its affiliates)
will be issued to the former NMM Shareholders on a pro rata basis based on their relative proportionate pre-Merger ownership interests
in NMM. Following the closing of the Merger, NMM, as ApolloMed&rsquo;s subsidiary, continues to hold 1,111,111 shares of ApolloMed&rsquo;s
Series A preferred stock and 555,555 shares of ApolloMed&rsquo;s Series B preferred stock, which are considered to be issued and
not outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Change in Fiscal Year</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the effective
time of the closing of the Merger, our board of directors approved a change in our fiscal year-end from March 31 to December 31,
to correspond with the fiscal year-end of NMM prior to the Merger. As a result, our first fiscal year-end following the Merger
was December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Post-Merger Integration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing
of the Merger, we evaluated the sustainability of our subsidiaries and VIEs and opportunities to strengthen our operations. As
a result of such evaluation, we decided to consolidate our operations and restructure the operations of certain entities, which
include the winding down of the BAHA and APS operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion to NGACO</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operated three MSSP
ACOs, AP-ACO, APCN-ACO and Apollo-ACO. Following the establishment of APAACO, our NGACO, and the selection of APAACO by CMS to
participate in the NGACO Model, we have converted physicians and patients from our MSSP ACOs to our NGACO. As providers continue
to enroll in our NGACO and their patients become beneficiaries under our NGACO, we have transitioned the three MSSP ACOs&rsquo;
operations. To position ourselves to participate in the NGACO Model, we have devoted, and intend to continue to devote, significant
effort and resources, financial and otherwise, to the NGACO Model, and refocused away from certain other parts of our historic
business and revenue streams, which will receive less emphasis in the future and could result in reduced revenue from these activities.
Our NGACO currently is eligible for receiving monthly AIPBP payments at a rate of approximately $7.3 million per month from CMS.
We currently anticipate that revenue from the NGACO Model will be a significant source of revenue for us in fiscal 2018 and future
periods, although no assurance of that can be given at this time. AP-ACO terminated its participation in the MSSP effective as
of December 31, 2016, and APCN-ACO and Apollo-ACO terminated their participation in the MSSP effective as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Strategic Transactions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2017, with
an effective date of December 1, 2017, NMM entered into a ten-year Management Services Agreement (&ldquo;MSA&rdquo;) with Accountable
Health Care IPA (&ldquo;Accountable IPA&rdquo;), one of the largest IPAs in California, which provides quality healthcare services
to more than 160,000 patients through a network of over 450 primary care physicians and 1,700 specialty care physicians and has
multiple product lines, including Medicare Advantage, Commercial, Medi-Cal managed care and Healthy Families.&nbsp;Pursuant to
the terms of the ten-year MSA, NMM is responsible for managing all health plan members assigned or delegated to Accountable IPA,
as well as all hospital risk pools.&nbsp;This effort is expected to be supported by our population health management platform,
which includes administrative, clinical and technology capabilities. One of our VIEs has extended a line of credit of up to $18
million to George M. Jayatilaka, M.D. a shareholder of Accountable IPA, to fund the working capital needs of Accountable IPA. The
VIE has the right, but not the obligation, to convert a portion or all of the outstanding principal amount into shares of Accountable
IPA&rsquo;s capital stock.&nbsp;Concurrent with the funding, the board of directors of Accountable IPA was reconstituted to be
comprised of two directors, including one director appointed by APC-LSMA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NMM entered into a
MSA with Joseph M. Molina, M.D., Professional Corporation &ndash; Southern California dba Golden Shore Medical Group, a California
professional corporation (&ldquo;GSMG&rdquo;), which provides quality healthcare services to more than 100,000 patients and operates
17 clinics in four California counties. The MSA requires the payment of management fees in accordance with the management fee schedule
therein. The initial term of the MSA commenced on January 1, 2018 and will expire on December 31, 2020. The MSA may be extended
in writing at the sole option of GSMG for an additional two-year term following the expiration of the initial term. GSMG will have
the right to terminate the MSA if certain conditions, as defined in the MSA, are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have expanded our
operations, including hiring a significant number of employees and engaging other personnel, in preparation of serving additional
patients that we are responsible for managing under the Accountable IPA and GSMG MSAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sixth Amendment to the NNA Registration
Rights Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, ApolloMed
entered into a Sixth Amendment (the &ldquo;Sixth Amendment&rdquo;) with NNA of Nevada, Inc. (&ldquo;NNA&rdquo;), an affiliate of
Fresenius Medical Care North America. The Sixth Amendment amended the Registration Rights Agreement, dated as of March 28, 2014,
between ApolloMed and NNA, as subsequently amended, to extend (i) the deadline for ApolloMed to file a resale registration statement
covering NNA&rsquo;s registrable securities to November 30, 2018, and (ii) the date by which ApolloMed is required to use commercially
reasonable best efforts to cause such registration statement to be declared effective to May 31, 2019 (or, if earlier, the fifth
(5th) trading day after the date on which the SEC notifies ApolloMed that such registration statement will not be &ldquo;reviewed&rdquo;
or will not be subject to further review).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compliance with the California Department
of Managed Health Care (&ldquo;DMHC&rdquo;)<BR>
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As risk-bearing organizations,
APC and MMG are required to follow regulations of the DMHC, including maintenance of minimum working capital, tangible net equity
(&ldquo;TNE&rdquo;), cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net equity
less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.
At March 31, 2018 and December 31, 2017, APC was in compliance with these regulations. At March 31, 2018 and December 31, 2017,
MMG was not in compliance with these regulations. As a result, the California DMHC required MMG to develop and implement a corrective
action plan (&ldquo;CAP&rdquo;) for such deficiency. The Company has been in communication with the DMHC regarding MMG&rsquo;s
business plans that, if implemented, could result in a significant reduction in the health plan enrollment assigned to MMG. MMG
received confirmation from substantially all of MMG&rsquo;s direct contracted health plans, that they have moved membership out
of MMG effective May 1, 2018. MMG is currently working with DMHC on providing a CAP plan.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Purchase of Real Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2018, APC
acquired a 50% membership interest in a joint venture limited liability company. The joint venture entered into an agreement, effective
as of April 10, 2018, to purchase real property of approximately 109,000 square feet including a building containing approximately
89,000 rentable square feet situated in the City of Los Angeles, and provided a securing deposit into an escrow account. The transaction
is expected to close on May 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Financial Measures and Indicators</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenue primarily
consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&ldquo;AIPBP&rdquo;)
revenue, management fee income and fee-for-services (&ldquo;FFS&rdquo;) revenue. The form of billing and related risk of collection
for such services may&nbsp;vary by type of revenue and the customer.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our largest expense
is the patient care cost paid to contracted physicians, cost of hiring staff to provide management and administrative support services
to our affiliated physician groups, as further described below. These services include payroll, benefits, human resource services,
physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and
other consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Apollo Medical Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">For the Three Months Ended</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">March 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">March 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">$ Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">REVENUE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-left: 9pt">Capitation, net</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">85,905,284</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">64,716,133</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">21,189,151</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">33</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Risk pool settlements and incentives</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,986,736</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,137,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,849,536</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">62</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Management fee income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,074,572</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,537,110</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,537,462</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">85</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Fee-for-services, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,748,109</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,663,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,084,196</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">191</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">452,026</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">281,706</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">170,320</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">124,166,727</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">85,336,062</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38,830,665</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">EXPENSES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">Cost of services</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84,670,608</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">59,607,514</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,063,094</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,735,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,211,633</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,524,265</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,058,512</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,836,351</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">222,161</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">101,465,018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69,655,498</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">31,809,520</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">INCOME FROM OPERATIONS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,701,709</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,680,564</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,021,145</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">45</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">OTHER INCOME (EXPENSES):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">(Loss) income from equity method investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(28,024</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,227,262</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,255,286</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-101</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(85,001</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(811</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84,190</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10381</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">269,818</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">182,285</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">87,533</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">Change in fair value of derivative instrument</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,522,222</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,522,222</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-100</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,993</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,514</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">86,479</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5712</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">244,786</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,932,472</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,687,686</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-94</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">INCOME BEFORE PROVISION FOR INCOME TAXES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,946,495</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,613,036</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,333,459</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,228,840</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,889,245</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(660,405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-8</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">15,717,655</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,723,791</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,993,864</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">34</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net income attributable to noncontrolling interests</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,557,200</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,374,130</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,183,070</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">84</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET INCOME ATTRIBUTABLE TO APOLLO MEDICAL HOLDINGS, INC.</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,160,455</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,349,661</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,189,206</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-50</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Net Income
Attributable to Apollo Medical Holdings, Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net income attributable
to Apollo Medical Holdings, Inc. (excluding noncontrolling interests) for the three months ended March 31, 2018 was $2.2 million,
as compared to $4.3 million for the same period in 2017, a decrease of $2.1 million, or 50%. The decrease in net income was due
to post-Merger integration related costs and investments to support two new management services agreements. The Company expects
to substantially complete such integration by the end of the second quarter of 2018 and does not expect any further material expenditures
to support the new contracts beyond the first quarter of 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Physician Groups
and Patients</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2018
and 2017, the total number of affiliated physician groups managed by us was 11 groups, and the total number of patients for whom
we managed the delivery of healthcare services was 962,922 and 795,960, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenue for the
three months ended March 31, 2018 was $124.2 million, as compared to $85.3 million for the same period in 2017, an increase of
$38.8 million, or 46%. The increase in revenue was attributable to (i) an increase of $21.2 million in capitation revenue due to
increase in membership and capitation rates, (ii) an increase of $6.8 million in risk pool revenue due to favorable healthcare
utilization trends, (iii) an increase in management fee income of $5.5 million, which was mainly driven by an increase in the number
of patients served by our affiliated physician groups, (iv) an increase in fees-for-service revenue of $5.1 million, which was
mainly due to increased surgery center income from the increase in patients and fees received, and (v) increases in other income
of $0.2 million. The remaining difference is primarily due to ApolloMed&rsquo;s pre-Merger operations, which did not have any comparable
results from the accounting acquirer (NMM) for the three months ended March 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Cost of Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expenses related to
cost of services for the three months ended March 31, 2018 were $84.7 million, as compared to $59.6 million for the same period
in 2017, an increase of $25.1 million, or 42%. The increase is mainly due to ApolloMed and MMG&rsquo;s operations of $26.5 million
for the three months ended March 31, 2018 compared to zero in the same period of the prior year and the increase of $4.3 million
in medical claims, capitation and other health services expense. This overall increase was offset by the decrease of $5.6 million
for provider bonus and incentive for the three months ended March 31, 2018 compared to the three months ended March 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>General and Administrative
Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the three months ended March 31, 2018 were $11.7 million, as compared to $5.2 million for the same period in 2017,
an increase of $6.5 million, or 125%. The overall increase is mainly due to ApolloMed and MMG&rsquo;s operations of $3.8 million
for the three months ended March 31, 2018 compared to zero in the same period of the prior year, $0.6 million increase in shared-based
compensation expenses, $0.4 million increase in accounting expenses, and $1.1 million increase in reimbursement expenses to Accountable
Health Care IPA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Depreciation
and Amortization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depreciation and amortization
expense for the three months ended March 31, 2018 was $5.1 million, as compared to $4.8 million for the same period in 2017, an
increase of $0.2 million, or 5%. The increase was attributable to additional property and equipment purchased during 2017 and the
addition of intangible assets from the Merger, offset by a reduction of intangible assets from impairment recorded in the fourth
quarter of 2017. The remaining difference is primarily due to ApolloMed&rsquo;s pre-Merger operations, which did not have any comparable
results from the accounting acquirer (NMM) for the three months ended March 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>(Loss) Income
from Equity Method Investments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(Loss) income from
equity method investments for the three months ended March 31, 2018 were $(28,000), as compared to $2.2 million for the same period
in 2017, a decrease of $2.3 million, or 101%. This decrease is mainly due to the loss of $(0.4) million from our investment in
LMA&rsquo;s IPA line of business, offset by the income of $0.3 million allocated from our investment in DMG for the three months
ended March 31, 2018, compared to income from our investment in LMA&rsquo;s IPA line of business of $1.3 million, income from our
investment in UCI of $0.5 million and income from our investment in DMG of $0.4 million for the three months ended March 31, 2017.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Interest Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense for
the three months ended March 31, 2018 increased by approximately $84,000 as compared to the same period in 2017 due to interest
on debt obligations associated with bank loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Interest Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest income for
the three months ended March 31, 2018 was $0.3 million, as compared to $0.2 million for the same period in 2017, an increase of
$0.1 million, or 48%, mainly due to more cash held in money market accounts which resulted in more interest earned and the interest
from notes receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Change in Fair
Value of Derivative Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain from change in
fair value of derivative instruments for the three months ended March 31, 2017 was approximately $1.5 million mainly due to changes
in stock price of ApolloMed&rsquo;s common stock during the first quarter of 2017 with no recurring amounts for the same period
in 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Other Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income for the
three months ended March 31, 2018 was approximately $88,000 as compared to approximately $1,500 for the same period in 2017 mainly
due to rental income received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Provision for
Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provision for income
taxes was $7.2 million for the three months ended March 31, 2018, as compared to $7.9 million for the same period in 2017, a decrease
of $0.7 million or 8%. The decrease is due to the decrease in the effective tax rate for the three months ended March 31, 2018,
compared to the three months ended March 31, 2017, which resulted primarily from a decrease in the federal statutory rate of 35%
to 21% enacted on December 22, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Net Income Attributable
to Noncontrolling Interests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net income attributable
to noncontrolling interests was $13.6 million for the three months ended March 31, 2018, compared to $7.4 million for the three
months ended March 31, 2017, an increase of $6.2 million, or 84%. This increase was primarily due to net income generated from
APC mainly attributable to its increased revenue and certain tax benefits.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash, cash equivalents
and investment in marketable securities at March 31, 2018 totaled $104.9 million. Working capital totaled $70.0 million at March
31, 2018, compared to $34.6 million at December 31, 2017, an increase of $35.4 million, or 103%.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have historically
financed our operations primarily through internally generated funds. We generate cash primarily from capitations, risk pool settlements
and incentives, fees for medical management services provided to our affiliated physician groups, as well as FFS reimbursements.
We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient
liquidity to fund our operations at least through May 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash, cash equivalents
and restricted cash increased by $4.0 million from $118.5 million at December 31, 2017 to $122.5 million at March 31, 2018. Cash
provided by operating activities during the three months ended March 31, 2018 was $4.7 million, as compared to $21.1 million for
the same period in the prior year. The cash generated from operations during the three months ended March 31, 2018 is a function
of net income of $15.7 million, adjusted for the following non-cash operating items: depreciation and amortization of $5.1 million,
share-based compensation of $0.8 million, loss from disposal of property and equipment of approximately $42,000, loss from equity
method investments of approximately $28,000 and change in deferred tax liability of $2.8 million. Our cash provided by operating
activities includes a net decrease in operating assets and liabilities of $19.8 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in investing activities during the three months ended March 31, 2018 was $0.5 million, as compared
to cash used in investing activities of $4.3 million during the three months ended March 31, 2017. The net change in cash flow
from investing activities of $3.8 million is attributable to advances to related parties of $5.0 million and purchases of property
and equipment of $0.3 million, offset by dividends received from equity method investments of $1.0 million during the three months
ended March 31, 2017, compared to $0.5 million of purchases of property and equipment during the three months ended March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in financing
activities during the three months ended March 31, 2018 was $0.2 million, as compared to cash used in financing activities of $8.4
million during the three months ended March 31, 2017. This decrease of $8.2 million was primarily attributable to dividend payments
of $8.8 million, offset by proceeds from exercise of stock options and warrants of $0.4 million, during the three months ended
March 31, 2017, compared to dividend payments of $2.0 million, repayment of bank loans of $0.1 million, offset by proceeds from
exercise of stock options and warrants of $1.9 million, during the three months ended March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Credit Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Lines of Credit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2012, NMM
entered into a promissory note with Preferred Bank, which was amended in April 2016 and April 2017 to borrow up to $20,000,000.
This credit facility was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018. The interest
rate is based on the Wall Street Journal &ldquo;prime rate&rdquo; plus 0.125% and was 4.875% and 4.625% as of March 31, 2018 and
December 31, 2017, respectively. As of December&nbsp;31, 2017, the Company was not in compliance with certain financial debt covenant
requirements contained in the loan agreement, for which NMM obtained a waiver through March 31, 2018. As of March 31, 2018, NMM
was in compliance with such financial debt covenant requirements. The amount outstanding as of both March 31, 2018 and December
31, 2017 was $5,000,000 and is classified as current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2012, APC
entered into a promissory note with Preferred Bank, which was amended in April 2016 and April 2017 to borrow up to $10,000,000.
This credit facility was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018. The interest
rate is based on the Wall Street Journal &ldquo;prime rate&rdquo; plus 0.125% and was 4.875% and 4.625% as of March 31, 2018 and
December 31, 2017, respectively. As of December 31, 2017 and March 31, 2018, APC was not in compliance with certain financial debt
covenant requirements contained in the loan agreement. APC obtained a waiver from the bank for noncompliance of the financial debt
covenant requirements as of December 31, 2017 and through June 30, 2018. No amounts have been drawn on this facility.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I>In December
2010, ICC borrowed $4,600,000 in the form of a loan from a financial institution. The interest rate is based on the Wall Street
Journal &ldquo;prime rate&rdquo; but shall not be less than 4.5% per annum. The loan matures on December 31, 2018. As of March
31, 2018 and December 31, 2017, the balance outstanding was $394,783 and $510,391, respectively, and is classified as current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Intercompany
Loans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of AMH, MMG, BAHA,
ACC, AKM and SCHC has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan
commitment to each such affiliated entities in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan
Agreement provides that AMM&rsquo;s obligation to make any advances automatically terminates concurrently with the termination
of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that
(i) any material breach by Dr. Hosseinion of the applicable Physician Shareholder Agreement or (ii) the termination of the management
agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the
intercompany loans have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31, 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Maximum</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Interest rate per</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Balance During</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Ending</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Principal Paid</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Interest Paid</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Entity</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Facility</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Expiration</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Annum</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Balance</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">During Period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">During Period</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif">AMH</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">09/30/2018</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,150,678</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0pt 0">5,023,599</P>


</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(836,135</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">ACC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">07/31/2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287,843</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">MMG</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11/22/2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,854,559</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,854,559</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,181</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">AKM</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">05/30/2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">SCHC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">07/21/2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,468,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,468,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">BAHA</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt">07/22/2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,780,543</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,780,543</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,250,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,542,123</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,415,044</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(837,316</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
and related disclosures in conformity with accounting principles generally accepted in the United States of America (&ldquo;U.S.
GAAP&rdquo;) requires our management to make judgments, assumptions and estimates that affect the amounts of revenue, expenses,
income, assets and liabilities, reported in our condensed consolidated financial statements and accompanying notes. Actual results
and the timing of recognition of such amounts could differ from those judgments, assumptions and estimates. In addition, judgments,
assumptions and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information.
Understanding our accounting policies and the extent to which our management uses judgment, assumptions and estimates in applying
these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are
defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different
results under different assumptions and conditions.&nbsp;We summarize our most significant accounting policies in relation to
the accompanying condensed consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies
section of Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a net increase to beginning retained earnings and noncontrolling interest in APC
of $1.0 million and $7.4 million, respectively, as of January 1, 2018 due to the cumulative impact of adopting Accounting Standards
Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The impact to beginning retained earnings
and noncontrolling interest was primarily driven by the determination of risk pool settlement revenue (including the estimation
of constraints and incurred but not reported completion factor). The adoption of this ASU did not have a significant impact on
revenue when comparing the amount of revenue recognized for the three months ended March 31, 2018 to the revenue that would have
been recognized under the prior revenue standard ASC 605, such that comparisons of revenues and operating profit performance between
periods are not affected by the adoption of this ASU. Refer to Notes 2 and 13 to the accompanying condensed consolidated financial
statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 2 to the accompanying condensed
consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards
and the future adoption of such standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2018, we had no off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="item3"></A>ITEM 3.&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="item4"></A>ITEM 4.&nbsp;&nbsp;CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted an evaluation, under the supervision
and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended) as of the end of the period covered by this quarterly report. Based on this evaluation, our co-chief
executive officers and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures
were effective at the reasonable assurance level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our disclosure controls and procedures
are designed to ensure that the information relating to our company, including our consolidated subsidiaries, required to be disclosed
in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and
is accumulated and communicated to our management, including our co-chief executive officers and chief financial officer, as appropriate
to allow for timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, including our co-chief
executive officers and chief financial officer, does not expect that our disclosure controls or our internal control over financial
reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide
only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of any system of controls
is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions, and must reflect the facts that there are resource
constraints and that the benefits of controls have to be considered relative to their costs. The inherent limitations in internal
control over financial reporting include the realities that judgments can be faulty and that breakdowns can occur because of simple
error or mistake. Controls also can be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of controls. In addition, over time, controls may become inadequate because of changes in circumstances,
or the degree of compliance with the policies and procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have not been any changes in our
internal control over financial reporting (as defined in Rule&nbsp;13a-15(f)&nbsp;under the Securities Exchange Act of 1934, as
amended) during the period covered by this quarterly report that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="part2"></A>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="part2item1"></A>ITEM 1.&nbsp;&nbsp;LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of our business,
we from time to time become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical
malpractice related to medical services that are provided by our affiliated hospitalists. Many of the Company&rsquo;s payor and
provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision
of medical services, which may not come to light until a substantial period of time has passed following contract implementation.
We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of
the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding, which in
the opinion of management is expected to individually or in the aggregate have a material adverse effect on us or our business.
Nonetheless, the resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect
on the Company&rsquo;s financial condition, cash flows or results of operations. Nonetheless, the resolution of any claim or litigation
is subject to inherent uncertainty and could have a material adverse effect on the Company&rsquo;s financial condition, cash flows
or results of operations. See Note 11 - &ldquo;<I>Commitments and Contingencies</I>&rdquo; to the accompanying unaudited condensed
consolidated financial statements for additional comments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="part2item1a"></A>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business, financial condition and operating
results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare
industry as well as&nbsp;risks that affect businesses in general. In addition to the information and risk factors set forth in
this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A, &ldquo;Risk Factors&rdquo; in our
Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on April 2, 2018. The risks disclosed in such
Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results
of operations and thus our stock price. While we believe there have been no material changes in our risk factors from those disclosed
in the Annual Report, other than those discussed below, additional risks and uncertainties not currently known or we currently
deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risk factors may be important to
understanding other statements in this Quarterly Report and should be read in conjunction with the condensed consolidated financial
statements and related notes in Part I, Item 1, &ldquo;Financial Statements&rdquo; and Part I, Item 2, &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; of this Quarterly Report. Because of suck risk
factors, as well as other factors affecting the Company&rsquo;s financial condition and operating results, past financial performance
should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate
results or trends in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="part2item2"></A>ITEM 2.&nbsp;&nbsp;UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="part2item3"></A><B>ITEM 3.&nbsp;&nbsp;DEFAULTS UPON SENIOR SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="part2item4"></A>ITEM 4. MINE SAFETY DISCLOSURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="part2item5"></A>ITEM 5.&nbsp;&nbsp;OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="item6"></A>ITEM 6.&nbsp;&nbsp;EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are either incorporated
by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 12%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>No.</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 86%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&dagger;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (the &ldquo;Merger Agreement&rdquo;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="tv493730_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv493730_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated Certificate of Incorporation, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="tv493730_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv493730_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated Bylaws, as amended.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on October 19, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on April 4, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Annual Report on Form 10-K filed on April 2, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&rsquo;s Annual Report on Form 10-K filed on April 2, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&rsquo;s Annual Report on Form 10-K filed on April 2, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant (&ldquo;Series A Warrant&rdquo;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed on October 19, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&rsquo;s Annual Report on Form 10-K filed on April 2, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant (&ldquo;Series B Warrant&rdquo;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed on April 4, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&rsquo;s Annual Report on Form 10-K filed on April 2, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416133045/v452465_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420416133045/v452465_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant dated November 4, 2016, issued by Apollo Medical Holdings, Inc., to Scott Enderby, D.O. (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K filed on November 10, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417009037/v459268_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420417009037/v459268_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant dated November 17, 2016, issued by Apollo Medical Holdings, Inc. to Liviu Chindris, M.D. (incorporated herein by reference to Exhibit 4.1 to the Company&rsquo;s Quarterly Report on Form 10-Q filed on February 14, 2017).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418015735/tv488920_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1083446/000114420418015735/tv488920_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth Amendment between Apollo Medical Holdings, Inc. and NNA of Nevada, Inc., dated March 16, 2018 (incorporated herein by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on March 20, 2018).</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 46; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 12%"><A HREF="tv493730_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 86%"><A HREF="tv493730_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="tv493730_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv493730_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="tv493730_ex31-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv493730_ex31-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="tv493730_ex32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32**</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv493730_ex32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The schedules and exhibits thereof have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="signature"></A>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APOLLO MEDICAL HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 15</FONT>,
2018</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mihir Shah</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mihir Shah</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tv493730_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 3.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED CERTIFICATE OF INCORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Apollo Medical Holdings, Inc., a Delaware
corporation, hereby certifies as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the corporation is Apollo Medical Holdings, Inc. The date of filing of its original Certificate of Incorporation with the
Secretary of State was November 1, 1985 under the name McKinnely Investments, Inc. A Certificate of Amendment changing the name
of the corporation to Acculine Industries, Incorporated was filed with the Secretary of State on November 5, 1986. A Certificate
of Amendment changing the name of the corporation to Siclone Industries, Incorporated was filed with the Secretary of State on
May 24, 1988. A Certificate of Ownership changing the name of the corporation to Apollo Medical Holdings, Inc. was filed with the
Secretary of State on July 3, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Restated Certificate of Incorporation of the corporation attached hereto as Exhibit &ldquo;A&rdquo;, which is incorporated herein
by this reference, only restates and integrates, and does not further amend, the provisions of the Certificate of Incorporation
as heretofore amended or supplemented, and there is no discrepancy between those provisions and the provisions of the Restated
Certificate of Incorporation. The Restated Certificate of Incorporation has been duly adopted by the Board of Directors in accordance
with Section 245 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
this corporation has caused this Restated Certificate of Incorporation to be signed by its duly authorized officer, and the foregoing
facts stated herein are true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dated: January 16,
2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0">APOLLO MEDICAL HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 35%; border-bottom: Black 1pt solid">/s/ Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Warren Hosseinion&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chief Executive Officer&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT &ldquo;A&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED CERTIFICATE OF INCORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
I<BR>
<BR>
NAME</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of the corporation
hereby created shall be Apollo Medical Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
II<BR>
<BR>
DURATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall
continue in existence perpetually unless sooner dissolved according to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
III<BR>
<BR>
PURPOSES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purposes for which
this Corporation is organized are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To acquire by purchase or otherwise, own, hold, lease, rent, mortgage or otherwise, to trade with and deal in real estate,
lands and interests in lands and all other property of every kind and nature;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To manufacture, use, work, sell and deal in chemicals, biologicals, pharmaceuticals, electronics and products of all types
and also to privileges or rights, owned or hereafter owned by it for manufacturing, using and vending any device or devices, machine
or machines or manufacturing, working or producing any or all products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To
borrow money and to execute notes and obligations and security contracts therefore, to lend any of the monies or funds of the
Corporation and to take evidence of indebtedness therefore; and to negotiate loans; to carry on a general mercantile and merchandise
business and to purchase, sell and deal in such goods, supplies, and merchandise of every kind and nature;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To guarantee the payment of dividends or interest on any other contract or obligation of any corporation whenever proper
or necessary for the business of the Corporation in the judgment of its directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To do all and everything necessary, suitable, convenient, or proper for the accomplishment of any of the purposes or the
attainment of any one or more of the objects herein enumerated or incidental to the powers therein named or which shall at any
time appear conclusive or expedient for the protection or benefit of the Corporation, with all the powers hereafter conferred by
the laws under which this Corporation is organized; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To engage in any and all other lawful purposes, activities and pursuits, whether similar or dissimilar to the foregoing,
and the Corporation shall have all the powers allowed or permitted by the laws of the state of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
IV<BR>
<BR>
CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall
have authority to issue an aggregate of 105,000,000 shares, of which 100,000,000 shares shall be Common Stock having a one-tenth
(1/10) of one cent ($.001) par value each and 5,000,000 shares shall be Preferred Stock having a one-tenth (1/10) of one cent ($.001)
par value each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
V<BR>
<BR>
CLASSES OF STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A statement of the
designations and the powers, preferences, and rights, and the qualifications, limitations, or restrictions thereof, of the shares
of stock of each class which the Corporation shall be authorized to issue, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Preferred Stock</U>. Shares of preferred stock may be issued from time to time in one or more series as may from time
to time be determined by the Board of Directors. Each series shall be distinctly designated. All shares of any one series of the
preferred stock shall be alike in every particular, except that there may be different dates from which dividends thereon, if any,
shall be cumulative, if made cumulative. The powers, preferences, participating, optional and other rights of each such series
and qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time
outstanding. Subject to the provisions of subparagraph (i) of Paragraph (c) of this Article&nbsp;V, the Board of Directors of this
Corporation is hereby expressly granted authority to fix by resolution or resolutions adopted prior to the issuance of any shares
of each particular series of preferred stock, the designation, powers, preferences and relative, participating, optional and other
rights and the qualifications, limitations and restrictions thereof, if any, of such series, including, without limiting the generality
of the foregoing the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
distinctive designation of, and the number of shares of preferred stock which shall constitute, the series, which number may be
increased (except as otherwise fixed by the Board of Directors) or decreased (but not below the number of shares thereof outstanding)
from time to time by action of the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The rate and times at which, and the terms and conditions upon which, dividends, if any, on shares of the series shall be
paid, the extent of preferences or relation, if any, of such dividends to the dividends payable on any other class or classes of
stock of this Corporation, or on any series of preferred stock, and whether such dividends shall be cumulative or noncumulative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The right, if any, of the holders of shares of the series to convert the same into, or exchange the same for any other series,
or any other class or classes of stock of this Corporation, and the terms and conditions of such conversion or exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Whether
shares of the series shall be subject to redemption, and the redemption price or prices, including, without limitation, a redemption
price or prices payable in shares of the Common Stock, cash or other property and the time or times at which, and the terms and
conditions upon which, shares of the series may be redeemed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
rights, if any, of the holders of shares of the series upon voluntary or involuntary liquidation merger, consolidation, distribution
or, sale of assets, dissolution or winding up of this Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
terms of the sinking fund or redemption or purchase account, if any, to be provided for shares of the series; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The voting powers, if any, of the holders of shares of the series which may, without limiting the generality of the foregoing,
include (A) the right to more or less than one vote per share on any or all matters voted upon by the shareholders and (B) the
right to vote as a series by itself or together without preferred stock as a class, upon such matters, under such circumstances
and upon such conditions as the Board of Directors may fix, including, without limitation, the right, voting as a series by itself
or together with other series of preferred or together with all series of preferred stock as a class, to elect one or more directors
of this Corporation in the event there shall have been a default in the payment of dividends on any one or more series of preferred
stock or under such other circumstances and upon such conditions as the Board may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Common
Stock</U>. The Common Stock shall be non-assessable and shall not have cumulative voting rights. In addition, the Common Stock
shall have the following powers, preferences, rights, qualifications, limitations and restrictions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>After the requirements with respect to preferential dividends of preferred stock (fixed in accordance with the provisions
of Paragraph (a) of this Article&nbsp;V), if any, shall have been met and after this Corporation shall comply with all the requirements,
if any, with respect to the setting aside of funds as sinking funds or redemption or purchase accounts (fixed in accordance with
provisions of Paragraph (a) of this Article&nbsp;V) and subject further to any other conditions which may be fixed in accordance
with the provisions of Paragraph (a) of this Article&nbsp;V, the, but not otherwise, the holders of Common Stock shall be entitled
to receive such dividends, if any, as may be declared from time to time by the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>After distribution in full of the preferential amount (fixed in accordance with the provisions of Paragraph (a) of this
Article&nbsp;V), if any, to be distributed to the holders of preferred stock in the event of a voluntary or involuntary liquidation,
distribution or sale of assets, dissolution or winding up of this Corporation, the holders of the Common Stock shall be entitled
to receive all of the remaining assets of this Corporation, tangible and intangible, of whatever kind available for distribution
to stockholders, ratably in proportion to the number of shares of the Common Stock held by each; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Shares of the Common Stock may be issued from time to time as the Board of Directors shall determine and on such terms and
for such consideration as shall be fixed by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
relative powers, preferences and rights of each series of preferred stock in relation to the powers, preferences and rights of
each other series of preferred stock shall, in each case, be as fixed from time to time by the Board of Directors in the resolution
or resolutions adopted pursuant to authority granted in Paragraph (a) of this Article&nbsp;V, and the consent by class or series
vote or otherwise, of the holders of the preferred stock of such of the series of preferred stock as are from time to time outstanding
shall not be required for the issuance by the Board of Directors of any other series of preferred stock whether the powers, preferences
and rights of such other series shall be fixed by the Board of Directors as senior to, or on a parity with the powers, preferences
and rights of such outstanding series, or any of them; provided, however, that the Board of Directors may provide in such resolution
or resolutions adopted with respect to any series of preferred stock that the consent of the holders of a majority (or such greater
proportion as shall be therein fixed) of the outstanding shares of such series voting thereon shall be required for the issuance
of any or all other series of preferred stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject
to the provisions of subparagraph (i) of this Paragraph, shares of any series of preferred stock may be issued from time to time
as the Board of Directors shall determine and on such terms and for such consideration as shall be fixed by the Board of Directors;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Shares of the Common Stock may be issued from time to time as the Board of Directors shall determine and on such terms and
for such consideration as shall be fixed by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VI<BR>
<BR>
BYLAWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In furtherance and
not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter or repeal the
Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VII<BR>
<BR>
MEETINGS AND RECORDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Meetings of stockholders
may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may be kept (subject
to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time
to time by the Board of Directors or in the Bylaws of the Corporation. Elections of directors need not be by written ballot unless
the Bylaws of the Corporation so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VIII<BR>
<BR>
REGISTERED OFFICE AND AGENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The address of its
registered office in the State of Delaware is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left">Registered Agent Solutions, Inc.<BR>
1679 S. Dupont Hwy, Ste. 100<BR>
City of Dover<BR>
County of Kent, 19901</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
IX<BR>
<BR>
REMOVAL OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any director of the
Corporation may be removed for cause at any annual or special meeting of the shareholders by the same vote as that required to
elect a director provided, that such director prior to his removal shall receive a copy of the charges against him, delivered to
him personally or by mail at his address appearing on the records of the Corporation, at least thirty (30) days prior to the meeting
at which such removal is to be considered, and such director has an opportunity to be heard on such charges at the meeting of shareholders
of the Corporation at which the question of his removal is to be considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
X<BR>
<BR>
INDEMNIFICATION OF OFFICERS AND DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liability to the Corporation or its Stockholders</U>. To the fullest extent permitted by the Delaware General Corporation
Law, as it presently exists or may hereafter be amended from time to time, a director of the Corporation shall not be personally
liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Neither any amendment
to, modification of, nor repeal of this Article, nor the adoption of any provision of the Corporation&rsquo;s Certificate of Incorporation
inconsistent with this Article, shall (i) eliminate, or reduce the effect of this Article&nbsp;in respect of any matter occurring,
or any cause of action, suit or proceeding accruing or arising or that, but for this Article, would accrue or arise, prior to such
amendment, modification, repeal or adoption of an inconsistent provision or (ii) eliminate, reduce or otherwise adversely affect
any right or protection of a current or former director of the Corporation existing at the time of such amendment, modification,
repeal or adoption. If the Delaware General Corporation law is amended to authorize corporate action further eliminating or limiting
the personal liability of directors, then the liability of a director to the Corporation or its stockholders shall be eliminated
or limited to the fullest extent permitted by the Delaware General Corporation Law, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification and Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Right
to Indemnification</U>. Each person who was or is a party or is made a party, threatened to be made a party or is involved in
any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &ldquo;proceeding&rdquo;),
by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer
of the Corporation or is or was serving at the request of the Corporation as a director, a member of any committee of the Corporation&rsquo;s
Board of Directors, or an officer of another corporation, or as its representative in a partnership, joint venture, trust or other
enterprise, including service with respect to employee benefit plans (hereinafter an &ldquo;indemnitee&rdquo;), whether the basis
of such proceeding is alleged action in an official capacity as a director, committee member, officer or representative or in
any other capacity while serving as a director, committee member, officer or representative, shall be indemnified and held harmless
by the Corporation to the fullest extent permitted by the Delaware General Corporation Law, as the same exists or may hereafter
be amended (but in the case of any such amendment to the fullest extent permitted by law, only to the extent that such amendment
permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to
such amendment), against all expenses, liability and loss (including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes
or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith
and such indemnification will continue as to an indemnitee who has ceased to be a director, committee member, officer or representative
and shall inure to the benefit of his or her heirs, executors and administrators. Such right shall be a contract right and shall
include, except as otherwise provided in this Article&nbsp;X, the right to be paid by the Corporation the expenses incurred in
defending any such proceeding in advance of its final disposition (hereinafter an &ldquo;advancement&rdquo;); provided, however,
if the Delaware General Corporation Law requires, such advancement shall be made only upon delivery to the Corporation of an undertaking,
by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision
from which there is no further right to appeal that such indemnitee is not entitled to be indemnified under this Article&nbsp;or
otherwise; and provided, further, however, that the Corporation may make, but is not obligated to make with respect to any officer
under this Article&nbsp;X, nor shall any officer have any right or entitlement under this Article&nbsp;X to, any advancement with
respect to an action brought directly by the Corporation against such officer for malfeasance, defalcation, fraud or other willful
misconduct in connection with, or in contravention of, such officer&rsquo;s duties. Unless otherwise required by law, the burden
of proving that the indemnitee is not entitled to be indemnified or to such advancement of expenses under this Article&nbsp;X
shall be on the Corporation. Notwithstanding anything to the contrary in this Article&nbsp;X and except as provided in Section
(b)(ii) of this Article&nbsp;X with respect to proceedings to enforce rights to indemnification, the Corporation shall not be
required by this Article&nbsp;X to indemnify any indemnitee against expenses incurred in connection with a proceeding (or part
thereof) initiated by such indemnitee unless the initiation of the proceeding (or part thereof) was approved by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Indemnitee Claims; Burden of Proof</U>. If a claim under this Article&nbsp;X is not paid in full by the Corporation
within thirty days after a written claim has been received by the Corporation, the indemnitee may at any time thereafter bring
suit against the Corporation to recover the unpaid amount of the claim and if successful, in whole or in part, the indemnitee shall
be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action
brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the undertaking,
if any is required, has been tendered to the Corporation) that the indemnitee has not met the standards of conduct which make it
permissible under the Delaware General Corporation Law for the Corporation to indemnify the indemnitee for the amount claimed,
but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board
of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action
that indemnification of the indemnitee is proper in the circumstances because he or she has met the applicable standard of conduct
set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board of Directors,
independent legal counsel, or its stockholders) that the indemnitee had not met such applicable standard of conduct, shall be a
defense to the action or create a presumption that the indemnitee had not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Exclusivity of Rights</U>. The rights conferred by this Article&nbsp;X shall not be exclusive of any other right
which indemnitees may have or hereafter acquire under bylaw, agreement, vote of directors or stockholders or otherwise, and shall
inure to the benefit of the heirs, executors and administrators of such indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Amendments</U>. Any amendment, modification or repeal of this Article&nbsp;X that adversely affects the right
of an indemnitee or his or her successors shall be prospective only and shall not limit or eliminate such right with respect to
any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment,
modification or repeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>. The Corporation may maintain insurance, at its expense, to protect itself or any indemnitee whether or
not the Corporation would have the power or obligation to indemnify such person against such expense, liability or loss under this
Article&nbsp;or the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Indemnification</U>. This Article&nbsp;X shall not limit the right of the Corporation, to the extent and in the
manner permitted by law, to indemnify and advance expenses to indemnitees or persons other than indemnitees when and as authorized
by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XI<BR>
<BR>
AMENDMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth
herein and in the General Corporation Law of the state of Delaware, the Corporation reserves the right to amend, alter, change
or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and
all rights conferred upon stockholders are granted subject to this reservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XII<BR>
<BR>
OFFICERS&rsquo; AND DIRECTORS&rsquo; CONTRACTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No contract or other
transactions between this Corporation and any other firm or corporation shall be affected by the fact that a director or officer
of this Corporation has an interest in, or is a director or officer of such firm or other corporation. Any officer or director,
individually or with others, may be a party to, or may have an interest in, any transaction of this Corporation or any transaction
in which this Corporation is a party or has an interest. Each person who is now or may become an officer or director of this Corporation
is hereby relieved from liability that he might otherwise obtain in the event such officer or director contracts with this Corporation
for the benefit of himself or any other firm or corporation in which he may have an interest, provided such officer or director
acts in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XIII<BR>
<BR>
DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall
have not less than three (3) nor more than nine (9) directors as determined from time to time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED CERTIFICATE OF INCORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Apollo Medical Holdings,
Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &ldquo;Corporation&rdquo;),
does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FIRST: The name of
the Corporation is Apollo Medical Holdings, Inc. This Certificate of Amendment amends the Corporation&rsquo;s Restated Certificate
of Incorporation filed on January 16, 2015, and was duly adopted in accordance with the provisions of Section 242 of the Delaware
General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECOND: That Article&nbsp;IV
of the Restated Certificate of Incorporation of the Corporation, as amended and/or restated to date, be amended and restated in
its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;The Corporation shall have authority
to issue an aggregate of 105,000,000 shares, of which 100,000,000 shares shall be Common Stock having a (1/10) of one cent ($.001)
par value each and 5,000,000 shares shall be Preferred Stock having a (1/10) of one cent ($.001) par value each. Effective as of
the date of the filing of this Certificate of Amendment to the Restated Certificate of Incorporation of the Corporation (the &ldquo;Effective
Time&rdquo;), a one-for-ten reverse stock split of the Corporation&rsquo;s Common Stock shall become effective, pursuant to which
each ten shares of Common Stock, par value $.001 per share, issued and outstanding or held as treasury shares at the Effective
Time, shall be reclassified and combined into one share of Common Stock, par value $.001 per share, automatically and without any
action by the holder thereof. No fractional shares of Common Stock shall be issued as a result of such reclassification and combination
and the Corporation shall pay cash in lieu of any fractional shares resulting from such reclassification and combination.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIRD: This Certificate
of Amendment to the Restated Certificate of Incorporation has been duly adopted by the Board of Directors and stockholders of the
Corporation in accordance with Section 242 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 24th day of April,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: left; text-indent: 0">APOLLO MEDICAL HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: left; text-indent: 0">a Delaware corporation&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 35%; border-bottom: Black 1pt solid">/s/ Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Warren Hosseinion, M.D.&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED CERTIFICATE OF INCORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APOLLO MEDICAL HOLDINGS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Apollo Medical Holdings,
Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &ldquo;Corporation&rdquo;),
does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FIRST:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name
of the Corporation is Apollo Medical Holdings, Inc. This Certificate of Amendment amends the Corporation&rsquo;s Restated Certificate
of Incorporation filed on January 16, 2015, and was duly adopted in accordance with the provisions of Section 242 of the Delaware
General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SECOND:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That Article&nbsp;IV
of the Restated Certificate of Incorporation of the Corporation, as amended and/or restated to date, be amended and restated in
its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;The Corporation shall have authority
to issue an aggregate of 105,000,000 shares, of which 100,000,000 shares shall be Common Stock having a (1/10) of one cent ($.001)
par value each and 5,000,000 shares shall be Preferred Stock having a (1/10) of one cent ($.001) par value each. Effective as of
the date of the filing of this Certificate of Amendment to the Restated Certificate of Incorporation of the Corporation (the &ldquo;Effective
Time&rdquo;), a one-for-ten reverse stock split of the Corporation&rsquo;s Common Stock shall become effective, pursuant to which
each ten shares of Common Stock, par value $.001 per share, issued and outstanding or held as treasury shares at the Effective
Time, shall be reclassified and combined into one share of Common Stock, par value $.001 per share, automatically and without any
action by the holder thereof. No fractional shares of Common Stock shall be issued as a result of such reclassification and combination
and the Corporation shall pay cash in lieu of any fractional shares resulting from such reclassification and combination.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIRD:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Certificate
of Amendment to the Restated Certificate of Incorporation has been duly adopted by the Board of Directors and stockholders of the
Corporation in accordance with Section 242 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 24th day of April,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: left; text-indent: 0">APOLLO MEDICAL HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 35%; border-bottom: Black 1pt solid">/s/ Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Warren Hosseinion, M.D.&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>tv493730_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 3.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Apollo Medical Holdings, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED BY-LAWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE I - OFFICES</TD>
    <TD STYLE="width: 10%; text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 1.1 - Principal Office</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 1.2 - Other Offices</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE II - SHAREHOLDERS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.1 - Annual Meeting</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.2 - Special Meetings</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.3 - Notice of Meetings</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.4 - Quorum</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">2</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.5 - Organization</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">2</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.6 - Conduct of Business</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">2</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.7 - Proxies and Voting</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">2</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.8 - Shareholder Action By Written Consent</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.9 - Stock List</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 2.10
    - Meetings by Telecommunication</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE III - BOARD OF DIRECTORS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.1 - Number and Term of Office</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.2 - Vacancies</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.3 - Regular Meetings</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.4 - Special Meetings</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.5 - Quorum</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.6 - Participation in Meetings by Conference Telephone</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.7 - Conduct of Business</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.8 - Powers</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.9 - Compensation of Directors</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.10 - Interested Directors</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 3.11 - Loans</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE IV - COMMITTEES</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 4.1 - Committees of the Board of Directors</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">6</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 4.2 - Conduct of Business</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">7</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">i</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in; width: 90%">ARTICLE V - OFFICERS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt; width: 10%">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.1 - Generally</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.2 - President</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.3 - Vice-president</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.4 - Treasurer</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.5 - Secretary</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.6 - General Manager</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.7 - Delegation of Authority</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.8 - Removal</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 5.9 - Action with Respect to Securities of Other Corporation</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">8</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE VI - INDEMNIFICATION OF DIRECTORS, OFFICERS AND OTHERS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.1 - Generally</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.2 - Expenses</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">9</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.3 - Determination by Board of Directors</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.4 - Non-exclusive Right</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.5 - Insurance</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">10</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.6 - Violation of Law</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 6.7 - Coverage</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE VII - STOCK</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 7.1 - Certificates of Stock</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 7.2 - Transfers of Stock</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">11</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 7.3 - Record Date</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 7.4 - Lost, Stolen or Destroyed Certificates</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 7.5 - Regulations</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE VIII - NOTICES</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 8.1 - Notices</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 8.2 - Waivers</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE IX - MISCELLANEOUS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 9.1 - Facsimile Signatures</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 9.2 - Corporate Seal</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 9.3 - Reliance upon Books, Reports and Records</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 9.4 - Fiscal Year</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 9.5 - Time Periods</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in">ARTICLE X - AMENDMENTS</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.75in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1.25in">Section 10.1 - Amendments</TD>
    <TD STYLE="text-align: center; padding-top: 0in; padding-bottom: 6pt">13</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">ii</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE I - OFFICES</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 1.1 - Principal
Office</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal executive
office of the corporation shall be such location as deemed necessary from time to time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 1.2 - Other
Offices</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation may
also have such other offices, either within or without the State of Delaware, as the Board of Directors may from time to time determine
or the business of the corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE II - SHAREHOLDERS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.1 - Annual
Meeting</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual meeting of
the shareholders, for the selection of directors to succeed those whose terms expire and for the transaction of such other business
as may properly come before the meeting, shall be held at the principal office of the corporation on the second Monday of January
or, if such date shall fall on a holiday, the next business day thereafter. The Board of Directors may change the date or elect
to have no annual meeting for a particular year. If the election of directors is not held on the day designated for any annual
meeting of the shareholders or at any adjournment of the meeting, the Board of Directors shall call for the election to be held
at a special meeting of the Shareholders as soon thereafter as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.2 - Special
Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special meetings of
the shareholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors,
the president, the chief executive officer, or the holders of not less than one-tenth of all the shares entitled to vote at the
meeting, and shall be held at such place, on such date, and at such time as they or he shall fix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.3 - Notice
of Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Written notice of the
place, date and time of all meetings of the shareholders shall be given, not less than ten nor more than fifty days before the
date on which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise provided herein
or required by law (meaning, here and hereinafter, as required from time to time by the corporation statutes of the State of Delaware).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a meeting is adjourned
to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are
announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more
than thirty days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned
meeting, written notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith. At any adjourned
meeting, any business may be transacted which might have been transacted at the original meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.4 - Quorum</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any meeting of the
shareholders, the holders of a majority of all of the shares of the stock entitled to vote at the meeting, present in person or
by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a quorum shall fail
to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of the stock entitled to vote who
are present, in person or by proxy, may adjourn the meeting to another place, date or time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a notice of any
adjourned special meeting of shareholders is sent to all shareholders entitled to vote thereat, stating that it will be held with
those present constituting a quorum, then except as otherwise required by law, those present at such adjourned meeting shall constitute
a quorum, and all matters shall be determined by a majority of the votes cast at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.5 - Organization</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such person as the
Board of Directors may have designated or, in the absence of such a person, the highest ranking officer of the corporation who
is present shall call to order any meeting of the shareholders and act as chairman of the meeting. In the absence of the Secretary
of the corporation, the secretary of the meeting shall be the person the chairman appoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.6 - Conduct
of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chairman of any
meeting of shareholders shall determine the order of business and the procedure at the meeting, including such regulation of the
manner of voting and the conduct of discussion as seem to him in order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.7 - Proxies
and Voting</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any meeting of the
shareholders, every shareholder entitled to vote may vote in person or by proxy authorized by an instrument in writing filed in
accordance with the procedure established for the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each shareholder shall
have one vote for every share of stock entitled to vote which is registered in his name on the record date for the meeting, except
as otherwise provided herein or required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All voting, except
on the election of directors and where otherwise required by law, may be by a voice vote; provided, however, that upon demand therefor
by a shareholder entitled to vote or his proxy, a stock vote shall be taken. Every stock vote shall be taken by ballots, each of
which shall state the name of the shareholder or proxy voting and such other information as may be required under the procedure
established for the meeting. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman
of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a quorum is present,
the affirmative vote of the majority of the shares represented at the meeting and entitled to vote on the subject matter shall
be the act of the shareholders, unless the vote of a greater number or voting by class is required by law, the Articles of Incorporation,
or these By-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 2.8 - Shareholder Action
By Written Consent</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any action which may
be taken at a meeting of the Shareholders may be taken by written consent without a meeting if such action is taken in conformance
with the Delaware Corporations Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 2.9 - Stock
List</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A complete list of
shareholders entitled to vote at any meeting of shareholders, arranged in alphabetical order for each class of stock and showing
the address of each such shareholder and the number of shares registered in his name, shall be open to the examination of any such
shareholder, for any purpose germane to the meeting, during ordinary business hours for a period of at least ten (10) days prior
to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice
of the meeting, or if not so specified, at the place where the meeting is to be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Stock list shall
also be kept at the place of the meeting during the whole time thereof and shall be open to the examination of any such shareholder
who is present. This list shall presumptively determine the identity of the shareholders entitled to vote at the meeting and the
number of shares held by each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><U>Section
2.10 - Meetings by Telecommunication</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any meeting of the
shareholders may be conducted through the use of any means of communication which allows persons participating in the meeting to
hear one another.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE III - BOARD OF DIRECTORS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.1 - Number
and Term of Office</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorized number
of directors shall be fixed from time to time by the board of directors, provided that the authorized number of directors shall
not be less than one (1). Each director shall be selected for a term of one year and until his successor is elected and qualified,
except as otherwise provided herein or required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever the authorized
number of directors is increased between annual meetings of the shareholders, a majority of the directors then in office shall
have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any
decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then
in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.2 - Vacancies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vacancies in the board
of directors may be filled by a majority vote of the remaining directors, though less than a quorum, by a sole remaining director,
or by the shareholders. Each director so elected shall hold office until a successor is elected at an annual or a special meeting
of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A vacancy in the board
of directors shall be deemed to exist in case of the death, resignation or removal of any director; if the authorized number of
directors is increased; or if the shareholders fail to elect the full authorized number of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shareholders may
elect a director at any time to fill any vacancy not filled by the directors. If the board of directors accepts the resignation
of a director tendered to take effect at a future time, the board or the shareholders shall have power to elect a successor to
take office when the resignation is to become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No reduction of the
authorized number of directors shall have the effect of removing any director prior to the expiration of the director&rsquo;s term
of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.3 - Regular
Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regular meetings of
the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been
established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.4 - Special
Meetings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special meetings of
the Board of Directors may be called by one-third of the directors then in office or by the chief executive officer and shall be
held at such place, on such date and at such time as they or he shall fix. Notice of the place, date and time of each such special
meeting shall be given by each director by whom it is not waived by mailing written notice not less than three days before the
meeting or by telegraphing the same not less than eighteen hours before the meeting. Unless otherwise indicated in the notice thereof,
any and all business may be transacted at a special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.5 - Quorum</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any meeting of the
Board of Directors, a majority of the total number of the whole board shall constitute a quorum for all purposes. If a quorum shall
fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time, without further
notice or waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.6 - Participation
in Meetings by Conference Telephone</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of the Board
of Directors or of any committee thereof, may participate in a meeting of such board or committee by means of conference telephone
or similar communications equipment that enables all persons participating in the meeting to hear each other. Such participation
shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.7 - Conduct
of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any meeting of the
Board of Directors, business shall be transacted in such order and manner as the board may from time to time determine, and all
matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required
by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing, and
the writing or writings are filed with the minutes of proceedings of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.8 - Powers</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may, except as otherwise required by law, exercise all such powers and do all such acts and things as may be exercised or done
by the corporation, including, without limiting the generality of the foregoing, the unqualified power:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">To declare dividends from time to time in accordance with law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">To purchase or otherwise acquire any property, rights or privileges on such terms as it shall determine;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">To authorize the creation, making and issuance, in such form as it may determine, of written obligations
of every kind, negotiable or non-negotiable, secured or unsecured, and to do all things necessary in connection therewith;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">To remove any officer of the corporation with or without cause, and from time to time to devolve
the powers and duties of any officer upon any other person for the time being;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">To confer upon any officer of the corporation the power to appoint, remove and suspend subordinate
officers and agents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">To adopt from time to time such stock option, stock purchase, bonus or other compensation plans
for directors, officers and agents of the corporation and its subsidiaries as it may determine;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">To adopt from time to time such insurance, retirement and other benefit plans for directors, officers
and agents of the corporation and its subsidiaries as it may determine; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">To adopt from time to time regulations, not inconsistent with these By-laws, for the management
of the corporation's business and affairs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.9 - Compensation
of Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors, as such,
may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors,
including, without limitation, their services as members of committees of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.10 - Interested
Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No
contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any
other corporation, partnership, association, or other organization in which one or more of its directors or officers, are directors
or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or
officer is present at or participates in the meeting of the board or committee which authorizes the contract or transaction, or
solely because his or their votes are counted for such purpose, if;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board
of Directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative
votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to
the shareholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the
shareholders; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the
Board of Directors, a committee or the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors
or of a committee which authorizes the contract or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 3.11 - Loans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation shall
not lend money to or use its credit to assist its officers, directors or other control persons without authorization in the particular
case by the shareholders, but may lend money to and use its credit to assist any employee, excluding such officers, directors or
other control persons of the corporation or of a subsidiary, if such loan or assistance benefits the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE IV - COMMITTEES</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 4.1 - Committees
of the Board of Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors,
by a vote of a majority of the whole board, may from time to time designate committees of the board, with such lawfully powers
and duties as it thereby confers, to serve at the pleasure of the board and shall, for those committees and any others provided
for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternative
members who may replace any absent or disqualified member at any meeting of the committee. Any committee so designated may exercise
the power and authority of the Board of Directors to declare a dividend or to authorize the issuance of stock if the resolution
which designates the committee or a supplemental resolution of the Board of Directors shall so provide. In the absence or disqualification
of any member of any committee and any alternate member in his place, the member or members of the committee present at the meeting
and not disqualified from voting, whether or not he or they constitute a quorum, may by unanimous vote appoint another member of
the Board of Directors to act at the meeting in the place of the absent or disqualified member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 4.2 - Conduct
of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each committee may
determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise
provided herein or required by law. Adequate provisions shall be made for notice to members of all meetings; a majority of the
members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute
a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without
a meeting if all members thereof consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings
of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE V - OFFICERS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.1 - Generally</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The officers of the
corporation shall consist of a president, one or more vice-presidents, a secretary, a treasurer and such other subordinate officers
as may from time to time be appointed by the Board of Directors. Officers shall be elected by the Board of Directors, which shall
consider that subject at its first meeting after every annual meeting of shareholders. Each officer shall hold his office until
his successor is elected and qualified or until his earlier resignation or removal. Any number of offices may be held by the same
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.2 - President</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The President shall
be the chief executive officer of the corporation, except as set forth in Section 5.6 of this Article. Subject to the provisions
of these By-laws and to the direction of the Board of Directors, he shall have the responsibility for the general management and
control of the affairs and business of the corporation and shall perform all duties and have all powers which are commonly incident
to the office of chief executive or which are delegated to him by the Board of Directors. He shall have power to sign all stock
certificates, contracts and other instruments of the corporation which are authorized. He shall have general supervision and direction
of all of the other officers and agents of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.3 - Vice-president</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each vice-president
shall perform such duties as the Board of Directors shall prescribe. In the absence or disability of the President, the vice-president
who has served in such capacity for the longest time shall perform the duties and exercise the powers of the President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.4 - Treasurer</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The treasurer shall
have the custody of the monies and securities of the corporation and shall keep regular books of account. He shall make such disbursements
of the funds of the corporation as are proper and shall render from time to time an account of all such transactions and of the
financial condition of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.5 - Secretary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The secretary shall
issue all authorized notices for, and shall keep minutes of, all meetings of the shareholders and the Board of Directors and shall
have charge of the corporate books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.6 - General
Manager</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may employ and appoint a general manager who may, or may not, be one of the officers or directors of the corporation. If employed
by the Board of Directors he shall be the chief operating officer of the corporation and, subject to the directions of the Board
of Directors, shall have general charge of the business operations of the corporation and general supervision over its employees
and agents. He shall have the exclusive management of the business of the corporation and of all of its dealings, but at all times
subject to the control of the Board of Directors. Subject to the approval of the Board of Directors or a committee, he shall employ
all employees of the corporation, or delegate such employment to subordinate officers, or division officers, or division chiefs,
and shall have authority to discharge any person so employed. He shall make a report to the President and directors quarterly,
or more often if required to do so, setting forth the results of the operations under his charge, together with suggestions regarding
the improvement and betterment of the condition of the corporation, and shall perform such other duties as the Board of Directors
shall require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.7 - Delegation
of Authority</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may, from time to time, delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.8 - Removal</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any officer of the
corporation may be removed at any time, with or without cause, by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 5.9 - Action
with Respect to Securities of Other Corporation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise directed
by the Board of Directors, the president shall have power to vote and otherwise act on behalf of the corporation, in person or
by proxy, at any meeting of shareholders of or with respect to any action of shareholders of any other corporation in which this
corporation may hold securities and otherwise to exercise any and all rights and powers which this corporation may possess by reason
of its ownership of securities in such other corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE VI - INDEMNIFICATION OF DIRECTORS, OFFICERS AND OTHERS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.1 - Generally</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation shall
have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the
right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or
is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner
he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by
judgment, order, settlement, conviction, or upon a plea of nolo contendere or items equivalent, shall not, of itself, create a
presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the
best interests of the corporation, and with respect to any criminal action or proceeding, had reasonable cause to believe that
his conduct was lawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation shall
have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he
is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as
a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses
(including attorney's fees) actually and reasonably incurred by him in connection with the defense or settlement of such action
or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation
and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable for negligence or misconduct in the performance of his duty to the corporation unless and only to the extent
that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability
but in view of all circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which
such court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.2 - Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
a director, officer, employee or agent of the corporation has been successful on the merits or otherwise in defense of any action,
suit or proceeding referred to in Section 6.1 of this Article, or in defense of any claim, issue or matter therein, he shall be
indemnified against expenses (including attorney's fees) actually and reasonably incurred by him in connection therewith. Expenses
incurred in defending a civil or criminal action, suit or proceeding may be paid by the corporation in advance of the final disposition
of such action, suit or proceeding as authorized in the manner provided in Section 6.3 of this Article upon receipt of an undertaking
by or on behalf of the director, officer, employee or agent to repay such amount unless it shall ultimately be determined that
he is entitled to be indemnified by the corporation as authorized in this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.3 - Determination
by Board of Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any indemnification
under Section 6.1 of this Article (unless ordered by a court) shall be made by the corporation only as authorized in the specific
case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances because
he has met the applicable standard of conduct set forth in Section 6.1 of this Article. Such determination shall be made by the
Board of Directors by a majority vote of a quorum of the directors, or by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.4 - Non-exclusive
Right</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnification
provided by this Article shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any
by-law, agreement, vote of shareholders or interested directors or otherwise, both as to action in his official capacity and as
to action in another capacity while holding such office and shall continue as to a person who has ceased to be a director, officer,
employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.5 - Insurance</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation shall
have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such
capacity or arising out of his status as such, whether or not the corporation would have the power to indemnify him against such
liability under the provisions of this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The corporation's indemnity
of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
shall be reduced by any amounts such person may collect as indemnification (i) under any policy of insurance purchased and maintained
on his behalf by the corporation or (ii) from such other corporation, partnership, joint venture, trust or other enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.6 - Violation
of Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing contained in
this Article, or elsewhere in these By-laws, shall operate to indemnify any director or officer if such indemnification is for
any reason contrary to law, either as a matter of public policy, or under the provisions of the Federal Securities Act of 1933,
the Securities Exchange Act of 1934, or any other applicable state or federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 6.7 - Coverage</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purposes of
this Article, references to &quot;the corporation&quot; include all constituent corporations absorbed in a consolidation or merger
as well as the resulting or surviving corporation so that any person who is or was a director, officer, employee or agent of such
a constituent corporation or is or was serving at the request of such a constituent corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise shall stand in the same position under the
provisions of this Article with respect to the resulting or surviving corporation as he would if he had served the resulting or
surviving corporation in the same capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE VII - STOCK</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 7.1 - Certificates
of Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of stock
of the corporation shall be represented by a certificate, unless and until the Board of Directors adopts a resolution permitting
shares to be uncertificated. Notwithstanding the adoption of any such resolution providing for uncertificated shares, every holder
of stock of the corporation theretofore represented by certificates and, upon request, every holder of uncertificated shares, shall
be entitled to a certificate signed by, or in the name of the corporation by, the President or a vice-president, and by the secretary
or an assistant secretary, or the treasurer or an assistant treasurer, certifying the number of shares owned by him. Any of or
all the signatures on the certificate may be facsimile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 7.2 - Transfers
of Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock of the corporation
shall be transferable in the manner prescribed by applicable law and in these By-laws. Transfers of stock shall be made on the
books of the corporation, and in the case of certificated shares of stock, only by the person named in the certificate or by such
person&rsquo;s attorney lawfully constituted in writing and, except where a certificate is issued in accordance with Section 7.4
of this Article, upon the surrender of the certificate therefor, properly endorsed for transfer and payment of all necessary transfer
taxes; or, in the case of uncertificated shares of stock, upon receipt of proper transfer instructions from the registered holder
of the shares or by such person&rsquo;s attorney lawfully constituted in writing, and upon payment of all necessary transfer taxes
and compliance with appropriate procedures for transferring shares in uncertificated form; provided, however, that such surrender
and endorsement, compliance or payment of taxes shall not be required in any case in which the officers of the corporation shall
determine to waive such requirement. With respect to certificated shares of stock, every certificate exchanged, returned or surrendered
to the corporation shall be marked &ldquo;Cancelled,&rdquo; with the date of cancellation, by the secretary or assistant secretary
of the corporation or the transfer agent thereof. No transfer of stock shall be valid as against the corporation for any purpose
until it shall have been entered in the stock records of the corporation by an entry showing from and to whom transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 7.3 - Record
Date</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may fix a record date, which shall not be more than fifty nor less than ten days before the date of any meeting of shareholders,
nor more than fifty days prior to the time for the other action hereinafter described, as of which there shall be determined the
shareholders who are entitled: to notice of or to vote at any meeting of shareholders or any adjournment thereof; to express consent
to corporate action in writing without a meeting; to receive payment of any dividend or other distribution or allotment of any
rights; or to exercise any rights with respect of any change, conversion or exchange of stock or with respect to any other lawful
action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 7.4 - Lost,
Stolen or Destroyed Certificates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of the
loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the
Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory
bond or bonds of indemnity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 7.5 - Regulations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issue, transfer,
conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may
establish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE VIII - NOTICES</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 8.1 - Notices</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever notice is
required to be given to any shareholder, director, officer, or agent, such requirement shall not be construed to mean personal
notice. Such notice may in every instance be effectively given by depositing a writing in a post office or letter box, in a postpaid,
sealed wrapper, or by dispatching a prepaid telegram, addressed to such shareholder, director, officer, or agent at his or her
address as the same appears on the books of the corporation. The time when such notice is dispatched shall be the time of the giving
of the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 8.2 - Waivers</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A written waiver of
any notice, signed by a shareholder, director, officer or agent, whether before or after the time of the event for which notice
is given, shall be deemed equivalent to the notice required to be given to such shareholder, director, officer or agent. Neither
the business nor the purpose of any meeting need be specified in such a waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE IX - MISCELLANEOUS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.1 - <U>Facsimile
Signatures</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
provisions for the use of facsimile signatures elsewhere specifically authorized in these By-laws, facsimile signatures of any
officer or officers of the corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 9.2 - Corporate
Seal</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may provide a suitable seal, containing the name of the corporation, which seal shall be in the charge of the secretary. If and
when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the treasurer
or by the assistant secretary or assistant treasurer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 9.3 - Reliance
upon Books, Reports and Records</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, each
member of any committee designated by the Board of Directors, and each officer of the corporation shall, in the performance of
his duties, be fully protected in relying in good faith upon the books of account or other records of the corporation, including
reports made to the corporation by any of its officers, by an independent certified public accountant, or by an appraiser selected
with reasonable care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 9.4 - Fiscal
Year</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fiscal year of
the corporation shall be as fixed by resolution of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 9.5 - Time
Periods</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In applying any of
these By-laws which require that an act be done or not done a specified number of days prior to any event or that an act be done
during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall
be excluded and the day of the event shall be included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> ARTICLE X - AMENDMENTS</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Section 10.1 - Amendments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These By-laws, or any
portion hereof, may be amended or repealed by the Board of Directors at any meeting or by the shareholders at any meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT OF RESTATED
BY-LAWS, AS AMENDED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I, the undersigned,
do hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
I am duly elected and acting Chief Executive Officer of Apollo Medical Holdings, Inc., a Delaware corporation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
by Unanimous Written Consent of the Board of Directors of the corporation effective October 12, 2015, the first sentence of Section
3.1, Article III of the corporation&rsquo;s Restated By-laws was amended to read in full as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;The authorized
number of directors shall be fixed from time to time by the board of directors, provided that the authorized number of directors
shall not be less than one (1).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
I have hereunto subscribed my name as of October 12, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0; width: 35%; border-bottom: Black 1pt solid">/s/ Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Warren Hosseinion, M.D.&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: left; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amendment to Sections 3.1 and 3.2 of
Article III of the Bylaws of<BR>
Apollo Medical Holdings, Inc.,<BR>
a Delaware corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.1 of Article
III of the Bylaws of this Corporation shall be amended to by appending the following to Section 3.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;The Board of Directors shall
be divided into three (3) classes, Class I, Class II and Class III, effective at the same time that the stockholders appoint and
elect directors to the inaugural classes of Class I, Class II and Class III. Each director shall serve for a term expiring at the
third annual meeting following his or her election; provided, that, with respect to the directors serving in the inaugural classes
of Class I, Class II and Class III, the terms of the directors serving in Class I shall expire at the Corporation&rsquo;s first
annual meeting of stockholders held after the effectiveness of the division of the Board of Directors into three (3) classes; the
terms of the directors serving in Class II shall expire at the Corporation&rsquo;s second annual meeting of stockholders held after
such effectiveness; and the terms of the directors serving in Class III shall expire at the Corporation&rsquo;s third annual meeting
of stockholders held after such effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.2 of Article
III of the Bylaws of this Corporation shall be amended by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">appending the following language to the end of the first sentence of the first paragraph of Section
3.2:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;and directors so chosen shall
serve for a term expiring at the annual meeting of stockholders at which the term of office of the class to which they have been
elected expires or until such director&rsquo;s successor shall have been duly elected and qualified&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deleting
the second sentence of the first paragraph of Section 3.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amendments to Sections 2.1, 2.3 and
2.7 of Article II and 7.3 of Article VII<BR>
of the Restated Bylaws of<BR>
Apollo Medical Holdings, Inc.,<BR>
a Delaware corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Defined
Terms</U>. Unless otherwise defined herein, the capitalized terms used herein shall have the same meanings set forth in the Restated
Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
2.1 of Article II of the Restated Bylaws is hereby amended to read in full as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;An annual meeting of the shareholders,
for the selection of directors to succeed those whose terms expire and for the transaction of such other business as may properly
come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall fix. If the
Board of Directors does not designate a location for the annual meeting of the shareholders, such meeting shall be held at the
principal executive offices of the Corporation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
first paragraph of Section 2.3 of Article II of the Restated Bylaws is hereby amended to read in full as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;Written notice of the place,
date and time of all meetings of the shareholders shall be given, not less than ten nor more than sixty days before the date on
which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise provided herein or required
by law (meaning, here and hereinafter, as required from time to time by the corporation statutes of the State of Delaware).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fourth paragraph of Section 2.7 of Article II of the Restated Bylaws is hereby amended to read in full as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;If a quorum is present, all
matters shall be determined by a majority of the votes cast affirmatively or negatively, unless a greater number or voting by class
is required by law, the Certificate of Incorporation of the Corporation or these By-laws. Notwithstanding the preceding sentence
and anything in the last paragraph of Section 2.4 to the contrary, all director elections shall be determined by a plurality of
the votes cast.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
7.3 of Article VII of the Restated Bylaws is hereby amended to read in full as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;The Board of Directors may fix
a record date, which shall not be more than sixty nor less than ten days before the date of any meeting of shareholders, nor more
than sixty days prior to the time for the other action hereinafter described, as of which there shall be determined the shareholders
who are entitled: to notice of or to vote at any meeting of shareholders or any adjournment thereof&#894; to express consent to
corporate action in writing without a meeting&#894; to receive payment of any dividend or other distribution or allotment of any
rights&#894; or to exercise any rights with respect of any change, conversion or exchange of stock or with respect to any other
lawful action.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Full
Force and Effect. In all other respects, the Restated Bylaws, as amended, shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tv493730_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and Rules 13a-14 and 15d-14 under the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Thomas S. Lam, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q of Apollo Medical Holdings, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financing reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 15, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 61%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Thomas S. Lam</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Thomas S. Lam</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Co-Chief Executive Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tv493730_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and Rules 13a-14 and 15d-14 under the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Warren Hosseinion, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q of Apollo Medical Holdings, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financing reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 15, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 61%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Warren Hosseinion</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Warren Hosseinion</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Co-Chief Executive Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>6
<FILENAME>tv493730_ex31-3.htm
<DESCRIPTION>EXHIBIT 31.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and Rules 13a-14 and 15d-14 under the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Mihir Shah, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q of Apollo Medical Holdings, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financing reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 15, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 61%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Mihir Shah</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Mihir Shah</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Chief Financial Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>tv493730_ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification of Periodic Financial Report
by the Chief Executive Officer and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chief Financial Officer Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Solely for the purposes
of complying with 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we, the undersigned
duly elected and acting Chief Executive Officer and Chief Financial Officer of Apollo Medical Holdings, Inc. (the &ldquo;Company&rdquo;),
hereby certify, based on our knowledge, that this Quarterly Report on Form 10-Q of the Company for the quarter ended March 31,
2018 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as
amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 61%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Date: May 15, 2018</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; width: 39%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Thomas S. Lam</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Thomas S. Lam</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Co-Chief Executive Officer</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 61%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Date: May 15, 2018</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; width: 39%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Warren Hosseinion</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Warren Hosseinion</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Co-Chief Executive Officer</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Date: May 15, 2018</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Mihir Shah</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Mihir Shah</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: center"><B>Chief Financial Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>A signed original of this written statement
required by Section 1350 of Chapter 63 of Title 18 of the United States Code has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff on request.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The foregoing certification is being
furnished to the Securities and Exchange Commission pursuant to &sect; 18 U.S.C. Section 1350. It is not being filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of
the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>ameh-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:ameh="http://www.apollomed.net/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="ameh-20180331.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2017To03_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To01_02_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-01-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_31_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2018To03_21_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>

      <xbrli:endDate>2018-03-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_21_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_09_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApollomedMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ApollomedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_31_2016_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_15_2016_InternationalCancerCenterIccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:InternationalCancerCenterIccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_15_2016_InternationalCancerCenterIccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:InternationalCancerCenterIccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_04_2014_UniversalCareAcquisitionPartnersLlcMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-06-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_CustomerAMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerAMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_MoneyMarketFundsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MinimumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ameh:WarrantLiabilityMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MaximumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ameh:WarrantLiabilityMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ameh:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ameh:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApaacoMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2017To12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-12-01</xbrli:startDate>

      <xbrli:endDate>2017-12-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantOneMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:WarrantOneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantTwoMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:WarrantTwoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_30_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_ConvertiblePromissoryNoteMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApaAcoIncMemberusgaapConsolidatedEntitiesAxis_NetworkMedicalManagementIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApaAcoIncMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_NetworkMedicalManagementIncMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_CommonClassBMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_MaverickMedicalGroupIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_NetworkMedicalManagementIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ExclusivityMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ExclusivityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ApcLsmaMemberusgaapOwnershipAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_01_2015_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_10_2015_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_10_2015_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VotingCommonStockTwoMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_10_2015_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_10_2015_AncillaryServiceContractMemberamehContractTypeAxis_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VotingCommonStockTwoMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_14_2016_ApcLsmaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_14_2016_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_15_2016_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ApcMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2010_IccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:IccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_IccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:IccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_IccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:IccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2012_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_07_2017_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-04-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_21_2016_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_22_2016_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_03_2017_ApaacoMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_03_2017_ApcMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_ContractedPhysiciansAndOtherServicesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ameh:ContractedPhysiciansAndOtherServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ContractedPhysiciansAndOtherServicesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ameh:ContractedPhysiciansAndOtherServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_NetworkMedicalManagementIncNmmMemberusgaapBusinessAcquisitionAxis_StockCompensationPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:NetworkMedicalManagementIncNmmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_StockCompensationPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_16_2015_UniversalCareIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-11-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AdvanceDiagnosticSurgeryCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AdvanceDiagnosticSurgeryCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_LmaMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_LmaMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_LmaMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_PmiocMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_PmiocMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_PmiocMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AmgIncMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AmgIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AmgIncMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AmgIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2015_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:RobMikitarianMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:RobMikitarianMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_DmgMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_DmgMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MedicalPropertyPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApcShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_ApcShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ShareholdersAndOfficersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_ShareholdersAndOfficersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ApollomedMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:ApollomedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MinimumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MaximumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AncillaryServiceContractMemberamehContractTypeAxis_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AncillaryServiceContractMemberamehContractTypeAxis_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_IccMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:IccMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApcMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ApaacoMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_ApcMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_ExclusivityAmendmentAgreementApcMemberamehAmendmentAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="ameh:AmendmentAgreementAxis">ameh:ExclusivityAmendmentAgreementApcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">ameh:WarrantExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_FormerShareholdersOfNmmMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ameh:FormerShareholdersOfNmmMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AmehMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmehMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2018To04_30_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>

      <xbrli:endDate>2018-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MedicalInvestmentGroupLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalInvestmentGroupLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MedicalInvestmentGroupLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalInvestmentGroupLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorDMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorDMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorEMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorEMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_PacificAmbulatorySurgeryCenterMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:PacificAmbulatorySurgeryCenterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2018_RealEstateMemberusgaapCollateralAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:RealEstateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2018_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2018To04_18_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>

      <xbrli:endDate>2018-04-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:RobMikitarianMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MedicalPropertyPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2018_DmgMemberusgaapConsolidatedEntitiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_15_2012_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_ApcLsmaMemberusgaapOwnershipAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">ameh:AlliedPacificOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-10-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_PayorDMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_PayorDMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_CustomerBMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_CustomerBMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_CustomerCMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerCMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2018To03_23_2018_CustomerAMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerAMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>

      <xbrli:endDate>2018-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2018To03_23_2018_CustomerCMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CustomerCMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>

      <xbrli:endDate>2018-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_02_2018_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-01-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_CommercialMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MedicareMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_MedicaidMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To03_31_2018_OtherThirdPartiesMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_CommercialMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MedicareMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_MedicaidMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_OtherThirdPartiesMemberusgaapMajorCustomersAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="acre">
    <xbrli:measure>utr:acre</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2018To03_31_2018" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2018To03_31_2018" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2018To03_31_2018" id="Factid_3">2018-03-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2018To03_31_2018" id="Factid_4">2018</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2018To03_31_2018" id="Factid_5">Q1</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2018To03_31_2018" id="Factid_6">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2018To03_31_2018" id="Factid_7">0001083446</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2018To03_31_2018" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2018To03_31_2018" id="Factid_9">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:TradingSymbol contextRef="P01_01_2018To03_31_2018" id="Factid_10">AMEH</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn05_09_2018" id="Factid_11" unitRef="shares" decimals="INF">33334059</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2017" id="Factid_12" unitRef="USD" decimals="0">99749199</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2018" id="Factid_13" unitRef="USD" decimals="0">103731761</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn03_31_2018" id="Factid_14" unitRef="USD" decimals="0">3525437</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_15" unitRef="USD" decimals="0">3126866</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2018" id="Factid_16" unitRef="USD" decimals="0">180615388</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_17" unitRef="USD" decimals="0">144159562</us-gaap:AssetsCurrent>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018" id="Factid_18" unitRef="USD" decimals="0">99138657</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017" id="Factid_19" unitRef="USD" decimals="0">103533558</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:Goodwill contextRef="PAsOn03_31_2018" id="Factid_20" unitRef="USD" decimals="0">188933191</us-gaap:Goodwill>

  <us-gaap:Goodwill contextRef="PAsOn12_31_2017" id="Factid_21" unitRef="USD" decimals="0">189847202</us-gaap:Goodwill>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn03_31_2018" id="Factid_22" unitRef="USD" decimals="0">1585850</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2017" id="Factid_23" unitRef="USD" decimals="0">1632406</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn03_31_2018" id="Factid_24" unitRef="USD" decimals="0">521593913</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2017" id="Factid_25" unitRef="USD" decimals="0">490635793</us-gaap:Assets>

  <us-gaap:RestrictedCashCurrent contextRef="PAsOn03_31_2018" id="Factid_26" unitRef="USD" decimals="0">18028116</us-gaap:RestrictedCashCurrent>

  <us-gaap:RestrictedCashCurrent contextRef="PAsOn12_31_2017" id="Factid_27" unitRef="USD" decimals="0">18005661</us-gaap:RestrictedCashCurrent>

  <us-gaap:AssetsHeldInTrustCurrent contextRef="PAsOn03_31_2018" id="Factid_28" unitRef="USD" decimals="0">1386474</us-gaap:AssetsHeldInTrustCurrent>

  <us-gaap:AssetsHeldInTrustCurrent contextRef="PAsOn12_31_2017" id="Factid_29" unitRef="USD" decimals="0">2017437</us-gaap:AssetsHeldInTrustCurrent>

  <us-gaap:MarketableSecuritiesCurrent contextRef="PAsOn03_31_2018" id="Factid_30" unitRef="USD" decimals="0">1138477</us-gaap:MarketableSecuritiesCurrent>

  <us-gaap:MarketableSecuritiesCurrent contextRef="PAsOn12_31_2017" id="Factid_31" unitRef="USD" decimals="0">1143095</us-gaap:MarketableSecuritiesCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn03_31_2018" id="Factid_32" unitRef="USD" decimals="0">52805123</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2017" id="Factid_33" unitRef="USD" decimals="0">20117304</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2018" id="Factid_34" unitRef="USD" decimals="0">13700034</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2017" id="Factid_35" unitRef="USD" decimals="0">13814306</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn03_31_2018" id="Factid_36" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_37" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <us-gaap:LoansReceivableNet contextRef="PAsOn03_31_2018" id="Factid_38" unitRef="USD" decimals="0">10000000</us-gaap:LoansReceivableNet>

  <us-gaap:LoansReceivableNet contextRef="PAsOn12_31_2017" id="Factid_39" unitRef="USD" decimals="0">10000000</us-gaap:LoansReceivableNet>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018" id="Factid_40" unitRef="USD" decimals="0">21875500</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017" id="Factid_41" unitRef="USD" decimals="0">21903524</us-gaap:EquityMethodInvestments>

  <us-gaap:RestrictedCashNoncurrent contextRef="PAsOn03_31_2018" id="Factid_42" unitRef="USD" decimals="0">745293</us-gaap:RestrictedCashNoncurrent>

  <us-gaap:RestrictedCashNoncurrent contextRef="PAsOn12_31_2017" id="Factid_43" unitRef="USD" decimals="0">745235</us-gaap:RestrictedCashNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn03_31_2018" id="Factid_44" unitRef="USD" decimals="0">340978525</us-gaap:AssetsNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn12_31_2017" id="Factid_45" unitRef="USD" decimals="0">346476231</us-gaap:AssetsNoncurrent>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_46" unitRef="USD" decimals="0">490635793</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2018" id="Factid_47" unitRef="USD" decimals="0">521593913</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2018" id="Factid_48" unitRef="USD" decimals="0">12110530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_49" unitRef="USD" decimals="0">13279620</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <ameh:MedicalLiabilitiesCurrent contextRef="PAsOn03_31_2018" id="Factid_50" unitRef="USD" decimals="0">69110826</ameh:MedicalLiabilitiesCurrent>

  <ameh:MedicalLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_51" unitRef="USD" decimals="0">63972318</ameh:MedicalLiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2018" id="Factid_52" unitRef="USD" decimals="0">110616762</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_53" unitRef="USD" decimals="0">109601999</us-gaap:LiabilitiesCurrent>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2017" id="Factid_54" unitRef="USD" decimals="0">24916598</us-gaap:DeferredTaxLiabilities>

  <us-gaap:Liabilities contextRef="PAsOn03_31_2018" id="Factid_55" unitRef="USD" decimals="0">160451458</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2017" id="Factid_56" unitRef="USD" decimals="0">154322623</us-gaap:Liabilities>

  <us-gaap:CommonStockValue contextRef="PAsOn03_31_2018" id="Factid_57" unitRef="USD" decimals="0">32653</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2017" id="Factid_58" unitRef="USD" decimals="0">32305</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn03_31_2018" id="Factid_59" unitRef="USD" decimals="0">160736190</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2017" id="Factid_60" unitRef="USD" decimals="0">158181192</us-gaap:AdditionalPaidInCapital>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2018" id="Factid_61" unitRef="USD" decimals="0">4897454</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2017" id="Factid_62" unitRef="USD" decimals="0">1734531</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:MinorityInterest contextRef="PAsOn03_31_2018" id="Factid_63" unitRef="USD" decimals="0">4821846</us-gaap:MinorityInterest>

  <us-gaap:MinorityInterest contextRef="PAsOn12_31_2017" id="Factid_64" unitRef="USD" decimals="0">4235398</us-gaap:MinorityInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2018" id="Factid_65" unitRef="USD" decimals="0">170488143</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2017" id="Factid_66" unitRef="USD" decimals="0">164183426</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn03_31_2018" id="Factid_67" unitRef="USD" decimals="0">30055819</us-gaap:DeferredTaxLiabilities>

  <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_68" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_69" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_70" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_71" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <ameh:IncentivePayableCurrent contextRef="PAsOn12_31_2017" id="Factid_72" unitRef="USD" decimals="0">21500000</ameh:IncentivePayableCurrent>

  <ameh:IncentivePayableCurrent contextRef="PAsOn03_31_2018" id="Factid_73" unitRef="USD" decimals="0">14900000</ameh:IncentivePayableCurrent>

  <ameh:FiduciaryAccountsPayableCurrent contextRef="PAsOn03_31_2018" id="Factid_74" unitRef="USD" decimals="0">1386474</ameh:FiduciaryAccountsPayableCurrent>

  <ameh:FiduciaryAccountsPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_75" unitRef="USD" decimals="0">2017437</ameh:FiduciaryAccountsPayableCurrent>

  <us-gaap:AccruedIncomeTaxesCurrent contextRef="PAsOn03_31_2018" id="Factid_76" unitRef="USD" decimals="0">7614669</us-gaap:AccruedIncomeTaxesCurrent>

  <us-gaap:AccruedIncomeTaxesCurrent contextRef="PAsOn12_31_2017" id="Factid_77" unitRef="USD" decimals="0">3198495</us-gaap:AccruedIncomeTaxesCurrent>

  <us-gaap:CapitalLeaseObligationsCurrent contextRef="PAsOn03_31_2018" id="Factid_78" unitRef="USD" decimals="0">99480</us-gaap:CapitalLeaseObligationsCurrent>

  <us-gaap:CapitalLeaseObligationsCurrent contextRef="PAsOn12_31_2017" id="Factid_79" unitRef="USD" decimals="0">98738</us-gaap:CapitalLeaseObligationsCurrent>

  <ameh:LiabilityForUnissuedEquitySharesNoncurrent contextRef="PAsOn03_31_2018" id="Factid_80" unitRef="USD" decimals="0">1185025</ameh:LiabilityForUnissuedEquitySharesNoncurrent>

  <ameh:LiabilityForUnissuedEquitySharesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_81" unitRef="USD" decimals="0">1185025</ameh:LiabilityForUnissuedEquitySharesNoncurrent>

  <ameh:DividendPayableNoncurrent contextRef="PAsOn03_31_2018" id="Factid_82" unitRef="USD" decimals="0">18000000</ameh:DividendPayableNoncurrent>

  <ameh:DividendPayableNoncurrent contextRef="PAsOn12_31_2017" id="Factid_83" unitRef="USD" decimals="0">18000000</ameh:DividendPayableNoncurrent>

  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="PAsOn03_31_2018" id="Factid_84" unitRef="USD" decimals="0">593852</us-gaap:CapitalLeaseObligationsNoncurrent>

  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="PAsOn12_31_2017" id="Factid_85" unitRef="USD" decimals="0">619001</us-gaap:CapitalLeaseObligationsNoncurrent>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn03_31_2018" id="Factid_86" unitRef="USD" decimals="0">49834696</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn12_31_2017" id="Factid_87" unitRef="USD" decimals="0">44720624</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="PAsOn03_31_2018" id="Factid_88" unitRef="USD" decimals="0">190654312</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>

  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="PAsOn12_31_2017" id="Factid_89" unitRef="USD" decimals="0">172129744</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn03_31_2018" id="Factid_90" unitRef="USD" decimals="0">394783</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn12_31_2017" id="Factid_91" unitRef="USD" decimals="0">510391</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:LinesOfCreditCurrent contextRef="PAsOn03_31_2018" id="Factid_92" unitRef="USD" decimals="0">5000000</us-gaap:LinesOfCreditCurrent>

  <us-gaap:LinesOfCreditCurrent contextRef="PAsOn12_31_2017" id="Factid_93" unitRef="USD" decimals="0">5025000</us-gaap:LinesOfCreditCurrent>

  <us-gaap:CostOfServices contextRef="P01_01_2017To03_31_2017" id="Factid_94" unitRef="USD" decimals="0">59607514</us-gaap:CostOfServices>

  <us-gaap:CostOfServices contextRef="P01_01_2018To03_31_2018" id="Factid_95" unitRef="USD" decimals="0">84670608</us-gaap:CostOfServices>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2017To03_31_2017" id="Factid_96" unitRef="USD" decimals="0">5211633</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2018To03_31_2018" id="Factid_97" unitRef="USD" decimals="0">11735898</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P01_01_2017To03_31_2017" id="Factid_98" unitRef="USD" decimals="0">4836351</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P01_01_2018To03_31_2018" id="Factid_99" unitRef="USD" decimals="0">5058512</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:InterestExpense contextRef="P01_01_2017To03_31_2017" id="Factid_100" unitRef="USD" decimals="0">811</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2018To03_31_2018" id="Factid_101" unitRef="USD" decimals="0">85001</us-gaap:InterestExpense>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017" id="Factid_102" unitRef="USD" decimals="0">19613036</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018" id="Factid_103" unitRef="USD" decimals="0">22946495</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2017To03_31_2017" id="Factid_104" unitRef="USD" decimals="0">7374130</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2018To03_31_2018" id="Factid_105" unitRef="USD" decimals="0">13557200</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:ProfitLoss contextRef="P01_01_2018To03_31_2018" id="Factid_106" unitRef="USD" decimals="0">15717655</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2017To03_31_2017" id="Factid_107" unitRef="USD" decimals="0">11723791</us-gaap:ProfitLoss>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2018To03_31_2018" id="Factid_108" unitRef="USD" decimals="0">244786</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2017To03_31_2017" id="Factid_109" unitRef="USD" decimals="0">3932472</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P01_01_2018To03_31_2018" id="Factid_110" unitRef="USD" decimals="0">87993</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:OtherNonoperatingIncomeExpense contextRef="P01_01_2017To03_31_2017" id="Factid_111" unitRef="USD" decimals="0">1514</us-gaap:OtherNonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To03_31_2017" id="Factid_112" unitRef="USD" decimals="0">4349661</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2018To03_31_2018" id="Factid_113" unitRef="USD" decimals="0">2160455</us-gaap:NetIncomeLoss>

  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="P01_01_2017To03_31_2017" id="Factid_114" unitRef="USD" decimals="0">1522222</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>

  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="P01_01_2018To03_31_2018" id="Factid_115" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2017To03_31_2017" id="Factid_116" unitRef="USD" decimals="0">15680564</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2018To03_31_2018" id="Factid_117" unitRef="USD" decimals="0">22701709</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingExpenses contextRef="P01_01_2017To03_31_2017" id="Factid_118" unitRef="USD" decimals="0">69655498</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2018To03_31_2018" id="Factid_119" unitRef="USD" decimals="0">101465018</us-gaap:OperatingExpenses>

  <us-gaap:EarningsPerShareBasic contextRef="P01_01_2018To03_31_2018" id="Factid_120" unitRef="USD_per_Share" decimals="2">0.07</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareBasic contextRef="P01_01_2017To03_31_2017" id="Factid_121" unitRef="USD_per_Share" decimals="2">0.17</us-gaap:EarningsPerShareBasic>

  <us-gaap:EarningsPerShareDiluted contextRef="P01_01_2018To03_31_2018" id="Factid_122" unitRef="USD_per_Share" decimals="2">0.06</us-gaap:EarningsPerShareDiluted>

  <us-gaap:EarningsPerShareDiluted contextRef="P01_01_2017To03_31_2017" id="Factid_123" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:EarningsPerShareDiluted>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P01_01_2018To03_31_2018" id="Factid_124" unitRef="shares" decimals="INF">32421467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="P01_01_2017To03_31_2017" id="Factid_125" unitRef="shares" decimals="INF">25067954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P01_01_2018To03_31_2018" id="Factid_126" unitRef="shares" decimals="INF">38098373</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="P01_01_2017To03_31_2017" id="Factid_127" unitRef="shares" decimals="INF">28445647</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>

  <us-gaap:ManagementFeesRevenue contextRef="P01_01_2018To03_31_2018" id="Factid_128" unitRef="USD" decimals="0">12074572</us-gaap:ManagementFeesRevenue>

  <us-gaap:ManagementFeesRevenue contextRef="P01_01_2017To03_31_2017" id="Factid_129" unitRef="USD" decimals="0">6537110</us-gaap:ManagementFeesRevenue>

  <us-gaap:OtherSalesRevenueNet contextRef="P01_01_2018To03_31_2018" id="Factid_130" unitRef="USD" decimals="0">452026</us-gaap:OtherSalesRevenueNet>

  <us-gaap:OtherSalesRevenueNet contextRef="P01_01_2017To03_31_2017" id="Factid_131" unitRef="USD" decimals="0">281706</us-gaap:OtherSalesRevenueNet>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018" id="Factid_132" unitRef="USD" decimals="0">-28024</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017" id="Factid_133" unitRef="USD" decimals="0">2227262</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:HealthCareOrganizationCapitationRevenue contextRef="P01_01_2018To03_31_2018" id="Factid_134" unitRef="USD" decimals="0">85905284</us-gaap:HealthCareOrganizationCapitationRevenue>

  <us-gaap:HealthCareOrganizationCapitationRevenue contextRef="P01_01_2017To03_31_2017" id="Factid_135" unitRef="USD" decimals="0">64716133</us-gaap:HealthCareOrganizationCapitationRevenue>

  <us-gaap:HealthCareOrganizationOtherRevenue contextRef="P01_01_2018To03_31_2018" id="Factid_136" unitRef="USD" decimals="0">17986736</us-gaap:HealthCareOrganizationOtherRevenue>

  <us-gaap:HealthCareOrganizationOtherRevenue contextRef="P01_01_2017To03_31_2017" id="Factid_137" unitRef="USD" decimals="0">11137200</us-gaap:HealthCareOrganizationOtherRevenue>

  <us-gaap:HealthCareOrganizationPatientServiceRevenue contextRef="P01_01_2018To03_31_2018" id="Factid_138" unitRef="USD" decimals="0">7748109</us-gaap:HealthCareOrganizationPatientServiceRevenue>

  <us-gaap:HealthCareOrganizationPatientServiceRevenue contextRef="P01_01_2017To03_31_2017" id="Factid_139" unitRef="USD" decimals="0">2663913</us-gaap:HealthCareOrganizationPatientServiceRevenue>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2018To03_31_2018" id="Factid_140" unitRef="USD" decimals="0">124166727</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2017To03_31_2017" id="Factid_141" unitRef="USD" decimals="0">85336062</us-gaap:SalesRevenueNet>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2018To03_31_2018" id="Factid_142" unitRef="USD" decimals="0">269818</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2017To03_31_2017" id="Factid_143" unitRef="USD" decimals="0">182285</us-gaap:InvestmentIncomeInterest>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2018To03_31_2018" id="Factid_144" unitRef="USD" decimals="0">7228840</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2017To03_31_2017" id="Factid_145" unitRef="USD" decimals="0">7889245</us-gaap:IncomeTaxExpenseBenefit>

  <ameh:IncreaseDecreaseInMedicalLiabilities contextRef="P01_01_2017To03_31_2017" id="Factid_146" unitRef="USD" decimals="0">-257945</ameh:IncreaseDecreaseInMedicalLiabilities>

  <ameh:IncreaseDecreaseInMedicalLiabilities contextRef="P01_01_2018To03_31_2018" id="Factid_147" unitRef="USD" decimals="0">5138508</ameh:IncreaseDecreaseInMedicalLiabilities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2017To03_31_2017" id="Factid_148" unitRef="USD" decimals="0">-4295122</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2018To03_31_2018" id="Factid_149" unitRef="USD" decimals="0">-489053</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="P01_01_2018To03_31_2018" id="Factid_150" unitRef="USD" decimals="0">59444</us-gaap:IncreaseDecreaseInOtherOperatingAssets>

  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="P01_01_2017To03_31_2017" id="Factid_151" unitRef="USD" decimals="0">54368</us-gaap:IncreaseDecreaseInOtherOperatingAssets>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2018To03_31_2018" id="Factid_152" unitRef="USD" decimals="0">-1169363</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2017To03_31_2017" id="Factid_153" unitRef="USD" decimals="0">-2350949</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2018To03_31_2018" id="Factid_154" unitRef="USD" decimals="0">4735359</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2017To03_31_2017" id="Factid_155" unitRef="USD" decimals="0">21105648</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="P01_01_2018To03_31_2018" id="Factid_156" unitRef="USD" decimals="0">398571</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>

  <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="P01_01_2017To03_31_2017" id="Factid_157" unitRef="USD" decimals="0">428871</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>

  <us-gaap:UnrealizedGainLossOnInvestments contextRef="P01_01_2018To03_31_2018" id="Factid_158" unitRef="USD" decimals="0">-8550</us-gaap:UnrealizedGainLossOnInvestments>

  <us-gaap:UnrealizedGainLossOnInvestments contextRef="P01_01_2017To03_31_2017" id="Factid_159" unitRef="USD" decimals="0">0</us-gaap:UnrealizedGainLossOnInvestments>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2018To03_31_2018" id="Factid_160" unitRef="USD" decimals="0">833944</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To03_31_2017" id="Factid_161" unitRef="USD" decimals="0">321233</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="P01_01_2018To03_31_2018" id="Factid_162" unitRef="USD" decimals="0">4416174</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>

  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="P01_01_2017To03_31_2017" id="Factid_163" unitRef="USD" decimals="0">4267804</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>

  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="P01_01_2018To03_31_2018" id="Factid_164" unitRef="USD" decimals="0">3932</us-gaap:PaymentsToAcquireMarketableSecurities>

  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="P01_01_2017To03_31_2017" id="Factid_165" unitRef="USD" decimals="0">1301</us-gaap:PaymentsToAcquireMarketableSecurities>

  <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="P01_01_2018To03_31_2018" id="Factid_166" unitRef="USD" decimals="0">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>

  <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="P01_01_2017To03_31_2017" id="Factid_167" unitRef="USD" decimals="0">5000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>

  <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="P01_01_2018To03_31_2018" id="Factid_168" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>

  <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="P01_01_2017To03_31_2017" id="Factid_169" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>

  <ameh:ProceedsFromSaleOfCostMethodInvestments contextRef="P01_01_2018To03_31_2018" id="Factid_170" unitRef="USD" decimals="0">0</ameh:ProceedsFromSaleOfCostMethodInvestments>

  <ameh:ProceedsFromSaleOfCostMethodInvestments contextRef="P01_01_2017To03_31_2017" id="Factid_171" unitRef="USD" decimals="0">25000</ameh:ProceedsFromSaleOfCostMethodInvestments>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2018To03_31_2018" id="Factid_172" unitRef="USD" decimals="0">21087819</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P01_01_2017To03_31_2017" id="Factid_173" unitRef="USD" decimals="0">-14410196</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2018To03_31_2018" id="Factid_174" unitRef="USD" decimals="0">485121</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2017To03_31_2017" id="Factid_175" unitRef="USD" decimals="0">318821</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="P01_01_2018To03_31_2018" id="Factid_176" unitRef="USD" decimals="0">2807407</us-gaap:DeferredIncomeTaxExpenseBenefit>

  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="P01_01_2017To03_31_2017" id="Factid_177" unitRef="USD" decimals="0">2109535</us-gaap:DeferredIncomeTaxExpenseBenefit>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2018To03_31_2018" id="Factid_178" unitRef="USD" decimals="0">-241231</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2017To03_31_2017" id="Factid_179" unitRef="USD" decimals="0">-8383455</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2018To03_31_2018" id="Factid_180" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2017To03_31_2017" id="Factid_181" unitRef="USD" decimals="0">1511000</us-gaap:IncomeTaxesPaid>

  <us-gaap:InterestPaidNet contextRef="P01_01_2018To03_31_2018" id="Factid_182" unitRef="USD" decimals="0">73610</us-gaap:InterestPaidNet>

  <us-gaap:InterestPaidNet contextRef="P01_01_2017To03_31_2017" id="Factid_183" unitRef="USD" decimals="0">811</us-gaap:InterestPaidNet>

  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="P01_01_2018To03_31_2018" id="Factid_184" unitRef="USD" decimals="0">24407</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>

  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="P01_01_2017To03_31_2017" id="Factid_185" unitRef="USD" decimals="0">30980</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>

  <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="P01_01_2018To03_31_2018" id="Factid_186" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>

  <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="P01_01_2017To03_31_2017" id="Factid_187" unitRef="USD" decimals="0">-27500</us-gaap:ProceedsFromPaymentsToMinorityShareholders>

  <us-gaap:PaymentsOfDividends contextRef="P01_01_2018To03_31_2018" id="Factid_188" unitRef="USD" decimals="0">2000000</us-gaap:PaymentsOfDividends>

  <us-gaap:PaymentsOfDividends contextRef="P01_01_2017To03_31_2017" id="Factid_189" unitRef="USD" decimals="0">8750000</us-gaap:PaymentsOfDividends>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P01_01_2018To03_31_2018" id="Factid_190" unitRef="USD" decimals="0">140608</us-gaap:RepaymentsOfRelatedPartyDebt>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P01_01_2017To03_31_2017" id="Factid_191" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfRelatedPartyDebt>

  <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement contextRef="P01_01_2018To03_31_2018" id="Factid_192">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_ApollomedMemberusgaapConsolidatedEntitiesAxis" id="Factid_193" unitRef="pure" decimals="4">0.0490</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="P01_01_2011To12_31_2011_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis" id="Factid_194" unitRef="USD" decimals="0">625000</us-gaap:PaymentsToAcquireEquityMethodInvestments>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2011_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis" id="Factid_195" unitRef="pure" decimals="4">0.4159</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn05_31_2016_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis" id="Factid_196" unitRef="pure" decimals="4">0.4380</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn07_31_2016_ConcourseDiagnosticSurgeryCenterLlcMemberusgaapConsolidatedEntitiesAxis" id="Factid_197" unitRef="pure" decimals="4">0.4343</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn11_15_2016_InternationalCancerCenterIccMemberdeiLegalEntityAxis" id="Factid_198" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P11_01_2016To11_15_2016_InternationalCancerCenterIccMemberdeiLegalEntityAxis" id="Factid_199" unitRef="USD" decimals="0">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn06_04_2014_UniversalCareAcquisitionPartnersLlcMemberusgaapConsolidatedEntitiesAxis" id="Factid_200" unitRef="pure" decimals="0">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:CashUninsuredAmount contextRef="PAsOn03_31_2018" id="Factid_201" unitRef="USD" decimals="-5">135000000</us-gaap:CashUninsuredAmount>

  <ameh:RestrictedCashInterestRate contextRef="PAsOn03_31_2018_MinimumMemberusgaapRangeAxis" id="Factid_202" unitRef="pure" decimals="4">0.0005</ameh:RestrictedCashInterestRate>

  <ameh:RestrictedCashInterestRate contextRef="PAsOn03_31_2018_MaximumMemberusgaapRangeAxis" id="Factid_203" unitRef="pure" decimals="4">0.0010</ameh:RestrictedCashInterestRate>

  <us-gaap:RestrictedCash contextRef="PAsOn03_31_2018" id="Factid_204" unitRef="USD" decimals="0">18028116</us-gaap:RestrictedCash>

  <us-gaap:RestrictedCash contextRef="PAsOn12_31_2017" id="Factid_205" unitRef="USD" decimals="0">18005661</us-gaap:RestrictedCash>

  <us-gaap:IncreaseInRestrictedCash contextRef="P01_01_2018To03_31_2018" id="Factid_206" unitRef="USD" decimals="0">18000000</us-gaap:IncreaseInRestrictedCash>

  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="PAsOn03_31_2018" id="Factid_207" unitRef="USD" decimals="0">763205</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>

  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="PAsOn12_31_2017" id="Factid_208" unitRef="USD" decimals="0">407953</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_CustomerAMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_209" unitRef="pure" decimals="3">0.129</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_210" unitRef="USD" decimals="0">42300818</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_211" unitRef="USD" decimals="0">1061022</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_212" unitRef="USD" decimals="0">77455</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_213" unitRef="USD" decimals="0">43439295</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_214" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_215" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_216" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_217" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_218" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_219" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_220" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_221" unitRef="USD" decimals="0">42300818</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" id="Factid_222" unitRef="USD" decimals="0">1061022</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_EquitySecuritiesMemberusgaapInvestmentTypeAxis" id="Factid_223" unitRef="USD" decimals="0">77455</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_224" unitRef="USD" decimals="0">41231405</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_225" unitRef="USD" decimals="0">1057090</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_226" unitRef="USD" decimals="0">42374500</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_227" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_228" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_229" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_230" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_231" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_232" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_MoneyMarketFundsMemberusgaapInvestmentTypeAxis" id="Factid_233" unitRef="USD" decimals="0">41231405</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" id="Factid_234" unitRef="USD" decimals="0">1057090</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn12_31_2016" id="Factid_235" unitRef="USD" decimals="0">5338886</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>

  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease contextRef="P01_01_2017To03_31_2017" id="Factid_236" unitRef="USD" decimals="0">1522222</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>

  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn03_31_2017" id="Factid_237" unitRef="USD" decimals="0">6861108</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To03_31_2017_MinimumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_238" unitRef="pure" decimals="4">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To03_31_2017_MaximumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_239" unitRef="pure" decimals="4">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To03_31_2017_MaximumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_240" unitRef="pure" decimals="3">0.623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To03_31_2017_MinimumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_241" unitRef="pure" decimals="3">0.624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:SharePrice contextRef="PAsOn03_31_2017_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_242" unitRef="USD_per_Share" decimals="2">9.00</us-gaap:SharePrice>

  <ameh:PercentageForDownRoundFinancing contextRef="P01_01_2017To03_31_2017_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_243" unitRef="pure" decimals="0">0</ameh:PercentageForDownRoundFinancing>

  <us-gaap:DerivativeAssetsNoncurrent contextRef="PAsOn03_31_2017_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_244" unitRef="USD" decimals="-5">6900000</us-gaap:DerivativeAssetsNoncurrent>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To03_31_2017_MinimumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_245">P3Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To03_31_2017_MaximumMemberusgaapRangeAxis_WarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" id="Factid_246">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <ameh:EstimatedRevenuePercentage contextRef="P01_01_2018To03_31_2018_ApaacoMemberdeiLegalEntityAxis" id="Factid_247" unitRef="pure" decimals="0">1</ameh:EstimatedRevenuePercentage>

  <ameh:BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare contextRef="P12_01_2017To12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_248" unitRef="shares" decimals="INF">2566666</ameh:BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare>

  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_249" unitRef="pure" decimals="2">0.82</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantOneMemberusgaapClassOfWarrantOrRightAxis" id="Factid_250" unitRef="shares" decimals="INF">850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantOneMemberusgaapClassOfWarrantOrRightAxis" id="Factid_251" unitRef="USD_per_Share" decimals="2">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantTwoMemberusgaapClassOfWarrantOrRightAxis" id="Factid_252" unitRef="shares" decimals="INF">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_WarrantTwoMemberusgaapClassOfWarrantOrRightAxis" id="Factid_253" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P03_01_2017To03_30_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_ConvertiblePromissoryNoteMemberusgaapDebtInstrumentAxis" id="Factid_254" unitRef="shares" decimals="INF">520081</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P03_01_2017To03_30_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_ConvertiblePromissoryNoteMemberusgaapDebtInstrumentAxis" id="Factid_255" unitRef="USD" decimals="-4">4990000</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_ApaAcoIncMemberusgaapConsolidatedEntitiesAxis_NetworkMedicalManagementIncMemberdeiLegalEntityAxis" id="Factid_256" unitRef="pure" decimals="1">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_ApaAcoIncMemberusgaapConsolidatedEntitiesAxis" id="Factid_257" unitRef="pure" decimals="1">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="P01_01_2018To03_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_258" unitRef="USD" decimals="0">19118000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>

  <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="P01_01_2018To03_31_2018_NetworkMedicalManagementIncMemberdeiLegalEntityAxis_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_259" unitRef="USD" decimals="0">5129000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>

  <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_260" unitRef="USD" decimals="0">187333</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>

  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="P01_01_2018To03_31_2018" id="Factid_261" unitRef="USD" decimals="0">85526383</us-gaap:BusinessCombinationConsiderationTransferred1>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P12_01_2017To12_08_2017_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_262" unitRef="shares" decimals="INF">6109205</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <us-gaap:BusinessAcquisitionSharePrice contextRef="PAsOn03_31_2018" id="Factid_263" unitRef="USD_per_Share" decimals="0">10</us-gaap:BusinessAcquisitionSharePrice>

  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="P01_01_2018To03_31_2018" id="Factid_264" unitRef="USD" decimals="0">61092050</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>

  <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis_CommonClassBMemberusgaapStatementClassOfStockAxis" id="Factid_265" unitRef="USD" decimals="0">6373000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_266">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_267" unitRef="pure" decimals="3">0.379</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_268" unitRef="pure" decimals="3">0.018</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_269" unitRef="USD" decimals="0">12745000</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="PAsOn03_31_2018" id="Factid_270" unitRef="USD" decimals="0">36367555</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="PAsOn03_31_2018" id="Factid_271" unitRef="USD" decimals="0">7261588</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="PAsOn03_31_2018" id="Factid_272" unitRef="USD" decimals="0">3211028</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="PAsOn03_31_2018" id="Factid_273" unitRef="USD" decimals="0">249193</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="PAsOn03_31_2018" id="Factid_274" unitRef="USD" decimals="0">1114332</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>

  <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash contextRef="PAsOn03_31_2018" id="Factid_275" unitRef="USD" decimals="0">745220</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn03_31_2018" id="Factid_276" unitRef="USD" decimals="0">14984000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="PAsOn03_31_2018" id="Factid_277" unitRef="USD" decimals="0">217241</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="PAsOn03_31_2018" id="Factid_278" unitRef="USD" decimals="0">8632893</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>

  <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities contextRef="PAsOn03_31_2018" id="Factid_279" unitRef="USD" decimals="0">39353540</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities>

  <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit contextRef="PAsOn03_31_2018" id="Factid_280" unitRef="USD" decimals="0">25000</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit>

  <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable contextRef="PAsOn03_31_2018" id="Factid_281" unitRef="USD" decimals="0">5376215</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable>

  <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty contextRef="PAsOn03_31_2018" id="Factid_282" unitRef="USD" decimals="0">9921938</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty>

  <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="PAsOn03_31_2018" id="Factid_283" unitRef="USD" decimals="0">3142000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="PAsOn03_31_2018" id="Factid_284" unitRef="USD" decimals="0">66451586</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="PAsOn03_31_2018" id="Factid_285" unitRef="USD" decimals="0">-913468</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>

  <ameh:PaymentsForAgreementTermination contextRef="P01_01_2018To03_31_2018" id="Factid_286" unitRef="USD" decimals="0">400000</ameh:PaymentsForAgreementTermination>

  <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="PAsOn03_31_2018_MaverickMedicalGroupIncMemberusgaapBusinessAcquisitionAxis" id="Factid_287" unitRef="USD" decimals="0">100</us-gaap:BusinessCombinationContingentConsiderationAsset>

  <ameh:PaymentsForAgreementTermination contextRef="P01_01_2018To03_31_2018_NetworkMedicalManagementIncMemberdeiLegalEntityAxis" id="Factid_288" unitRef="USD" decimals="0">400000</ameh:PaymentsForAgreementTermination>

  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="P01_01_2017To03_31_2017" id="Factid_289" unitRef="USD" decimals="0">98467260</us-gaap:BusinessAcquisitionsProFormaRevenue>

  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="P01_01_2017To03_31_2017" id="Factid_290" unitRef="USD" decimals="0">-351982</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>

  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="P01_01_2017To03_31_2017" id="Factid_291" unitRef="USD_per_Share" decimals="2">-0.01</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>

  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted contextRef="P01_01_2017To03_31_2017" id="Factid_292" unitRef="USD_per_Share" decimals="2">-0.01</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_293">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_294">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_295">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_296" unitRef="USD" decimals="0">22832000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_297" unitRef="USD" decimals="0">6696000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_298" unitRef="USD" decimals="0">2060000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_299" unitRef="USD" decimals="0">1011000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_300" unitRef="USD" decimals="0">109883000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_301" unitRef="USD" decimals="0">1994000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_302" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_303" unitRef="USD" decimals="0">39179025</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_304" unitRef="USD" decimals="0">5646843</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_305" unitRef="USD" decimals="0">357292</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_306" unitRef="USD" decimals="0">137333</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_307" unitRef="USD" decimals="0">16850</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_308" unitRef="USD" decimals="0">1994000</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_309" unitRef="USD" decimals="0">70703975</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_310" unitRef="USD" decimals="0">17185157</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_311" unitRef="USD" decimals="0">6338708</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_312" unitRef="USD" decimals="0">1922667</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_313" unitRef="USD" decimals="0">994150</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2016To12_31_2016_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_314">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_315" unitRef="USD" decimals="0">22832000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_316" unitRef="USD" decimals="0">6696000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_317" unitRef="USD" decimals="0">35842508</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_318" unitRef="USD" decimals="0">5014886</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_319" unitRef="USD" decimals="0">46500</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_ManagementContractsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_320" unitRef="USD" decimals="0">17817114</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_321" unitRef="USD" decimals="0">6649500</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_322" unitRef="USD" decimals="0">74040492</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_323" unitRef="USD" decimals="0">109883000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition contextRef="P01_01_2018To03_31_2018" id="Factid_324" unitRef="USD" decimals="0">4394901</ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition>

  <ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition contextRef="P01_01_2017To03_31_2017" id="Factid_325" unitRef="USD" decimals="0">4374841</ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition>

  <ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition contextRef="P01_01_2018To03_31_2018_ExclusivityMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_326" unitRef="USD" decimals="0">106000</ameh:FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="PAsOn03_31_2018" id="Factid_327" unitRef="USD" decimals="0">12262000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="PAsOn03_31_2018" id="Factid_328" unitRef="USD" decimals="0">14480000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="PAsOn03_31_2018" id="Factid_329" unitRef="USD" decimals="0">12671000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="PAsOn03_31_2018" id="Factid_330" unitRef="USD" decimals="0">10961000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="PAsOn03_31_2018" id="Factid_331" unitRef="USD" decimals="0">9448000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="PAsOn03_31_2018" id="Factid_332" unitRef="USD" decimals="0">37323000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>

  <us-gaap:EquityMethodInvestmentAggregateCost contextRef="PAsOn12_31_2012_ApcLsmaMemberusgaapOwnershipAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_333" unitRef="USD" decimals="0">5000000</us-gaap:EquityMethodInvestmentAggregateCost>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2012_ApcLsmaMemberusgaapOwnershipAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_334" unitRef="pure" decimals="2">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_335" unitRef="USD" decimals="0">9099975</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_336" unitRef="USD" decimals="0">9452767</us-gaap:EquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_337" unitRef="USD" decimals="0">-352792</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_338" unitRef="USD" decimals="0">1311738</us-gaap:IncomeLossFromEquityMethodInvestments>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_339" unitRef="USD" decimals="0">22064701</ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_340" unitRef="USD" decimals="0">21065105</ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_341" unitRef="USD" decimals="0">3005144</ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_342" unitRef="USD" decimals="0">2433116</ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_343" unitRef="USD" decimals="0">2173110</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_344" unitRef="USD" decimals="0">1565606</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_345" unitRef="USD" decimals="0">1250000</ameh:EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_346" unitRef="USD" decimals="0">1250000</ameh:EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_347" unitRef="USD" decimals="0">664612</ameh:EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_348" unitRef="USD" decimals="0">662109</ameh:EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_349" unitRef="USD" decimals="0">29157567</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_350" unitRef="USD" decimals="0">26975936</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_351" unitRef="USD" decimals="0">23946133</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_352" unitRef="USD" decimals="0">20353337</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_353" unitRef="USD" decimals="0">5211434</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_354" unitRef="USD" decimals="0">6622599</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_355" unitRef="USD" decimals="0">29157567</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_356" unitRef="USD" decimals="0">26975936</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue contextRef="P01_01_2018To03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_357" unitRef="USD" decimals="0">52983791</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue contextRef="P01_01_2017To03_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_358" unitRef="USD" decimals="0">49753004</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales contextRef="P01_01_2018To03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_359" unitRef="USD" decimals="0">54002458</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales contextRef="P01_01_2017To03_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_360" unitRef="USD" decimals="0">44506050</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss contextRef="P01_01_2018To03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_361" unitRef="USD" decimals="0">-1018667</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss contextRef="P01_01_2017To03_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_362" unitRef="USD" decimals="0">5246954</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>

  <us-gaap:EquityMethodInvestmentAggregateCost contextRef="PAsOn07_01_2015_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_363" unitRef="USD" decimals="0">1200000</us-gaap:EquityMethodInvestmentAggregateCost>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn07_01_2015_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_364" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_365" unitRef="USD" decimals="0">51080</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_366" unitRef="USD" decimals="0">1374668</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_367" unitRef="USD" decimals="0">1400693</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn08_10_2015_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis" id="Factid_368" unitRef="pure" decimals="0">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <ameh:EquityMethodInvestmentsPurchaseOfShares contextRef="PAsOn08_10_2015_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VotingCommonStockTwoMemberusgaapStatementClassOfStockAxis" id="Factid_369" unitRef="shares" decimals="INF">100000</ameh:EquityMethodInvestmentsPurchaseOfShares>

  <ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock contextRef="PAsOn08_10_2015_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VotingCommonStockTwoMemberusgaapStatementClassOfStockAxis" id="Factid_370" unitRef="pure" decimals="1">0.5</ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock>

  <us-gaap:EquityMethodInvestmentAggregateCost contextRef="PAsOn08_10_2015_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_371" unitRef="USD" decimals="0">10000000</us-gaap:EquityMethodInvestmentAggregateCost>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_372" unitRef="USD" decimals="0">-20202</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_373" unitRef="USD" decimals="0">523301</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_374" unitRef="USD" decimals="0">8589253</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_375" unitRef="USD" decimals="0">8609455</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn08_10_2015_AncillaryServiceContractMemberamehContractTypeAxis_UniversalCareAcquisitionPartnersLlcMemberusgaapOwnershipAxis_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VotingCommonStockTwoMemberusgaapStatementClassOfStockAxis" id="Factid_376" unitRef="pure" decimals="3">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:PaymentsForAdvanceToAffiliate contextRef="P01_01_2015To12_31_2015_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_377" unitRef="USD" decimals="0">5000000</us-gaap:PaymentsForAdvanceToAffiliate>

  <us-gaap:LoansReceivableBasisSpreadOnVariableRate contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_378" unitRef="pure" decimals="2">0.01</us-gaap:LoansReceivableBasisSpreadOnVariableRate>

  <ameh:LoansReceivableInterestRate contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_379" unitRef="pure" decimals="4">0.0575</ameh:LoansReceivableInterestRate>

  <ameh:LoansReceivableInterestRate contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_380" unitRef="pure" decimals="4">0.0550</ameh:LoansReceivableInterestRate>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_381" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_382" unitRef="USD" decimals="0">22595206</ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_383" unitRef="USD" decimals="0">21872894</ameh:EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_384" unitRef="USD" decimals="0">23862184</ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_385" unitRef="USD" decimals="0">18618760</ameh:EquityMethodInvestmentSummarizedFinancialInformationReceivables>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_386" unitRef="USD" decimals="0">18870831</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_387" unitRef="USD" decimals="0">13021520</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherAssets contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_388" unitRef="USD" decimals="0">2259507</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherAssets contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_389" unitRef="USD" decimals="0">3754470</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherAssets>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_390" unitRef="USD" decimals="0">1770157</ameh:EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_391" unitRef="USD" decimals="0">1576621</ameh:EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_392" unitRef="USD" decimals="0">69357885</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_393" unitRef="USD" decimals="0">58844265</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_394" unitRef="USD" decimals="0">64984078</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_395" unitRef="USD" decimals="0">54421532</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_396" unitRef="USD" decimals="0">10044340</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_397" unitRef="USD" decimals="0">10051952</ameh:EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_398" unitRef="USD" decimals="0">-5670533</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_399" unitRef="USD" decimals="0">-5629219</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_400" unitRef="USD" decimals="0">69357885</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_401" unitRef="USD" decimals="0">58844265</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_402" unitRef="USD" decimals="0">72665437</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue contextRef="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_403" unitRef="USD" decimals="0">46540892</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_404" unitRef="USD" decimals="0">72154950</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales contextRef="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_405" unitRef="USD" decimals="0">44757246</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_406" unitRef="USD" decimals="0">510487</ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes contextRef="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_407" unitRef="USD" decimals="0">1783646</ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_408" unitRef="USD" decimals="0">-551800</ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit>

  <ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit contextRef="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_409" unitRef="USD" decimals="0">-713500</ameh:EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_410" unitRef="USD" decimals="0">-41313</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>

  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss contextRef="P01_01_2017To03_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_411" unitRef="USD" decimals="0">1070146</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn05_14_2016_ApcLsmaMemberusgaapOwnershipAxis" id="Factid_412" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="P05_01_2016To05_14_2016_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_413" unitRef="USD" decimals="0">1600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_414" unitRef="USD" decimals="0">329042</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_415" unitRef="USD" decimals="0">361644</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_416" unitRef="USD" decimals="0">2176453</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_417" unitRef="USD" decimals="0">1847411</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn11_15_2016_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_418" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentAggregateCost contextRef="PAsOn11_15_2016_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_419" unitRef="USD" decimals="0">800000</us-gaap:EquityMethodInvestmentAggregateCost>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_420" unitRef="USD" decimals="0">41953</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2017To03_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_421" unitRef="USD" decimals="0">-20501</us-gaap:IncomeLossFromEquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_422" unitRef="USD" decimals="0">635151</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_423" unitRef="USD" decimals="0">593198</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_424" unitRef="USD" decimals="0">635151</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_PacificAmbulatorySurgeryCenterLlcMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_425" unitRef="USD" decimals="0">593198</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_426" unitRef="USD" decimals="0">8589253</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_427" unitRef="USD" decimals="0">9099975</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_428" unitRef="USD" decimals="0">2176453</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_429" unitRef="USD" decimals="0">8609455</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_430" unitRef="USD" decimals="0">9452767</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_DiagnosticMedicalGroupMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_431" unitRef="USD" decimals="0">1847411</us-gaap:EquityMethodInvestments>

  <us-gaap:LoansReceivableNet contextRef="PAsOn12_31_2017_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_432" unitRef="USD" decimals="0">10000000</us-gaap:LoansReceivableNet>

  <us-gaap:LineOfCredit contextRef="PAsOn12_31_2017_ApcMemberdeiLegalEntityAxis" id="Factid_433" unitRef="USD" decimals="0">5000000</us-gaap:LineOfCredit>

  <us-gaap:LineOfCredit contextRef="PAsOn12_31_2017_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_434" unitRef="USD" decimals="0">5000000</us-gaap:LineOfCredit>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_435" unitRef="pure" decimals="4">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <ameh:ExtendableAmountOnCreditFacility contextRef="PAsOn03_31_2018" id="Factid_436" unitRef="USD" decimals="0">8000000</ameh:ExtendableAmountOnCreditFacility>

  <ameh:PercentageOfManagingResponsibleOfHealthPlanship contextRef="P01_01_2018To03_31_2018" id="Factid_437" unitRef="pure" decimals="0">1</ameh:PercentageOfManagingResponsibleOfHealthPlanship>

  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="PAsOn12_31_2017" id="Factid_438" unitRef="USD" decimals="0">4343341</us-gaap:WorkersCompensationLiabilityCurrent>

  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="PAsOn03_31_2018" id="Factid_439" unitRef="USD" decimals="0">3543524</us-gaap:WorkersCompensationLiabilityCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn03_31_2018" id="Factid_440" unitRef="USD" decimals="0">3356677</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_441" unitRef="USD" decimals="0">3786381</us-gaap:AccountsPayableCurrent>

  <ameh:SpecialtyCapitationPayableCurrent contextRef="PAsOn03_31_2018" id="Factid_442" unitRef="USD" decimals="0">300000</ameh:SpecialtyCapitationPayableCurrent>

  <ameh:SpecialtyCapitationPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_443" unitRef="USD" decimals="0">547307</ameh:SpecialtyCapitationPayableCurrent>

  <ameh:SubcontractorIpaRiskPoolPayable contextRef="PAsOn03_31_2018" id="Factid_444" unitRef="USD" decimals="0">1472985</ameh:SubcontractorIpaRiskPoolPayable>

  <ameh:SubcontractorIpaRiskPoolPayable contextRef="PAsOn12_31_2017" id="Factid_445" unitRef="USD" decimals="0">1348376</ameh:SubcontractorIpaRiskPoolPayable>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn03_31_2018" id="Factid_446" unitRef="USD" decimals="0">2727238</us-gaap:AccruedProfessionalFeesCurrent>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn12_31_2017" id="Factid_447" unitRef="USD" decimals="0">3004215</us-gaap:AccruedProfessionalFeesCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn03_31_2018" id="Factid_448" unitRef="USD" decimals="0">710106</us-gaap:DeferredRevenueCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2017" id="Factid_449" unitRef="USD" decimals="0">250000</us-gaap:DeferredRevenueCurrent>

  <ameh:MedicalLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_450" unitRef="USD" decimals="0">18957465</ameh:MedicalLiabilitiesCurrent>

  <ameh:AdjustmentsForMedicalLiabilities contextRef="P01_01_2017To12_31_2017" id="Factid_451" unitRef="USD" decimals="0">-633386</ameh:AdjustmentsForMedicalLiabilities>

  <ameh:AdjustmentsForMedicalLiabilities contextRef="P01_01_2018To03_31_2018" id="Factid_452" unitRef="USD" decimals="0">-56478</ameh:AdjustmentsForMedicalLiabilities>

  <ameh:MedicalLiabilitiesAddedFromMerger contextRef="P01_01_2018To03_31_2018" id="Factid_453" unitRef="USD" decimals="0">0</ameh:MedicalLiabilitiesAddedFromMerger>

  <ameh:MedicalLiabilitiesAddedFromMerger contextRef="P01_01_2017To12_31_2017" id="Factid_454" unitRef="USD" decimals="0">39353540</ameh:MedicalLiabilitiesAddedFromMerger>

  <us-gaap:HealthCareOrganizationExpensesNet contextRef="P01_01_2018To03_31_2018" id="Factid_455" unitRef="USD" decimals="0">44634257</us-gaap:HealthCareOrganizationExpensesNet>

  <us-gaap:HealthCareOrganizationExpensesNet contextRef="P01_01_2017To12_31_2017" id="Factid_456" unitRef="USD" decimals="0">121846375</us-gaap:HealthCareOrganizationExpensesNet>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn12_31_2010_IccMemberdeiLegalEntityAxis" id="Factid_457" unitRef="USD" decimals="0">4600000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2018_IccMemberdeiLegalEntityAxis" id="Factid_458" unitRef="pure" decimals="4">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn03_31_2018_IccMemberdeiLegalEntityAxis" id="Factid_459" unitRef="USD" decimals="0">394783</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2018To03_31_2018_IccMemberdeiLegalEntityAxis" id="Factid_460">2018-12-31</us-gaap:DebtInstrumentMaturityDate>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn04_30_2012_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_461" unitRef="USD" decimals="0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn04_07_2017_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_462" unitRef="USD" decimals="0">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="PAsOn03_31_2018_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_463" unitRef="pure" decimals="5">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>

  <us-gaap:LineOfCredit contextRef="PAsOn03_31_2018_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_464" unitRef="USD" decimals="0">5000000</us-gaap:LineOfCredit>

  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="PAsOn03_31_2018_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_465" unitRef="USD" decimals="0">8300671</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>

  <ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties contextRef="PAsOn03_31_2018_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_466" unitRef="USD" decimals="0">1000000</ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn04_21_2016_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_467" unitRef="USD" decimals="0">2000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn04_22_2016_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_468" unitRef="USD" decimals="0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="PAsOn03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_469" unitRef="pure" decimals="5">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>

  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="PAsOn12_31_2017_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_470" unitRef="pure" decimals="5">0.04675</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>

  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="PAsOn03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_471" unitRef="USD" decimals="0">9694984</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>

  <ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties contextRef="PAsOn03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_472" unitRef="USD" decimals="0">1000000</ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn03_03_2017_ApaacoMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis" id="Factid_473" unitRef="USD" decimals="0">6699329</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="PAsOn03_03_2017_ApcMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis" id="Factid_474" unitRef="USD" decimals="0">305016</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_475" unitRef="shares" decimals="INF">1141040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_476" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_477" unitRef="shares" decimals="INF">1041504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_478" unitRef="shares" decimals="INF">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_479" unitRef="shares" decimals="INF">129536</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_480" unitRef="shares" decimals="INF">1041504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_481" unitRef="USD_per_Share" decimals="2">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_482" unitRef="USD_per_Share" decimals="2">9.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_483" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_484" unitRef="USD_per_Share" decimals="2">4.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_485" unitRef="USD_per_Share" decimals="2">4.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_486" unitRef="USD_per_Share" decimals="2">6.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_487" unitRef="USD" decimals="2">11.86</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_488" unitRef="USD" decimals="2">11.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_489" unitRef="USD" decimals="2">19.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_490">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_491">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_492" unitRef="shares" decimals="INF">853800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_493" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_494" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_495" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_496" unitRef="shares" decimals="INF">853800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_497" unitRef="shares" decimals="INF">853800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_498" unitRef="USD_per_Share" decimals="3">0.167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_499" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_500" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_501" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_502" unitRef="USD_per_Share" decimals="3">0.167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_503" unitRef="USD_per_Share" decimals="3">0.167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_504">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_505" unitRef="USD" decimals="0">508864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_506" unitRef="USD" decimals="0">508864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_507" unitRef="USD" decimals="0">508864</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To03_31_2017_ContractedPhysiciansAndOtherServicesMemberusgaapIncomeStatementLocationAxis" id="Factid_508" unitRef="USD" decimals="0">321233</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2018To03_31_2018_ContractedPhysiciansAndOtherServicesMemberusgaapIncomeStatementLocationAxis" id="Factid_509" unitRef="USD" decimals="0">202382</us-gaap:ShareBasedCompensation>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn03_31_2018_NetworkMedicalManagementIncNmmMemberusgaapBusinessAcquisitionAxis_StockCompensationPlanMemberusgaapAwardTypeAxis" id="Factid_510" unitRef="USD" decimals="0">1214292</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_StockCompensationPlanMemberusgaapAwardTypeAxis" id="Factid_511">P1Y6M</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>

  <ameh:NumberOfWarrantsGranted contextRef="P01_01_2018To03_31_2018" id="Factid_512" unitRef="shares" decimals="INF">0</ameh:NumberOfWarrantsGranted>

  <ameh:NumberOfWarrantsExercised contextRef="P01_01_2018To03_31_2018" id="Factid_513" unitRef="shares" decimals="INF">-191625</ameh:NumberOfWarrantsExercised>

  <ameh:ClassOfWarrantOrRightCancelledInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_514" unitRef="shares" decimals="INF">-11250</ameh:ClassOfWarrantOrRightCancelledInPeriod>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_31_2018" id="Factid_515" unitRef="USD_per_Share" decimals="2">9.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_516" unitRef="USD_per_Share" decimals="0">0</ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod>

  <ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_517" unitRef="USD_per_Share" decimals="2">7.55</ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod>

  <ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_518" unitRef="USD_per_Share" decimals="0">0</ameh:ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018" id="Factid_519">P0Y</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018" id="Factid_520">P0Y</ameh:ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018" id="Factid_521">P0Y</ameh:ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018" id="Factid_522">P3Y8M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue contextRef="PAsOn03_31_2018" id="Factid_523" unitRef="USD" decimals="0">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>

  <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue contextRef="PAsOn03_31_2018" id="Factid_524" unitRef="USD" decimals="2">9.96</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>

  <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue contextRef="PAsOn03_31_2018" id="Factid_525" unitRef="USD" decimals="0">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>

  <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue contextRef="PAsOn03_31_2018" id="Factid_526" unitRef="USD" decimals="2">6.07</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn03_31_2018" id="Factid_527" unitRef="shares" decimals="INF">3445666</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="PAsOn11_16_2015_UniversalCareIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_528" unitRef="USD" decimals="0">5000000</us-gaap:AccountsAndOtherReceivablesNetCurrent>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn11_16_2015_UniversalCareIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_529" unitRef="pure" decimals="3">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_AdvanceDiagnosticSurgeryCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_530" unitRef="USD" decimals="0">22000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_AdvanceDiagnosticSurgeryCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_531" unitRef="USD" decimals="0">34000</ameh:PaymentMadeToRelatedParty>

  <us-gaap:RevenueFromRelatedParties contextRef="P01_01_2018To03_31_2018_LmaMemberusgaapConsolidatedEntitiesAxis" id="Factid_532" unitRef="USD" decimals="-5">4600000</us-gaap:RevenueFromRelatedParties>

  <us-gaap:RevenueFromRelatedParties contextRef="P01_01_2017To03_31_2017_LmaMemberusgaapConsolidatedEntitiesAxis" id="Factid_533" unitRef="USD" decimals="-5">4500000</us-gaap:RevenueFromRelatedParties>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_LmaMemberusgaapConsolidatedEntitiesAxis" id="Factid_534" unitRef="pure" decimals="2">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_PmiocMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_535" unitRef="USD" decimals="-5">400000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_PmiocMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_536" unitRef="USD" decimals="-5">500000</ameh:PaymentMadeToRelatedParty>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_PmiocMemberusgaapConsolidatedEntitiesAxis" id="Factid_537" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_AmgIncMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_538" unitRef="USD" decimals="-5">700000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_AmgIncMemberusgaapConsolidatedEntitiesAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_539" unitRef="USD" decimals="-5">800000</ameh:PaymentMadeToRelatedParty>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn09_30_2015_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_540" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn09_30_2015_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_541" unitRef="pure" decimals="2">0.03</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="PAsOn03_31_2018_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_542" unitRef="USD" decimals="0">150000</us-gaap:AccountsAndOtherReceivablesNetCurrent>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_DmgMemberusgaapConsolidatedEntitiesAxis" id="Factid_543" unitRef="USD" decimals="-5">1600000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_DmgMemberusgaapConsolidatedEntitiesAxis" id="Factid_544" unitRef="USD" decimals="-5">1400000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_MedicalPropertyPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_545" unitRef="USD" decimals="-5">300000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_ApcShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_546" unitRef="USD" decimals="-5">9200000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_ApcShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_547" unitRef="USD" decimals="-5">12800000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_ShareholdersAndOfficersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_548" unitRef="USD" decimals="-5">2300000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_ShareholdersAndOfficersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_549" unitRef="USD" decimals="-5">5400000</ameh:PaymentMadeToRelatedParty>

  <ameh:OperatingLossCarryforwardsLimitationRateOnTaxableIncome contextRef="P01_01_2017To12_31_2017" id="Factid_550" unitRef="pure" decimals="1">0.8</ameh:OperatingLossCarryforwardsLimitationRateOnTaxableIncome>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis" id="Factid_551" unitRef="pure" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <ameh:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares contextRef="P01_01_2018To03_31_2018" id="Factid_552" unitRef="shares" decimals="INF">1682110</ameh:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2018To03_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_553" unitRef="shares" decimals="INF">3039749</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2017To03_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_554" unitRef="shares" decimals="INF">2785328</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2018To03_31_2018_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_555" unitRef="shares" decimals="INF">1801367</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2017To03_31_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_556" unitRef="shares" decimals="INF">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_557" unitRef="shares" decimals="INF">835790</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="P01_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_558" unitRef="shares" decimals="INF">592365</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_559" unitRef="USD" decimals="0">58024188</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_560" unitRef="USD" decimals="0">54686370</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:RestrictedCashCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_561" unitRef="USD" decimals="0">18028116</us-gaap:RestrictedCashCurrent>

  <us-gaap:RestrictedCashCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_562" unitRef="USD" decimals="0">18005661</us-gaap:RestrictedCashCurrent>

  <ameh:FiduciaryCashCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_563" unitRef="USD" decimals="0">1386474</ameh:FiduciaryCashCurrent>

  <ameh:FiduciaryCashCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_564" unitRef="USD" decimals="0">2017437</ameh:FiduciaryCashCurrent>

  <us-gaap:MarketableSecuritiesCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_565" unitRef="USD" decimals="0">1061022</us-gaap:MarketableSecuritiesCurrent>

  <us-gaap:MarketableSecuritiesCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_566" unitRef="USD" decimals="0">1057090</us-gaap:MarketableSecuritiesCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_567" unitRef="USD" decimals="0">38844184</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_568" unitRef="USD" decimals="0">15183483</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_569" unitRef="USD" decimals="0">1960737</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_570" unitRef="USD" decimals="0">1821328</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_571" unitRef="USD" decimals="0">119304721</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_572" unitRef="USD" decimals="0">92771369</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_573" unitRef="USD" decimals="0">10201045</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_574" unitRef="USD" decimals="0">10167689</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_575" unitRef="USD" decimals="0">67670837</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_576" unitRef="USD" decimals="0">70841907</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:Goodwill contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_577" unitRef="USD" decimals="0">60012316</us-gaap:Goodwill>

  <us-gaap:Goodwill contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_578" unitRef="USD" decimals="0">60012316</us-gaap:Goodwill>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_579" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_580" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <us-gaap:LoansReceivableNet contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_581" unitRef="USD" decimals="0">5000000</us-gaap:LoansReceivableNet>

  <us-gaap:LoansReceivableNet contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_582" unitRef="USD" decimals="0">5000000</us-gaap:LoansReceivableNet>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_583" unitRef="USD" decimals="0">21875500</us-gaap:EquityMethodInvestments>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_584" unitRef="USD" decimals="0">21903524</us-gaap:EquityMethodInvestments>

  <us-gaap:CostMethodInvestments contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_585" unitRef="USD" decimals="0">4320000</us-gaap:CostMethodInvestments>

  <us-gaap:CostMethodInvestments contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_586" unitRef="USD" decimals="0">4320000</us-gaap:CostMethodInvestments>

  <us-gaap:Assets contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_587" unitRef="USD" decimals="0">295284826</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_588" unitRef="USD" decimals="0">272133704</us-gaap:Assets>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_589" unitRef="USD" decimals="0">3505047</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_590" unitRef="USD" decimals="0">3625610</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:LeaseIncentivePayableCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_591" unitRef="USD" decimals="0">14900000</us-gaap:LeaseIncentivePayableCurrent>

  <us-gaap:LeaseIncentivePayableCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_592" unitRef="USD" decimals="0">21500000</us-gaap:LeaseIncentivePayableCurrent>

  <ameh:FiduciaryAccountsPayableCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_593" unitRef="USD" decimals="0">1386474</ameh:FiduciaryAccountsPayableCurrent>

  <ameh:FiduciaryAccountsPayableCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_594" unitRef="USD" decimals="0">2017437</ameh:FiduciaryAccountsPayableCurrent>

  <ameh:MedicalLiabilitiesCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_595" unitRef="USD" decimals="0">25212116</ameh:MedicalLiabilitiesCurrent>

  <ameh:MedicalLiabilitiesCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_596" unitRef="USD" decimals="0">25186240</ameh:MedicalLiabilitiesCurrent>

  <us-gaap:TaxesPayableCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_597" unitRef="USD" decimals="0">3229058</us-gaap:TaxesPayableCurrent>

  <us-gaap:TaxesPayableCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_598" unitRef="USD" decimals="0">1463540</us-gaap:TaxesPayableCurrent>

  <us-gaap:DueFromAffiliateCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_599" unitRef="USD" decimals="0">28061953</us-gaap:DueFromAffiliateCurrent>

  <us-gaap:DueFromAffiliateCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_600" unitRef="USD" decimals="0">24889717</us-gaap:DueFromAffiliateCurrent>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_601" unitRef="USD" decimals="0">394783</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_602" unitRef="USD" decimals="0">510391</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:CapitalLeaseObligationsCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_603" unitRef="USD" decimals="0">99480</us-gaap:CapitalLeaseObligationsCurrent>

  <us-gaap:CapitalLeaseObligationsCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_604" unitRef="USD" decimals="0">98738</us-gaap:CapitalLeaseObligationsCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_605" unitRef="USD" decimals="0">76788911</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_606" unitRef="USD" decimals="0">79291673</us-gaap:LiabilitiesCurrent>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_607" unitRef="USD" decimals="0">27406818</us-gaap:DeferredTaxLiabilities>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_608" unitRef="USD" decimals="0">20970766</us-gaap:DeferredTaxLiabilities>

  <ameh:LiabilityForUnissuedEquitySharesNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_609" unitRef="USD" decimals="0">1185025</ameh:LiabilityForUnissuedEquitySharesNoncurrent>

  <ameh:LiabilityForUnissuedEquitySharesNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_610" unitRef="USD" decimals="0">1185025</ameh:LiabilityForUnissuedEquitySharesNoncurrent>

  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_611" unitRef="USD" decimals="0">593852</us-gaap:CapitalLeaseObligationsNoncurrent>

  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_612" unitRef="USD" decimals="0">619001</us-gaap:CapitalLeaseObligationsNoncurrent>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_613" unitRef="USD" decimals="0">29185695</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:LiabilitiesNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_614" unitRef="USD" decimals="0">22774792</us-gaap:LiabilitiesNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_615" unitRef="USD" decimals="0">102066465</us-gaap:Liabilities>

  <us-gaap:RestrictedCashNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_616" unitRef="USD" decimals="0">745293</us-gaap:RestrictedCashNoncurrent>

  <us-gaap:RestrictedCashNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_617" unitRef="USD" decimals="0">745235</us-gaap:RestrictedCashNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_618" unitRef="USD" decimals="0">1155114</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_619" unitRef="USD" decimals="0">1371664</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_620" unitRef="USD" decimals="0">175980105</us-gaap:AssetsNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn12_31_2017_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_621" unitRef="USD" decimals="0">179362335</us-gaap:AssetsNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn03_31_2018_VariableInterestEntityPrimaryBeneficiaryMemberusgaapVariableInterestEntitiesByClassificationOfEntityAxis" id="Factid_622" unitRef="USD" decimals="0">105974606</us-gaap:Liabilities>

  <ameh:RestrictedCashAcquiredFromAcquisition contextRef="P01_01_2018To03_31_2018" id="Factid_623" unitRef="USD" decimals="0">18000000</ameh:RestrictedCashAcquiredFromAcquisition>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2018" id="Factid_624" unitRef="USD" decimals="0">165666297</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_625" unitRef="USD" decimals="0">159948028</us-gaap:StockholdersEquity>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn03_31_2018" id="Factid_626" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2017" id="Factid_627" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_628" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_629" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_630" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_631" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_632" unitRef="shares" decimals="INF">1111111</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_633" unitRef="shares" decimals="INF">1111111</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2018_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_634" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_635" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_636" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_637" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_638" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_639" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_640" unitRef="shares" decimals="INF">555555</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_641" unitRef="shares" decimals="INF">555555</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2018_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_642" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_643" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2018" id="Factid_644" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017" id="Factid_645" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2018" id="Factid_646" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2017" id="Factid_647" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2018" id="Factid_648" unitRef="shares" decimals="INF">32652295</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2017" id="Factid_649" unitRef="shares" decimals="INF">32304876</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="P01_01_2018To03_31_2018" id="Factid_650" unitRef="USD" decimals="0">-41782</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>

  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="P01_01_2017To03_31_2017" id="Factid_651" unitRef="USD" decimals="0">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>

  <us-gaap:NatureOfOperations contextRef="P01_01_2018To03_31_2018" id="Factid_652">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 1.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; Description of Business&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Overview&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Apollo Medical Holdings, Inc. (&amp;#8220;ApolloMed&amp;#8221;), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the &amp;#8220;Merger Agreement&amp;#8221;) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (&amp;#8220;NMM&amp;#8221;), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the &amp;#8220;Merger&amp;#8221;). The Merger closed and became effective on December 8, 2017 (the &amp;#8220;Closing&amp;#8221;) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a &amp;#8220;reverse acquisition&amp;#8221; and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM&amp;#8217;s historical results of operations replaced ApolloMed&amp;#8217;s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed&amp;#8217;s board of directors approved a change in ApolloMed&amp;#8217;s fiscal year end from March 31 to December 31, to correspond with NMM&amp;#8217;s fiscal year end prior to the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the &amp;#8220;Company&amp;#8221;) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (&amp;#8220;HMOs&amp;#8221;), with a small portion of the Company&amp;#8217;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&amp;#8217;s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (&amp;#8220;AMM&amp;#8221;), APA ACO, Inc. (&amp;#8220;APAACO&amp;#8221;) and Apollo Care Connect, Inc. (&amp;#8220;Apollo Care Connect&amp;#8221;), and their consolidated entities.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;NMM was formed in 1994 as a management service organization (&amp;#8220;MSO&amp;#8221;) for the purposes of providing management services to medical companies and independent practice associations (&amp;#8220;IPAs&amp;#8221;). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&amp;#8220;APC&amp;#8221;) was incorporated on August&amp;#160;17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations (&amp;#8220;HMOs&amp;#8221;) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&amp;#8220;PMPM&amp;#8221;) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On July&amp;#160;1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;30&lt;/font&gt; years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (&amp;#8220;VIE&amp;#8221;) as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&amp;#8217;s economic performance through its majority representation of the APC Joint Planning Board; therefore APC is consolidated by NMM. As of March 31, 2018 and December 31, 2017, APC had an ownership interest of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.90&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.95&lt;/font&gt;% in ApolloMed, respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Concourse Diagnostic Surgery Center, LLC (&amp;#8220;CDSC&amp;#8221;) was formed on March&amp;#160;25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;625,000&lt;/font&gt; for a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 41.59&lt;/font&gt;% ownership in CDSC. Due to capital stock changes in 2016, APC&amp;#8217;s ownership percentage in CDSC&amp;#8217;s capital stock changed to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 43.80&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 43.43&lt;/font&gt;% on May&amp;#160;31, 2016 and July&amp;#160;31, 2016, respectively. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC also holds a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% ownership interest in Pacific Ambulatory Surgery Center, LLC (&amp;#8220;PASC&amp;#8221;), a multi-specialty outpatient surgery center.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC-LSMA was formed on October&amp;#160;15, 2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA&amp;#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes: The IPA line of business of LaSalle Medical Associates (&amp;#8220;LMA&amp;#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&amp;#8220;PMIOC&amp;#8221;), Diagnostic Medical Group (&amp;#8220;DMG&amp;#8221;) and AHMC International Cancer Center (&amp;#8220;ICC&amp;#8221;).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November&amp;#160;15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% of the aggregate issued and outstanding shares of capital stock of ICC for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400,000&lt;/font&gt; in cash. Certain requirements to complete the investment transaction was completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to receive benefits that could potentially be significant to ICC. The results of operations of ICC from October 31, 2017 to December 31, 2017 were de minimis.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Universal Care Acquisition Partners, LLC (&amp;#8220;UCAP&amp;#8221;), a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% owned subsidiary of APC, was formed on June&amp;#160;4, 2014, for the purpose of holding the investment in Universal Care, Inc. (&amp;#8220;UCI&amp;#8221;).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APAACO, jointly owned by NMM and AMM, participates in the next generation accountable care organization model (&amp;#8220;NGACO Model&amp;#8221;) of the Centers for Medicare &amp;#38; Medicaid Services (&amp;#8220;CMS&amp;#8221;) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (&amp;#8220;ACOs&amp;#8221;) that participated in the Medicare Shared Savings Program (&amp;#8220;MSSP&amp;#8221;), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an &amp;#8220;all or nothing&amp;#8221; basis.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (&amp;#8220;ApolloMed ACO&amp;#8221;) to participate in the MSSP.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On November&amp;#160;11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (&amp;#8220;APCN-ACO&amp;#8221;) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January&amp;#160;8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On December&amp;#160;18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (&amp;#8220;AP-ACO&amp;#8221;) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December&amp;#160;20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As the Company is transitioning to the NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. Effective on December 31, 2017, APCN-ACO&amp;#8217;s MSSP participation agreement with CMS was terminated. Effective on December 31, 2016, AP-ACO&amp;#8217;s MSSP participation agreement with CMS was terminated. Effective on December 31, 2017, ApolloMed ACO&amp;#8217;s MSSP participation agreement with CMS was terminated.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of Maverick Medical Group, Inc. (&amp;#8220;MMG&amp;#8221;). MMG has historically been included in the consolidated financial statements filed by ApolloMed.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (&amp;#8220;AMH&amp;#8221;), a hospitalist company, Southern California Heart Centers (&amp;#8220;SCHC&amp;#8221;), Bay Area Hospitalist Associates (&amp;#8220;BAHA&amp;#8221;), a medical corporation, ApolloMed Care Clinic (&amp;#8220;ACC&amp;#8221;) and AKM Medical Group, Inc. (&amp;#8220;AKM&amp;#8221;). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operates a hospitalist, intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several skilled nursing facilities. ACC and AKM are no longer active to any material extent.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;ApolloMed also has a controlling interest in Apollo Palliative Services, LLC (&amp;#8220;APS&amp;#8221;), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (&amp;#8220;BCHC&amp;#8221;) and Holistic Care Home Health Agency, Inc. (&amp;#8220;HCHHA&amp;#8221;) and provides palliative care services.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;ApolloMed also operated Pulmonary Critical Care Management, Inc. (&amp;#8220;PCCM&amp;#8221;) and Verdugo Medical Management, Inc. (&amp;#8220;VMM&amp;#8221;), which operated as physician practice management companies. PCCM and VMM are no longer active to any material extent.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2017_ApollomedMemberusgaapConsolidatedEntitiesAxis" id="Factid_653" unitRef="pure" decimals="4">0.0495</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_654">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;2.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Basis of Presentation&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company&amp;#8217;s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Principles of Consolidation&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM&amp;#8217;s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM&amp;#8217;s consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM&amp;#8217;s consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Business Combinations&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Reportable Segments&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (&amp;#8220;IBNR&amp;#8221;) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Reclassifications&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company&amp;#8217;s reported revenue, net income, cash flows or total assets.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&amp;#160;exceed the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;)&amp;#8217;s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company&amp;#8217;s deposit accounts with banks exceeded the FDIC&amp;#8217;s insured limit by approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;135.0&lt;/font&gt; million. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&amp;#8217;s concentration of risk&amp;#160;exposure.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;strong&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Restricted Cash&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.05&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.10&lt;/font&gt;%. Restricted cash also consists of cash held as collateral to secure standby letters of credits as required by certain contracts. As of March 31, 2018 and December 31, 2017, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,028,116&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,005,661&lt;/font&gt; included in restricted cash short-term, respectively, in the accompanying condensed consolidated balance sheets. Approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,000,000&lt;/font&gt; of such restricted cash was related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), will be held in an escrow account for distribution to former NMM shareholders (see Note 17).&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Receivables&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Capitation and claims receivable relate to the health plan&amp;#8217;s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company&amp;#8217;s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) ASC 606 (see Note 13). Other receivables include fee-for-services (&amp;#8220;FFS&amp;#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December&amp;#160;31, 2017, the Company recorded an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;763,205&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;407,953&lt;/font&gt;, respectively.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Concentrations of Risks&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company had major payors that contributed the following percentage of net revenue:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Three&amp;#160;Months&lt;br/&gt; Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160; &amp;#160;* Less than 10% &lt;font style="BACKGROUND-COLOR: transparent"&gt;of total net revenues&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;March&lt;br/&gt; 31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;December&lt;br/&gt; 31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;25.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;23.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor E&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;38.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;30.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Fair Value Measurements of Financial Instruments&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables &amp;#150; long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;FASB ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt; (&amp;#8220;ASC 820&amp;#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&amp;#160;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt; &amp;#151;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;2&lt;/i&gt; &amp;#151;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt; &amp;#151;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&amp;#8217;s own data.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of March 31, 2018 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of December&amp;#160;31, 2017 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;* &lt;i&gt;Included in cash and cash equivalents&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Derivative&lt;br/&gt; Assets&lt;br/&gt; (Warrants)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,338,886&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Change in fair value of warrant liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,522,222&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at March 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6,861,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The fair value of the warrant derivative asset of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.9&lt;/font&gt; million at March&amp;#160;31, 2017 was estimated using the Black-Scholes valuation model, using the following inputs: term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3.54&lt;/font&gt; &amp;#150; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.00&lt;/font&gt; years, risk free rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.62&lt;/font&gt;% - &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.71&lt;/font&gt;%, no dividends, volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 62.3&lt;/font&gt;% - &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 62.4&lt;/font&gt;%, share price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.00&lt;/font&gt; per share based on the trading price of ApolloMed&amp;#8217;s common stock adjusted for a marketability discount, and a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% probability of redemption of the warrant shares issued along with the shares of ApolloMed&amp;#8217;s convertible preferred stock issued in the financing.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Intangible Assets and Long-Lived Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&amp;#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&amp;#160;31, 2018 and 2017.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under the ASC 350, &lt;i&gt;Intangibles &amp;#150; Goodwill and Other&lt;/i&gt; (&amp;#8220;ASC 350&amp;#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At least annually, at the Company&amp;#8217;s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March&amp;#160;31, 2018 and 2017.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Investments in Other Entities - Equity Method&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&amp;#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate.&lt;/font&gt; Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&amp;#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &amp;#8220;Income from equity method investments&amp;#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. No impairment loss was recorded on equity method investments for the three months ended March&amp;#160;31, 2018 and 2017.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Medical Liabilities&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO&amp;#8217;s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of the revenue less actual claims processed for or paid to in-network providers (after taking into account the average discount negotiated with the in-network providers). The Company plans to use the traditional lag models as the claims history matures. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&amp;#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&amp;#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Revenue Recognition&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (&amp;#8220;ASU&amp;#8221;)&amp;#160;2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221;, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company&amp;#8217;s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Share-Based Compensation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&amp;#8217;s repurchase right (but not obligation) that lapses based on performance of services in the future.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 &lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;. As such the fair value of such shares is periodically re-measured using an appropriate valuation model and income or expense is recognized over the vesting period.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Basic and Diluted Earnings Per Share&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) is computed by dividing net income attributable to holders of the Company&amp;#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b):&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; a)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;The income of the legal acquiree (NMM) attributable to holders of the Company&amp;#8217;s common stock in such period.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; b)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;The legal acquiree&amp;#8217;s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Noncontrolling Interests&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company&amp;#8217;s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Mezzanine Equity&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Pursuant to APC&amp;#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221; (&amp;#8220;ASU 2014-09&amp;#8221;). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2016, the FASB issued ASU No. 2016-01, &amp;#8220;Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221; (&amp;#8220;ASU 2016-01&amp;#8221;). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; (&amp;#8220;ASU 2016-02&amp;#8221;). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, &amp;#8220;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&amp;#8221; (&amp;#8220;ASU 2016-13&amp;#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In August 2016, the FASB issued ASU No. 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230) &amp;#150; Classification of Certain Cash Receipts and Cash Payments&amp;#8221; (&amp;#8220;ASU 2016-15&amp;#8221;). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In December 2016, the FASB issued ASU No. 2016-18, &amp;#8220;Statement of Cash Flows (Topic 230) &amp;#150; Restricted Cash&amp;#8221; (&amp;#8220;ASU 2016-18&amp;#8221;). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2017, the FASB issued ASU No. 2017-01, &amp;#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business&amp;#8221; (&amp;#8220;ASU 2017-01&amp;#8221;). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2017, the FASB issued ASU No. 2017-04, &amp;#8220;Intangibles &amp;#150; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&amp;#8221; (&amp;#8220;ASU 2017-04&amp;#8221;). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#8221; (&amp;#8220;ASU 2017-09&amp;#8221;), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: rgb(46,46,46); font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In July 2017, the FASB issued ASU No. 2017-11, &amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception&amp;#8221; (&amp;#8220;ASU 2017-11&amp;#8221;). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&amp;#8217;s financial position, results of operations and cash flows.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_655">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company&amp;#8217;s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>

  <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_656">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;Principles of Consolidation&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM&amp;#8217;s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM&amp;#8217;s consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM&amp;#8217;s consolidated VIE, APC, APC&amp;#8217;s subsidiary, UCAP, and APC&amp;#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>

  <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_657">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;Business Combinations&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessCombinationsPolicy>

  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_658">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Reportable Segments&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>

  <us-gaap:UseOfEstimates contextRef="P01_01_2018To03_31_2018" id="Factid_659">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (&amp;#8220;IBNR&amp;#8221;) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="P01_01_2018To03_31_2018" id="Factid_660">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company&amp;#8217;s reported revenue, net income, cash flows or total assets.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_661">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&amp;#160;exceed the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;)&amp;#8217;s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company&amp;#8217;s deposit accounts with banks exceeded the FDIC&amp;#8217;s insured limit by approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;135.0&lt;/font&gt; million. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&amp;#8217;s concentration of risk&amp;#160;exposure.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_662">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.05&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.10&lt;/font&gt;%. Restricted cash also consists of cash held as collateral to secure standby letters of credits as required by certain contracts. As of March 31, 2018 and December 31, 2017, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,028,116&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,005,661&lt;/font&gt; included in restricted cash short-term, respectively, in the accompanying condensed consolidated balance sheets. Approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,000,000&lt;/font&gt; of such restricted cash was related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), will be held in an escrow account for distribution to former NMM shareholders (see Note 17).&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>

  <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_663">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Receivables&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Capitation and claims receivable relate to the health plan&amp;#8217;s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company&amp;#8217;s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) ASC 606 (see Note 13). Other receivables include fee-for-services (&amp;#8220;FFS&amp;#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December&amp;#160;31, 2017, the Company recorded an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;763,205&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;407,953&lt;/font&gt;, respectively.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>

  <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2018To03_31_2018" id="Factid_664">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Concentrations of Risks&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company had major payors that contributed the following percentage of net revenue:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Three&amp;#160;Months&lt;br/&gt; Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160; &amp;#160;* Less than 10% &lt;font style="BACKGROUND-COLOR: transparent"&gt;of total net revenues&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;March&lt;br/&gt; 31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;December&lt;br/&gt; 31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;25.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;23.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor E&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;38.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;30.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>

  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_665">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;Fair Value Measurements of Financial Instruments&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables &amp;#150; long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;FASB ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt; (&amp;#8220;ASC 820&amp;#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&amp;#160;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt; &amp;#151;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;2&lt;/i&gt; &amp;#151;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt; &amp;#151;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&amp;#8217;s own data.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of March 31, 2018 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of December&amp;#160;31, 2017 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;* &lt;i&gt;Included in cash and cash equivalents&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Derivative&lt;br/&gt; Assets&lt;br/&gt; (Warrants)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,338,886&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Change in fair value of warrant liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,522,222&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at March 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6,861,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The fair value of the warrant derivative asset of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.9&lt;/font&gt; million at March&amp;#160;31, 2017 was estimated using the Black-Scholes valuation model, using the following inputs: term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3.54&lt;/font&gt; &amp;#150; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.00&lt;/font&gt; years, risk free rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.62&lt;/font&gt;% - &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.71&lt;/font&gt;%, no dividends, volatility of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 62.3&lt;/font&gt;% - &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 62.4&lt;/font&gt;%, share price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.00&lt;/font&gt; per share based on the trading price of ApolloMed&amp;#8217;s common stock adjusted for a marketability discount, and a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% probability of redemption of the warrant shares issued along with the shares of ApolloMed&amp;#8217;s convertible preferred stock issued in the financing.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>

  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_666">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Intangible Assets and Long-Lived Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&amp;#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&amp;#160;31, 2018 and 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>

  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_667">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under the ASC 350, &lt;i&gt;Intangibles &amp;#150; Goodwill and Other&lt;/i&gt; (&amp;#8220;ASC 350&amp;#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At least annually, at the Company&amp;#8217;s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March&amp;#160;31, 2018 and 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>

  <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_668">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Investments in Other Entities - Equity Method&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&amp;#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate.&lt;/font&gt; Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&amp;#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &amp;#8220;Income from equity method investments&amp;#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. No impairment loss was recorded on equity method investments for the three months ended March&amp;#160;31, 2018 and 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>

  <us-gaap:HealthCareCostsPolicyPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_669">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Medical Liabilities&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO&amp;#8217;s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of the revenue less actual claims processed for or paid to in-network providers (after taking into account the average discount negotiated with the in-network providers). The Company plans to use the traditional lag models as the claims history matures. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&amp;#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&amp;#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>

  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_670">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (&amp;#8220;ASU&amp;#8221;)&amp;#160;2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221;, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company&amp;#8217;s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_671">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2018To03_31_2018" id="Factid_672">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&amp;#8217;s repurchase right (but not obligation) that lapses based on performance of services in the future.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 &lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;. As such the fair value of such shares is periodically re-measured using an appropriate valuation model and income or expense is recognized over the vesting period.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_673">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Basic and Diluted Earnings Per Share&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) is computed by dividing net income attributable to holders of the Company&amp;#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b):&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; a)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;The income of the legal acquiree (NMM) attributable to holders of the Company&amp;#8217;s common stock in such period.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; b)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;The legal acquiree&amp;#8217;s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <ameh:MinorityInterestPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_674">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Noncontrolling Interests&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company&amp;#8217;s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:MinorityInterestPolicyTextBlock>

  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_675">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Mezzanine Equity&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Pursuant to APC&amp;#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityPolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_676">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers (Topic 606)&amp;#8221; (&amp;#8220;ASU 2014-09&amp;#8221;). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2016, the FASB issued ASU No. 2016-01, &amp;#8220;Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221; (&amp;#8220;ASU 2016-01&amp;#8221;). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; (&amp;#8220;ASU 2016-02&amp;#8221;). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, &amp;#8220;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&amp;#8221; (&amp;#8220;ASU 2016-13&amp;#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In August 2016, the FASB issued ASU No. 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230) &amp;#150; Classification of Certain Cash Receipts and Cash Payments&amp;#8221; (&amp;#8220;ASU 2016-15&amp;#8221;). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In December 2016, the FASB issued ASU No. 2016-18, &amp;#8220;Statement of Cash Flows (Topic 230) &amp;#150; Restricted Cash&amp;#8221; (&amp;#8220;ASU 2016-18&amp;#8221;). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18.&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2017, the FASB issued ASU No. 2017-01, &amp;#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business&amp;#8221; (&amp;#8220;ASU 2017-01&amp;#8221;). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In January 2017, the FASB issued ASU No. 2017-04, &amp;#8220;Intangibles &amp;#150; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&amp;#8221; (&amp;#8220;ASU 2017-04&amp;#8221;). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#8221; (&amp;#8220;ASU 2017-09&amp;#8221;), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: rgb(46,46,46); font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In July 2017, the FASB issued ASU No. 2017-11, &amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception&amp;#8221; (&amp;#8220;ASU 2017-11&amp;#8221;). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&amp;#8217;s financial position, results of operations and cash flows.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_677">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of March 31, 2018 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,300,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;77,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;43,439,295&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The carrying amounts and fair values of the Company&amp;#8217;s financial instruments as of December&amp;#160;31, 2017 are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Money market accounts*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;41,231,405&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; certificates of deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Marketable securities &amp;#150; equity securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;86,005&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;42,374,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>

  <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_678">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Derivative&lt;br/&gt; Assets&lt;br/&gt; (Warrants)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,338,886&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Change in fair value of warrant liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,522,222&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance at March 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6,861,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>

  <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_679">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company had major payors that contributed the following percentage of net revenue:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Three&amp;#160;Months&lt;br/&gt; Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10.9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160; &amp;#160;* Less than 10% &lt;font style="BACKGROUND-COLOR: transparent"&gt;of total net revenues&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;March&lt;br/&gt; 31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;As&amp;#160;of&amp;#160;December&lt;br/&gt; 31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;25.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;23.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"&gt; &lt;div&gt;Payor E&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;38.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;30.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018" id="Factid_680" unitRef="USD" decimals="0">43439295</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn03_31_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_681" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017" id="Factid_682" unitRef="USD" decimals="0">42374500</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_683" unitRef="USD" decimals="0">86005</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_684" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_685" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:AssetsFairValueDisclosure contextRef="PAsOn12_31_2017_EquitySecuritiesMemberusgaapInvestmentTypeAxis" id="Factid_686" unitRef="USD" decimals="0">86005</us-gaap:AssetsFairValueDisclosure>

  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_687">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;3.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Mergers and Acquisitions&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On December 8, 2017, (the &amp;#8220;Effective Time&amp;#8221;) the merger (the &amp;#8220;Merger&amp;#8221;) of ApolloMed&amp;#8217;s wholly-owned subsidiary, Apollo Acquisition Corp., with and into Network Medical Management, Inc. as the surviving entity was completed, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017), by and among the Company, Merger Sub, NMM and Kenneth Sim, M.D., as the NMM shareholders&amp;#8217; representative. As a result of the Merger, NMM now is a wholly-owned subsidiary of ApolloMed and former NMM shareholders own a majority of the issued and outstanding common stock of the Company. Both companies are considered to be a business under the guidance outlined in ASC 805, Business Combinations. The combined company operates under the Apollo Medical Holdings name. NMM is the larger entity in terms of assets, revenues and earnings. In addition, as of the closing of the Merger, the majority of the board of directors of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed is considered to be the legal acquirer (and accounting acquiree) whereas NMM is considered to be the accounting acquirer (and legal acquiree) and, accordingly, the merger transaction is a reverse acquisition. Accordingly, as of the Effective Time, NMM&amp;#8217;s historical results of operations replaced ApolloMed&amp;#8217;s historical results of operations for all periods prior to the Merger, and the results of operations of both companies will be included in the Company&amp;#8217;s financial statements for all periods following the Merger. As of the Effective Time, the Company&amp;#8217;s board of directors approved a change in the Company&amp;#8217;s fiscal year end from March 31 to December 31, to correspond with NMM&amp;#8217;s fiscal year end prior to the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of NMM common stock converted into the right to receive (i) such number of fully paid and nonassessable shares of ApolloMed&amp;#8217;s common stock that resulted in the NMM shareholders having a right to receive an aggregate number of shares of ApolloMed&amp;#8217;s common stock that represented &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 82&lt;/font&gt;% of the total issued and outstanding shares of ApolloMed common stock immediately following the Effective Time, with no NMM dissenting shareholder interests as of the Effective Time (the &amp;#8220;exchange ratio&amp;#8221;), plus (ii) an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,566,666&lt;/font&gt; ApolloMed&amp;#8217;s common stock, with no NMM dissenting shareholder interests as of the Effective Time, and (iii) common stock warrants to purchase a pro-rata portion of an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 850,000&lt;/font&gt; shares of common stock of ApolloMed, exercisable at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11.00&lt;/font&gt; per share and warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 900,000&lt;/font&gt; shares of common stock of ApolloMed at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.00&lt;/font&gt; per share. At the Effective Time, pre-Merger ApolloMed stockholders held their existing shares of ApolloMed&amp;#8217;s common stock. At the Effective Time, ApolloMed held back 10% of the total number of shares of ApolloMed&amp;#8217;s common stock issuable to pre-Merger NMM shareholders in the Merger to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. Separately, indemnification of pre-Merger NMM shareholders under the Merger Agreement was made by the issuance by ApolloMed to pre-Merger NMM shareholders of new additional shares of common stock (capped at the same number of shares of ApolloMed&amp;#8217;s common stock as are subject to the holdback for the indemnification of ApolloMed). These holdback shares will be held for a period of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger agreement, by NMM. Half of these shares will be issued on the first and second anniversary of the Effective Time respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;For purposes of calculating the exchange ratio, (A) the aggregate number of shares of ApolloMed common stock held by the NMM shareholders immediately following the Effective Time excluded (i) any shares of ApolloMed common stock owned by NMM shareholders immediately prior to the Effective Time, (ii) the Series A warrant and Series B warrant issued by ApolloMed to NMM to purchase ApolloMed common stock (the &amp;#8220;ApolloMed Warrants&amp;#8221;) and (iii) any shares of ApolloMed common stock issued or issuable to NMM shareholders pursuant to the exercise of the ApolloMed Warrants, and (B) the total number of issued and outstanding shares of ApolloMed common stock immediately following the Effective Time excluded &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 520,081&lt;/font&gt; shares of ApolloMed common stock issued or issuable under a Convertible Promissory Note to Alliance Apex, LLC (&amp;#8220;Alliance&amp;#8221;) for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.99&lt;/font&gt; million and accrued interest pursuant to the Securities Purchase Agreement between ApolloMed and Alliance dated as of March 30, 2017.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In addition, the fair value of NMM&amp;#8217;s &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;% interest in APAACO, an entity that was owned &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;% by ApolloMed and 50% by NMM, was remeasured at fair value as of the Effective Time and added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&amp;#8217;s noncontrolling interest in APAACO has been estimated to be $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,129,000&lt;/font&gt;.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Total estimated purchase consideration consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equity consideration (1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,092,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of ApolloMed preferred stock held by NMM (2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19,118,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of NMM&amp;#8217;s noncontrolling interest in APAACO (3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,129,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of the outstanding ApolloMed stock options (4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;187,333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total estimated purchase consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,526,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (1)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Equity consideration&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0px 0in -0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,109,205&lt;/font&gt; shares of ApolloMed common stock.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The equity consideration, which represents a portion of the consideration deemed transferred to the pre-Merger ApolloMed stockholders in the Merger, is calculated based on the number of shares of the combined company that the pre-Merger ApolloMed stockholders would own as of the closing of the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders &lt;sup style="font-style:normal"&gt;(1)&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6,109,205&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Multiplied by the price per share of ApolloMed&amp;#8217;s common stock &lt;sup style="font-style:normal"&gt;(2)&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equity consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,092,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; (1)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; (2)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; Represents the closing price of ApolloMed&amp;#8217;s common stock on December 8, 2017.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (2)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of ApolloMed&amp;#8217;s preferred shares held by NMM&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.01in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger.&amp;#160; As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed.&amp;#160; The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,118,000&lt;/font&gt;.&amp;#160;The valuation methodology was based on an Option Pricing Method (&amp;#8220;OPM&amp;#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company.&amp;#160; OPM assumptions included an expected term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; years, volatility rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 37.9&lt;/font&gt;%, and a risk-free rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.8&lt;/font&gt;%.&amp;#160; The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12,745,000&lt;/font&gt; and the fair value of the conversion option was determined to be $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,373,000&lt;/font&gt; or an aggregate total fair value of $19,118,000.&lt;/div&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (3)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of NMM&amp;#8217;s 50% share of APA ACO Inc.&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&amp;#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&amp;#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (4)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of the ApolloMed outstanding stock options&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see &amp;#8220;MMG Transaction&amp;#8221; below), with the excess recorded as goodwill:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;36,367,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounts receivable, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,261,588&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,211,028&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;249,193&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,114,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;745,220&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair value of intangible assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14,984,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,301,972&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;217,241&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;66,452,129&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Liabilities assumed&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounts payable and accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8,632,893&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medical liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;39,353,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Line of credit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Convertible note payable, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,376,215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Convertible note payable - related party&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,921,938&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncontrolling interest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,142,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total liabilities assumed and noncontrolling interest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;66,451,586&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net liabilities assumed&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(913,468)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,525,840&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Goodwill is not deductible for tax purposes. During the three months ended March 31, 2018, the deferred tax assets balance was increased by approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.9&lt;/font&gt; million with an offset to goodwill as a result of the allocation of transaction costs related to the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Merger from&lt;/font&gt; ApolloMed to NMM.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The purchase consideration and purchase price allocation are preliminary and subject to change as more information becomes available, which will be finalized as soon as practicable within the measurement period of no later than one year following the Effective Time of the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;i&gt;MMG Transaction&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of MMG. MMG has historically been included in the consolidated financial statements filed by ApolloMed. APC-LSMA &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;agreed to&lt;/font&gt; pay $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100&lt;/font&gt; in consideration for all the shares of MMG. As the transaction is between related parties, the purchase consideration of MMG reflected in the purchase price allocation was determined to be the fair value of MMG. MMG and AMM terminated the existing Management Services Agreement between them (the &amp;#8220;MMG Management Agreement&amp;#8221;) and APC-LSMA paid AMM $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400,000&lt;/font&gt; as a termination payment on the Effective Time. APC-LSMA is consolidated by APC which in turn is consolidated by NMM, and as a result, the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;400,000&lt;/font&gt; amount is eliminated upon consolidation.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;i&gt;Pro Forma Combined Historical Results&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Three&amp;#160;Months&lt;br/&gt; Ended&lt;br/&gt; March&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;98,467,260&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net loss attributable to Apollo Medical Holdings, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(351,982)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted average common shares outstanding:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,601,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Earnings per share:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(0.01)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted average common shares outstanding:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,601,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Earnings per share:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(0.01)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The pro forma information has been prepared for comparative purposes only and does not purport to be indicative of what would have occurred had the acquisition actually been made at such date, nor is it necessarily indicative of future operating results.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>

  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_688">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Total estimated purchase consideration consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equity consideration (1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,092,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of ApolloMed preferred stock held by NMM (2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19,118,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of NMM&amp;#8217;s noncontrolling interest in APAACO (3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,129,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated fair value of the outstanding ApolloMed stock options (4)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;187,333&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total estimated purchase consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,526,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (1)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Equity consideration&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0px 0in -0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,109,205&lt;/font&gt; shares of ApolloMed common stock.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (2)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of ApolloMed&amp;#8217;s preferred shares held by NMM&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.01in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger.&amp;#160; As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed.&amp;#160; The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,118,000&lt;/font&gt;.&amp;#160;The valuation methodology was based on an Option Pricing Method (&amp;#8220;OPM&amp;#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company.&amp;#160; OPM assumptions included an expected term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; years, volatility rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 37.9&lt;/font&gt;%, and a risk-free rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.8&lt;/font&gt;%.&amp;#160; The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12,745,000&lt;/font&gt; and the fair value of the conversion option was determined to be $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,373,000&lt;/font&gt; or an aggregate total fair value of $19,118,000.&lt;/div&gt; &lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (3)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of NMM&amp;#8217;s 50% share of APA ACO Inc.&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&amp;#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&amp;#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; (4)&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;i&gt; Estimated fair value of the ApolloMed outstanding stock options&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>

  <ameh:BusinessCombonationequityConsiderationTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_689">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders &lt;sup style="font-style:normal"&gt;(1)&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6,109,205&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Multiplied by the price per share of ApolloMed&amp;#8217;s common stock &lt;sup style="font-style:normal"&gt;(2)&lt;/sup&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equity consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,092,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; (1)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 3%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; (2)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; Represents the closing price of ApolloMed&amp;#8217;s common stock on December 8, 2017.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:BusinessCombonationequityConsiderationTableTextBlock>

  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_690">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see &amp;#8220;MMG Transaction&amp;#8221; below), with the excess recorded as goodwill:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;36,367,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounts receivable, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,261,588&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,211,028&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;249,193&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property, plant and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,114,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;745,220&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair value of intangible assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14,984,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,301,972&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;217,241&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;66,452,129&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Liabilities assumed&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounts payable and accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8,632,893&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medical liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;39,353,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Line of credit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Convertible note payable, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5,376,215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Convertible note payable - related party&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,921,938&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncontrolling interest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,142,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total liabilities assumed and noncontrolling interest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;66,451,586&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net liabilities assumed&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(913,468)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,525,840&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>

  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_691">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Three&amp;#160;Months&lt;br/&gt; Ended&lt;br/&gt; March&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;98,467,260&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Net loss attributable to Apollo Medical Holdings, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(351,982)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted average common shares outstanding:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,601,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Earnings per share:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(0.01)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted average common shares outstanding:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,601,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Earnings per share:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(0.01)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>

  <ameh:EquityMethodInvestmentSignificantInfluenceDescription contextRef="P01_01_2018To03_31_2018" id="Factid_692">Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investees board of directors, are considered in determining whether the equity method of accounting is appropriate.</ameh:EquityMethodInvestmentSignificantInfluenceDescription>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P01_01_2018To03_31_2018" id="Factid_693" unitRef="shares" decimals="INF">6109205</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <ameh:BusinessCombinationconsiderationDescription contextRef="P01_01_2018To03_31_2018_ApolloMedicalHoldingsIncMemberusgaapBusinessAcquisitionAxis" id="Factid_694">The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).</ameh:BusinessCombinationconsiderationDescription>

  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_695">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;4.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Intangible Assets, Net&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;At March&amp;#160;31, 2018, the Company&amp;#8217;s intangible assets, net, consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Useful&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Gross&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Accumulated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;(Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Indefinite Lived Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Medicare license&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;N/A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Amortized Intangible Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Network relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11-15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,883,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(39,179,025)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;70,703,975&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Management contracts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,832,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,646,843)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,185,157&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Member relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,696,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(357,292)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,338,708&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Patient management platform&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,060,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(137,333)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,922,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Tradename/trademarks&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,011,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(16,850)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;994,150&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,476,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(45,337,343)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99,138,657&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At December&amp;#160;31, 2017, the Company&amp;#8217;s intangible assets, net, consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Useful&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Gross&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Accumulated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Indefinite Lived Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Medicare license&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;N/A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Amortized Intangible Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Network relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11-15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,883,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(35,842,508)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;74,040,492&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Management contracts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,832,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,014,886)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,817,114&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Member relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,696,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(46,500)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,649,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Patient management platform&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,060,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34,336)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,025,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Tradename/trademarks&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,011,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(4,212)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,006,788&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,476,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(40,942,442)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;103,533,558&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,394,901&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,374,841&lt;/font&gt;, (excluding $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;106,000&lt;/font&gt; amortization expense for exclusivity incentives) for the three months ended March&amp;#160;31, 2018 and 2017, respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Future amortization expense is estimated to be as follows for the years ending December&amp;#160;31:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2018 (remaining nine months)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,262,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,671,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,961,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,448,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,323,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;97,145,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>

  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_696">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At March&amp;#160;31, 2018, the Company&amp;#8217;s intangible assets, net, consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Useful&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Gross&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Accumulated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;(Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Indefinite Lived Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Medicare license&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;N/A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Amortized Intangible Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Network relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11-15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,883,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(39,179,025)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;70,703,975&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Management contracts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,832,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,646,843)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,185,157&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Member relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,696,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(357,292)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,338,708&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Patient management platform&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,060,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(137,333)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,922,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Tradename/trademarks&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,011,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(16,850)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;994,150&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,476,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(45,337,343)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99,138,657&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At December&amp;#160;31, 2017, the Company&amp;#8217;s intangible assets, net, consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Useful&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Gross&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Accumulated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Indefinite Lived Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Medicare license&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;N/A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,994,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Amortized Intangible Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Network relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;11-15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,883,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(35,842,508)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;74,040,492&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Management contracts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,832,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,014,886)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17,817,114&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Member relationships&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,696,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(46,500)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,649,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Patient management platform&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,060,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34,336)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,025,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;Tradename/trademarks&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,011,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(4,212)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,006,788&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,476,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(40,942,442)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;103,533,558&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_697">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Future amortization expense is estimated to be as follows for the years ending December&amp;#160;31:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2018 (remaining nine months)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,262,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,480,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,671,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,961,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,448,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,323,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;97,145,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn03_31_2018" id="Factid_698" unitRef="USD" decimals="0">45337343</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn03_31_2018" id="Factid_699" unitRef="USD" decimals="0">144476000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_700">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_701" unitRef="USD" decimals="0">2060000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_702" unitRef="USD" decimals="0">1011000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis" id="Factid_703" unitRef="USD" decimals="0">144476000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>

  <ameh:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill contextRef="PAsOn12_31_2016_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_704" unitRef="USD" decimals="0">1994000</ameh:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_705" unitRef="USD" decimals="0">2025664</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_706" unitRef="USD" decimals="0">1006788</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_FiniteLivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis" id="Factid_707" unitRef="USD" decimals="0">103533558</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="PAsOn12_31_2017_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_708" unitRef="USD" decimals="0">1994000</us-gaap:IntangibleAssetsNetExcludingGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017" id="Factid_709" unitRef="USD" decimals="0">40942442</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017_IndefinitelivedIntangibleAssetsMemberusgaapFairValueByAssetClassAxis_MedicareLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_710" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_711" unitRef="USD" decimals="0">34336</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn12_31_2017_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_712" unitRef="USD" decimals="0">4212</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2017To12_31_2017_MemberRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_713">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2017To12_31_2017_PatientManagementPlatformMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_714">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2017To12_31_2017_TradeNamesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_715">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_MinimumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_716">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2018To03_31_2018_MaximumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_717">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_718">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis_NetworkRelationshipsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_719">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn03_31_2018" id="Factid_720" unitRef="USD" decimals="0">97145000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_721">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;5.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Investments in Other Entities&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Equity Method Investments&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;LaSalle Medical Associates&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;LaSalle Medical Associates (&amp;#8220;LMA&amp;#8221;) was founded by Dr. Albert Arteaga in 1996 and currently operates four neighborhood medical centers employing more than 120 dedicated healthcare professionals, treating children, adults and seniors in San Bernardino County. LMA&amp;#8217;s patients are primarily served by Medi-Cal and they also accept Blue Cross, Blue Shield, Molina, Care 1&lt;sup style="font-style:normal"&gt;st&lt;/sup&gt;, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high quality care to more than 245,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; for a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% interest in LMA&amp;#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&amp;#8217;s operations. For the three months ended March&amp;#160;31, 2018 and 2017, APC recorded (loss) income from this investment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(352,792)&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,311,738&lt;/font&gt;, respectively, in the accompanying consolidated statements of income. The investment balance was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,099,975&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,452,767&lt;/font&gt; at March 31, 2018 and December&amp;#160;31, 2017, respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;LMA&amp;#8217;s IPA line of business summarized balance sheets at March 31, 2018 and December&amp;#160;31, 2017 and summarized statements of income for the three months ended March&amp;#160;31, 2018 and 2017 are as follows (unaudited):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Balance Sheets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,064,701&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,065,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,005,144&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,433,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,173,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,565,606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Loan receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Restricted cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;664,612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;662,109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,157,567&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26,975,936&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Liabilities and Stockholders&amp;#8217; Equity&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;23,946,133&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,353,337&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Stockholders&amp;#8217; equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,211,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,622,599&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total liabilities and stockholders&amp;#8217; equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,157,567&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26,975,936&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Statements of Income&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;52,983,791&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;49,753,004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,002,458&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,506,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,018,667)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,246,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography at their facilities.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In July&amp;#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,200,000&lt;/font&gt; for a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% ownership in PMIOC.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.4&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt; million for the three months ended March&amp;#160;31, 2018 and 2017, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&amp;#8217;s operations. During the three months ended March&amp;#160;31, 2018 and 2017, APC recorded (loss) income from this investment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(26,025)&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;51,080&lt;/font&gt; respectively, in the accompanying consolidated statements of income and has an investment balance of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,374,668&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,400,693&lt;/font&gt; at March 31, 2018 and December&amp;#160;31, 2017, respectively.&lt;/div&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Universal Care, Inc.&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;UCI is a privately held health plan that has been in operation since 1985 in order to help its members through the complexities of the healthcare system. UCI holds a license under the California Knox-Keene Health Care Services Plan Act (&amp;#8220;Knox-Keene Act&amp;#8221;) to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On August&amp;#160;10, 2015, UCAP, an entity solely owned &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% by APC with APC&amp;#8217;s executives, Dr.&amp;#160;Thomas Lam, Dr. Pen Lee and Dr. Kenneth Sim, as designated managers of UCAP, purchased from UCI &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,000&lt;/font&gt; shares of UCI class A-2 voting common stock (comprising &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 48.9&lt;/font&gt;% of the total outstanding UCI shares, but &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;% of UCI&amp;#8217;s voting common stock) for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000,000&lt;/font&gt;. APC accounts for its investment in UCI under the equity method of accounting as APC has the ability to exercise significant influence, but not control over UCI&amp;#8217;s operations. During the three months ended March&amp;#160;31, 2018 and 2017, the Company recorded (loss) income from this investment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(20,202)&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;523,301&lt;/font&gt;, respectively, in the accompanying consolidated statements of income and has an investment balance of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,589,253&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,609,455&lt;/font&gt; at March 31, 2018 and December&amp;#160;31, 2017, respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In 2015, the Company also advanced $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; to UCI for working capital purposes. The subordinated loan accrues interest at the prime rate plus &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1&lt;/font&gt;%, or &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.75&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.50&lt;/font&gt;% as of March 31, 2018 and December&amp;#160;31, 2017, respectively, with interest to be paid monthly. Pursuant to the stock purchase agreement, the principal repayment schedule is based on certain contingent criteria, and accordingly, the entire note receivable has been classified as non-current loans receivable - related parties on the consolidated balance sheets in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; as of March 31, 2018 and December 31, 2017.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;UCI&amp;#8217;s balance sheets at March 31, 2018 and December&amp;#160;31, 2017 and statements of income for the three months ended March&amp;#160;31, 2018 and 2017 are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Balance Sheets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,595,206&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,872,894&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;23,862,184&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,618,760&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,870,831&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,021,520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,259,507&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,754,470&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,770,157&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,576,621&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,357,885&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,844,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Liabilities and Stockholders&amp;#8217; Deficit&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;64,984,078&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,421,532&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,044,340&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,051,952&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Stockholders&amp;#8217; deficit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,670,533)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,629,219)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total liabilities and stockholders&amp;#8217; deficit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,357,885&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,844,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Statements of Income Operations&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;72,665,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;46,540,892&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;72,154,950&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,757,246&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Income before provision for income taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,487&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,783,646&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Provision for income taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;551,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;713,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(41,313)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,070,146&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Diagnostic Medical Group&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On May&amp;#160;14, 2016, David C.P. Chen M.D., Inc., a California professional corporation doing business as Diagnostic Medical Group (&amp;#8220;DMG&amp;#8221;), David C.P. Chen M.D., individually (collectively &amp;#8220;Seller&amp;#8221;) and APC-LSMA, a designated shareholder professional corporation formed on October&amp;#160;15, 2012, which is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% owned by Dr. Thomas Lam (CEO of APC) and is controlled and consolidated by APC who is the primary beneficiary of this VIE, entered into a share purchase agreement whereby APC-LSMA acquired a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% ownership interest in DMG for total cash consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,600,000&lt;/font&gt;.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&amp;#8217;s operations. APC recorded income from this investment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;329,042&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;361,644&lt;/font&gt; for the three months ended March 31, 2018 and 2017, respectively, in the accompanying consolidated statements of operations. The investment balance was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,176,453&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,847,411&lt;/font&gt; at March 31, 2018 and December&amp;#160;31, 2017, respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Pacific Ambulatory Surgery Center, LLC&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;PASC, a California limited liability company, is a multi-specialty outpatient surgery center that is certified to participate in the Medicare program and is accredited by the Accreditation Association for Ambulatory Health Care. PASC has entered into agreements with organizations such as healthcare service plans, independent physician practice associations, medical groups and other purchasers of healthcare services for the arrangement of the provision of outpatient surgery center services to subscribers or enrollees of such health plans. On November&amp;#160;15, 2016, PASC and APC, entered into a membership interest purchase agreement whereby PASC sold &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% of its aggregate issued and outstanding membership interests to APC for total consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;800,000&lt;/font&gt;.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In connection with the membership interest purchase agreement, PASC entered into a management services agreement with NMM, which requires the payment of management fees computed at predetermined percentage (as defined) of PASC revenues. The term of the management services agreement commenced on the effective date and extend for a period of 60 months thereafter, and may&amp;#160;be extended in writing at the sole option of NMM for an additional period of 60 months following the expiration of the initial term and is automatically renewed for additional consecutive terms of three years unless terminated by either party. PASC shall not be permitted to terminate the management services agreement for any reason during the initial term and, if extended, the extended term.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC accounts for its investment in PASC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PASC&amp;#8217;s operations. APC recorded income (loss) from this investment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;41,953&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(20,501)&lt;/font&gt; for the three months ended March 31, 2018 and 2017, respectively, in the accompanying consolidated statements of income and has an investment balance of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;635,151&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;593,198&lt;/font&gt; at March 31, 2018 and December&amp;#160;31, 2017, respectively.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;Equity Method Investment Summary&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Investments in other entities &amp;#150; equity method consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Universal Care, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,589,253&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,609,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;LaSalle Medical Associates &amp;#150; IPA Line of Business&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,099,975&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,452,767&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Diagnostic Medical Group&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,176,453&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,847,411&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Pacific Medical Imaging &amp;#38; Oncology Center, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,374,668&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,400,693&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Pacific Ambulatory Surgery Center, LLC&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;635,151&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;593,198&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,875,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,903,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>

  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_722">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Investments in other entities &amp;#150; equity method consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Universal Care, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,589,253&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,609,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;LaSalle Medical Associates &amp;#150; IPA Line of Business&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,099,975&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,452,767&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Diagnostic Medical Group&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,176,453&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,847,411&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Pacific Medical Imaging &amp;#38; Oncology Center, Inc.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,374,668&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,400,693&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Pacific Ambulatory Surgery Center, LLC&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;635,151&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;593,198&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,875,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,903,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>

  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="P01_01_2018To03_31_2018_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_723">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;UCI&amp;#8217;s balance sheets at March 31, 2018 and December&amp;#160;31, 2017 and statements of income for the three months ended March&amp;#160;31, 2018 and 2017 are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Balance Sheets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,595,206&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,872,894&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;23,862,184&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,618,760&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,870,831&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,021,520&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,259,507&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,754,470&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,770,157&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,576,621&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,357,885&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,844,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Liabilities and Stockholders&amp;#8217; Deficit&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;64,984,078&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,421,532&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,044,340&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,051,952&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Stockholders&amp;#8217; deficit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,670,533)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(5,629,219)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total liabilities and stockholders&amp;#8217; deficit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,357,885&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,844,265&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Statements of Income Operations&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;72,665,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;46,540,892&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;72,154,950&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,757,246&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Income before provision for income taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,487&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,783,646&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Provision for income taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;551,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;713,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(41,313)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,070,146&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>

  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="P01_01_2018To03_31_2018_LasalleMedicalAssociatesIpaMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_724">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;LMA&amp;#8217;s IPA line of business summarized balance sheets at March 31, 2018 and December&amp;#160;31, 2017 and summarized statements of income for the three months ended March&amp;#160;31, 2018 and 2017 are as follows (unaudited):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Balance Sheets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,064,701&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,065,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,005,144&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,433,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,173,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,565,606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Loan receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Restricted cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;664,612&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;662,109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,157,567&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26,975,936&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Liabilities and Stockholders&amp;#8217; Equity&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;23,946,133&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,353,337&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Stockholders&amp;#8217; equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,211,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,622,599&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Total liabilities and stockholders&amp;#8217; equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,157,567&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26,975,936&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Statements of Income&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;52,983,791&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;49,753,004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,002,458&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,506,050&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div&gt;Net (loss) income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,018,667)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,246,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>

  <us-gaap:PaymentsForFees contextRef="P01_01_2018To03_31_2018_AncillaryServiceContractMemberamehContractTypeAxis_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_725" unitRef="USD" decimals="-5">400000</us-gaap:PaymentsForFees>

  <us-gaap:PaymentsForFees contextRef="P01_01_2017To03_31_2017_AncillaryServiceContractMemberamehContractTypeAxis_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_726" unitRef="USD" decimals="-5">500000</us-gaap:PaymentsForFees>

  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="P01_01_2018To03_31_2018_PacificMedicalImagingAndOncologyCenterIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_727" unitRef="USD" decimals="0">-26025</us-gaap:IncomeLossFromEquityMethodInvestments>

  <ameh:LoanReceivableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_728">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 6.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt;Loan Receivable&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On October&amp;#160;9, 2017, NMM and APC-LSMA entered into an agreement with Accountable Health Care IPA (&amp;#8220;Accountable&amp;#8221;), a California professional medical corporation, Signal Health Solutions, Inc. (&amp;#8220;Signal&amp;#8221;), a California corporation and George M. Jayatilaka, M.D. (&amp;#8220;Dr.&amp;#160;Jay&amp;#8221;), individually, whereby concurrent with the execution of the agreement, APC-LSMA extended a line of credit to Dr. Jay in the principal amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000,000&lt;/font&gt; (&amp;#8220;Dr. Jay Loan&amp;#8221;) to fund the working capital needs of Accountable ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; of which was funded by APC on behalf of APC-LSMA and the other $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; was funded by NMM to Dr. Jay). Interest on the Dr. Jay Loan accrues at a rate that is equal to the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;prime rate plus 1%&lt;/font&gt; (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.75&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.50&lt;/font&gt;% as of March 31, 2018 and December 31, 2017, respectively) and payable in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The Dr. Jay Loan will not be subordinated. The Dr. Jay Loan shall at all times be secured by a first-lien security interest in shares of Accountable owned by Dr. Jay. The outstanding balance as of both March 31, 2018 and December 31, 2017 was $10,000,000.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Concurrently with the funding of the Dr. Jay Loan, Dr. Jay will loan to Accountable the entire proceeds of the Dr. Jay Loan at the same interest rate and maturity date as the Dr. Jay Loan (&amp;#8220;Dr.&amp;#160;Jay-Accountable Subordinated Loan&amp;#8221;). Repayment of the Dr. Jay-Accountable Subordinated Loan will be subordinated to Accountable&amp;#8217;s creditors in a manner acceptable to the California Department of Managed Health Care (&amp;#8220;DMHC&amp;#8221;).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountable&amp;#8217;s capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountable&amp;#8217;s then-current valuation.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Subsequent to the funding of the Dr. Jay Loan, to the extent needed by Accountable for working capital needs as determined by APC-LSMA, APC-LSMA will extend an additional line of credit in the principal amount up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,000,000&lt;/font&gt;. The funding mechanism, interest rate and maturity date of such additional line of credit shall be the same as the Dr. Jay Loan and additional collateral security in Accountable&amp;#8217;s issued and outstanding shares will be required.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As a condition of funding the Dr. Jay Loan, Accountable entered into a management service agreement with NMM on October&amp;#160;27, 2017, to commence on the termination of the Accountable&amp;#8217;s existing management agreement with MedPoint Management to be effective on December&amp;#160;1, 2017 and have a term of ten (10) years from its effective date. NMM will be responsible for managing &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100&lt;/font&gt;% of all health plan membership assigned and delegated to Accountable, and all hospital risk pools. The management service agreement requires the payment of IPA management fees as set forth therein.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Concurrent with the initial funding of the Dr. Jay Loan, the Accountable Board of Directors shall be automatically reconstituted to be comprised of two directors, which will comprise of Dr. Jay and a director appointed by APC-LSMA. Dr. Jay and APC-LSMA will have two and one votes as a director, respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Based on management&amp;#8217;s assessment, Accountable is a variable interest entity, however, the Company does not have the power to the direct the activities of Accountable that most significantly impact its economic performance and as such, the Company is not the primary beneficiary of Accountable.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:LoanReceivableTextBlock>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2017_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_729" unitRef="pure" decimals="4">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentPaymentTerms contextRef="P01_01_2018To03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_730">Interest on the Dr. Jay Loan accrues at a rate that is equal to the prime rate plus 1% (5.75% and 5.50% as of March 31, 2018 and December 31, 2017, respectively) and payable in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full.</us-gaap:DebtInstrumentPaymentTerms>

  <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="P01_01_2018To03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_731">At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountables capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountables then-current valuation.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>

  <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="P01_01_2018To03_31_2018_DrJayLoanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_732">prime rate plus 1%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>

  <ameh:TermOfManagementServiceAgreement contextRef="P01_01_2018To03_31_2018" id="Factid_733">P10Y</ameh:TermOfManagementServiceAgreement>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_734">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;7.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Accounts Payable and Accrued Expenses&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s accounts payable and accrued expenses consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accounts payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,356,677&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,786,381&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Specialty capitation payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;300,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;547,307&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Subcontractor IPA risk pool payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,472,985&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,348,376&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,727,238&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,004,215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Deferred revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;710,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accrued compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,543,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,343,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,110,530&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,279,620&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_735">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s accounts payable and accrued expenses consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accounts payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,356,677&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,786,381&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Specialty capitation payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;300,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;547,307&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Subcontractor IPA risk pool payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,472,985&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,348,376&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,727,238&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,004,215&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Deferred revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;710,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accrued compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,543,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,343,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,110,530&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;13,279,620&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>

  <ameh:MedicalLiabilitiesTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_736">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;8.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Medical Liabilities&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s medical liabilities consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Balance, beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63,972,318&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,957,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Medical liabilities assumed from Merger&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;39,353,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Claims paid for previous period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(28,633,287)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(23,075,516)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Incurred health care costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,634,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;121,846,375&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Claims paid for current period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(10,805,984)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(92,476,160)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Adjustments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(56,478)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(633,386)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Balance, end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,110,826&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63,972,318&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:MedicalLiabilitiesTextBlock>

  <ameh:BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_737">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 9.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt;Bank Loan, Lines of Credit and Loan Payable &amp;#150; Related Party&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Bank Loans&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In December 2010, ICC borrowed $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,600,000&lt;/font&gt; loan from a financial institution. The loan bears interest based on the Wall Street Journal &amp;#8220;prime rate&amp;#8221; or &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.75&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.50&lt;/font&gt;% per annum as of March 31, 2018 and December 31, 2017, respectively. The loan is collateralized by one if its shareholders and the medical equipment ICC owns. The loan matures on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; December 31, 2018&lt;/font&gt;. As of March 31, 2018 and December 31, 2017, the balance outstanding was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;394,783&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;510,391&lt;/font&gt;, respectively, and is classified as current liabilities. As of March 31, 2018 and December&amp;#160;31, 2017, ICC was in compliance with all affirmative and negative covenants contained in the loan agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Lines of Credit&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In April&amp;#160;2012, NMM entered into a promissory note agreement with a bank, which was amended on April&amp;#160;9, 2016 and April 7, 2017 (as amended, the &amp;#8220;NMM Business Loan Agreement&amp;#8221;). The NMM Business Loan Agreement was amended on April 7, 2017 to increase the loan availability from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000,000&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000,000&lt;/font&gt;. The interest rate is based on the Wall Street Journal &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#8220;prime rate&amp;#8221; plus 0.125%&lt;/font&gt;&lt;/font&gt; or &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.875&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.675&lt;/font&gt;% as of March&amp;#160;31, 2018 and December 31, 2017, respectively. As of December&amp;#160;31, 2017, the Company was not in compliance with certain financial debt covenant requirements contained in the loan agreement for which NMM obtained a waiver through March 31, 2018. As of March 31, 2018, NMM was in compliance with such financial debt covenant requirements.&amp;#160;The loan is personally guaranteed by 14 former shareholders of NMM, 13 of which are also members of former NMM&amp;#8217;s board of directors, and a Trust held by NMM&amp;#8217;s CEO, each of which guarantees is capped at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000,000&lt;/font&gt;. The loan is collateralized by substantially all assets of NMM. In October 2017, NMM borrowed $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; on this line of credit to provide to Accountable Health Care IPA (see Note 6). The line of credit was amended on April 18, 2018 to extend the maturity date from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;April 22, 2018&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;June 22, 2018&lt;/font&gt;. The amount outstanding as of both March 31, 2018 and December 31, 2017 was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt;&lt;/font&gt;. As of both March 31, 2018 and December 31, 2017, availability under this line of credit was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,300,671&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In April&amp;#160;2012, APC entered into a promissory note agreement with a bank, which was amended on April&amp;#160;22, 2016 and April 7, 2017 (as amended, the &amp;#8220;APC Business Loan Agreement&amp;#8221;). The APC Business Loan Agreement modifies certain terms of the promissory note agreement in order to (i) increase the original loan availability amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000,000&lt;/font&gt;, (ii)&amp;#160;extend the maturity date under the promissory note agreement to April&amp;#160;22, 2018, and (iii) add six additional guarantees. The interest rate is based on the Wall Street Journal &amp;#8220;prime rate&amp;#8221; plus 0.125% or &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.875&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.675&lt;/font&gt;% as of March&amp;#160;31, 2018 and December 31, 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company was not in compliance with certain financial debt covenant requirements contained in the loan agreement for which APC obtained a waiver from the bank through June 30, 2018. The loan is personally guaranteed by 14 shareholders of APC, 13 of which are also members of APC&amp;#8217;s board of directors, and a Trust held by NMM&amp;#8217;s CEO, each of which guarantees is capped at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000,000&lt;/font&gt;. The loan is also collateralized by substantially all assets of APC. No amounts were drawn on this line during the three months ended March 31, 2018 and no amounts were outstanding as of March 31, 2018 and December&amp;#160;31, 2017. As of both March 31, 2018 and December 31, 2017, availability under this line of credit was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,694,984&lt;/font&gt;&lt;/font&gt;. The line of credit was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Standby Letters of Credit&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On March 3, 2017, APAACO established an irrevocable standby letter of credit with a financial institution (through the NMM Business Loan Agreement) for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,699,329&lt;/font&gt; for the benefit of CMS. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.&lt;/font&gt; APAACO may continue to draw from the letter of credit for one year following the bank&amp;#8217;s notification of non-renewal.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC established irrevocable standby letters of credit with a financial institution for a total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;305,016&lt;/font&gt; for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2017_IccMemberdeiLegalEntityAxis" id="Factid_738" unitRef="pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="PAsOn12_31_2017_IccMemberdeiLegalEntityAxis" id="Factid_739" unitRef="USD" decimals="0">510391</us-gaap:ShortTermBankLoansAndNotesPayable>

  <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="P01_01_2018To03_31_2018_ApcMemberdeiLegalEntityAxis" id="Factid_740">prime rate plus 0.125%</us-gaap:LineOfCreditFacilityInterestRateDescription>

  <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="P01_01_2018To03_31_2018_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_741">prime rate plus 0.125%</us-gaap:LineOfCreditFacilityInterestRateDescription>

  <us-gaap:LineOfCreditFacilityDescription contextRef="P01_01_2018To03_31_2018_ApaacoMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis" id="Factid_742">The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.</us-gaap:LineOfCreditFacilityDescription>

  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="PAsOn12_31_2017_NmmBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_743" unitRef="pure" decimals="5">0.04675</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>

  <us-gaap:LineOfCredit contextRef="PAsOn03_31_2018_ApcMemberdeiLegalEntityAxis" id="Factid_744" unitRef="USD" decimals="0">5000000</us-gaap:LineOfCredit>

  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="P01_01_2018To03_31_2018_ApcMemberdeiLegalEntityAxis" id="Factid_745">2018-04-22</us-gaap:LineOfCreditFacilityExpirationDate1>

  <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="P01_01_2018To03_31_2018_ApaacoMemberdeiLegalEntityAxis_StandbyLettersOfCreditMemberusgaapInvestmentTypeAxis" id="Factid_746">2018-04-22</us-gaap:LineOfCreditFacilityExpirationDate1>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2018To03_31_2018_ExclusivityAmendmentAgreementApcMemberamehAmendmentAgreementAxis" id="Factid_747">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; Outstanding stock options granted to primary care physicians to purchase shares of APC&amp;#8217;s common stock consisted of the following: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options expired/forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercisable at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_748">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company&amp;#8217;s outstanding stock options consisted of the following: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,141,040&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;30,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(129,536)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;15.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,504&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercisable at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,504&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_749">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s outstanding warrants consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants outstanding at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,648,541&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(191,625)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.96&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants expired/forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(11,250)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.07&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Exercise&amp;#160;Price&amp;#160;Per&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Per&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Share&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Share&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,116,111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2.53&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,116,111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,455,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.05&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,455,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;850,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;850,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50 &amp;#150;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2018To03_31_2018_ContractedPhysiciansAndOtherServicesMemberusgaapIncomeStatementLocationAxis" id="Factid_750">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC&amp;#8217;s common stock, recognized over their respective vesting periods, consisted of the following: &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contracted physicians and other services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;202,382&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;321,233&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_751">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_752">P1Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2018To03_31_2018_AlliedPacificOfCaliforniaMemberusgaapOwnershipAxis" id="Factid_753">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2017" id="Factid_754" unitRef="shares" decimals="INF">3648541</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn12_31_2017" id="Factid_755" unitRef="USD_per_Share" decimals="2">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm contextRef="P01_01_2017To12_31_2017" id="Factid_756">P3Y8M26D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue contextRef="PAsOn12_31_2017" id="Factid_757" unitRef="USD" decimals="2">14.25</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>

  <ameh:ClassOfWarrantOrRightIssuedInPeriod contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_758" unitRef="shares" decimals="INF">24000</ameh:ClassOfWarrantOrRightIssuedInPeriod>

  <ameh:ClassOfWarrantOrRightIssuedInPeriod contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_759" unitRef="shares" decimals="INF">1116111</ameh:ClassOfWarrantOrRightIssuedInPeriod>

  <ameh:ClassOfWarrantOrRightIssuedInPeriod contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_760" unitRef="shares" decimals="INF">1455555</ameh:ClassOfWarrantOrRightIssuedInPeriod>

  <ameh:ClassOfWarrantOrRightIssuedInPeriod contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_761" unitRef="shares" decimals="INF">850000</ameh:ClassOfWarrantOrRightIssuedInPeriod>

  <ameh:ClassOfWarrantOrRightIssuedInPeriod contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_762" unitRef="shares" decimals="INF">3445666</ameh:ClassOfWarrantOrRightIssuedInPeriod>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_763">P7M6D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_764">P2Y6M11D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_765">P4Y18D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_766">P4Y8M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm contextRef="P01_01_2018To03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_767">P3Y8M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>

  <ameh:ClassOfWarrantOrRightExercisable contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_768" unitRef="shares" decimals="INF">24000</ameh:ClassOfWarrantOrRightExercisable>

  <ameh:ClassOfWarrantOrRightExercisable contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_769" unitRef="shares" decimals="INF">1116111</ameh:ClassOfWarrantOrRightExercisable>

  <ameh:ClassOfWarrantOrRightExercisable contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_770" unitRef="shares" decimals="INF">1455555</ameh:ClassOfWarrantOrRightExercisable>

  <ameh:ClassOfWarrantOrRightExercisable contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_771" unitRef="shares" decimals="INF">850000</ameh:ClassOfWarrantOrRightExercisable>

  <ameh:ClassOfWarrantOrRightExercisable contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_772" unitRef="shares" decimals="INF">3445666</ameh:ClassOfWarrantOrRightExercisable>

  <ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeOneMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_773" unitRef="USD_per_Share" decimals="2">4.50</ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights>

  <ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeTwoMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_774" unitRef="USD_per_Share" decimals="2">9.00</ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights>

  <ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeThreeMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_775" unitRef="USD_per_Share" decimals="2">10.00</ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights>

  <ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeFourMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_776" unitRef="USD_per_Share" decimals="2">11.00</ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights>

  <ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights contextRef="PAsOn03_31_2018_WarrantExercisePriceRangeFiveMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_777" unitRef="USD_per_Share" decimals="2">9.88</ameh:ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2018_FormerShareholdersOfNmmMemberusgaapTitleOfIndividualAxis" id="Factid_778" unitRef="shares" decimals="INF">1000970</us-gaap:SharesOutstanding>

  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="P01_01_2018To03_31_2018_AmehMemberusgaapBusinessAcquisitionAxis" id="Factid_779" unitRef="shares" decimals="INF">3039749</us-gaap:StockRepurchasedDuringPeriodShares>

  <us-gaap:LossContingencyDamagesSoughtValue contextRef="P04_01_2018To04_30_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_780" unitRef="USD" decimals="-6">5000000</us-gaap:LossContingencyDamagesSoughtValue>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_781">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 12.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On November&amp;#160;16, 2015, APC entered into a subordinated note receivable agreement with UCI, a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 48.9&lt;/font&gt;% owned equity method investee (see Note 5), in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;34,000&lt;/font&gt;, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, NMM received approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.6&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.5&lt;/font&gt; million, respectively, in management fees from LMA, which is accounted for under the equity method based on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% equity ownership interest held by APC in LMA&amp;#8217;s IPA line of business (see Note 5).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.4&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt;&amp;#160;million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% equity ownership interest held by APC (see Note 5).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.7&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.8&lt;/font&gt;&amp;#160;million, respectively, to AMG, Inc. for services as a provider. AMG, Inc. shares common ownership with certain board members of APC.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In September 2015, ApolloMed entered into a note receivable with Rob Mikitarian, a minority owner in APS, in the amount of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;150,000&lt;/font&gt;. The note accrues interest at &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt;% per annum and currently due on demand. As of March 31, 2018 and December 31, 2017, the balance of the note was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;150,000&lt;/font&gt; and is included in other receivables in the accompanying consolidated balance sheets.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In addition, affiliates wholly-owned by the Company&amp;#8217;s officers, including Dr. Lam and Dr. Hosseinion, are reported in the accompanying consolidated statement of income on a consolidated basis, together with the Company&amp;#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&amp;#8217;s subsidiaries as related party transactions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.6&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.4&lt;/font&gt;&amp;#160;million, respectively, to DMG for provider services, which is accounted for under the equity method based on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% equity ownership interest held by APC (see Note 5).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, NMM paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt;&amp;#160;million to Medical Property Partners (&amp;#8220;MPP&amp;#8221;) for office lease. MPP shares common ownership with certain board members of NMM.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;90,000&lt;/font&gt;&lt;/font&gt; to Tag-2 Medical Investment Group, LLC (&amp;#8220;Tag-2&amp;#8221;) for office lease. Tag-2 shares common ownership with certain board members of APC.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the three months ended March&amp;#160;31, 2018 and 2017, APC paid an aggregate of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.2&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12.8&lt;/font&gt; million, respectively, to shareholders of APC for provider services, which include approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.3&lt;/font&gt;&amp;#160;million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.4&lt;/font&gt; million, respectively, to shareholders who are also officers of APC.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;For loans receivable from related parties, see Note 6.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2018To03_31_2018_MedicalInvestmentGroupLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_782" unitRef="USD" decimals="0">90000</ameh:PaymentMadeToRelatedParty>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_MedicalInvestmentGroupLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_783" unitRef="USD" decimals="0">90000</ameh:PaymentMadeToRelatedParty>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_784">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 14.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation known as the Tax Cuts and Jobs Act (the &amp;#8220;TCJA&amp;#8221;). The TCJA establishes new tax laws that will take effect in 2018, including, but not limited to (1) a reduction of the U.S. federal corporate tax rate from a maximum of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 35&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 21&lt;/font&gt;%; (2) elimination of the corporate alternative minimum tax; (3) a new limitation on deductible interest expense; (4) limitations on the deductibility of certain executive compensation; (5) changes to the bonus depreciation rules for fixed asset additions; and (6) limitations on net operating losses generated after December 31, 2017, to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 80&lt;/font&gt;% of taxable income.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;ASC 740, Income Taxes, generally requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA&amp;#8217;s provisions, the SEC staff issued Staff Accounting Bulletin 118 (&amp;#8220;SAB 118&amp;#8221;), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent that a company&amp;#8217;s accounting for certain income tax effects of the TCJA is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the TCJA.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;At March 31, 2018 and December 31, 2017, the Company did not complete its accounting for the tax effects of enactment of the TCJA; however, the Company has made a reasonable estimate of the effects of the TCJA&amp;#8217;s change in the federal rate and revalued its deferred tax assets based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. The Company recorded a decrease in its deferred tax assets and deferred tax liabilities of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.6&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16.3&lt;/font&gt; million, respectively, with a corresponding net adjustment to deferred income tax benefit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.7&lt;/font&gt; million,&amp;#160;for the year ended December 31, 2017. The Company&amp;#8217;s provisional estimates are expected to be adjusted during the measurement period defined under SAB 118, based upon ongoing analysis of data and tax positions along with the new guidance from regulators and interpretations of the TCJA. The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on the differences between the Company&amp;#8217;s financial statements and tax bases of assets and liabilities using enacted tax rates.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&amp;#8217;s estimated effective tax rate. If and when this occurs, the income tax provision (benefit) will be adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&amp;#8217;s deferred taxes and related valuation allowance, may create fluctuations in the Company&amp;#8217;s overall effective tax rate from quarter to quarter.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As of March 31, 2018, due to overall cumulative losses incurred, prior to the merger with NMM, in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these assets is uncertain. The Company&amp;#8217;s effective tax rate for the three months ended March 31, 2018 differed from the U.S. federal statutory rate primarily due to state income taxes. As of March 31, 2018, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&amp;#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2013 through December 31, 2016 and for the years ended December 31, 2014 through December 31, 2016, respectively. The Company currently does not anticipate material unrecognized tax benefits within the next 12 months.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_785" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <ameh:IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_786" unitRef="USD" decimals="-5">6600000</ameh:IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate>

  <ameh:IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_787" unitRef="USD" decimals="-5">16300000</ameh:IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate>

  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_788" unitRef="USD" decimals="-5">9700000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2018To03_31_2018_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorDMemberusgaapMajorCustomersAxis" id="Factid_789" unitRef="pure" decimals="3">0.256</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorDMemberusgaapMajorCustomersAxis" id="Factid_790" unitRef="pure" decimals="3">0.238</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2018To03_31_2018_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorEMemberusgaapMajorCustomersAxis" id="Factid_791" unitRef="pure" decimals="3">0.382</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_PayorEMemberusgaapMajorCustomersAxis" id="Factid_792" unitRef="pure" decimals="3">0.305</us-gaap:ConcentrationRiskPercentage1>

  <ameh:BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic contextRef="P01_01_2017To03_31_2017" id="Factid_793" unitRef="shares" decimals="INF">33601022</ameh:BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic>

  <ameh:BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted contextRef="P01_01_2017To03_31_2017" id="Factid_794" unitRef="shares" decimals="INF">33601022</ameh:BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted>

  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_795">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Below is a summary of the earnings per share computations:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Earnings per share &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.07&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.17&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Earnings per share &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.06&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,421,467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,067,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,098,373&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,445,647&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>

  <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_796">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Below is a summary of the shares included in the diluted earnings per share computations:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,421,467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,067,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;10% shares held back pursuant to indemnification clause&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,039,749&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,785,328&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;835,790&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;592,365&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,801,367&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,098,373&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,445,647&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>

  <ameh:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares contextRef="P01_01_2017To03_31_2017" id="Factid_797" unitRef="shares" decimals="INF">1682110</ameh:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares>

  <ameh:IncreaseDecreaseInIncentivesPayable contextRef="P01_01_2018To03_31_2018" id="Factid_798" unitRef="USD" decimals="0">-6600000</ameh:IncreaseDecreaseInIncentivesPayable>

  <ameh:IncreaseDecreaseInIncentivesPayable contextRef="P01_01_2017To03_31_2017" id="Factid_799" unitRef="USD" decimals="0">-9721645</ameh:IncreaseDecreaseInIncentivesPayable>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_PacificAmbulatorySurgeryCenterMemberusgaapConsolidatedEntitiesAxis" id="Factid_800" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2018To03_31_2018" id="Factid_801" unitRef="USD" decimals="0">1923784</us-gaap:ProceedsFromStockOptionsExercised>

  <us-gaap:ProceedsFromStockOptionsExercised contextRef="P01_01_2017To03_31_2017" id="Factid_802" unitRef="USD" decimals="0">425025</us-gaap:ProceedsFromStockOptionsExercised>

  <ameh:CashlessExerciseOfStockOptions contextRef="P01_01_2018To03_31_2018" id="Factid_803" unitRef="USD" decimals="0">43</ameh:CashlessExerciseOfStockOptions>

  <ameh:CashlessExerciseOfStockOptions contextRef="P01_01_2017To03_31_2017" id="Factid_804" unitRef="USD" decimals="0">0</ameh:CashlessExerciseOfStockOptions>

  <us-gaap:StockIssued1 contextRef="P01_01_2018To03_31_2018" id="Factid_805" unitRef="USD" decimals="0">0</us-gaap:StockIssued1>

  <us-gaap:StockIssued1 contextRef="P01_01_2017To03_31_2017" id="Factid_806" unitRef="USD" decimals="0">425025</us-gaap:StockIssued1>

  <ameh:DeferredTaxLiabilityAdjustmentToGoodwill contextRef="P01_01_2018To03_31_2018" id="Factid_807" unitRef="USD" decimals="0">914011</ameh:DeferredTaxLiabilityAdjustmentToGoodwill>

  <ameh:DeferredTaxLiabilityAdjustmentToGoodwill contextRef="P01_01_2017To03_31_2017" id="Factid_808" unitRef="USD" decimals="0">0</ameh:DeferredTaxLiabilityAdjustmentToGoodwill>

  <ameh:CumulativeEffectAdjustmentIncludedInAccountsReceivable contextRef="P01_01_2018To03_31_2018" id="Factid_809" unitRef="USD" decimals="0">11600000</ameh:CumulativeEffectAdjustmentIncludedInAccountsReceivable>

  <ameh:CumulativeEffectAdjustmentIncludedInAccountsReceivable contextRef="P01_01_2017To03_31_2017" id="Factid_810" unitRef="USD" decimals="0">0</ameh:CumulativeEffectAdjustmentIncludedInAccountsReceivable>

  <ameh:CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities contextRef="P01_01_2018To03_31_2018" id="Factid_811" unitRef="USD" decimals="0">3246098</ameh:CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities>

  <ameh:CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities contextRef="P01_01_2017To03_31_2017" id="Factid_812" unitRef="USD" decimals="0">0</ameh:CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities>

  <us-gaap:LiabilitiesAssumed1 contextRef="P01_01_2018To03_31_2018" id="Factid_813" unitRef="USD" decimals="0">630963</us-gaap:LiabilitiesAssumed1>

  <us-gaap:LiabilitiesAssumed1 contextRef="P01_01_2017To03_31_2017" id="Factid_814" unitRef="USD" decimals="0">32485</us-gaap:LiabilitiesAssumed1>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent contextRef="PAsOn03_31_2018" id="Factid_815" unitRef="USD" decimals="0">2301972</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn03_31_2018" id="Factid_816" unitRef="USD" decimals="0">66452129</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn03_31_2018" id="Factid_817" unitRef="USD" decimals="0">122505170</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn03_31_2017" id="Factid_818" unitRef="USD" decimals="0">63352783</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2017" id="Factid_819" unitRef="USD" decimals="0">63251651</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:RestrictedCashNoncurrent contextRef="PAsOn03_31_2017" id="Factid_820" unitRef="USD" decimals="0">101132</us-gaap:RestrictedCashNoncurrent>

  <us-gaap:RestrictedCashCurrent contextRef="PAsOn03_31_2017" id="Factid_821" unitRef="USD" decimals="0">0</us-gaap:RestrictedCashCurrent>

  <us-gaap:TreasuryStockCommonShares contextRef="PAsOn03_31_2018" id="Factid_822" unitRef="shares" decimals="INF">1682110</us-gaap:TreasuryStockCommonShares>

  <us-gaap:TreasuryStockCommonShares contextRef="PAsOn12_31_2017" id="Factid_823" unitRef="shares" decimals="INF">1682110</us-gaap:TreasuryStockCommonShares>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_824">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 17.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In April 2018, NMM distributed approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000,000&lt;/font&gt; to former NMM shareholders, which was previously classified as restricted cash and dividends payable as of March 31, 2018, with $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,000,000&lt;/font&gt; of restricted cash resulting from the Merger continuing to be held for distribution.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In April 2018, APC acquired a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;% membership interest in a joint venture limited liability company. The joint venture entered into an agreement, effective as of April 10, 2018, to purchase real property of approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 109,000&lt;/font&gt; square feet including a building containing approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 89,000&lt;/font&gt; rentable square feet situated in the City of Los Angeles, and provided a securing deposit into an escrow account. The transaction is expected to close on May 31, 2018.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="PAsOn03_31_2018" id="Factid_825" unitRef="USD" decimals="0">8000000</us-gaap:DividendsPayableCurrentAndNoncurrent>

  <us-gaap:Dividends contextRef="P04_01_2018To04_30_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_826" unitRef="USD" decimals="0">10000000</us-gaap:Dividends>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn04_30_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_827" unitRef="pure" decimals="1">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:AreaOfLand contextRef="PAsOn04_30_2018_RealEstateMemberusgaapCollateralAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_828" unitRef="acre" decimals="0">109000</us-gaap:AreaOfLand>

  <us-gaap:AreaOfLand contextRef="PAsOn04_30_2018_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_829" unitRef="acre" decimals="0">89000</us-gaap:AreaOfLand>

  <us-gaap:DebtInstrumentMaturityDateRangeStart1 contextRef="P04_01_2018To04_18_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_830">2018-04-22</us-gaap:DebtInstrumentMaturityDateRangeStart1>

  <us-gaap:DebtInstrumentMaturityDateRangeEnd1 contextRef="P04_01_2018To04_18_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_831">2018-06-22</us-gaap:DebtInstrumentMaturityDateRangeEnd1>

  <us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_832">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The cumulative effect of changes made to the Company&amp;#8217;s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance&amp;#160;at&lt;br/&gt; December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Adjustments&lt;br/&gt; due&amp;#160;to&amp;#160;Topic&amp;#160;606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance&amp;#160;at&lt;br/&gt; January&amp;#160;1,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Current Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;20,117,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11,600,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;31,717,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Liabilities, Mezzanine Equity and Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncurrent Liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,916,598&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,246,098&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;28,162,696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Mezzanine equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncontrolling interest in Allied Pacific of California IPA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;172,129,744&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,351,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;179,481,178&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,734,531&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,002,468&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,736,999&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock>

  <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_833">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The following table presents disaggregated revenue generated by each payor type:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commercial&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;105,350,102&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;83,848,918&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medicare&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;18,541,115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,453,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medicaid&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;176,350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other third parties&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;99,160&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,441&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;124,166,727&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,336,062&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_834">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;10.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Mezzanine and Stockholders&amp;#8217; Equity&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;All the historical NMM share and per share information has been adjusted to reflect the exchange ratio from the Merger (see Note 3).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;u&gt;Mezzanine&lt;/u&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;APC&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;u&gt;Stockholders&amp;#8217; Equity&lt;/u&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As of the date of this Quarterly Report on Form 10-Q, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,970&lt;/font&gt; shares, which are net of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,039,749&lt;/font&gt; holdback shares and&amp;#160;are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants.&amp;#160; Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares on the Effective Date of the Merger.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On March 21, 2018, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 37,593&lt;/font&gt; shares of the Company&amp;#8217;s common stock to the Company&amp;#8217;s Chief Operating Officer for prior services rendered. The stock price on the date of issuance was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16.80&lt;/font&gt;, which resulted in the Company recording $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;631,562&lt;/font&gt; of share-based compensation expense.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s outstanding stock options consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,141,040&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.79&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;19.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;30,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(129,536)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;15.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,504&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercisable at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,504&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.66&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; During the quarter ended March 31, 2018, stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 54,536&lt;/font&gt; shares of the Company&amp;#8217;s common stock, which resulted in the Company issuing &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 43,201&lt;/font&gt; net shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the quarter ended March 31, 2018, stock options were exercised for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 75,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock, which resulted in proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;479,000&lt;/font&gt;. The exercise price ranged from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.10&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.00&lt;/font&gt; per share.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Outstanding stock options granted to primary care physicians to purchase shares of APC&amp;#8217;s common stock consisted of the following:&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at January 1, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options expired/forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options exercisable at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;853,800&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.167&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;508,864&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of common stock as of March 31, 2018.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC&amp;#8217;s common stock, recognized over their respective vesting periods, consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contracted physicians and other services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;202,382&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;321,233&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The remaining unrecognized share-based compensation expense of stock option awards granted to primary care physicians to purchase shares of APC&amp;#8217;s common stock as of March 31, 2018 was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,214,292&lt;/font&gt;, which is expected to be recognized over the remaining term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.50&lt;/font&gt; years.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s outstanding warrants consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants outstanding at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,648,541&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(191,625)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.96&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants expired/forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(11,250)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants outstanding at March 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.07&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Exercise&amp;#160;Price&amp;#160;Per&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Per&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Share&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Share&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,116,111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2.53&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,116,111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,455,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.05&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,455,555&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;850,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;850,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.50 &amp;#150;11.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,445,666&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;During the quarter ended March 31, 2018, common stock warrants were exercised for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 191,625&lt;/font&gt; shares of the Company&amp;#8217;s common stock, which resulted in proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.4&lt;/font&gt; million. The exercise price ranged from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.00&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.00&lt;/font&gt; per share.&lt;/div&gt; &lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;Treasury Stock&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;APC owns &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,682,110&lt;/font&gt; shares of ApolloMed&amp;#8217;s common stock as of March 31, 2018, which are legally issued and outstanding but excluded from shares of common stock outstanding in the condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2018To03_21_2018" id="Factid_835" unitRef="shares" decimals="INF">37593</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2017_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_836" unitRef="USD" decimals="0">11600000</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn12_31_2017_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_837" unitRef="USD" decimals="0">31717304</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2017_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_838" unitRef="USD" decimals="0">3246098</us-gaap:DeferredTaxLiabilities>

  <us-gaap:DeferredTaxLiabilities contextRef="PAsOn12_31_2017_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_839" unitRef="USD" decimals="0">28162696</us-gaap:DeferredTaxLiabilities>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn03_21_2018" id="Factid_840" unitRef="USD_per_Share" decimals="2">16.80</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P03_01_2018To03_21_2018" id="Factid_841" unitRef="USD" decimals="0">631562</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="PAsOn12_31_2017_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_842" unitRef="USD" decimals="0">7351434</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>

  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="PAsOn12_31_2017_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_843" unitRef="USD" decimals="0">179481178</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2017_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_844" unitRef="USD" decimals="0">1002468</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2017_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_845" unitRef="USD" decimals="0">2736999</us-gaap:RetainedEarningsAccumulatedDeficit>

  <ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_846" unitRef="shares" decimals="INF">54536</ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod>

  <ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet contextRef="P01_01_2018To03_31_2018" id="Factid_847" unitRef="shares" decimals="INF">43201</ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2018To03_31_2018" id="Factid_848" unitRef="shares" decimals="INF">75000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2018To03_31_2018" id="Factid_849" unitRef="USD" decimals="0">479000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_MinimumMemberusgaapRangeAxis" id="Factid_850" unitRef="USD_per_Share" decimals="2">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_31_2018_MaximumMemberusgaapRangeAxis" id="Factid_851" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_852" unitRef="shares" decimals="INF">191625</ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod>

  <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised contextRef="P01_01_2018To03_31_2018" id="Factid_853" unitRef="USD" decimals="-5">1400000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>

  <ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_MinimumMemberusgaapRangeAxis" id="Factid_854" unitRef="shares" decimals="INF">4.00</ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice>

  <ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice contextRef="P01_01_2018To03_31_2018_MaximumMemberusgaapRangeAxis" id="Factid_855" unitRef="shares" decimals="INF">10.00</ameh:SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice>

  <us-gaap:EquityFairValueAdjustment contextRef="P01_01_2018To03_31_2018" id="Factid_856" unitRef="USD" decimals="0">10208000</us-gaap:EquityFairValueAdjustment>

  <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 contextRef="P01_01_2018To03_31_2018" id="Factid_857" unitRef="USD" decimals="0">1392000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>

  <us-gaap:FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent contextRef="PAsOn03_31_2018" id="Factid_858" unitRef="USD" decimals="0">3246098</us-gaap:FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent>

  <us-gaap:TreasuryStockCommonShares contextRef="PAsOn03_31_2018_AlliedPacificOfCaliforniaMemberusgaapBusinessAcquisitionAxis" id="Factid_859" unitRef="shares" decimals="INF">1682110</us-gaap:TreasuryStockCommonShares>

  <us-gaap:ContractWithCustomerLiability contextRef="PAsOn03_31_2018" id="Factid_860" unitRef="USD" decimals="0">710106</us-gaap:ContractWithCustomerLiability>

  <us-gaap:ContractWithCustomerLiability contextRef="PAsOn12_31_2017" id="Factid_861" unitRef="USD" decimals="0">250000</us-gaap:ContractWithCustomerLiability>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_862">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; 11.&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;&lt;b&gt; Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Regulatory Matters&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As risk-bearing organizations, APC and MMG are required to follow regulations of the DMHC, including maintenance of minimum working capital, tangible net equity (&amp;#8220;TNE&amp;#8221;), cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At March 31, 2018 and December 31, 2017, APC was in compliance with these regulations. At March 31, 2018 and December 31, 2017, MMG was not in compliance with these regulations. As a result, the California DMHC required MMG to develop and implement a corrective action plan (&amp;#8220;CAP&amp;#8221;) for such deficiency. The Company has been in communication with the DMHC regarding MMG&amp;#8217;s business plans that, if implemented, could result in a significant reduction in the health plan enrollment assigned to MMG. MMG received confirmation from substantially all of MMG&amp;#8217;s direct-contracted health plans, that they have moved membership out of MMG effective May 1, 2018. MMG is currently working with DMHC on providing a CAP plan.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Many of the Company&amp;#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&amp;#8217;s financial condition, cash flows or results of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On or about March 23, 2018 and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &amp;#8220;Prospect&amp;#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services (&amp;#8220;JAMS&amp;#8221;), arising out of MMG&amp;#8217;s purported business plans, seeking damages in excess of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&amp;#8217;s current and future economic relationships with its health plans and their members. MMG, ApolloMed and AMM each disputes the allegations and intends to vigorously defend itself in this matter. At this time, it is too early in the process to assess the probability of the outcome of this matter and/or amount of loss, if any.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <ameh:AllinclusivePopulationbasedPaymentsToBeReceived contextRef="PAsOn01_31_2018" id="Factid_863" unitRef="USD" decimals="-5">7300000</ameh:AllinclusivePopulationbasedPaymentsToBeReceived>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn12_31_2017" id="Factid_864" unitRef="USD" decimals="0">118500095</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn12_31_2016" id="Factid_865" unitRef="USD" decimals="0">54925712</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_866">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;15.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Earnings Per Share&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Basic net income per share is calculated using the weighted average number of shares of the Company&amp;#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income by the weighted average number of shares of the Company&amp;#8217;s common stock issued and outstanding during such period. Diluted net income per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Pursuant to the Merger Agreement, ApolloMed held back 10% of the shares of its common stock that were issuable to NMM shareholders (&amp;#8220;Holdback Shares&amp;#8221;) to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback Shares are excluded from the computation of basic earnings per share, but included in diluted earnings per share. As of both March 31, 2018 and 2017, APC held &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,682,110&lt;/font&gt;&lt;/font&gt; shares of ApolloMed&amp;#8217;s and NMM&amp;#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 10).&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Below is a summary of the earnings per share computations:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Earnings per share &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.07&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.17&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Earnings per share &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.06&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,421,467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,067,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,098,373&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,445,647&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; basic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,421,467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,067,954&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;10% shares held back pursuant to indemnification clause&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,039,749&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,785,328&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;835,790&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;592,365&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,801,367&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Weighted average shares of common stock outstanding &amp;#150; diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,098,373&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,445,647&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>

  <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_867">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;16.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Variable Interest Entities (VIEs)&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&amp;#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s VIEs include APC and other immaterial entities.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against the Company&amp;#8217;s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on the Company&amp;#8217;s general assets; rather, they represent claims against the specific assets of the VIE.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company evaluates its relationships with its VIEs on an ongoing basis to ensure that it continues to be the primary beneficiary.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investments in other entities &amp;#150; cost method and amounts due to affiliate, which are eliminated upon consolidation with the NMM, are included in the accompanying consolidated balance sheets.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&lt;br/&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;br/&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,024,188&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,686,370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Restricted cash &amp;#150; short-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,028,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,005,661&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Fiduciary cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,386,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,017,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investment in marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,844,184&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,183,483&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Prepaid expenses and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,960,737&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,821,328&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;119,304,721&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;92,771,369&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Noncurrent assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Land, property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,201,045&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,167,689&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;67,670,837&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;70,841,907&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60,012,316&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60,012,316&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Loans receivable &amp;#150; related parties&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Loan receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investments in other entities &amp;#150; equity method&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,875,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,903,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investments in other entities &amp;#150; cost method&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,320,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,320,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Restricted cash &amp;#150; long-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;745,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;745,235&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,155,114&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,371,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total noncurrent assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;175,980,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;179,362,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;295,284,826&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;272,133,704&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accounts payable and accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,505,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,625,610&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Incentives payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,900,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Fiduciary accounts payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,386,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,017,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Medical liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,212,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,186,240&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Income taxes payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,229,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,463,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Amount due to affiliate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,061,953&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24,889,717&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Bank loan, short-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;394,783&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,391&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Capital lease obligations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99,480&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;98,738&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;76,788,911&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;79,291,673&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Noncurrent liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,406,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,970,766&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Liability for unissued equity shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,185,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,185,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Capital lease obligations, net of current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;593,852&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;619,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total noncurrent liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,185,695&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,774,792&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;105,974,606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;102,066,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;The assets of the Company&amp;#8217;s other consolidated VIEs were not considered significant.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,000,000&lt;/font&gt; of restricted cash is related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), was held for distribution to former NMM shareholders.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>

  <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_868">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investments in other entities &amp;#150; cost method and amounts due to affiliate, which are eliminated upon consolidation with the NMM, are included in the accompanying consolidated balance sheets.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&lt;br/&gt; 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&lt;br/&gt; 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;58,024,188&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;54,686,370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Restricted cash &amp;#150; short-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,028,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,005,661&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Fiduciary cash&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,386,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,017,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investment in marketable securities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,061,022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,057,090&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Receivables, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,844,184&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,183,483&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Prepaid expenses and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,960,737&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,821,328&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;119,304,721&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;92,771,369&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Noncurrent assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Land, property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,201,045&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,167,689&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Intangible assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;67,670,837&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;70,841,907&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60,012,316&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60,012,316&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Loans receivable &amp;#150; related parties&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Loan receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investments in other entities &amp;#150; equity method&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,875,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,903,524&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Investments in other entities &amp;#150; cost method&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,320,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,320,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Restricted cash &amp;#150; long-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;745,293&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;745,235&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,155,114&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,371,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total noncurrent assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;175,980,105&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;179,362,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;295,284,826&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;272,133,704&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Accounts payable and accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,505,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,625,610&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Incentives payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,900,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Fiduciary accounts payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,386,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,017,437&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Medical liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,212,116&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25,186,240&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Income taxes payable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,229,058&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,463,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Amount due to affiliate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,061,953&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24,889,717&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Bank loan, short-term&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;394,783&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;510,391&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Capital lease obligations&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99,480&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;98,738&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;76,788,911&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;79,291,673&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Noncurrent liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,406,818&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,970,766&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Liability for unissued equity shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,185,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,185,025&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Capital lease obligations, net of current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;593,852&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;619,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Total noncurrent liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29,185,695&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22,774,792&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Total liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;105,974,606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;102,066,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="P01_01_2018To03_31_2018" id="Factid_869" unitRef="USD" decimals="0">4005075</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="P01_01_2017To03_31_2017" id="Factid_870" unitRef="USD" decimals="0">8427071</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>

  <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod contextRef="P01_01_2018To03_31_2018" id="Factid_871" unitRef="USD" decimals="0">28633287</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>

  <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod contextRef="P01_01_2017To12_31_2017" id="Factid_872" unitRef="USD" decimals="0">23075516</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>

  <us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods contextRef="P01_01_2018To03_31_2018" id="Factid_873" unitRef="USD" decimals="0">10805984</us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods>

  <us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods contextRef="P01_01_2017To12_31_2017" id="Factid_874" unitRef="USD" decimals="0">92476160</us-gaap:MalpracticeLossContingencyClaimsIncurredInPriorPeriods>

  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="PAsOn12_31_2017_NotesReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_RobMikitarianMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_875" unitRef="USD" decimals="0">150000</us-gaap:AccountsAndOtherReceivablesNetCurrent>

  <ameh:PaymentMadeToRelatedParty contextRef="P01_01_2017To03_31_2017_MedicalPropertyPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServiceMemberusgaapRelatedPartyTransactionAxis" id="Factid_876" unitRef="USD" decimals="-5">300000</ameh:PaymentMadeToRelatedParty>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2018_DmgMemberusgaapConsolidatedEntitiesAxis" id="Factid_877" unitRef="pure" decimals="1">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2018To03_31_2018_EmployeeStockOptionMemberusgaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" id="Factid_878" unitRef="USD" decimals="2">15.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="PAsOn12_31_2017_UniversalCareIncMemberusgaapScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" id="Factid_879" unitRef="USD" decimals="0">5000000</us-gaap:DueFromRelatedPartiesNoncurrent>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn10_15_2012_AlliedPacificOfCaliforniaMemberusgaapConsolidatedEntitiesAxis_ApcLsmaMemberusgaapOwnershipAxis" id="Factid_880" unitRef="pure" decimals="0">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="PAsOn12_31_2017_ApcBusinessLoanAgreementMemberdeiLegalEntityAxis" id="Factid_881" unitRef="USD" decimals="0">9694984</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>

  <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_882">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;13.&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt; &lt;strong&gt;Revenue Recognition&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;At the adoption of Topic 606, the majority of what was previously classified as the provision for bad debts in the consolidated statements of income is now reflected as implicit price concessions and, therefore, included as a reduction to revenues starting in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in operating expenses in the condensed consolidated statements of income.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In addition, the cumulative effect of initially applying the new revenue standard is required to be presented as an adjustment to the opening balance of retained earnings. This cumulative effect amount was determined to be related to the full risk pool arrangements of APC, a variable interest entity (see Note 1). Therefore, the cumulative net effect of initially applying Topic 606 in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,208,000&lt;/font&gt;, which is comprised of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11,600,000&lt;/font&gt; of additional revenue, offset by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,392,000&lt;/font&gt; in related management fee expense, has been presented as an adjustment to the opening balance of the mezzanine equity, &amp;#8220;Noncontrolling interest in Allied Pacific of California IPA.&amp;#8221; Consequently, as a result of APC recording additional receivables, NMM recorded a corresponding entry of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,392,000&lt;/font&gt; to retained earnings to record the related management fee income. These adjustments were offset by an aggregate adjustment to deferred tax liability of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,246,098&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The adoption of this ASU did not have a significant impact on the Company&amp;#8217;s revenue, when comparing the amount of revenue recognized for the three months ended March 31, 2018 to the revenue that would have been recognized under the prior revenue standard ASC 605, such that comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The cumulative effect of changes made to the Company&amp;#8217;s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance&amp;#160;at&lt;br/&gt; December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Adjustments&lt;br/&gt; due&amp;#160;to&amp;#160;Topic&amp;#160;606&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance&amp;#160;at&lt;br/&gt; January&amp;#160;1,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Current Assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Receivables&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;20,117,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;11,600,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;31,717,304&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Liabilities, Mezzanine Equity and Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncurrent Liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;24,916,598&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,246,098&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;28,162,696&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Mezzanine equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Noncontrolling interest in Allied Pacific of California IPA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;172,129,744&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,351,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;179,481,178&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Retained earnings&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,734,531&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,002,468&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,736,999&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company operates as one reportable segment, the healthcare delivery segment. The Company disaggregates revenue from contracts by service type and by payor.&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.&lt;/font&gt; The condensed consolidated statements of income presents disaggregated revenue by service type. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents disaggregated revenue generated by each payor type:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&amp;#160;2018&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&amp;#160;2017&lt;br/&gt; (unaudited)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Commercial&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;105,350,102&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;83,848,918&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medicare&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;18,541,115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,453,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medicaid&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;176,350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other third parties&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;99,160&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33,441&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;124,166,727&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;85,336,062&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third party payors (e.g., hospitals); and (v) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 8.75pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursements are often subject to interpretation that could result in payments that differ from the Company&amp;#8217;s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under the new revenue standard, the Company has elected to apply the following practical expedients and optional exemptions:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within general and administrative expenses.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&amp;#8217;s services completed to date.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed, and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;Use a portfolio approach for the fee-for-service (FFS) revenue stream to group contracts with similar characteristics and analyze historical cash collections trends.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Times New Roman, Times, Serif"&gt;No adjustment is made for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&lt;u&gt;Nature of Services and Revenue Streams&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&amp;#8220;AIPBP&amp;#8221;) revenue, management fee income, MSSP surplus revenue and FFS revenue. Revenue is recorded in the period in which services are rendered. The form of billing and related risk of collection for such services may&amp;#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&amp;#8217;s billing arrangements and how revenue is recognized for each.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Capitation, net&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under either provider service agreements (each, a &amp;#8220;PSA&amp;#8221;) or capitated arrangements directly made with various managed care providers including HMOs. Capitation revenue under the PSAs and HMO contracts is prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months&amp;#8217; capitation, primarily arising from contracted HMOs finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &amp;#8220;Risk Adjustment model,&amp;#8221; which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 6.65pt 0pt 2pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Per member per month (PMPM) managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes per member per month fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&amp;#8217;s net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Risk Pool Settlements and Incentives&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APC and APAACO enter into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC and APAACO is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC and APAACO generally receives a percentage of the net surplus from the affiliated hospital&amp;#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for IBNR completion factor and constraint percentages were used by management in applying the most likely method.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under capitated arrangements with certain HMOs, APC and APAACO participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC and APAACO is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished. Risk pool settlements under arrangements with HMOs are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR, risk adjustment factors, stop loss provisions, etc., an estimate cannot be developed. Due to these limitations, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; APAACO&lt;/font&gt; cannot determine the amount of surplus or deficit that will probably not be reversed in the future and therefore this shared risk pool revenue is considered to be fully constrained.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &amp;#8220;pay-for-performance&amp;#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed the quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for efforts it takes to improve the quality of services and for efficient and effective use of pharmacy supplemental benefits provided to the HMO&amp;#8217;s members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. Incentives under &amp;#8220;pay-for-performance&amp;#8221; programs are recognized using the most likely methodology. As the Company does not have sufficient insight from the health plans on the amount and timing of the incentive payments, this revenue is considered to be fully constrained and is only recorded when such payments are received.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Generally for the foregoing arrangements, the final settlement is dependent on each distinct day&amp;#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e. the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;NGACO AIPBP Revenue&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Under the NGACO Model, CMS grants the Company a pool of patients to manage (direct care and pay providers) based on a budget established with CMS. The Company is responsible for managing medical costs for these patients. The patients will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed or paid by CMS and the Company&amp;#8217;s profits or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&amp;#8217;s risk share agreement with CMS, the Company will be eligible to receive the surplus or be liable for the deficit according to the budget established by CMS based on the Company&amp;#8217;s efficiency or lack thereof, respectively, in managing how the patients assigned to the Company by CMS are served by in-network and out-of-network providers. The Company&amp;#8217;s profits or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. In accordance with the guidance in ASC 606-10-55-36 through 55-40 on principal versus agent considerations, the Company records such revenues in the gross amount of consideration.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company also has arrangements for billing and payment services with the medical providers within the NGACO network. The Company retains certain defined percentages of the payments made to the providers in exchange for using the Company&amp;#8217;s billing and payment services. The revenue for this service is earned as payments are made to medical providers.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;APAACO and CMS entered into a Next Generation ACO Model Participation Agreement (the &amp;#8220;Participation Agreement&amp;#8221;) with a term of two performance years through December 31, 2018. CMS may offer to renew the Participation Agreement for additional terms of two performance years.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;For each performance year, the Company shall submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;For each performance year, CMS shall pay the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies owed. If CMS owes the Company shared savings or other monies owed, CMS shall pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company shall pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&amp;#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As it relates specifically to the Company&amp;#8217;s Participation Agreement with CMS, the Company recognizes capitation revenue in the month in which the Company is obligated to provide services. Also, because the Company&amp;#8217;s arrangement with CMS is new (became effective in 2017), numerous factors create uncertainty regarding the risk pool settlement and incentive amounts that the Company is entitled to receive and limited historical data exists to develop reasonable and reliable estimates. As a result, the Company recognizes revenue from risk pool settlements and incentives under the arrangement with CMS in the period in which amounts are estimable and collection is reasonably assured. The Company will continue to evaluate and assess the reliability and reasonableness of data available to it in order develop future estimates, and will recognize risk pool settlements and incentives revenue based on such estimates only to the extent it is probable that a significant reversal of cumulative revenue will not occur in future periods.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In October 2017, CMS notified the Company that it would not be renewed for participation in the AIPBP payment mechanism of the NGACO Model for performance year 2018 due to certain alleged deficiencies in performance. The Company submitted a reconsideration request. In December 2017, the Company received the official decision on its reconsideration request that CMS reversed the prior decision against the Company&amp;#8217;s continued participation in the AIPBP mechanism. As a result, the Company is eligible for receiving monthly AIPBP payments currently at a rate of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.3&lt;/font&gt; million per month from CMS starting February 2018. The Company, however, will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Management Fee Income&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. Such variable supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. The Company&amp;#8217;s MSA revenue also includes revenue sharing payments from the Company&amp;#8217;s partners based on their non-medical services.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company provides a significant service of integrating the services selected by the Company&amp;#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&amp;#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&amp;#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&amp;#8217;s performance obligation is satisfied as the Company completes each period&amp;#8217;s obligations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&amp;#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&amp;#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company&amp;#8217;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the respective contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Medicare Shared Savings Program Surplus Revenue&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company participates in the MSSP, which is sponsored by CMS. The goal of the MSSP is to improve the quality of patient care and outcomes through a more efficient and coordinated approach among providers. The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants&amp;#8217; cost savings benchmark. Revenues earned by the Company are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and will be contingent on various factors, including achievement of the minimum savings rate as determined by MSSP for the relevant period. Such payments are earned and made on an &amp;#8220;all or nothing&amp;#8221; basis. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined solely by CMS, which are subject to significant estimation risk. Accordingly, they are not recognized as revenue until the amounts are estimable and collection is reasonably assured, which is generally when notice is received from CMS that cash payments are to be imminently received.&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;Fee-for-Service Revenue&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&amp;#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&amp;#8217;s billing center for medical coding and entering into the Company&amp;#8217;s billing system and the verification of each patient&amp;#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&amp;#8217;s billing systems as well as an estimate of the revenue associated with medical services.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&amp;#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&lt;u&gt;Contract Assets&lt;/u&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&amp;#8217;s contract assets comprise accounts receivable. Generally, the Company does not have material amounts of other contract assets.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;i&gt;&lt;u&gt;Contract Liabilities (Deferred Revenue&lt;/u&gt;)&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&amp;#8217;s performance, which is generally uncommon. The Company&amp;#8217;s contract liability balance was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;710,106&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt; as of March 31, 2018 and December 31, 2017, respectively, and is presented within the &amp;#8220;Accounts Payable and Accrued Expenses&amp;#8221; line item of the condensed consolidated balance sheets. None of the amounts accrued as of December 31, 2017 was recognized as revenue for the three months ended March 31, 2018.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>

  <ameh:MedicalLiabilitiesTableTextBlockTableTextBlock contextRef="P01_01_2018To03_31_2018" id="Factid_883">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Company&amp;#8217;s medical liabilities consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Balance, beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63,972,318&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,957,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Medical liabilities assumed from Merger&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;39,353,540&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Claims paid for previous period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(28,633,287)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(23,075,516)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Incurred health care costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44,634,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;121,846,375&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Claims paid for current period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(10,805,984)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(92,476,160)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Adjustments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(56,478)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(633,386)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"&gt; &lt;div&gt;Balance, end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69,110,826&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;63,972,318&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ameh:MedicalLiabilitiesTableTextBlockTableTextBlock>

  <ameh:IncreaseDecreaseDeferredTaxAsset contextRef="P01_01_2018To03_31_2018" id="Factid_884" unitRef="USD" decimals="-5">900000</ameh:IncreaseDecreaseDeferredTaxAsset>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2018To03_31_2018_PayorDMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_885" unitRef="pure" decimals="3">0.109</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_PayorDMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_886" unitRef="pure" decimals="3">0.127</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2018To03_31_2018_CustomerBMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_887" unitRef="pure" decimals="3">0.120</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_CustomerBMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_888" unitRef="pure" decimals="3">0.240</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P01_01_2017To03_31_2017_CustomerCMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_889" unitRef="pure" decimals="3">0.119</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P03_01_2018To03_23_2018_CustomerAMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_890" unitRef="pure" xsi:nil="true" />

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P03_01_2018To03_23_2018_CustomerCMemberusgaapMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_891" unitRef="pure" xsi:nil="true" />

  <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 contextRef="P01_01_2018To01_02_2018" id="Factid_892" unitRef="USD" decimals="0">1392000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn01_02_2018_AccountingStandardsUpdate201409MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" id="Factid_893" unitRef="USD" decimals="0">11600000</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2018To03_31_2018_CommercialMemberusgaapMajorCustomersAxis" id="Factid_894" unitRef="USD" decimals="0">105350102</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2018To03_31_2018_MedicareMemberusgaapMajorCustomersAxis" id="Factid_895" unitRef="USD" decimals="0">18541115</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2018To03_31_2018_MedicaidMemberusgaapMajorCustomersAxis" id="Factid_896" unitRef="USD" decimals="0">176350</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2018To03_31_2018_OtherThirdPartiesMemberusgaapMajorCustomersAxis" id="Factid_897" unitRef="USD" decimals="0">99160</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2017To03_31_2017_CommercialMemberusgaapMajorCustomersAxis" id="Factid_898" unitRef="USD" decimals="0">83848918</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2017To03_31_2017_MedicareMemberusgaapMajorCustomersAxis" id="Factid_899" unitRef="USD" decimals="0">1453703</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2017To03_31_2017_MedicaidMemberusgaapMajorCustomersAxis" id="Factid_900" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueNet>

  <us-gaap:SalesRevenueNet contextRef="P01_01_2017To03_31_2017_OtherThirdPartiesMemberusgaapMajorCustomersAxis" id="Factid_901" unitRef="USD" decimals="0">33441</us-gaap:SalesRevenueNet>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_210" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">Included in cash and cash equivalents</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_214" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_220" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_221" xlink:type="locator" xlink:label="loc_5" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_224" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_227" xlink:type="locator" xlink:label="loc_7" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_230" xlink:type="locator" xlink:label="loc_8" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_233" xlink:type="locator" xlink:label="loc_9" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_258" xlink:type="locator" xlink:label="loc_10" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_10">Estimated fair value of ApolloMed&#8217;s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (&#8220;OPM&#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_10" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_259" xlink:type="locator" xlink:label="loc_12" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_12">Estimated fair value of NMM&#8217;s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_260" xlink:type="locator" xlink:label="loc_14" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_14">Estimated fair value of the ApolloMed outstanding stock options The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_14" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_263" xlink:type="locator" xlink:label="loc_16" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_16">Represents the closing price of ApolloMed&#8217;s common stock on December 8, 2017.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_16" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_264" xlink:type="locator" xlink:label="loc_18" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_18">Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_18" xlink:from="loc_18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_693" xlink:type="locator" xlink:label="loc_20" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_20">Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_20" xlink:from="loc_20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_890" xlink:type="locator" xlink:label="loc_22" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_22">Less than 10% of total net revenues</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_22" xlink:from="loc_22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_891" xlink:type="locator" xlink:label="loc_24" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_22" xlink:from="loc_24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ameh-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.apollomed.net/20180331" elementFormDefault="qualified" xmlns:ameh="http://www.apollomed.net/20180331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.apollomed.net/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome" id="CondensedConsolidatedStatementsOfIncome">
        <link:definition>104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
        <link:definition>106 - Disclosure - Description of Business</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>107 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MergersAndAcquisitions" id="MergersAndAcquisitions">
        <link:definition>108 - Disclosure - Mergers and Acquisitions</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
        <link:definition>109 - Disclosure - Intangible Assets, Net</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntities" id="InvestmentsInOtherEntities">
        <link:definition>110 - Disclosure - Investments in Other Entities</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/LoanReceivable" id="LoanReceivable">
        <link:definition>111 - Disclosure - Loan Receivable</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>112 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MedicalLiabilities" id="MedicalLiabilities">
        <link:definition>113 - Disclosure - Medical Liabilities</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedParty" id="BankLoanLinesOfCreditAndLoanPayableRelatedParty">
        <link:definition>114 - Disclosure - Bank Loan, Lines of Credit and Loan Payable &#150; Related Party</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquity" id="MezzanineAndStockholdersEquity">
        <link:definition>115 - Disclosure - Mezzanine and Stockholders&#8217; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>116 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>117 - Disclosure - Related Party Transactions</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/RevenueRecognition" id="RevenueRecognition">
        <link:definition>118 - Disclosure - Revenue Recognition</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>119 - Disclosure - Income Taxes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/EarningsPerShare" id="EarningsPerShare">
        <link:definition>120 - Disclosure - Earnings Per Share</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVies" id="VariableInterestEntitiesVies">
        <link:definition>121 - Disclosure - Variable Interest Entities (VIEs)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>122 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>123 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsTables" id="MergersAndAcquisitionsTables">
        <link:definition>125 - Disclosure - Mergers and Acquisitions (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
        <link:definition>126 - Disclosure - Intangible Assets, Net (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables" id="InvestmentsInOtherEntitiesTables">
        <link:definition>127 - Disclosure - Investments in Other Entities (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>128 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" id="MedicalLiabilitiesTables">
        <link:definition>129 - Disclosure - Medical Liabilities (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables" id="MezzanineAndStockholdersEquityTables">
        <link:definition>130 - Disclosure - Mezzanine and Stockholders&#8217; Equity (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
        <link:definition>131 - Disclosure - Revenue Recognition (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/EarningsPerShareTables" id="EarningsPerShareTables">
        <link:definition>132 - Disclosure - Earnings Per Share (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/VariableInterestEntitiesViesTables" id="VariableInterestEntitiesViesTables">
        <link:definition>133 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail" id="DescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>134 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>135 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail" id="PercentageOfNetRevenueAndTotalAccountsReceivableDetail">
        <link:definition>136 - Disclosure - Percentage of Net Revenue and Total Accounts Receivable (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail" id="CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail">
        <link:definition>137 - Disclosure - Carrying Amounts and Fair Values of Company&#39;s Financial Instruments (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail" id="SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail">
        <link:definition>138 - Disclosure - Summarizes activity of Level 3 inputs measured on a recurring basis (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail" id="MergersAndAcquisitionsAdditionalInformationDetail">
        <link:definition>139 - Disclosure - Mergers and Acquisitions - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail" id="TotalEstimatedPurchaseConsiderationDetail">
        <link:definition>140 - Disclosure - Total Estimated Purchase Consideration (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail" id="CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail">
        <link:definition>141 - Disclosure - Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail" id="AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail">
        <link:definition>142 - Disclosure - Assumption of Identifiable Assets Acquired and Liabilities (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail" id="ProFormaCombinedHistoricalResultsDetail">
        <link:definition>143 - Disclosure - Pro Forma Combined Historical Results (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail" id="IntangibleAssetsNetAdditionalInformationDetail">
        <link:definition>144 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail" id="ScheduleOfIntangibleAssetsDetail">
        <link:definition>145 - Disclosure - Schedule of intangible assets (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail" id="ScheduleOfFutureAmortizationExpenseDetail">
        <link:definition>146 - Disclosure - Schedule of future amortization expense (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail" id="InvestmentsInOtherEntitiesAdditionalInformationDetail">
        <link:definition>147 - Disclosure - Investments in Other Entities - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail" id="InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail">
        <link:definition>148 - Disclosure - Investments in Other Entities (Summarized Balance Sheets and Statements of Income) (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail" id="InvestmentsInOtherEntitiesEquityMethodDetail">
        <link:definition>149 - Disclosure - Investments in Other Entities (Equity Method) (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail" id="LoanReceivableAdditionalInformationDetail">
        <link:definition>150 - Disclosure - Loan Receivable - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesDetail">
        <link:definition>151 - Disclosure - Accounts payable and accrued expenses (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetail" id="MedicalLiabilitiesDetail">
        <link:definition>152 - Disclosure - Medical Liabilities (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail" id="BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail">
        <link:definition>153 - Disclosure - Bank Loan, Lines of Credit and Loan Payable - Related Party - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail" id="MezzanineAndStockholdersEquityAdditionalInformationDetail">
        <link:definition>154 - Disclosure - Mezzanine and Stockholders&#8217; Equity - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail" id="ScheduleOfStockOptionsActivityDetail">
        <link:definition>155 - Disclosure - Schedule of Stock Options Activity (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail" id="SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail">
        <link:definition>156 - Disclosure - Summary of Share-based Compensation Expense Related to Common Stock Option Awards Granted (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SummaryOfWarrantDetail" id="SummaryOfWarrantDetail">
        <link:definition>157 - Disclosure - Summary of Warrant (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/WarrantsDetail" id="WarrantsDetail">
        <link:definition>158 - Disclosure - Warrants (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>159 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>160 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail" id="RevenueRecognitionAdditionalInformationDetail">
        <link:definition>161 - Disclosure - Revenue Recognition - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail" id="ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail">
        <link:definition>162 - Disclosure - Schedule of Prospective Adoption of New Accounting Pronouncements (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/DisaggregationOfRevenueDetail" id="DisaggregationOfRevenueDetail">
        <link:definition>163 - Disclosure - Disaggregation of Revenue (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>164 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail" id="EarningsPerShareAdditionalInformationDetail">
        <link:definition>165 - Disclosure - Earnings Per Share - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail" id="BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail">
        <link:definition>166 - Disclosure - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail" id="SummaryOfSharesIncludedInDilutedEarningsPerShareDetail">
        <link:definition>167 - Disclosure - Summary of Shares Included in Diluted Earnings Per Share (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail" id="VieAssetsAdditionalInformationDetail">
        <link:definition>168 - Disclosure - VIE Assets - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail" id="EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail">
        <link:definition>169 - Disclosure - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
        <link:definition>170 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ameh-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DocumentAndEntityInformationAbstract" />

  <element name="IncentivePayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_IncentivePayableCurrent" />

  <element name="FiduciaryAccountsPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_FiduciaryAccountsPayableCurrent" />

  <element name="MedicalLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_MedicalLiabilitiesCurrent" />

  <element name="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" />

  <element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ameh_SummaryOfSignificantAccountingPoliciesTable" />

  <element name="PercentageForDownRoundFinancing" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PercentageForDownRoundFinancing" />

  <element name="MedicareLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicareLicenseMember" />

  <element name="AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ameh_AccountsPayableAndAccruedLiabilitiesTable" />

  <element name="AccountPayableAndAccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AccountPayableAndAccruedLiabilitiesLineItems" />

  <element name="SpecialtyCapitationPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_SpecialtyCapitationPayableCurrent" />

  <element name="DisclosureWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DisclosureWarrantsAbstract" />

  <element name="WarrantExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantExercisePriceRangeOneMember" />

  <element name="WarrantExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantExercisePriceRangeTwoMember" />

  <element name="WarrantExercisePriceRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantExercisePriceRangeThreeMember" />

  <element name="WarrantExercisePriceRangeFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantExercisePriceRangeFourMember" />

  <element name="WarrantExercisePriceRangeFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantExercisePriceRangeFiveMember" />

  <element name="ClassOfWarrantOrRightIssuedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightIssuedInPeriod" />

  <element name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" />

  <element name="ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightExercisable" />

  <element name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" />

  <element name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />

  <element name="CashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_CashlessExerciseOfStockOptions" />

  <element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ameh_CommitmentsAndContingenciesTable" />

  <element name="NetworkRelationshipsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NetworkRelationshipsMember" />

  <element name="DeferredTaxLiabilityAdjustmentToGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_DeferredTaxLiabilityAdjustmentToGoodwill" />

  <element name="DescriptionOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ameh_DescriptionOfBusinessTable" />

  <element name="CumulativeEffectAdjustmentIncludedInAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" />

  <element name="CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" />

  <element name="LiabilityForUnissuedEquitySharesNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_LiabilityForUnissuedEquitySharesNoncurrent" />

  <element name="DividendPayableNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_DividendPayableNoncurrent" />

  <element name="SubcontractorIpaRiskPoolPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_SubcontractorIpaRiskPoolPayable" />

  <element name="IncreaseDecreaseInIncentivesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseInIncentivesPayable" />

  <element name="IncreaseDecreaseInMedicalLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseInMedicalLiabilities" />

  <element name="ProfessionalFeesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ameh_ProfessionalFeesAxis" />

  <element name="AccountsReceivableAndNetRevenueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ameh_AccountsReceivableAndNetRevenueTable" />

  <element name="AccountsReceivableAndNetRevenueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AccountsReceivableAndNetRevenueLineItems" />

  <element name="CustomerAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_CustomerAMember" />

  <element name="CustomerBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_CustomerBMember" />

  <element name="CustomerCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_CustomerCMember" />

  <element name="MinorityInterestPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MinorityInterestPolicyTextBlock" />

  <element name="ProfessionalFeesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ProfessionalFeesDomain" />

  <element name="PayorDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PayorDMember" />

  <element name="PayorEMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PayorEMember" />

  <element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ameh_AgreementAxis" />

  <element name="FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" />

  <element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AgreementDomain" />

  <element name="RobMikitarianMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_RobMikitarianMember" />

  <element name="WarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantLiabilityMember" />

  <element name="IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" />

  <element name="RestrictedCashInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_RestrictedCashInterestRate" />

  <element name="MezzanineEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MezzanineEquityAbstract" />

  <element name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" />

  <element name="UniversalCareIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_UniversalCareIncMember" />

  <element name="PaymentMadeToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_PaymentMadeToRelatedParty" />

  <element name="ServiceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ServiceMember" />

  <element name="AdvanceDiagnosticSurgeryCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AdvanceDiagnosticSurgeryCenterMember" />

  <element name="LmaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_LmaMember" />

  <element name="PmiocMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PmiocMember" />

  <element name="AmgIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AmgIncMember" />

  <element name="DmgMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DmgMember" />

  <element name="MedicalPropertyPartnersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicalPropertyPartnersMember" />

  <element name="MedicalInvestmentGroupLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicalInvestmentGroupLlcMember" />

  <element name="ApcShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApcShareholdersMember" />

  <element name="ShareholdersAndOfficersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ShareholdersAndOfficersMember" />

  <element name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" />

  <element name="DescriptionOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DescriptionOfBusinessLineItems" />

  <element name="ApollomedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApollomedMember" />

  <element name="ConcourseDiagnosticSurgeryCenterLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" />

  <element name="UniversalCareAcquisitionPartnersLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_UniversalCareAcquisitionPartnersLlcMember" />

  <element name="InternationalCancerCenterIccMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_InternationalCancerCenterIccMember" />

  <element name="ProceedsFromSaleOfCostMethodInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_ProceedsFromSaleOfCostMethodInvestments" />

  <element name="EquityMethodInvestmentSignificantInfluenceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSignificantInfluenceDescription" />

  <element name="LoanReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_LoanReceivableAbstract" />

  <element name="LoanReceivableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_LoanReceivableTextBlock" />

  <element name="ExtendableAmountOnCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_ExtendableAmountOnCreditFacility" />

  <element name="TermOfManagementServiceAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_TermOfManagementServiceAgreement" />

  <element name="PercentageOfManagingResponsibleOfHealthPlanship" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PercentageOfManagingResponsibleOfHealthPlanship" />

  <element name="DrJayLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DrJayLoanMember" />

  <element name="ApcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApcMember" />

  <element name="NmmBusinessLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NmmBusinessLoanAgreementMember" />

  <element name="DisclosureOfMedicalLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DisclosureOfMedicalLiabilitiesAbstract" />

  <element name="MedicalLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicalLiabilitiesTextBlock" />

  <element name="MedicalLiabilitiesTableTextBlockTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" />

  <element name="MedicalLiabilitiesAddedFromMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_MedicalLiabilitiesAddedFromMerger" />

  <element name="DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" />

  <element name="BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" />

  <element name="IccMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_IccMember" />

  <element name="ApcBusinessLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApcBusinessLoanAgreementMember" />

  <element name="ApaacoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApaacoMember" />

  <element name="ExclusivityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ExclusivityMember" />

  <element name="ManagementContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ManagementContractsMember" />

  <element name="MemberRelationshipsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MemberRelationshipsMember" />

  <element name="PatientManagementPlatformMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PatientManagementPlatformMember" />

  <element name="BusinessCombonationequityConsiderationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessCombonationequityConsiderationTableTextBlock" />

  <element name="NetworkMedicalManagementIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NetworkMedicalManagementIncMember" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" />

  <element name="BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" />

  <element name="BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" />

  <element name="BusinessAcquisitionProformaEarningsPerShareBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" />

  <element name="BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" />

  <element name="BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" />

  <element name="BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" />

  <element name="ApolloMedicalHoldingsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApolloMedicalHoldingsIncMember" />

  <element name="BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" />

  <element name="WarrantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantOneMember" />

  <element name="WarrantTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WarrantTwoMember" />

  <element name="ConvertiblePromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ConvertiblePromissoryNoteMember" />

  <element name="BusinessCombinationconsiderationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_BusinessCombinationconsiderationDescription" />

  <element name="ApaAcoIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApaAcoIncMember" />

  <element name="PaymentsForAgreementTermination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_PaymentsForAgreementTermination" />

  <element name="MaverickMedicalGroupIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MaverickMedicalGroupIncMember" />

  <element name="LasalleMedicalAssociatesIpaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_LasalleMedicalAssociatesIpaMember" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" />

  <element name="EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" />

  <element name="DiagnosticMedicalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_DiagnosticMedicalGroupMember" />

  <element name="PacificMedicalImagingAndOncologyCenterIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" />

  <element name="PacificAmbulatorySurgeryCenterLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PacificAmbulatorySurgeryCenterLlcMember" />

  <element name="AmendmentAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ameh_AmendmentAgreementAxis" />

  <element name="ApcLsmaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ApcLsmaMember" />

  <element name="AlliedPacificOfCaliforniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AlliedPacificOfCaliforniaMember" />

  <element name="AmendmentAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AmendmentAgreementDomain" />

  <element name="ContractTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ameh_ContractTypeAxis" />

  <element name="ExclusivityAmendmentAgreementApcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ExclusivityAmendmentAgreementApcMember" />

  <element name="ContractedPhysiciansAndOtherServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ContractedPhysiciansAndOtherServicesMember" />

  <element name="EquityMethodInvestmentsPurchaseOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentsPurchaseOfShares" />

  <element name="ContractTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ContractTypeDomain" />

  <element name="AncillaryServiceContractMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AncillaryServiceContractMember" />

  <element name="EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" />

  <element name="LoansReceivableInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ameh_LoansReceivableInterestRate" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />

  <element name="SharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SharesAbstract" />

  <element name="NumberOfWarrantsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NumberOfWarrantsGranted" />

  <element name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NumberOfWarrantsExercised" />

  <element name="ClassOfWarrantOrRightCancelledInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightCancelledInPeriod" />

  <element name="WeightedaverageexercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WeightedaverageexercisePriceAbstract" />

  <element name="ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" />

  <element name="ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" />

  <element name="ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" />

  <element name="WeightedaverageremainingcontractualtermyearsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" />

  <element name="ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" />

  <element name="ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" />

  <element name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" />

  <element name="AggregateintrinsicvalueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AggregateintrinsicvalueAbstract" />

  <element name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" />

  <element name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" />

  <element name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" />

  <element name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" />

  <element name="NetworkMedicalManagementIncNmmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_NetworkMedicalManagementIncNmmMember" />

  <element name="AmehMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_AmehMember" />

  <element name="FiduciaryCashCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_FiduciaryCashCurrent" />

  <element name="RestrictedCashAcquiredFromAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_RestrictedCashAcquiredFromAcquisition" />

  <element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_CommitmentsAndContingenciesLineItems" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />

  <element name="LineOfCreditFacilityGuaranteeGivenByRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" />

  <element name="OperatingLossCarryforwardsLimitationRateOnTaxableIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" />

  <element name="IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" />

  <element name="FormerShareholdersOfNmmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_FormerShareholdersOfNmmMember" />

  <element name="IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" />

  <element name="VotingCommonStockTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_VotingCommonStockTwoMember" />

  <element name="EstimatedRevenuePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_EstimatedRevenuePercentage" />

  <element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" />

  <element name="PacificAmbulatorySurgeryCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_PacificAmbulatorySurgeryCenterMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" />

  <element name="CommercialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_CommercialMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" />

  <element name="WarrantIssuedDuringPeriodValueStockOptionsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" />

  <element name="MedicareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicareMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" />

  <element name="MedicaidMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_MedicaidMember" />

  <element name="OtherThirdPartiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_OtherThirdPartiesMember" />

  <element name="AllinclusivePopulationbasedPaymentsToBeReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_AllinclusivePopulationbasedPaymentsToBeReceived" />

  <element name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" />

  <element name="AdjustmentsForMedicalLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_AdjustmentsForMedicalLiabilities" />

  <element name="IncreaseDecreaseDeferredTaxAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ameh_IncreaseDecreaseDeferredTaxAsset" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ameh-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedStatementsOfIncome" roleURI="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfFutureAmortizationExpenseDetail" roleURI="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpensesDetail" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities" />

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaap_CostOfServices" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostOfServices" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="80" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="100" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="110" weight="-1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInIncentivesPayable" xlink:label="loc_ameh_IncreaseDecreaseInIncentivesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ameh_IncreaseDecreaseInIncentivesPayable" use="optional" order="120" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities" use="optional" order="130" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="140" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="150" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProceedsFromSaleOfCostMethodInvestments" xlink:label="loc_ameh_ProceedsFromSaleOfCostMethodInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ameh_ProceedsFromSaleOfCostMethodInvestments" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDividends" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_Goodwill" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_LoansReceivableNet" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_EquityMethodInvestments" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="80" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DividendPayableNoncurrent" xlink:label="loc_ameh_DividendPayableNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_ameh_DividendPayableNoncurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LinesOfCreditCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncentivePayableCurrent" xlink:label="loc_ameh_IncentivePayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ameh_IncentivePayableCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ameh_MedicalLiabilitiesCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SpecialtyCapitationPayableCurrent" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SubcontractorIpaRiskPoolPayable" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_ameh_SubcontractorIpaRiskPoolPayable" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent" use="optional" order="60" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" use="optional" order="60" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ameh-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DocumentAndEntityInformation" roleURI="http://www.apollomed.net/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MezzanineAndStockholdersEquityTables" roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedStatementsOfIncome" roleURI="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfIntangibleAssetsDetail" roleURI="http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfFutureAmortizationExpenseDetail" roleURI="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpensesDetail" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#WarrantsDetail" roleURI="http://www.apollomed.net/role/WarrantsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DescriptionOfBusinessAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#PercentageOfNetRevenueAndTotalAccountsReceivableDetail" roleURI="http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IntangibleAssetsNetAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail" roleURI="http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfSharesIncludedInDilutedEarningsPerShareDetail" roleURI="http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EarningsPerShareAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail" roleURI="http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#LoanReceivableAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MedicalLiabilitiesDetail" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MergersAndAcquisitionsTables" roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#TotalEstimatedPurchaseConsiderationDetail" roleURI="http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail" roleURI="http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail" roleURI="http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ProFormaCombinedHistoricalResultsDetail" roleURI="http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MergersAndAcquisitionsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesEquityMethodDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfStockOptionsActivityDetail" roleURI="http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfWarrantDetail" roleURI="http://www.apollomed.net/role/SummaryOfWarrantDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MezzanineAndStockholdersEquityAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail" roleURI="http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail" roleURI="http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#VieAssetsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail" roleURI="http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail" roleURI="http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DisaggregationOfRevenueDetail" roleURI="http://www.apollomed.net/role/DisaggregationOfRevenueDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RevenueRecognitionAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4939" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_LegalEntityAxis_4939" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4940" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4939" xlink:to="loc_dei_EntityDomain_4940" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4940_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4939" xlink:to="loc_dei_EntityDomain_4940_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_14" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_14" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_15" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_15" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1355" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1355" xlink:to="loc_us-gaap_StatementTable_61" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_dei_LegalEntityAxis_62" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_62" xlink:to="loc_dei_EntityDomain_63" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_63_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_62" xlink:to="loc_dei_EntityDomain_63_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1356" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64" xlink:to="loc_us-gaap_ClassOfStockDomain_1356" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1356_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64" xlink:to="loc_us-gaap_ClassOfStockDomain_1356_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2887" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1356" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2887" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1356" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2956" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1355" xlink:to="loc_us-gaap_AssetsAbstract_65" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3658" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_RestrictedCashCurrent_3659" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_3660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_3660" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3661" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3661" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AssetsCurrent_74" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_3662" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_3662" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_76" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_Goodwill_78" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_3663" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_3663" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_3664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_LoansReceivableNet_3664" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_3665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_EquityMethodInvestments_3665" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3668" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3668" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_79" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_3670" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_AssetsNoncurrent_3670" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_Assets_80" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1355" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3671" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent_1347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_LinesOfCreditCurrent_1347" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_83" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncentivePayableCurrent" xlink:label="loc_ameh_IncentivePayableCurrent_3673" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_IncentivePayableCurrent_3673" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_3674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_3674" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_84" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3675" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3675" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_3765" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_3765" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_3677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_3677" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_LiabilitiesCurrent_87" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_DeferredTaxLiabilities_92" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_3679" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_3679" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DividendPayableNoncurrent" xlink:label="loc_ameh_DividendPayableNoncurrent_3680" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_ameh_DividendPayableNoncurrent_3680" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_3681" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_3681" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3682" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3682" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_Liabilities_93" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_CommitmentsAndContingencies_94" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MezzanineEquityAbstract" xlink:label="loc_ameh_MezzanineEquityAbstract_3287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_ameh_MezzanineEquityAbstract_3287" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3683" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_3287" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3683" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_PreferredStockValue_96" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_CommonStockValue_97" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_AdditionalPaidInCapital_98" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_100" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_StockholdersEquity_101" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_MinorityInterest_102" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_103" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_104" use="optional" order="59" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4359" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4359" xlink:to="loc_us-gaap_StatementTable_4320" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4321" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4321" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4322" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4321" xlink:to="loc_us-gaap_ClassOfStockDomain_4322" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4322_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4321" xlink:to="loc_us-gaap_ClassOfStockDomain_4322_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4335" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4335" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementAxis" xlink:label="loc_ameh_AmendmentAgreementAxis_4326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_ameh_AmendmentAgreementAxis_4326" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementDomain" xlink:label="loc_ameh_AmendmentAgreementDomain_4341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_AmendmentAgreementAxis_4326" xlink:to="loc_ameh_AmendmentAgreementDomain_4341" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementDomain" xlink:label="loc_ameh_AmendmentAgreementDomain_4341_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_AmendmentAgreementAxis_4326" xlink:to="loc_ameh_AmendmentAgreementDomain_4341_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityAmendmentAgreementApcMember" xlink:label="loc_ameh_ExclusivityAmendmentAgreementApcMember_4345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AmendmentAgreementDomain_4341" xlink:to="loc_ameh_ExclusivityAmendmentAgreementApcMember_4345" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4339" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4361" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4361_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4361_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractedPhysiciansAndOtherServicesMember" xlink:label="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4361" xlink:to="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4363" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4359" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_147" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4359" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_151" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_dei_LegalEntityAxis_156" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_156" xlink:to="loc_dei_EntityDomain_157" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_157_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_156" xlink:to="loc_dei_EntityDomain_157_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaacoMember" xlink:label="loc_ameh_ApaacoMember_4812" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_157" xlink:to="loc_ameh_ApaacoMember_4812" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_MajorCustomersAxis_159" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_159" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_160" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_160_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_159" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_160_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" xlink:to="loc_us-gaap_RelatedPartyDomain_165" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_165_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" xlink:to="loc_us-gaap_RelatedPartyDomain_165_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_171" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_171" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_171" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_RangeAxis_179" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_179" xlink:to="loc_us-gaap_RangeMember_180" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_180_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_179" xlink:to="loc_us-gaap_RangeMember_180_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_180" xlink:to="loc_us-gaap_MaximumMember_181" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_180" xlink:to="loc_us-gaap_MinimumMember_182" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FinancialInstrumentAxis_183" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_187" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_187" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_188" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_188_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_187" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_188_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_190" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_190" xlink:to="loc_us-gaap_EquityComponentDomain_191" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_191_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_190" xlink:to="loc_us-gaap_EquityComponentDomain_191_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903_default" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2902" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2902" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2902" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2902" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906_default" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantLiabilityMember" xlink:label="loc_ameh_WarrantLiabilityMember_3145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" xlink:to="loc_ameh_WarrantLiabilityMember_3145" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2905" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2905" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2905" xlink:to="loc_us-gaap_SegmentDomain_3147" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3147_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2905" xlink:to="loc_us-gaap_SegmentDomain_3147_default" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289_default" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3288" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3793" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3288" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3793" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3793_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3288" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3793_default" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3792" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3792" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4814" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3792" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4814" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4814_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3792" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4814_default" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_197" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_197" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_198" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_199" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_SharePrice_201" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageForDownRoundFinancing" xlink:label="loc_ameh_PercentageForDownRoundFinancing_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_PercentageForDownRoundFinancing_202" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_3135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_CashUninsuredAmount_3135" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashInterestRate" xlink:label="loc_ameh_RestrictedCashInterestRate_3639" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_RestrictedCashInterestRate_3639" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_3910" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_RestrictedCash_3910" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash_3911" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_IncreaseInRestrictedCash_3911" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3915" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3915" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_3940" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_3940" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSignificantInfluenceDescription" xlink:label="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription_3955" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription_3955" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EstimatedRevenuePercentage" xlink:label="loc_ameh_EstimatedRevenuePercentage_4811" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_EstimatedRevenuePercentage_4811" use="optional" order="63" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1360" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_253" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_StatementTable_253" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_253" xlink:to="loc_dei_LegalEntityAxis_254" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_254" xlink:to="loc_dei_EntityDomain_255" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_255_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_254" xlink:to="loc_dei_EntityDomain_255_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_1361" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1361_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_1361_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2841" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1361" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2841" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2957" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1361" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2957" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_257" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_258" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_258" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesIssued_259" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2842" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2842" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_260" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_260" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_261" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_263" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3684" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3684" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_StatementTable_414" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_414" xlink:to="loc_dei_LegalEntityAxis_415" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_415" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_415" xlink:to="loc_dei_EntityDomain_416_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_RevenuesAbstract_1447" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationCapitationRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationCapitationRevenue_3694" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationCapitationRevenue_3694" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationOtherRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationOtherRevenue_3686" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationOtherRevenue_3686" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeesRevenue" xlink:label="loc_us-gaap_ManagementFeesRevenue_3687" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_ManagementFeesRevenue_3687" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue_3858" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue_3858" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_3689" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_OtherSalesRevenueNet_3689" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_3860" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_SalesRevenueNet_3860" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OperatingExpensesAbstract_419" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaap_CostOfServices_420" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_CostOfServices_420" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_421" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_421" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_422" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_OperatingExpenses_423" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OperatingIncomeLoss_424" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3690" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3690" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_InterestExpense_426" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3867" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3867" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_427" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_428" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_429" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_430" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_431" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_ProfitLoss_432" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_433" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NetIncomeLoss_434" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareBasic_439" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareDiluted_440" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_443" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareAbstract_438" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_441" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_435" use="optional" order="36" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareLicenseMember" xlink:label="loc_ameh_MedicareLicenseMember_1199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_MedicareLicenseMember_1199" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkRelationshipsMember" xlink:label="loc_ameh_NetworkRelationshipsMember_465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_NetworkRelationshipsMember_465" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_us-gaap_TradeNamesMember_466" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ManagementContractsMember" xlink:label="loc_ameh_ManagementContractsMember_4094" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_ManagementContractsMember_4094" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MemberRelationshipsMember" xlink:label="loc_ameh_MemberRelationshipsMember_4095" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_MemberRelationshipsMember_4095" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PatientManagementPlatformMember" xlink:label="loc_ameh_PatientManagementPlatformMember_4096" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_PatientManagementPlatformMember_4096" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_467" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_467" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_467" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_3265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_3265" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_3266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_3266" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_RangeAxis_3263" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4098" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3263" xlink:to="loc_us-gaap_RangeMember_4098" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4098_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3263" xlink:to="loc_us-gaap_RangeMember_4098_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4099" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4098" xlink:to="loc_us-gaap_MaximumMember_4099" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4098" xlink:to="loc_us-gaap_MinimumMember_4100" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3173" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3191" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3184" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3195" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_3177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_3177" use="optional" order="25" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_482" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_482_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_482_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_485" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_486" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_487" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_488" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2305" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2305" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4688" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4688" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2306" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountPayableAndAccruedLiabilitiesLineItems" xlink:label="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" xlink:to="loc_dei_LegalEntityAxis_493" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_493" xlink:to="loc_dei_EntityDomain_494" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_493" xlink:to="loc_dei_EntityDomain_494_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_3948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccountsPayableCurrent_3948" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SpecialtyCapitationPayableCurrent" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_3949" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_3949" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SubcontractorIpaRiskPoolPayable" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable_3950" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_ameh_SubcontractorIpaRiskPoolPayable_3950" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_501" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3952" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3952" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_498" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_498" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_502" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/WarrantsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_986" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_986" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_987" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_dei_LegalEntityAxis_987" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_988" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_988" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_988_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_988_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeOneMember" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_993" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_993" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeTwoMember" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_994" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_994" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeThreeMember" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_995" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_995" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFourMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_996" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_996" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFiveMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFiveMember_997" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeFiveMember_997" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1003" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_us-gaap_RangeAxis_1003" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3054" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1003" xlink:to="loc_us-gaap_RangeMember_3054" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3054_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1003" xlink:to="loc_us-gaap_RangeMember_3054_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_1005" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_1005" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1006" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1006" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisable" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_1007" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_1007" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights_1008" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights_1008" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3937" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1011" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_StatementTable_1011" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1012" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_dei_LegalEntityAxis_1012" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1013" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1012" xlink:to="loc_dei_EntityDomain_1013" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1013_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1012" xlink:to="loc_dei_EntityDomain_1013_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1014" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_DebtInstrumentAxis_1014" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1696" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1014" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1696" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1696_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1014" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1696_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1695" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1695" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1699" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1695" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1699" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1699_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1695" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1699_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1698" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1698" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1698" xlink:to="loc_us-gaap_ClassOfStockDomain_3115" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3115_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1698" xlink:to="loc_us-gaap_ClassOfStockDomain_3115_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_3114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_3114" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_3932" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_3114" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_3932" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_3932_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_3114" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_3932_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3931" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3931" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3935" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3931" xlink:to="loc_us-gaap_EquityComponentDomain_3935" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3935_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3931" xlink:to="loc_us-gaap_EquityComponentDomain_3935_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3934" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_AwardTypeAxis_3934" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1016" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_ProfitLoss_1016" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1018" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1018" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3271" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1020" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1020" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_3875" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_3875" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1023" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1023" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3881" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3881" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3907" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3907" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1025" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1025" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3104" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1029" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1029" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1030" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1030" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInIncentivesPayable" xlink:label="loc_ameh_IncreaseDecreaseInIncentivesPayable_4851" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInIncentivesPayable_4851" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_1031" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_1031" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3884" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3884" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1032" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1032" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3887" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3887" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_3891" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_3891" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_3892" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_3892" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProceedsFromSaleOfCostMethodInvestments" xlink:label="loc_ameh_ProceedsFromSaleOfCostMethodInvestments_3893" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_ameh_ProceedsFromSaleOfCostMethodInvestments_3893" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1035" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1035" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1036" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1036" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3916" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3916" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_3917" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_PaymentsOfDividends_3917" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1040" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1040" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3920" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3920" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1709" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1709" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1044" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1044" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4941" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4941" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4935" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4935" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1050" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" xlink:to="loc_us-gaap_IncomeTaxesPaid_1050" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1049" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" xlink:to="loc_us-gaap_InterestPaidNet_1049" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CashlessExerciseOfStockOptions" xlink:label="loc_ameh_CashlessExerciseOfStockOptions_4855" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CashlessExerciseOfStockOptions_4855" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_3313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_us-gaap_StockIssued1_3313" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xlink:label="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill_4856" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill_4856" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable_4857" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable_4857" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities_4858" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities_4858" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2976" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2976" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4860" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4860" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4861" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4861" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4862" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_RestrictedCashCurrent_4862" use="optional" order="71" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4870" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1077" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_StatementTable_1077" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1078" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1078" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1079" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1078" xlink:to="loc_us-gaap_ClassOfStockDomain_1079" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1079_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1078" xlink:to="loc_us-gaap_ClassOfStockDomain_1079_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1080" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1080" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1081" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1080" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1081" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1081_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1080" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1081_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1082" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1081" xlink:to="loc_us-gaap_SubsequentEventMember_1082" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1083" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_DebtInstrumentAxis_1083" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1084" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1083" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1084" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1084_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1083" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1084_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1089" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1089" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1090" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1089" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1090" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1090_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1089" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1090_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1092" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_CreditFacilityAxis_1092" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1093" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1092" xlink:to="loc_us-gaap_CreditFacilityDomain_1093" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1093_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1092" xlink:to="loc_us-gaap_CreditFacilityDomain_1093_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1106" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1106" xlink:to="loc_us-gaap_EquityComponentDomain_1107" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1107_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1106" xlink:to="loc_us-gaap_EquityComponentDomain_1107_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1110" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_dei_LegalEntityAxis_1116" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1116" xlink:to="loc_dei_EntityDomain_1653" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1653_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1116" xlink:to="loc_dei_EntityDomain_1653_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_1651" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_CollateralAxis_1651" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_4868" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_1651" xlink:to="loc_us-gaap_CollateralDomain_4868" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_4868_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_1651" xlink:to="loc_us-gaap_CollateralDomain_4868_default" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateMember" xlink:label="loc_us-gaap_RealEstateMember_4869" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_4868" xlink:to="loc_us-gaap_RealEstateMember_4869" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4872" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" xlink:to="loc_us-gaap_BuildingMember_4872" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1847" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1847" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_4864" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_Dividends_4864" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_4865" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_4865" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_4866" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_AreaOfLand_4866" use="optional" order="38" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesLineItems" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_4690" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesTable" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_1158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_4690" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_1158" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_dei_LegalEntityAxis_1159" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1161" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1159" xlink:to="loc_dei_EntityDomain_1161" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1161_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1159" xlink:to="loc_dei_EntityDomain_1161_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesAxis" xlink:label="loc_ameh_ProfessionalFeesAxis_2537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_ameh_ProfessionalFeesAxis_2537" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesDomain" xlink:label="loc_ameh_ProfessionalFeesDomain_2548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ProfessionalFeesAxis_2537" xlink:to="loc_ameh_ProfessionalFeesDomain_2548" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesDomain" xlink:label="loc_ameh_ProfessionalFeesDomain_2548_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ProfessionalFeesAxis_2537" xlink:to="loc_ameh_ProfessionalFeesDomain_2548_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1854" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1854" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1854" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1854" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" xlink:to="loc_us-gaap_RelatedPartyDomain_2602" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2602_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" xlink:to="loc_us-gaap_RelatedPartyDomain_2602_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2859" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_RangeAxis_2859" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2866" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2859" xlink:to="loc_us-gaap_RangeMember_2866" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2866_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2859" xlink:to="loc_us-gaap_RangeMember_2866_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_CreditFacilityAxis_3342" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3500" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3342" xlink:to="loc_us-gaap_CreditFacilityDomain_3500" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3500_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3342" xlink:to="loc_us-gaap_CreditFacilityDomain_3500_default" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3499" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3499" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3499" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3499" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510_default" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3509" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4691" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3509" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4691" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4691_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3509" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4691_default" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4692" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4691" xlink:to="loc_us-gaap_SubsequentEventMember_4692" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_4689" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_4690" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_4689" use="optional" order="42" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessLineItems" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_3807" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessTable" xlink:label="loc_ameh_DescriptionOfBusinessTable_1217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_ameh_DescriptionOfBusinessTable_1217" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_dei_LegalEntityAxis_1218" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1218" xlink:to="loc_dei_EntityDomain_1224" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1224_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1218" xlink:to="loc_dei_EntityDomain_1224_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InternationalCancerCenterIccMember" xlink:label="loc_ameh_InternationalCancerCenterIccMember_3817" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1224" xlink:to="loc_ameh_InternationalCancerCenterIccMember_3817" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_StatementScenarioAxis_1223" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_1223" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2234" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2234_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_1223" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2234_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_CreditFacilityAxis_2233" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2233" xlink:to="loc_us-gaap_CreditFacilityDomain_2448" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2448_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2233" xlink:to="loc_us-gaap_CreditFacilityDomain_2448_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2447" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2447" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2774" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2774_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2447" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2774_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_DebtInstrumentAxis_2773" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3462" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2773" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3462" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3462_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2773" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3462_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3461" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3461" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3461" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3466" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3466" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3466" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3469" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3469" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3808" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3469" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3808" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3808_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3469" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3808_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApollomedMember" xlink:label="loc_ameh_ApollomedMember_3809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_ApollomedMember_3809" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_3814" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_3814" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3815" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3815" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterMember_4850" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterMember_4850" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2771" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2771" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3447" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_3788" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_3788" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3806" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3806" use="optional" order="34" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3772" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1687" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_StatementTable_1687" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1688" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_DebtInstrumentAxis_1688" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1689" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1688" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1689" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1689_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1688" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1689_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1690" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_dei_LegalEntityAxis_1690" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1692" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1690" xlink:to="loc_dei_EntityDomain_1692" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1692_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1690" xlink:to="loc_dei_EntityDomain_1692_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1691" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1691" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1691" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1691" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementAxis" xlink:label="loc_ameh_AgreementAxis_2982" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_ameh_AgreementAxis_2982" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementDomain" xlink:label="loc_ameh_AgreementDomain_3120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_AgreementAxis_2982" xlink:to="loc_ameh_AgreementDomain_3120" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementDomain" xlink:label="loc_ameh_AgreementDomain_3120_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_AgreementAxis_2982" xlink:to="loc_ameh_AgreementDomain_3120_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" xlink:to="loc_us-gaap_RelatedPartyDomain_3123" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3123_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" xlink:to="loc_us-gaap_RelatedPartyDomain_3123_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RobMikitarianMember" xlink:label="loc_ameh_RobMikitarianMember_3124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_RobMikitarianMember_3124" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_3764" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_UniversalCareIncMember_3764" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_3771" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_3771" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalPropertyPartnersMember" xlink:label="loc_ameh_MedicalPropertyPartnersMember_3778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_MedicalPropertyPartnersMember_3778" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalInvestmentGroupLlcMember" xlink:label="loc_ameh_MedicalInvestmentGroupLlcMember_3779" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_MedicalInvestmentGroupLlcMember_3779" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcShareholdersMember" xlink:label="loc_ameh_ApcShareholdersMember_3780" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_ApcShareholdersMember_3780" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareholdersAndOfficersMember" xlink:label="loc_ameh_ShareholdersAndOfficersMember_3781" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_ShareholdersAndOfficersMember_3781" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaap_ReceivableTypeDomain_3132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" xlink:to="loc_us-gaap_ReceivableTypeDomain_3132" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaap_ReceivableTypeDomain_3132_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" xlink:to="loc_us-gaap_ReceivableTypeDomain_3132_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableMember" xlink:label="loc_us-gaap_NotesReceivableMember_3133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_3132" xlink:to="loc_us-gaap_NotesReceivableMember_3133" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3131" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3131" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3241" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3241_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3131" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3241_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3240" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3240" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3240" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3478" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3769" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3478" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3769" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3769_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3478" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3769_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ServiceMember" xlink:label="loc_ameh_ServiceMember_3770" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3769" xlink:to="loc_ameh_ServiceMember_3770" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3768" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3768" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3768" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3773" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3773_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3768" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3773_default" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LmaMember" xlink:label="loc_ameh_LmaMember_3774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_LmaMember_3774" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PmiocMember" xlink:label="loc_ameh_PmiocMember_3775" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_PmiocMember_3775" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmgIncMember" xlink:label="loc_ameh_AmgIncMember_3776" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_AmgIncMember_3776" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DmgMember" xlink:label="loc_ameh_DmgMember_3777" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_DmgMember_3777" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3128" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3128" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3129" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_3130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_3130" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3486" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentMadeToRelatedParty" xlink:label="loc_ameh_PaymentMadeToRelatedParty_3766" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_ameh_PaymentMadeToRelatedParty_3766" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3767" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3767" use="optional" order="50" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2097" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2097" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2098" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_RangeAxis_2098" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2099" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2098" xlink:to="loc_us-gaap_RangeMember_2099" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2099_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2098" xlink:to="loc_us-gaap_RangeMember_2099_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_dei_LegalEntityAxis_2100" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2100" xlink:to="loc_dei_EntityDomain_2121" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2121_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2100" xlink:to="loc_dei_EntityDomain_2121_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2120" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2120" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2586" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2586_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2120" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2586_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_StatementScenarioAxis_2585" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_4047" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2585" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_4047" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_4047_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2585" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_4047_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_4048" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_4047" xlink:to="loc_us-gaap_ScenarioPlanMember_4048" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2130" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xlink:label="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome_4717" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome_4717" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate_4722" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate_4722" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate_4724" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate_4724" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4725" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4725" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueTable" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" xlink:to="loc_us-gaap_SalesRevenueNetMember_2407" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" xlink:to="loc_us-gaap_AccountsReceivableMember_2408" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" xlink:to="loc_us-gaap_MajorCustomersAxis_2405" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_2405" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2410" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2410_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_2405" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2410_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerAMember" xlink:label="loc_ameh_CustomerAMember_2411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerAMember_2411" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerBMember" xlink:label="loc_ameh_CustomerBMember_2412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerBMember_2412" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerCMember" xlink:label="loc_ameh_CustomerCMember_2413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerCMember_2413" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorDMember" xlink:label="loc_ameh_PayorDMember_2599" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_PayorDMember_2599" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorEMember" xlink:label="loc_ameh_PayorEMember_2600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_PayorEMember_2600" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2404" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4079" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3027" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4079" xlink:to="loc_us-gaap_StatementTable_3027" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3028" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3028" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3029" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3028" xlink:to="loc_us-gaap_ClassOfStockDomain_3029" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3029_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3028" xlink:to="loc_us-gaap_ClassOfStockDomain_3029_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3030" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_dei_LegalEntityAxis_3030" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3033" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3030" xlink:to="loc_dei_EntityDomain_3033" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3033_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3030" xlink:to="loc_dei_EntityDomain_3033_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3215" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3215" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3488" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3488_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3215" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3488_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityMember" xlink:label="loc_ameh_ExclusivityMember_4087" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" xlink:to="loc_ameh_ExclusivityMember_4087" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xlink:label="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition_3031" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4079" xlink:to="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition_3031" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3711" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3708" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_StatementTable_3708" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3709" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3708" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3709" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3710" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3709" xlink:to="loc_us-gaap_ClassOfStockDomain_3710" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3710_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3709" xlink:to="loc_us-gaap_ClassOfStockDomain_3710_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3712" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_EarningsPerShareBasic_3712" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3714" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3714" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3716" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3716" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3717" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3717" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4743" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3719" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_StatementTable_3719" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3720" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3720" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3721" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3720" xlink:to="loc_us-gaap_ClassOfStockDomain_3721" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3721_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3720" xlink:to="loc_us-gaap_ClassOfStockDomain_3721_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3722" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3722" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3724" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3722" xlink:to="loc_us-gaap_EquityComponentDomain_3724" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3724_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3722" xlink:to="loc_us-gaap_EquityComponentDomain_3724_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3725" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3724" xlink:to="loc_us-gaap_CommonStockMember_3725" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_3737" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3724" xlink:to="loc_us-gaap_WarrantMember_3737" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4745" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4745" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3738" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3738" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3739" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3739" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3740" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3740" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3745" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3742" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3745" xlink:to="loc_us-gaap_StatementTable_3742" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3743" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3742" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3743" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3744" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3743" xlink:to="loc_us-gaap_ClassOfStockDomain_3744" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3744_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3743" xlink:to="loc_us-gaap_ClassOfStockDomain_3744_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares_3746" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3745" xlink:to="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares_3746" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3901" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3898" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_StatementTable_3898" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3899" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3898" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3899" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3900" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3899" xlink:to="loc_us-gaap_ClassOfStockDomain_3900" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3900_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3899" xlink:to="loc_us-gaap_ClassOfStockDomain_3900_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3902" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3902" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_3904" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_3904" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3980" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_StatementTable_3961" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3962" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3962" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3963" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3962" xlink:to="loc_us-gaap_ClassOfStockDomain_3963" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3963_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3962" xlink:to="loc_us-gaap_ClassOfStockDomain_3963_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3978" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" xlink:to="loc_us-gaap_RelatedPartyDomain_3978" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3978_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" xlink:to="loc_us-gaap_RelatedPartyDomain_3978_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DrJayLoanMember" xlink:label="loc_ameh_DrJayLoanMember_3979" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3978" xlink:to="loc_ameh_DrJayLoanMember_3979" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3977" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_dei_LegalEntityAxis_3977" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3981" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3977" xlink:to="loc_dei_EntityDomain_3981" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3981_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3977" xlink:to="loc_dei_EntityDomain_3981_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcMember" xlink:label="loc_ameh_ApcMember_3982" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3981" xlink:to="loc_ameh_ApcMember_3982" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NmmBusinessLoanAgreementMember" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_3983" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3981" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_3983" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_3966" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_LoansReceivableNet_3966" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_3967" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_LineOfCredit_3967" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_3968" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_3968" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3969" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3969" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_3970" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_3970" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_3971" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_3971" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExtendableAmountOnCreditFacility" xlink:label="loc_ameh_ExtendableAmountOnCreditFacility_3973" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_ExtendableAmountOnCreditFacility_3973" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_TermOfManagementServiceAgreement" xlink:label="loc_ameh_TermOfManagementServiceAgreement_3975" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_TermOfManagementServiceAgreement_3975" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageOfManagingResponsibleOfHealthPlanship" xlink:label="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship_3976" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship_3976" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3989" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3986" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_StatementTable_3986" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3987" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3986" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3987" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3988" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3987" xlink:to="loc_us-gaap_ClassOfStockDomain_3988" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3988_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3987" xlink:to="loc_us-gaap_ClassOfStockDomain_3988_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_3996" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_3996" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesAddedFromMerger" xlink:label="loc_ameh_MedicalLiabilitiesAddedFromMerger_4705" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_MedicalLiabilitiesAddedFromMerger_4705" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_4944" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_4944" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationExpensesNet" xlink:label="loc_us-gaap_HealthCareOrganizationExpensesNet_4846" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_HealthCareOrganizationExpensesNet_4846" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_4945" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_4945" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdjustmentsForMedicalLiabilities" xlink:label="loc_ameh_AdjustmentsForMedicalLiabilities_4001" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_AdjustmentsForMedicalLiabilities_4001" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4808" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4009" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_StatementTable_4009" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4010" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4010" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4011" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4010" xlink:to="loc_us-gaap_ClassOfStockDomain_4011" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4011_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4010" xlink:to="loc_us-gaap_ClassOfStockDomain_4011_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4012" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_dei_LegalEntityAxis_4012" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4014" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4012" xlink:to="loc_dei_EntityDomain_4014" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4014_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4012" xlink:to="loc_dei_EntityDomain_4014_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IccMember" xlink:label="loc_ameh_IccMember_4015" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_IccMember_4015" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcMember" xlink:label="loc_ameh_ApcMember_4016" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApcMember_4016" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NmmBusinessLoanAgreementMember" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_4017" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_4017" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcBusinessLoanAgreementMember" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_4018" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_4018" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaacoMember" xlink:label="loc_ameh_ApaacoMember_4021" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApaacoMember_4021" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4013" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4013" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4013" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4013" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4024" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_DebtInstrumentAxis_4024" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4031" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4024" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4031" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4031_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4024" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4031_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4027" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_InvestmentTypeAxis_4027" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4084" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4027" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4084" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4084_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4027" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4084_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4085" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4084" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4085" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4083" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4083" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4083" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4809" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4809_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4083" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4809_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4810" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4809" xlink:to="loc_us-gaap_SubsequentEventMember_4810" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4042" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4042" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4043" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4043" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4044" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4044" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_4060" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_4060" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4065" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4065" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_4066" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_4066" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_4067" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_4067" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_4068" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCredit_4068" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4069" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4069" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_4078" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_4078" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_4093" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_4093" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_4713" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_4713" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_4873" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_4873" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_4874" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_4874" use="optional" order="40" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MergersAndAcquisitionsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4125" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4117" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombonationequityConsiderationTableTextBlock" xlink:label="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock_4118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock_4118" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4119" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4120" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_StatementTable_4121" use="optional" order="5" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4122" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4122" xlink:to="loc_us-gaap_ClassOfStockDomain_4123" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4123_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4122" xlink:to="loc_us-gaap_ClassOfStockDomain_4123_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4121" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4124" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4124" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4124" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126_default" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4142" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_StatementTable_4129" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4130" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4130" xlink:to="loc_us-gaap_ClassOfStockDomain_4131" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4131_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4130" xlink:to="loc_us-gaap_ClassOfStockDomain_4131_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_dei_LegalEntityAxis_4132" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4132" xlink:to="loc_dei_EntityDomain_4134" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4134_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4132" xlink:to="loc_dei_EntityDomain_4134_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncMember" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_4135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4134" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_4135" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4133" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4133" xlink:to="loc_us-gaap_EquityComponentDomain_4139" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4139_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4133" xlink:to="loc_us-gaap_EquityComponentDomain_4139_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4139" xlink:to="loc_us-gaap_PreferredStockMember_4140" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4139" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4141" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4144" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4136" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4137" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4145" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4149" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_StatementTable_4146" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4146" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4147" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4147" xlink:to="loc_us-gaap_ClassOfStockDomain_4148" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4148_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4147" xlink:to="loc_us-gaap_ClassOfStockDomain_4148_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4150" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4151" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4152" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4156" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_StatementTable_4153" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4153" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4154" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4154" xlink:to="loc_us-gaap_ClassOfStockDomain_4155" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4155_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4154" xlink:to="loc_us-gaap_ClassOfStockDomain_4155_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4158" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4159" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_4160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_4160" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4161" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4161" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4162" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4162" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_4163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_4163" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4164" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent_4165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent_4165" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_4166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_4166" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4167" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4169" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities_4170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities_4170" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit_4171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit_4171" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable_4172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable_4172" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty_4173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty_4173" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4174" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4175" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4176" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_Goodwill_4177" use="optional" order="25" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4181" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_us-gaap_StatementTable_4178" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4178" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4179" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4179" xlink:to="loc_us-gaap_ClassOfStockDomain_4180" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4180_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4179" xlink:to="loc_us-gaap_ClassOfStockDomain_4180_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4182" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4183" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic_4185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic_4185" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4186" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted_4189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted_4189" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4191" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4571" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_StatementTable_4207" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4208" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4208" xlink:to="loc_us-gaap_ClassOfStockDomain_4209" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4209_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4208" xlink:to="loc_us-gaap_ClassOfStockDomain_4209_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_4245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4209" xlink:to="loc_us-gaap_CommonClassBMember_4245" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4210" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4210" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4210" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApolloMedicalHoldingsIncMember" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_4213" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_4213" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MaverickMedicalGroupIncMember" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_4247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_4247" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4216_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4216_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantOneMember" xlink:label="loc_ameh_WarrantOneMember_4217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" xlink:to="loc_ameh_WarrantOneMember_4217" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantTwoMember" xlink:label="loc_ameh_WarrantTwoMember_4218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" xlink:to="loc_ameh_WarrantTwoMember_4218" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_DebtInstrumentAxis_4215" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4215" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4223" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4223_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4215" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4223_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConvertiblePromissoryNoteMember" xlink:label="loc_ameh_ConvertiblePromissoryNoteMember_4224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4223" xlink:to="loc_ameh_ConvertiblePromissoryNoteMember_4224" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_dei_LegalEntityAxis_4222" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4222" xlink:to="loc_dei_EntityDomain_4230" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4230_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4222" xlink:to="loc_dei_EntityDomain_4230_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncMember" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_4231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4230" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_4231" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4229" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4229" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4233" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4233_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4229" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4233_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaAcoIncMember" xlink:label="loc_ameh_ApaAcoIncMember_4234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_4233" xlink:to="loc_ameh_ApaAcoIncMember_4234" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4232" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4232" xlink:to="loc_us-gaap_EquityComponentDomain_4238" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4238_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4232" xlink:to="loc_us-gaap_EquityComponentDomain_4238_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4238" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4239" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4238" xlink:to="loc_us-gaap_PreferredStockMember_4244" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4237" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4573" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4237" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4573" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4573_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4237" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4573_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xlink:label="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare_4214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare_4214" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4219" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4220" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4221" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4225" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4226" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationconsiderationDescription" xlink:label="loc_ameh_BusinessCombinationconsiderationDescription_4227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_BusinessCombinationconsiderationDescription_4227" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4228" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4235" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4236" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_4240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_4240" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_4241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_4241" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_4242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_4242" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_4243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_4243" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentsForAgreementTermination" xlink:label="loc_ameh_PaymentsForAgreementTermination_4246" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_PaymentsForAgreementTermination_4246" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationAsset_4248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationAsset_4248" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseDeferredTaxAsset" xlink:label="loc_ameh_IncreaseDecreaseDeferredTaxAsset_4948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_IncreaseDecreaseDeferredTaxAsset_4948" use="optional" order="52" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4269" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4269" xlink:to="loc_us-gaap_StatementTable_4263" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4263" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4264" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4264" xlink:to="loc_us-gaap_ClassOfStockDomain_4265" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4265_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4264" xlink:to="loc_us-gaap_ClassOfStockDomain_4265_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4263" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4270_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4270_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4271" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" xlink:to="loc_ameh_UniversalCareIncMember_4273" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_4267" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4269" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_4267" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4279" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_StatementTable_4275" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4276" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4275" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4276" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4276" xlink:to="loc_us-gaap_ClassOfStockDomain_4277" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4277_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4276" xlink:to="loc_us-gaap_ClassOfStockDomain_4277_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4275" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4280_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4280_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4281" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4281" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" xlink:to="loc_ameh_UniversalCareIncMember_4300" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents_4283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents_4283" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables_4284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables_4284" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets_4285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets_4285" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables_4286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables_4286" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash_4287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash_4287" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets_4301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets_4301" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment_4302" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment_4302" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4288" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_4290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_4290" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities_4303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities_4303" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_4291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_4291" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity_4292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity_4292" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_4293" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_4293" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_4295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_4295" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes_4296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes_4296" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit_4297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit_4297" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_4298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_4298" use="optional" order="29" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4312" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4312" xlink:to="loc_us-gaap_StatementTable_4308" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4308" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4309" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4309" xlink:to="loc_us-gaap_ClassOfStockDomain_4310" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4310_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4309" xlink:to="loc_us-gaap_ClassOfStockDomain_4310_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4308" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4314_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4314_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4315" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_UniversalCareIncMember_4315" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4316" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DiagnosticMedicalGroupMember" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_4317" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_4317" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4318" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4318" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4319" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4312" xlink:to="loc_us-gaap_EquityMethodInvestments_4313" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4377" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_StatementTable_4327" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4328" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4328" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4328" xlink:to="loc_us-gaap_ClassOfStockDomain_4329" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4329_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4328" xlink:to="loc_us-gaap_ClassOfStockDomain_4329_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_VotingCommonStockTwoMember" xlink:label="loc_ameh_VotingCommonStockTwoMember_4764" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4329" xlink:to="loc_ameh_VotingCommonStockTwoMember_4764" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_4330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_OwnershipAxis_4330" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OwnershipAxis_4330" xlink:to="loc_us-gaap_OwnershipDomain_4333" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4333_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OwnershipAxis_4330" xlink:to="loc_us-gaap_OwnershipDomain_4333_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcLsmaMember" xlink:label="loc_ameh_ApcLsmaMember_4334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_4333" xlink:to="loc_ameh_ApcLsmaMember_4334" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_4350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_4333" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_4350" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4332" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4332" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4338" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4338_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4332" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4338_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_4338" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4340" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4346_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4346_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4347" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4349" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_UniversalCareIncMember_4354" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DiagnosticMedicalGroupMember" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_4423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_4423" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4454" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4454" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeAxis" xlink:label="loc_ameh_ContractTypeAxis_4344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_ameh_ContractTypeAxis_4344" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeDomain" xlink:label="loc_ameh_ContractTypeDomain_4378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_4344" xlink:to="loc_ameh_ContractTypeDomain_4378" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeDomain" xlink:label="loc_ameh_ContractTypeDomain_4378_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_4344" xlink:to="loc_ameh_ContractTypeDomain_4378_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AncillaryServiceContractMember" xlink:label="loc_ameh_AncillaryServiceContractMember_4379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_4378" xlink:to="loc_ameh_AncillaryServiceContractMember_4379" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4356" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4356" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_4357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_4357" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4362" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestments_4365" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4366" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_4370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsForFees_4370" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4372" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate_4373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsForAdvanceToAffiliate_4373" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_4375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_4375" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4376" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_4385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_4385" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoansReceivableInterestRate" xlink:label="loc_ameh_LoansReceivableInterestRate_4414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_LoansReceivableInterestRate_4414" use="optional" order="38" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4520" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_us-gaap_StatementTable_4391" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4392" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4392" xlink:to="loc_us-gaap_ClassOfStockDomain_4393" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4393_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4392" xlink:to="loc_us-gaap_ClassOfStockDomain_4393_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4394" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4394" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4396" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4396_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4394" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4396_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_4395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_OwnershipAxis_4395" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OwnershipAxis_4395" xlink:to="loc_us-gaap_OwnershipDomain_4400" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4400_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OwnershipAxis_4395" xlink:to="loc_us-gaap_OwnershipDomain_4400_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_4400" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4401" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4523" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4523" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4403" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4405" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4539" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4407" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4417" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4410" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4411" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4549" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4549" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4413" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4416" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4419" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4563" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4552" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4562" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4553" use="optional" order="34" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfWarrantDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4459" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4456" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_us-gaap_StatementTable_4456" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4457" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4456" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4457" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4457" xlink:to="loc_us-gaap_ClassOfStockDomain_4458" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4458_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4457" xlink:to="loc_us-gaap_ClassOfStockDomain_4458_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharesAbstract" xlink:label="loc_ameh_SharesAbstract_4460" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_SharesAbstract_4460" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4461" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsGranted" xlink:label="loc_ameh_NumberOfWarrantsGranted_4463" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_NumberOfWarrantsGranted_4463" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsExercised" xlink:label="loc_ameh_NumberOfWarrantsExercised_4464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_NumberOfWarrantsExercised_4464" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_4465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_4465" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageexercisePriceAbstract" xlink:label="loc_ameh_WeightedaverageexercisePriceAbstract_4467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_WeightedaverageexercisePriceAbstract_4467" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4468" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4468" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod_4470" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod_4470" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod_4471" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod_4471" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod_4472" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod_4472" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4478" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm_4479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm_4479" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm_4480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm_4480" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_4481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_4481" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AggregateintrinsicvalueAbstract" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_4482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_4482" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4484" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4484" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_4486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_4486" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_4487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_4487" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4488" use="optional" order="24" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4831" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StatementTable_4491" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4492" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4492" xlink:to="loc_us-gaap_ClassOfStockDomain_4493" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4493_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4492" xlink:to="loc_us-gaap_ClassOfStockDomain_4493_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4494" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4496" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4494" xlink:to="loc_us-gaap_EquityComponentDomain_4496" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4496_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4494" xlink:to="loc_us-gaap_EquityComponentDomain_4496_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4495" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncNmmMember" xlink:label="loc_ameh_NetworkMedicalManagementIncNmmMember_4505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_NetworkMedicalManagementIncNmmMember_4505" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmehMember" xlink:label="loc_ameh_AmehMember_4506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_AmehMember_4506" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4655" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4503" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4503" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4534" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4534_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4503" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4534_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_4533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_TitleOfIndividualAxis_4533" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_4533" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_4533" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FormerShareholdersOfNmmMember" xlink:label="loc_ameh_FormerShareholdersOfNmmMember_4723" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" xlink:to="loc_ameh_FormerShareholdersOfNmmMember_4723" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" xlink:to="loc_us-gaap_RelatedPartyDomain_4543" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4543_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" xlink:to="loc_us-gaap_RelatedPartyDomain_4543_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4626" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4626_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4626_default" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4625" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_PlanNameAxis_4625" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4625" xlink:to="loc_us-gaap_PlanNameDomain_4674" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4674_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4625" xlink:to="loc_us-gaap_PlanNameDomain_4674_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4673" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_AwardTypeAxis_4673" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4673" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4673" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_4700" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" xlink:to="loc_us-gaap_StockCompensationPlanMember_4700" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_dei_LegalEntityAxis_4677" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4708" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4677" xlink:to="loc_dei_EntityDomain_4708" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4708_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4677" xlink:to="loc_dei_EntityDomain_4708_default" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_4707" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_VestingAxis_4707" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_4718" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_4707" xlink:to="loc_us-gaap_VestingDomain_4718" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_4718_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_4707" xlink:to="loc_us-gaap_VestingDomain_4718_default" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4716" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4716" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4730" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4716" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4730" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4730_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4716" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4730_default" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4729" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_RangeAxis_4729" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4823" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_4729" xlink:to="loc_us-gaap_RangeMember_4823" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4823_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_4729" xlink:to="loc_us-gaap_RangeMember_4823_default" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4824" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4823" xlink:to="loc_us-gaap_MinimumMember_4824" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4825" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4823" xlink:to="loc_us-gaap_MaximumMember_4825" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832_default" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4512" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4515" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_4528" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_4528" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4603" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4603" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4698" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4698" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_4699" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_4699" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4711" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4711" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4728" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_SharesOutstanding_4728" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4836" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4836" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4899" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4899" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod_4903" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod_4903" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet_4905" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet_4905" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4909" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4909" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod_4917" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod_4917" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_4919" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_4919" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice_4921" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice_4921" use="optional" order="69" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4576" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4576" xlink:to="loc_us-gaap_StatementTable_4566" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4567" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4566" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4567" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4568" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4567" xlink:to="loc_us-gaap_ClassOfStockDomain_4568" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4568_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4567" xlink:to="loc_us-gaap_ClassOfStockDomain_4568_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4566" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4569" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4569" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4577" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4577_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4569" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4577_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractedPhysiciansAndOtherServicesMember" xlink:label="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4578" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4577" xlink:to="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4578" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4576" xlink:to="loc_us-gaap_ShareBasedCompensation_4574" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4607" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4599" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_StatementTable_4599" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4599" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4600" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4600" xlink:to="loc_us-gaap_ClassOfStockDomain_4601" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4601_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4600" xlink:to="loc_us-gaap_ClassOfStockDomain_4601_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4599" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4609" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4609" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_4604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_AssetsAbstract_4604" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4605" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4606" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4606" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_RestrictedCashCurrent_4610" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryCashCurrent" xlink:label="loc_ameh_FiduciaryCashCurrent_4614" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_ameh_FiduciaryCashCurrent_4614" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4617" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4618" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4618" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4619" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_AssetsCurrent_4620" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_4622" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_4622" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4627" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4627" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4630" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4630" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_Goodwill_4632" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4633" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4633" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_4634" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_LoansReceivableNet_4634" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_EquityMethodInvestments_4635" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="loc_us-gaap_CostMethodInvestments_4636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_CostMethodInvestments_4636" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4828" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4828" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4829" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4829" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_4830" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_AssetsNoncurrent_4830" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4641" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_Assets_4641" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4644" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4648" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_4650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_4650" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_4652" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_4652" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_4654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_4654" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4656" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_TaxesPayableCurrent_4656" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_4657" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_4657" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4658" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_4659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_4659" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4662" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_LiabilitiesCurrent_4662" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4665" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_4666" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_4666" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_4667" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_4667" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4670" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4670" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_Liabilities_4671" use="optional" order="45" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4683" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4680" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4683" xlink:to="loc_us-gaap_StatementTable_4680" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4681" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4680" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4681" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4682" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4681" xlink:to="loc_us-gaap_ClassOfStockDomain_4682" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4682_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4681" xlink:to="loc_us-gaap_ClassOfStockDomain_4682_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashAcquiredFromAcquisition" xlink:label="loc_ameh_RestrictedCashAcquiredFromAcquisition_4685" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4683" xlink:to="loc_ameh_RestrictedCashAcquiredFromAcquisition_4685" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4775" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4772" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4775" xlink:to="loc_us-gaap_StatementTable_4772" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4773" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4773" xlink:to="loc_us-gaap_ClassOfStockDomain_4774" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4774_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4773" xlink:to="loc_us-gaap_ClassOfStockDomain_4774_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_InvestmentTypeAxis_4778" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4779" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4778" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4779" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4779_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4778" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4779_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4780" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4780" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4782" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4782" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_4781" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_EquitySecuritiesMember_4781" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4785" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4785" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4786" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4786" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4787" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4787" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4775" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4777" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4777" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4894" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4888" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_StatementTable_4888" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4889" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4888" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4889" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4890" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4889" xlink:to="loc_us-gaap_ClassOfStockDomain_4890" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4890_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4889" xlink:to="loc_us-gaap_ClassOfStockDomain_4890_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4888" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4895" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4895" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4895_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4895_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_4896" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4895" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_4896" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_4897" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4895" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_4897" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4892" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4892" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4893" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4892" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4893" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4900" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4900" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MezzanineEquityAbstract" xlink:label="loc_ameh_MezzanineEquityAbstract_4901" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_ameh_MezzanineEquityAbstract_4901" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4904" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_4901" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4904" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4908" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4908" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DisaggregationOfRevenueDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4914" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4910" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4914" xlink:to="loc_us-gaap_StatementTable_4910" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4911" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4910" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4911" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4912" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4911" xlink:to="loc_us-gaap_ClassOfStockDomain_4912" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4912_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4911" xlink:to="loc_us-gaap_ClassOfStockDomain_4912_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_4913" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4910" xlink:to="loc_us-gaap_MajorCustomersAxis_4913" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_4915" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_4913" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_4915" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_4915_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_4913" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_4915_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommercialMember" xlink:label="loc_ameh_CommercialMember_4916" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_CommercialMember_4916" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareMember" xlink:label="loc_ameh_MedicareMember_4920" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_MedicareMember_4920" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicaidMember" xlink:label="loc_ameh_MedicaidMember_4922" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_MedicaidMember_4922" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OtherThirdPartiesMember" xlink:label="loc_ameh_OtherThirdPartiesMember_4923" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_OtherThirdPartiesMember_4923" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4918" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4914" xlink:to="loc_us-gaap_SalesRevenueNet_4918" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4951" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4925" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_StatementTable_4925" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4926" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4925" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4926" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4927" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4926" xlink:to="loc_us-gaap_ClassOfStockDomain_4927" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4927_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4926" xlink:to="loc_us-gaap_ClassOfStockDomain_4927_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4925" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4952" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4952" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4952_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4952_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_4953" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4952" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_4953" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_4929" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_EquityFairValueAdjustment_4929" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_4930" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_4930" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent_4931" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent_4931" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4932" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4932" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xlink:label="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived_4934" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived_4934" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4954" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4954" use="optional" order="14" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ameh-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DocumentAndEntityInformationAbstract" xlink:label="loc_ameh_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DocumentAndEntityInformationAbstract" xlink:to="lab_ameh_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Acquisitions of non-controlling interest in BAHA</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#8217; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation Policy [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Reportable Segments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassifications</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash - short-term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash - short-term - distributions to former NMM shareholders</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Assets Held-in-trust, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Fiduciary cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustCurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable Securities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Investment in marketable securities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Receivables, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Noncurrent assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Noncurrent assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Land, property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, Mezzanine Equity and Shareholders&#8217; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xml:lang="en-US">Line of Credit, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xml:lang="en-US">Lines of credit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncentivePayableCurrent" xlink:label="loc_ameh_IncentivePayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncentivePayableCurrent" xml:lang="en-US">Incentive Payable current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_IncentivePayableCurrent" xml:lang="en-US">Incentives payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncentivePayableCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of Incentives to be paid and reflects the noncurrent portion of the liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncentivePayableCurrent" xlink:to="lab_ameh_IncentivePayableCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xml:lang="en-US">Fiduciary Accounts Payable Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xml:lang="en-US">Fiduciary accounts payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Medical Liabilities Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Medical liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Balance, beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Medical liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Balance, end of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xml:lang="en-US">Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalLiabilitiesCurrent" xlink:to="lab_ameh_MedicalLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Bank loan, short-term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Bank loan, short-term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="lab_us-gaap_ShortTermBankLoansAndNotesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Net deferred tax liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, par value $0.001; 100,000,000 shares authorized, 32,652,295 and 32,304,876 shares outstanding, excluding 1,682,110 shares held by APC, at March 31, 2018 and December 31, 2017, respectively (see Note 10)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in-capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; deficit attributable to Apollo Medical Holdings, Inc.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders&#39; Equity Attributable To Noncontrolling Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Balance as of January 31, 2013</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Balance as of January 31, 2014</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of intangible assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of future amortization expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accounts payable and accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Stock Option Transactions Under Stock Option Plans</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" xlink:label="loc_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" xml:lang="en-US">Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" xml:lang="en-US">Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" xlink:to="lab_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis" xlink:to="lab_us-gaap_MajorCustomersAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property Plant and Equipment By Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property Plant and Equipment Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Market value of common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageForDownRoundFinancing" xlink:label="loc_ameh_PercentageForDownRoundFinancing" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PercentageForDownRoundFinancing" xml:lang="en-US">Percentage For Down round financing</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_PercentageForDownRoundFinancing" xml:lang="en-US">Percentage for Down round financing.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageForDownRoundFinancing" xlink:to="lab_ameh_PercentageForDownRoundFinancing" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaap_CostOfServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfServices" xml:lang="en-US">Cost of Services, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfServices" xml:lang="en-US">Cost of services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostOfServices" xml:lang="en-US">Cost of Services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfServices" xlink:to="lab_us-gaap_CostOfServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">(Loss) income from equity method investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss (income) from equity method investments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (loss) from operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income Expense [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (expense) income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income before provision for income taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision (benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total provision for income taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income attributable to noncontrolling interests</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income attributable to noncontrolling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income attributable to noncontrolling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income attributable to non-controlling interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to Apollo Medical Holdings, Inc.</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to Apollo Medical Holdings, Inc.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings per share - basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">BASIC</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings per share - diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">DILUTED</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareLicenseMember" xlink:label="loc_ameh_MedicareLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicareLicenseMember" xml:lang="en-US">Medicare license [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicareLicenseMember" xml:lang="en-US">Medicare license</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_MedicareLicenseMember" xml:lang="en-US">Medicare License</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareLicenseMember" xlink:to="lab_ameh_MedicareLicenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2018 (remaining nine months)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2018</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2019</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2019</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2020</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2020</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2021</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2021</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2022</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2022</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AccountsPayableAndAccruedLiabilitiesTable" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="lab_ameh_AccountsPayableAndAccruedLiabilitiesTable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountPayableAndAccruedLiabilitiesLineItems" xlink:label="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AccountPayableAndAccruedLiabilitiesLineItems" xml:lang="en-US">Account Payable And Accrued Liabilities [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems" xlink:to="lab_ameh_AccountPayableAndAccruedLiabilitiesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SpecialtyCapitationPayableCurrent" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xml:lang="en-US">Specialty Capitation Payable Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xml:lang="en-US">Specialty capitation payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xml:lang="en-US">Represents the amount of specialty capitation payable current.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureWarrantsAbstract" xlink:label="loc_ameh_DisclosureWarrantsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DisclosureWarrantsAbstract" xml:lang="en-US">Disclosure Warrants [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_DisclosureWarrantsAbstract" xml:lang="en-US">Disclosure - Warrants [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DisclosureWarrantsAbstract" xlink:to="lab_ameh_DisclosureWarrantsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class Of Warrant Or Right [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types Of Debt and Equity Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeOneMember" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xml:lang="en-US">Warrant Exercise Price Range One [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xml:lang="en-US">Warrant Exercise Price Range One 4.50</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeTwoMember" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xml:lang="en-US">Warrant Exercise Price Range Two 9.00</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeThreeMember" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xml:lang="en-US">Warrant Exercise Price Range Three 10.00</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFourMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xml:lang="en-US">Warrant Exercise Price Range Four [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xml:lang="en-US">Warrant Exercise Price Range Four 11.00</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeFourMember" xlink:to="lab_ameh_WarrantExercisePriceRangeFourMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFiveMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFiveMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantExercisePriceRangeFiveMember" xml:lang="en-US">Warrant Exercise Price Range Five [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_WarrantExercisePriceRangeFiveMember" xml:lang="en-US">Warrant Exercise Price Range Five 4.50-11.00</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeFiveMember" xlink:to="lab_ameh_WarrantExercisePriceRangeFiveMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xml:lang="en-US">Warrants outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xml:lang="en-US">Class of Warrant or Right, Issued in Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisable" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class Of Warrant Or Right Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Warrants exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xml:lang="en-US">Weighted average exercise price per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right Exercisable Weighted Average Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss from investment in equity securities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Receivable, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xml:lang="en-US">Increase Decrease In Prepaid Expenses And Other Current Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Increase (Decrease) in Other Operating Assets, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Other assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of bank loan</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payments of Dividends</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Dividends paid</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">non-controlling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Change in noncontrolling interest capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for income taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CashlessExerciseOfStockOptions" xlink:label="loc_ameh_CashlessExerciseOfStockOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xml:lang="en-US">Cashless exercise of stock options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xml:lang="en-US">Cashless exercise of stock options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xml:lang="en-US">It represents cashless exercise of stock options.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashlessExerciseOfStockOptions" xlink:to="lab_ameh_CashlessExerciseOfStockOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Reclassification of stock options exercised to liability for unissued common shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature Of Operations [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Description of Business</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesTable" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments And Contingencies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkRelationshipsMember" xlink:label="loc_ameh_NetworkRelationshipsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NetworkRelationshipsMember" xml:lang="en-US">Network Relationships [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_NetworkRelationshipsMember" xml:lang="en-US">Network relationships</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xml:lang="en-US">Payment of capital lease obligations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xlink:label="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xml:lang="en-US">Deferred tax liability adjustment to goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xml:lang="en-US">Deferred tax liability adjustment to goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xml:lang="en-US">It represents the deferred tax liability adjustment to goodwill.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xlink:to="lab_ameh_DeferredTaxLiabilityAdjustmentToGoodwill" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessTable" xlink:label="loc_ameh_DescriptionOfBusinessTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DescriptionOfBusinessTable" xml:lang="en-US">Description Of Business [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative instrument</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative instrument</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain on change in fair value of warrant and conversion feature liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Loss on changes in fair value of warrant and conversion feature liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xml:lang="en-US">Cumulative effect adjustment included in accounts receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xml:lang="en-US">Cumulative effect adjustment for ASC 606 included in accounts receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xml:lang="en-US">It represents the cumulative effect adjustment included in accounts receivable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xlink:to="lab_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill - beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill - end of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xml:lang="en-US">Due from Related Parties, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xml:lang="en-US">Loans receivable - related parties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xml:lang="en-US">Loans receivable - related parties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options and warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansReceivableNet" xml:lang="en-US">Loans Receivable, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LoansReceivableNet" xml:lang="en-US">Loan receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansReceivableNet" xml:lang="en-US">Loan receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansReceivableNet" xlink:to="lab_us-gaap_LoansReceivableNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Investments in other entities - equity method</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Investments in other entities - equity method</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xml:lang="en-US">Cumulative effect adjustment included in deferred tax liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xml:lang="en-US">Cumulative effect adjustment for ASC 606 included in deferred tax liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xml:lang="en-US">It represents the cumulative effect adjustment included in deferred tax liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xlink:to="lab_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Reclassification of fiduciary cash to payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Capital Lease Obligations, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Capital lease obligations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Less current portion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Capital lease obligations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LiabilityForUnissuedEquitySharesNoncurrent" xml:lang="en-US">Liability For Unissued Equity shares Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_LiabilityForUnissuedEquitySharesNoncurrent" xml:lang="en-US">Liability for unissued equity shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_LiabilityForUnissuedEquitySharesNoncurrent" xml:lang="en-US">Liability for unissued equity shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_LiabilityForUnissuedEquitySharesNoncurrent" xml:lang="en-US">Amount recognized for unissued equity shares classified as noncurrent.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:to="lab_ameh_LiabilityForUnissuedEquitySharesNoncurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DividendPayableNoncurrent" xlink:label="loc_ameh_DividendPayableNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DividendPayableNoncurrent" xml:lang="en-US">Dividend Payable Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_DividendPayableNoncurrent" xml:lang="en-US">Dividends payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_DividendPayableNoncurrent" xml:lang="en-US">Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the noncurrent portion of the liabilities (due after one year or beyond the normal operating cycle if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DividendPayableNoncurrent" xlink:to="lab_ameh_DividendPayableNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US">Capital Lease Obligations, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US">Capital lease obligations, net of current portion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US">Long-term portion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent" xml:lang="en-US">Capital lease obligations, net of current portion</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xml:lang="en-US">Receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SubcontractorIpaRiskPoolPayable" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xml:lang="en-US">Subcontractor IPA Risk Pool Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xml:lang="en-US">Subcontractor IPA risk pool payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xml:lang="en-US">Represents the amount of subcontractor IPA risk pool payable current.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIpaRiskPoolPayable" xlink:to="lab_ameh_SubcontractorIpaRiskPoolPayable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInIncentivesPayable" xlink:label="loc_ameh_IncreaseDecreaseInIncentivesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseInIncentivesPayable" xml:lang="en-US">Increase decrease In Incentives Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_IncreaseDecreaseInIncentivesPayable" xml:lang="en-US">Incentives payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseInIncentivesPayable" xml:lang="en-US">The change in incentives payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInIncentivesPayable" xlink:to="lab_ameh_IncreaseDecreaseInIncentivesPayable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xml:lang="en-US">Increase Decrease In Medical Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xml:lang="en-US">Medical liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred tax</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Risks</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements of Financial Instruments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements of Financial Instruments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares of common stock outstanding - basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">BASIC</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares of common stock outstanding - basic</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares of common stock outstanding - diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">DILUTED</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares of common stock outstanding - diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share:</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Per share data:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average shares of common stock outstanding:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Intangible Assets and Long-Lived Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralAxis" xml:lang="en-US">Collateral [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesAxis" xlink:label="loc_ameh_ProfessionalFeesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ProfessionalFeesAxis" xml:lang="en-US">Professional Fees [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProfessionalFeesAxis" xlink:to="lab_ameh_ProfessionalFeesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax provision at U.S. Federal statutory rates</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xml:lang="en-US">Investments in Other Entities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xml:lang="en-US">Medical Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueTable" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerAMember" xlink:label="loc_ameh_CustomerAMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CustomerAMember" xml:lang="en-US">Customer [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_CustomerAMember" xml:lang="en-US">Customer A</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_CustomerAMember" xml:lang="en-US">Payor A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CustomerAMember" xlink:to="lab_ameh_CustomerAMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerBMember" xlink:label="loc_ameh_CustomerBMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CustomerBMember" xml:lang="en-US">Customer B [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_CustomerBMember" xml:lang="en-US">Customer B</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_CustomerBMember" xml:lang="en-US">Payor B [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CustomerBMember" xlink:to="lab_ameh_CustomerBMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerCMember" xlink:label="loc_ameh_CustomerCMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CustomerCMember" xml:lang="en-US">Customer C [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_CustomerCMember" xml:lang="en-US">Customer C</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_CustomerCMember" xml:lang="en-US">Payor C [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CustomerCMember" xlink:to="lab_ameh_CustomerCMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Basic and Diluted Earnings Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MinorityInterestPolicyTextBlock" xlink:label="loc_ameh_MinorityInterestPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MinorityInterestPolicyTextBlock" xml:lang="en-US">Minority Interest Policy [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_MinorityInterestPolicyTextBlock" xml:lang="en-US">Non-controlling Interests</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_MinorityInterestPolicyTextBlock" xml:lang="en-US">Minority Interest Policy.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Stockholders&#39; Equity, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Mezzanine Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesDomain" xlink:label="loc_ameh_ProfessionalFeesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ProfessionalFeesDomain" xml:lang="en-US">Professional Fees [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProfessionalFeesDomain" xlink:to="lab_ameh_ProfessionalFeesDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorDMember" xlink:label="loc_ameh_PayorDMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PayorDMember" xml:lang="en-US">Payor D [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorEMember" xlink:label="loc_ameh_PayorEMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PayorEMember" xml:lang="en-US">Payor E [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive loss:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from common stock offering</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Preferred Stock - Series A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total stockholders&#8217; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Preferred Stock - Series B [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementAxis" xlink:label="loc_ameh_AgreementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AgreementAxis" xlink:to="lab_ameh_AgreementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xlink:label="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Addition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Addition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xml:lang="en-US">Finite lived intangible assets accumulated amortization addition.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xlink:to="lab_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class Of Warrant Or Right [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xml:lang="en-US">Trading Activity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementDomain" xlink:label="loc_ameh_AgreementDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AgreementDomain" xlink:to="lab_ameh_AgreementDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xml:lang="en-US">Receivable Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RobMikitarianMember" xlink:label="loc_ameh_RobMikitarianMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_RobMikitarianMember" xml:lang="en-US">Rob Mikitarian [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RobMikitarianMember" xlink:to="lab_ameh_RobMikitarianMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Other receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaap_ReceivableTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivableTypeDomain" xml:lang="en-US">Receivable [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableMember" xlink:label="loc_us-gaap_NotesReceivableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesReceivableMember" xml:lang="en-US">Notes Receivable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashUninsuredAmount" xml:lang="en-US">Cash, Uninsured Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantLiabilityMember" xlink:label="loc_ameh_WarrantLiabilityMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantLiabilityMember" xml:lang="en-US">Warrant Liability [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantLiabilityMember" xlink:to="lab_ameh_WarrantLiabilityMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xml:lang="en-US">Class of Financing Receivable, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Weighted Average Life (Yrs)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Intangible Assets, Gross, Total, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Intangible Assets, Gross, Total, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated Amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Indefinite Lived Intangible Assets Gross Excluding Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Indefinite Lived Assets, Gross, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Indefinite Lived Assets, Gross, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xml:lang="en-US">Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsMember" xml:lang="en-US">Indefinite-lived Intangible Assets [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis" xlink:to="lab_us-gaap_ConsolidatedEntitiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xml:lang="en-US">Securities or Other Assets Sold under Agreements to Repurchase [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xml:lang="en-US">Class of Financing Receivable, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xml:lang="en-US">Assets Sold under Agreements to Repurchase, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="lab_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies (Note 11)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchases of marketable securities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Warrants Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashInterestRate" xlink:label="loc_ameh_RestrictedCashInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_RestrictedCashInterestRate" xml:lang="en-US">Restricted Cash Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_RestrictedCashInterestRate" xml:lang="en-US">Percentage of restricted cash interest amount.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RestrictedCashInterestRate" xlink:to="lab_ameh_RestrictedCashInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash - long-term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash - long-term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash - long-term - letters of credit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total noncurrent assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total noncurrent assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MezzanineEquityAbstract" xlink:label="loc_ameh_MezzanineEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MezzanineEquityAbstract" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MezzanineEquityAbstract" xml:lang="en-US">Mezzanine equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_ameh_MezzanineEquityAbstract" xml:lang="en-US">Mezzanine equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders&#8217; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders&#8217; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, mezzanine equity and stockholders&#8217; equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Noncontrolling interest in Allied Pacific of California IPA (&#8220;APC&#8221;)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Noncontrolling interest in Allied Pacific of California IPA</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationCapitationRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationCapitationRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationCapitationRevenue" xml:lang="en-US">Health Care Organization, Capitation Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationCapitationRevenue" xml:lang="en-US">Capitation, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationCapitationRevenue" xlink:to="lab_us-gaap_HealthCareOrganizationCapitationRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationOtherRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationOtherRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationOtherRevenue" xml:lang="en-US">Health Care Organization, Other Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationOtherRevenue" xml:lang="en-US">Risk pool settlements and incentives</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationOtherRevenue" xlink:to="lab_us-gaap_HealthCareOrganizationOtherRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeesRevenue" xlink:label="loc_us-gaap_ManagementFeesRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManagementFeesRevenue" xml:lang="en-US">Management Fees Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ManagementFeesRevenue" xml:lang="en-US">Management fee income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeesRevenue" xlink:to="lab_us-gaap_ManagementFeesRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationPatientServiceRevenue" xml:lang="en-US">Health Care Organization, Patient Service Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationPatientServiceRevenue" xml:lang="en-US">Patient fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationPatientServiceRevenue" xml:lang="en-US">Fee-for-service, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:to="lab_us-gaap_HealthCareOrganizationPatientServiceRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other (expense) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xml:lang="en-US">Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xlink:to="lab_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_UniversalCareIncMember" xml:lang="en-US">Universal Care Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentMadeToRelatedParty" xlink:label="loc_ameh_PaymentMadeToRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xml:lang="en-US">Payment Made To Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xml:lang="en-US">Revenue from Related Parties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ServiceMember" xlink:label="loc_ameh_ServiceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ServiceMember" xml:lang="en-US">Service [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ServiceMember" xlink:to="lab_ameh_ServiceMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain" xlink:to="lab_us-gaap_ConsolidatedEntitiesDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LmaMember" xlink:label="loc_ameh_LmaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LmaMember" xml:lang="en-US">LMA [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PmiocMember" xlink:label="loc_ameh_PmiocMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PmiocMember" xml:lang="en-US">PMIOC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmgIncMember" xlink:label="loc_ameh_AmgIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AmgIncMember" xml:lang="en-US">AMG, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DmgMember" xlink:label="loc_ameh_DmgMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DmgMember" xml:lang="en-US">DMG [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalPropertyPartnersMember" xlink:label="loc_ameh_MedicalPropertyPartnersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalPropertyPartnersMember" xml:lang="en-US">Medical Property Partners [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersMember" xlink:to="lab_ameh_MedicalPropertyPartnersMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalInvestmentGroupLlcMember" xlink:label="loc_ameh_MedicalInvestmentGroupLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalInvestmentGroupLlcMember" xml:lang="en-US">Medical Investment Group LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalInvestmentGroupLlcMember" xlink:to="lab_ameh_MedicalInvestmentGroupLlcMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcShareholdersMember" xlink:label="loc_ameh_ApcShareholdersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApcShareholdersMember" xml:lang="en-US">APC Shareholders [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareholdersAndOfficersMember" xlink:label="loc_ameh_ShareholdersAndOfficersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xml:lang="en-US">Shareholders And Officers [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xml:lang="en-US">Initial Fixed Term Of Amended and Restated Management and Administrative Services Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Payments to Acquire Equity Method Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Purchases of investments - equity method</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessLineItems" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xml:lang="en-US">Description Of Business [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApollomedMember" xlink:label="loc_ameh_ApollomedMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApollomedMember" xml:lang="en-US">ApolloMed [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApollomedMember" xlink:to="lab_ameh_ApollomedMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InternationalCancerCenterIccMember" xlink:label="loc_ameh_InternationalCancerCenterIccMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_InternationalCancerCenterIccMember" xml:lang="en-US">International Cancer Center ICC&#8221; [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InternationalCancerCenterIccMember" xlink:to="lab_ameh_InternationalCancerCenterIccMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSalesRevenueNet" xml:lang="en-US">Other Revenue, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherSalesRevenueNet" xml:lang="en-US">Other income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet" xlink:to="lab_us-gaap_OtherSalesRevenueNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Total revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense) income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xml:lang="en-US">Payments to Fund Long-term Loans to Related Parties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xml:lang="en-US">Advances to related parties - loans receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xml:lang="en-US">Dividends received from equity method investments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProceedsFromSaleOfCostMethodInvestments" xlink:label="loc_ameh_ProceedsFromSaleOfCostMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ProceedsFromSaleOfCostMethodInvestments" xml:lang="en-US">Proceeds From Sale Of Cost Method Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_ProceedsFromSaleOfCostMethodInvestments" xml:lang="en-US">Proceeds on sale of investments - cost method</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ProceedsFromSaleOfCostMethodInvestments" xml:lang="en-US">The cash inflow associated with the sale of cost method investments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromSaleOfCostMethodInvestments" xlink:to="lab_ameh_ProceedsFromSaleOfCostMethodInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseInRestrictedCash" xml:lang="en-US">Increase in Restricted Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseInRestrictedCash" xml:lang="en-US">Restricted cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseInRestrictedCash" xlink:to="lab_us-gaap_IncreaseInRestrictedCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xml:lang="en-US">Trading Activity, by Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xml:lang="en-US">Derivative Asset, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xml:lang="en-US">Derivative asset - warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US">Workers&#39; Compensation Liability, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US">Accrued compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="lab_us-gaap_WorkersCompensationLiabilityCurrent" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSignificantInfluenceDescription" xlink:label="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSignificantInfluenceDescription" xml:lang="en-US">Equity Method Investment, Significant Influence Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSignificantInfluenceDescription" xml:lang="en-US">The description of significant influence based on common stock or equity participation in the investee accounted for under the equity method of accounting.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription" xlink:to="lab_ameh_EquityMethodInvestmentSignificantInfluenceDescription" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoanReceivableAbstract" xlink:label="loc_ameh_LoanReceivableAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LoanReceivableAbstract" xml:lang="en-US">Loan Receivable [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableAbstract" xlink:to="lab_ameh_LoanReceivableAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoanReceivableTextBlock" xlink:label="loc_ameh_LoanReceivableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LoanReceivableTextBlock" xml:lang="en-US">Loan Receivable [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_LoanReceivableTextBlock" xml:lang="en-US">Loan Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_LoanReceivableTextBlock" xml:lang="en-US">The entire disclosure for note receivable and management services agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Line of credit facility amount outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="lab_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt, interest rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Convertible notes, interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms (Months)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Convertible notes payable, interest payment terms</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExtendableAmountOnCreditFacility" xlink:label="loc_ameh_ExtendableAmountOnCreditFacility" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ExtendableAmountOnCreditFacility" xml:lang="en-US">Extendable Amount On Credit Facility</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ExtendableAmountOnCreditFacility" xml:lang="en-US">Represents the amount of extendable amount on credit facility.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ExtendableAmountOnCreditFacility" xlink:to="lab_ameh_ExtendableAmountOnCreditFacility" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_TermOfManagementServiceAgreement" xlink:label="loc_ameh_TermOfManagementServiceAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_TermOfManagementServiceAgreement" xml:lang="en-US">Term Of Management Service Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_TermOfManagementServiceAgreement" xml:lang="en-US">Represents the term of management service agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermOfManagementServiceAgreement" xlink:to="lab_ameh_TermOfManagementServiceAgreement" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageOfManagingResponsibleOfHealthPlanship" xlink:label="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PercentageOfManagingResponsibleOfHealthPlanship" xml:lang="en-US">Percentage Of Managing Responsible Of Health Plan ship</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_PercentageOfManagingResponsibleOfHealthPlanship" xml:lang="en-US">Represents the percentage of managing responsible of health plan membership.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship" xlink:to="lab_ameh_PercentageOfManagingResponsibleOfHealthPlanship" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DrJayLoanMember" xlink:label="loc_ameh_DrJayLoanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DrJayLoanMember" xml:lang="en-US">Dr. Jay Loan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DrJayLoanMember" xlink:to="lab_ameh_DrJayLoanMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcMember" xlink:label="loc_ameh_ApcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApcMember" xml:lang="en-US">APC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcMember" xlink:to="lab_ameh_ApcMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NmmBusinessLoanAgreementMember" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NmmBusinessLoanAgreementMember" xml:lang="en-US">NMM Business Loan Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NmmBusinessLoanAgreementMember" xlink:to="lab_ameh_NmmBusinessLoanAgreementMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfMedicalLiabilitiesAbstract" xlink:label="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DisclosureOfMedicalLiabilitiesAbstract" xml:lang="en-US">Disclosure of Medical Liabilities [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract" xlink:to="lab_ameh_DisclosureOfMedicalLiabilitiesAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesTextBlock" xlink:label="loc_ameh_MedicalLiabilitiesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalLiabilitiesTextBlock" xml:lang="en-US">Medical Liabilities [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicalLiabilitiesTextBlock" xml:lang="en-US">Medical Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_MedicalLiabilitiesTextBlock" xml:lang="en-US">The entire disclosure for medical liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalLiabilitiesTextBlock" xlink:to="lab_ameh_MedicalLiabilitiesTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xlink:label="loc_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xml:lang="en-US">Medical Liabilities [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xml:lang="en-US">Medical Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xml:lang="en-US">Tabular disclosure of medical liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xlink:to="lab_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesAddedFromMerger" xlink:label="loc_ameh_MedicalLiabilitiesAddedFromMerger" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicalLiabilitiesAddedFromMerger" xml:lang="en-US">Medical Liabilities Added From Merger</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicalLiabilitiesAddedFromMerger" xml:lang="en-US">Medical liabilities assumed from Merger</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_MedicalLiabilitiesAddedFromMerger" xml:lang="en-US">The amount of medical liabilities derived from merger.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalLiabilitiesAddedFromMerger" xlink:to="lab_ameh_MedicalLiabilitiesAddedFromMerger" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" xlink:label="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" xml:lang="en-US">Disclosure of Bank Loan, Lines of Credit and Loan Payable - Related Party [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" xlink:to="lab_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xlink:label="loc_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xml:lang="en-US">Bank Loan Lines Of Credit And Loan Payable Related Party [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xml:lang="en-US">Bank Loan Lines Of Credit And Loan Payable Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xml:lang="en-US">The entire disclosure for bank loan, lines of credit and loan payable - related party.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xlink:to="lab_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IccMember" xlink:label="loc_ameh_IccMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IccMember" xml:lang="en-US">ICC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IccMember" xlink:to="lab_ameh_IccMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcBusinessLoanAgreementMember" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xml:lang="en-US">APC Business Loan Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaacoMember" xlink:label="loc_ameh_ApaacoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApaacoMember" xml:lang="en-US">APAACO [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_ApaacoMember" xml:lang="en-US">APA ACO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt, maturity date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt instrument, maturity date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xml:lang="en-US">Line of Credit Facility, Expiration Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationDate1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDescription" xml:lang="en-US">Line of Credit Facility, Interest Rate Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDescription" xml:lang="en-US">Line of credit facility, interest rate description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xml:lang="en-US">Standby Letters of Credit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityMember" xlink:label="loc_ameh_ExclusivityMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ExclusivityMember" xml:lang="en-US">Exclusivity [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ExclusivityMember" xml:lang="en-US">Exclusivity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ExclusivityMember" xlink:to="lab_ameh_ExclusivityMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityDescription" xml:lang="en-US">Line of Credit Facility, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDescription" xlink:to="lab_us-gaap_LineOfCreditFacilityDescription" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ManagementContractsMember" xlink:label="loc_ameh_ManagementContractsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ManagementContractsMember" xml:lang="en-US">Management contracts [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MemberRelationshipsMember" xlink:label="loc_ameh_MemberRelationshipsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MemberRelationshipsMember" xml:lang="en-US">Member relationships [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PatientManagementPlatformMember" xlink:label="loc_ameh_PatientManagementPlatformMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PatientManagementPlatformMember" xml:lang="en-US">Patient management platform [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombonationequityConsiderationTableTextBlock" xlink:label="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombonationequityConsiderationTableTextBlock" xml:lang="en-US">Business Combonation,Equity consideration [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_BusinessCombonationequityConsiderationTableTextBlock" xml:lang="en-US">Business Combination, Equity consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombonationequityConsiderationTableTextBlock" xml:lang="en-US">Tabular disclosure of equity consideration in business combination.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock" xlink:to="lab_ameh_BusinessCombonationequityConsiderationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Purchase Prices Allocations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xml:lang="en-US">Business Acquisition, Pro Forma Information</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncMember" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xml:lang="en-US">Network Medical Management, Inc. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Equity consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Equity consideration</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xml:lang="en-US">Business combination, step acquisition, equity interest in acquiree, fair value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interests [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Total purchase consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Total consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Total estimated purchase consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business acquisition, shares issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Multiplied by the price per share of ApolloMed&#8217;s common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">Assets acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Accounts receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Accounts receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xml:lang="en-US">Accounts receivable, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xml:lang="en-US">Other receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Assets, Restricted cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xml:lang="en-US">Restricted cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xml:lang="en-US">The amount of restricted cash recognized as of the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Identifiable intangible assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Fair value of intangible assets acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xml:lang="en-US">Deferred tax assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total fair value of assets acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">Liabilities assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Accounts payable and accrued liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Accounts payable and accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Medical Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xml:lang="en-US">Medical liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xml:lang="en-US">Amount of medical liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, NonCurrent Liabilities, Line Of Credit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xml:lang="en-US">Line of credit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xml:lang="en-US">Amount of line of credit due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, NonCurrent Liabilities, Convertible Note Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xml:lang="en-US">Convertible note payable, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xml:lang="en-US">Amount of convertible note payable due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, NonCurrent Liabilities, Convertible Note Payable To Related party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xml:lang="en-US">Convertible note payable - related party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xml:lang="en-US">Amount of convertible note payable to related party due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xml:lang="en-US">Noncontrolling interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed and noncontrolling interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net assets acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net assets acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net liabilities assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xml:lang="en-US">Net revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xml:lang="en-US">Net revenues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xml:lang="en-US">Net loss attributable to Apollo Medical Holdings, Inc.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xml:lang="en-US">Business Acquisition, Proforma Weighted Average Common Shares Outstanding, Basic [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xml:lang="en-US">Weighted average common shares outstanding:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xlink:to="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xml:lang="en-US">Business Acquisition, Proforma Weighted Average Common Shares Outstanding, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xml:lang="en-US">Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xml:lang="en-US">The proforma basic net weighted average outstanding for a period as if the business combination or combinations had been completed at the beginning of a period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xlink:to="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xml:lang="en-US">Basic income (loss) per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xml:lang="en-US">basic</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xml:lang="en-US">Business Acquisition, Proforma Earnings Per share, Basic [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xml:lang="en-US">Earnings per share:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xlink:to="lab_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xml:lang="en-US">Business Acquisition, Proforma Weighted Average Common Shares Outstanding, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xml:lang="en-US">Weighted average common shares outstanding:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xlink:to="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xml:lang="en-US">Business Acquisition, Proforma Weighted Average Common Shares Outstanding, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xml:lang="en-US">diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xml:lang="en-US">The proforma diluted net weighted average outstanding for a period as if the business combination or combinations had been completed at the beginning of a period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xlink:to="lab_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xml:lang="en-US">Business Acquisition, Proforma Earnings Per share, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xml:lang="en-US">Earnings per share:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xlink:to="lab_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xml:lang="en-US">Diluted income (loss) per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xml:lang="en-US">diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApolloMedicalHoldingsIncMember" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xlink:label="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Number of Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquire, Number of Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xml:lang="en-US">Number of shares at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xlink:to="lab_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantOneMember" xlink:label="loc_ameh_WarrantOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantOneMember" xml:lang="en-US">Warrant One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantOneMember" xlink:to="lab_ameh_WarrantOneMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantTwoMember" xlink:label="loc_ameh_WarrantTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantTwoMember" xml:lang="en-US">Warrant Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantTwoMember" xlink:to="lab_ameh_WarrantTwoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConvertiblePromissoryNoteMember" xlink:label="loc_ameh_ConvertiblePromissoryNoteMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConvertiblePromissoryNoteMember" xlink:to="lab_ameh_ConvertiblePromissoryNoteMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Shares issued in connection with convertible notes redemption (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Issuance of common stock on conversion of convertible note</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Shares issued in connection with convertible notes redemption</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationconsiderationDescription" xlink:label="loc_ameh_BusinessCombinationconsiderationDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_BusinessCombinationconsiderationDescription" xml:lang="en-US">Business Combination,Consideration Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_BusinessCombinationconsiderationDescription" xml:lang="en-US">Business Combination, Consideration Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_BusinessCombinationconsiderationDescription" xml:lang="en-US">Description of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationconsiderationDescription" xlink:to="lab_ameh_BusinessCombinationconsiderationDescription" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaAcoIncMember" xlink:label="loc_ameh_ApaAcoIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApaAcoIncMember" xml:lang="en-US">APA ACO, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaAcoIncMember" xlink:to="lab_ameh_ApaAcoIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life (years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Dividends</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentsForAgreementTermination" xlink:label="loc_ameh_PaymentsForAgreementTermination" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PaymentsForAgreementTermination" xml:lang="en-US">Payments for Agreement Termination</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_PaymentsForAgreementTermination" xml:lang="en-US">Cash payments made due to termination of agreement during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForAgreementTermination" xlink:to="lab_ameh_PaymentsForAgreementTermination" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MaverickMedicalGroupIncMember" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xml:lang="en-US">Maverick Medical Group, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationAsset" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationAsset" xml:lang="en-US">Business Combination, Contingent Consideration, Asset</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationAsset" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xml:lang="en-US">Investments in Other Entities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xml:lang="en-US">Equity Method Investments</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xml:lang="en-US">LaSalle Medical Associates - IPA Line of Business [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Cash and Cash Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xml:lang="en-US">The amount of cash and cash equivalents reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Receivables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xml:lang="en-US">The amount of receivables reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xml:lang="en-US">The amount of other current assets reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Loan Receivables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xml:lang="en-US">The amount of loan receivables reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Restricted Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xml:lang="en-US">The amount of restricted cash reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xml:lang="en-US">The amount of other assets reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Liabilities and Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Current Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Other Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xml:lang="en-US">The amount of other liabilities reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xml:lang="en-US">Equity Method Investment Summarized Financial Information, Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xml:lang="en-US">Equity Method Investment Summarized Financial Information, Stockholders&#39; deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Cost of Sales</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income Loss Before Income Taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income before provision for income taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xml:lang="en-US">The amount of income (loss) before income taxes reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income Taxes Benefit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Provision for income taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xml:lang="en-US">The amount of income taxes (benefit) reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Net Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Net (loss) income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Property And Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xml:lang="en-US">The amount of property and equipment reported by an equity method investment of the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xlink:to="lab_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Total liabilities and stockholders&#39; deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DiagnosticMedicalGroupMember" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xml:lang="en-US">Diagnostic Medical Group [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember" xml:lang="en-US">Pacific Ambulatory Surgery Center, LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:to="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementAxis" xlink:label="loc_ameh_AmendmentAgreementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AmendmentAgreementAxis" xml:lang="en-US">Amendment Agreement [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendmentAgreementAxis" xlink:to="lab_ameh_AmendmentAgreementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OwnershipAxis" xlink:to="lab_us-gaap_OwnershipAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OwnershipDomain" xlink:to="lab_us-gaap_OwnershipDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcLsmaMember" xlink:label="loc_ameh_ApcLsmaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ApcLsmaMember" xml:lang="en-US">APC LSMA [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AlliedPacificOfCaliforniaMember" xml:lang="en-US">Allied Pacific of California [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementDomain" xlink:label="loc_ameh_AmendmentAgreementDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AmendmentAgreementDomain" xml:lang="en-US">Amendment Agreement [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendmentAgreementDomain" xlink:to="lab_ameh_AmendmentAgreementDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeAxis" xlink:label="loc_ameh_ContractTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ContractTypeAxis" xml:lang="en-US">Contract Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityAmendmentAgreementApcMember" xlink:label="loc_ameh_ExclusivityAmendmentAgreementApcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ExclusivityAmendmentAgreementApcMember" xml:lang="en-US">Exclusivity Amendment Agreement, APC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ExclusivityAmendmentAgreementApcMember" xlink:to="lab_ameh_ExclusivityAmendmentAgreementApcMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractedPhysiciansAndOtherServicesMember" xlink:label="loc_ameh_ContractedPhysiciansAndOtherServicesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ContractedPhysiciansAndOtherServicesMember" xml:lang="en-US">Contracted physicians and other services [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractedPhysiciansAndOtherServicesMember" xlink:to="lab_ameh_ContractedPhysiciansAndOtherServicesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForFees" xml:lang="en-US">Payments for Other Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xml:lang="en-US">Equity Method Investments, Purchase of Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xml:lang="en-US">The number of shares purchased from equity method investment entities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForAdvanceToAffiliate" xml:lang="en-US">Payments for Advance to Affiliate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForAdvanceToAffiliate" xml:lang="en-US">Repayment of loan to affiliate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="lab_us-gaap_PaymentsForAdvanceToAffiliate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xml:lang="en-US">Loans Receivable, Basis Spread on Variable Rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeDomain" xlink:label="loc_ameh_ContractTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ContractTypeDomain" xml:lang="en-US">Contract Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AncillaryServiceContractMember" xlink:label="loc_ameh_AncillaryServiceContractMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AncillaryServiceContractMember" xml:lang="en-US">Ancillary Service Contract [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xml:lang="en-US">Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xml:lang="en-US">The proportion of investment in Voting common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:to="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Beginning balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Ending balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Options granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Shares issued for cash and exercise of options (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US">Weighted Average Per Share Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US">Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Beginning balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Ending balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoansReceivableInterestRate" xlink:label="loc_ameh_LoansReceivableInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LoansReceivableInterestRate" xml:lang="en-US">Loans Receivable, Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_LoansReceivableInterestRate" xml:lang="en-US">The interest rate for the loans receivable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoansReceivableInterestRate" xlink:to="lab_ameh_LoansReceivableInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Life (Years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Beginning Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Weighted Average Per Share Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Ending balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharesAbstract" xlink:label="loc_ameh_SharesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SharesAbstract" xml:lang="en-US">Shares [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesAbstract" xlink:to="lab_ameh_SharesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsGranted" xlink:label="loc_ameh_NumberOfWarrantsGranted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NumberOfWarrantsGranted" xml:lang="en-US">Number Of Warrants Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_NumberOfWarrantsGranted" xml:lang="en-US">Number of warrants, Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_NumberOfWarrantsGranted" xml:lang="en-US">Number Of Warrants Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsExercised" xlink:label="loc_ameh_NumberOfWarrantsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ameh_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xml:lang="en-US">Number of warrants, Cancelled</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xml:lang="en-US">Class of warrant or right, cancelled in period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageexercisePriceAbstract" xlink:label="loc_ameh_WeightedaverageexercisePriceAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WeightedaverageexercisePriceAbstract" xml:lang="en-US">Weighted Average Exercise Price [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract" xlink:to="lab_ameh_WeightedaverageexercisePriceAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xml:lang="en-US">Class Of Warrants Or Right, Exercise Price Of Warrants Grant In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xml:lang="en-US">Class Of Warrants Or Right, Exercise Price Of Warrants Exercised In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xml:lang="en-US">Class Of Warrants Or Right, Exercise Price Of Warrants Forfeited In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Exercised Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights exercised Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Forfeited Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights forfeited Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AggregateintrinsicvalueAbstract" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncNmmMember" xlink:label="loc_ameh_NetworkMedicalManagementIncNmmMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_NetworkMedicalManagementIncNmmMember" xml:lang="en-US">Network Medical Management, Inc &#39;NMM&#39; [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncNmmMember" xlink:to="lab_ameh_NetworkMedicalManagementIncNmmMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmehMember" xlink:label="loc_ameh_AmehMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AmehMember" xml:lang="en-US">AMEH [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmehMember" xlink:to="lab_ameh_AmehMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Shares issued for cash and exercise of options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Shares repurchased (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchase of common stock (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Vested and exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Vested and exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Options exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xml:lang="en-US">VIE Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xml:lang="en-US">Schedule of Variable Interest Entities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xml:lang="en-US">Variable Interest Entities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryCashCurrent" xlink:label="loc_ameh_FiduciaryCashCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_FiduciaryCashCurrent" xml:lang="en-US">Fiduciary Cash Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_FiduciaryCashCurrent" xml:lang="en-US">Fiduciary cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_FiduciaryCashCurrent" xml:lang="en-US">Represents the amount of fiduciary cash.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashCurrent" xlink:to="lab_ameh_FiduciaryCashCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="loc_us-gaap_CostMethodInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostMethodInvestments" xml:lang="en-US">Cost Method Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostMethodInvestments" xml:lang="en-US">Investments in other entities - cost method</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CostMethodInvestments" xml:lang="en-US">Investments in other entities - cost method</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMethodInvestments" xlink:to="lab_us-gaap_CostMethodInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent" xml:lang="en-US">Lease Incentive, Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent" xml:lang="en-US">Incentives payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentivePayableCurrent" xlink:to="lab_us-gaap_LeaseIncentivePayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Income taxes payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Due from Affiliate, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Due from Affiliates</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xml:lang="en-US">Amount due to affiliate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashAcquiredFromAcquisition" xlink:label="loc_ameh_RestrictedCashAcquiredFromAcquisition" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_RestrictedCashAcquiredFromAcquisition" xml:lang="en-US">Restricted Cash Acquired from Acquisition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_RestrictedCashAcquiredFromAcquisition" xml:lang="en-US">The cash inflow associated with the acquisition of business during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RestrictedCashAcquiredFromAcquisition" xlink:to="lab_ameh_RestrictedCashAcquiredFromAcquisition" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesLineItems" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Grant Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xml:lang="en-US">Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award options grant weighted average remaining contractual term.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Stock Compensation Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Common stock options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xml:lang="en-US">Claims paid for previous period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xml:lang="en-US">Line of Credit Facility, Guarantee Given by Related Parties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xml:lang="en-US">The amount of guarantee given by related parties for line of credit facility.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:to="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xlink:label="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xml:lang="en-US">Operating Loss Carryforwards, Limitation Rate on Taxable Income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xml:lang="en-US">The percentage represents the limitation of using the net operating loss carry forwards on taxable income.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xlink:to="lab_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xml:lang="en-US">Increase Decrease in Deferred Tax Assets Due To Change in Enacted Tax Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xml:lang="en-US">The amount of increase or decrease in deferred tax assets due to change in enacted tax rates.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xlink:to="lab_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FormerShareholdersOfNmmMember" xlink:label="loc_ameh_FormerShareholdersOfNmmMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_FormerShareholdersOfNmmMember" xml:lang="en-US">Former Shareholders of NMM [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FormerShareholdersOfNmmMember" xlink:to="lab_ameh_FormerShareholdersOfNmmMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xml:lang="en-US">Increase Decrease in Deferred Tax Liabilities Due To Change in Enacted Tax Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xml:lang="en-US">The amount of increase or decrease in deferred tax liabilities due to change in enacted tax rates.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xlink:to="lab_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in federal tax rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_VotingCommonStockTwoMember" xlink:label="loc_ameh_VotingCommonStockTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_VotingCommonStockTwoMember" xml:lang="en-US">Voting Common Stock A Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_VotingCommonStockTwoMember" xlink:to="lab_ameh_VotingCommonStockTwoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Brokerage money market account</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EstimatedRevenuePercentage" xlink:label="loc_ameh_EstimatedRevenuePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_EstimatedRevenuePercentage" xml:lang="en-US">Estimated Revenue Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_EstimatedRevenuePercentage" xml:lang="en-US">Estimated revenue percentage from the program of the company.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EstimatedRevenuePercentage" xlink:to="lab_ameh_EstimatedRevenuePercentage" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for services (shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationExpensesNet" xlink:label="loc_us-gaap_HealthCareOrganizationExpensesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationExpensesNet" xml:lang="en-US">Health Care Organization, Expenses, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationExpensesNet" xml:lang="en-US">Incurred health care costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationExpensesNet" xlink:to="lab_us-gaap_HealthCareOrganizationExpensesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred in Prior Periods</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xml:lang="en-US">Claims paid for current period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:to="lab_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_PacificAmbulatorySurgeryCenterMember" xml:lang="en-US">Pacific Ambulatory Surgery Center [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificAmbulatorySurgeryCenterMember" xlink:to="lab_ameh_PacificAmbulatorySurgeryCenterMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Dividends" xml:lang="en-US">Dividends</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_Dividends" xml:lang="en-US">Dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xml:lang="en-US">Dividends Payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollateralDomain" xml:lang="en-US">Collateral [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateMember" xlink:label="loc_us-gaap_RealEstateMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RealEstateMember" xml:lang="en-US">Real Estate [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateMember" xlink:to="lab_us-gaap_RealEstateMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingMember" xml:lang="en-US">Building [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" xml:lang="en-US">Debt Instrument, Maturity Date Range, Start</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeStart1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xml:lang="en-US">Debt Instrument, Maturity Date Range, End</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateRangeEnd1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xml:lang="en-US">Schedule of Prospective Adoption of New Accounting Pronouncements [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xml:lang="en-US">Schedule of Prospective Adoption of New Accounting Pronouncements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xml:lang="en-US">Adjustments for New Accounting Principle, Early Adoption [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xml:lang="en-US">Number of gross cashless options exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:to="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xml:lang="en-US">Number of net cashless options exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xlink:to="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommercialMember" xlink:label="loc_ameh_CommercialMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_CommercialMember" xml:lang="en-US">Commercial [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, warrants, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xml:lang="en-US">Number of warrants exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Warrant Issued During Period, Value, Stock Options Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Value of warrant exercise during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareMember" xlink:label="loc_ameh_MedicareMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicareMember" xml:lang="en-US">Medicare [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ameh_MedicareMember" xml:lang="en-US">Medicare</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrant, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xml:lang="en-US">The weighted-average price of warrants exercised during period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xlink:to="lab_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicaidMember" xlink:label="loc_ameh_MedicaidMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_MedicaidMember" xml:lang="en-US">Medicaid [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OtherThirdPartiesMember" xlink:label="loc_ameh_OtherThirdPartiesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_OtherThirdPartiesMember" xml:lang="en-US">Other third parties [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xml:lang="en-US">Equity, Fair Value Adjustment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" xml:lang="en-US">Fresh-Start Adjustment, Increase (Decrease), Deferred Income Tax Liabilities, Noncurrent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xlink:label="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xml:lang="en-US">All-Inclusive Population-Based Payments to be Received</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xml:lang="en-US">The amount of All-Inclusive Population-Based payments to be received.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xlink:to="lab_ameh_AllinclusivePopulationbasedPaymentsToBeReceived" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdjustmentsForMedicalLiabilities" xlink:label="loc_ameh_AdjustmentsForMedicalLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_AdjustmentsForMedicalLiabilities" xml:lang="en-US">Adjustments For Medical Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ameh_AdjustmentsForMedicalLiabilities" xml:lang="en-US">Adjustments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_AdjustmentsForMedicalLiabilities" xml:lang="en-US">Represents the amount of adjustments for medical liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdjustmentsForMedicalLiabilities" xlink:to="lab_ameh_AdjustmentsForMedicalLiabilities" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseDeferredTaxAsset" xlink:label="loc_ameh_IncreaseDecreaseDeferredTaxAsset" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ameh_IncreaseDecreaseDeferredTaxAsset" xml:lang="en-US">Increase Decrease Deferred Tax Asset</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ameh_IncreaseDecreaseDeferredTaxAsset" xml:lang="en-US">The amount of increase decrease in deferred tax assets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseDeferredTaxAsset" xlink:to="lab_ameh_IncreaseDecreaseDeferredTaxAsset" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ameh-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 15-May-2018 [03:20:28] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DocumentAndEntityInformation" roleURI="http://www.apollomed.net/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MergersAndAcquisitions" roleURI="http://www.apollomed.net/role/MergersAndAcquisitions" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntities" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntities" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#LoanReceivable" roleURI="http://www.apollomed.net/role/LoanReceivable" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BankLoanLinesOfCreditAndLoanPayableRelatedParty" roleURI="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedParty" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MezzanineAndStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CommitmentsAndContingencies" roleURI="http://www.apollomed.net/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RevenueRecognition" roleURI="http://www.apollomed.net/role/RevenueRecognition" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#VariableInterestEntitiesVies" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVies" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MergersAndAcquisitionsTables" roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MezzanineAndStockholdersEquityTables" roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RevenueRecognitionTables" roleURI="http://www.apollomed.net/role/RevenueRecognitionTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CondensedConsolidatedStatementsOfIncome" roleURI="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#VariableInterestEntitiesViesTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesViesTables" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DescriptionOfBusinessAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#PercentageOfNetRevenueAndTotalAccountsReceivableDetail" roleURI="http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail" roleURI="http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail" roleURI="http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MergersAndAcquisitionsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#TotalEstimatedPurchaseConsiderationDetail" roleURI="http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail" roleURI="http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail" roleURI="http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ProFormaCombinedHistoricalResultsDetail" roleURI="http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IntangibleAssetsNetAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfIntangibleAssetsDetail" roleURI="http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfFutureAmortizationExpenseDetail" roleURI="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#InvestmentsInOtherEntitiesEquityMethodDetail" roleURI="http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#LoanReceivableAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#AccountsPayableAndAccruedExpensesDetail" roleURI="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MedicalLiabilitiesDetail" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#MezzanineAndStockholdersEquityAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfStockOptionsActivityDetail" roleURI="http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail" roleURI="http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfWarrantDetail" roleURI="http://www.apollomed.net/role/SummaryOfWarrantDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#WarrantsDetail" roleURI="http://www.apollomed.net/role/WarrantsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#RevenueRecognitionAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DescriptionOfBusiness" roleURI="http://www.apollomed.net/role/DescriptionOfBusiness" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail" roleURI="http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#DisaggregationOfRevenueDetail" roleURI="http://www.apollomed.net/role/DisaggregationOfRevenueDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EarningsPerShareAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail" roleURI="http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SummaryOfSharesIncludedInDilutedEarningsPerShareDetail" roleURI="http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#VieAssetsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail" roleURI="http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail" />

  <roleRef xlink:type="simple" xlink:href="ameh-20180331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail" />

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DocumentAndEntityInformationAbstract" xlink:label="loc_ameh_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4939" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_LegalEntityAxis_4939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4940" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4939" xlink:to="loc_dei_EntityDomain_4940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_14" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_14" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_15" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_15" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MergersAndAcquisitions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_19" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_20" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_22" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_23" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4260" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4260" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_4261" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/LoanReceivable">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoanReceivableAbstract" xlink:label="loc_ameh_LoanReceivableAbstract_3957" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoanReceivableTextBlock" xlink:label="loc_ameh_LoanReceivableTextBlock_3958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LoanReceivableAbstract_3957" xlink:to="loc_ameh_LoanReceivableTextBlock_3958" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_25" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_26" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MedicalLiabilities">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfMedicalLiabilitiesAbstract" xlink:label="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3992" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesTextBlock" xlink:label="loc_ameh_MedicalLiabilitiesTextBlock_3993" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3992" xlink:to="loc_ameh_MedicalLiabilitiesTextBlock_3993" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedParty">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" xlink:label="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract_4006" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock" xlink:label="loc_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock_4007" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract_4006" xlink:to="loc_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock_4007" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MezzanineAndStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_37" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60" xlink:to="loc_us-gaap_StatementTable_61" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_dei_LegalEntityAxis_62" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_62" xlink:to="loc_dei_EntityDomain_63" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64" xlink:to="loc_us-gaap_ClassOfStockDomain_1356" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2887" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1356" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2887" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1356" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2956" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementLineItems_1355" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1355" xlink:to="loc_us-gaap_AssetsAbstract_65" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3658" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_RestrictedCashCurrent_3659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_3660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_3660" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3661" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3661" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3658" xlink:to="loc_us-gaap_AssetsCurrent_74" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_3662" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_3662" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_76" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_77" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_Goodwill_78" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_3663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_3663" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_3664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_LoansReceivableNet_3664" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_3665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_EquityMethodInvestments_3665" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3668" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3668" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_79" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_3670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_3662" xlink:to="loc_us-gaap_AssetsNoncurrent_3670" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_65" xlink:to="loc_us-gaap_Assets_80" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1355" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3671" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent_1347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_LinesOfCreditCurrent_1347" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_83" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncentivePayableCurrent" xlink:label="loc_ameh_IncentivePayableCurrent_3673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_IncentivePayableCurrent_3673" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_3674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_3674" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_84" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3675" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3675" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_3765" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_3765" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_3677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_3677" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3671" xlink:to="loc_us-gaap_LiabilitiesCurrent_87" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_DeferredTaxLiabilities_92" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_3679" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_3679" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DividendPayableNoncurrent" xlink:label="loc_ameh_DividendPayableNoncurrent_3680" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_ameh_DividendPayableNoncurrent_3680" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_3681" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_3681" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3682" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_3678" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3682" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_Liabilities_93" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_CommitmentsAndContingencies_94" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MezzanineEquityAbstract" xlink:label="loc_ameh_MezzanineEquityAbstract_3287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_ameh_MezzanineEquityAbstract_3287" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3683" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_3287" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3683" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_PreferredStockValue_96" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_CommonStockValue_97" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_AdditionalPaidInCapital_98" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_100" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_StockholdersEquity_101" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_MinorityInterest_102" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_103" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_104" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_41" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1436" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1436" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RevenueRecognition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4880" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4882" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4880" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4882" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_35" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3696" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3697" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3696" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4588" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4588" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4590" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_43" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_44" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_47" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_48" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2379" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2642" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_UseOfEstimates_2383" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2453" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_2380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_2380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2381" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2382" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1325" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_3827" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_3827" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_52" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1479" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1397" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2490" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_55" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MinorityInterestPolicyTextBlock" xlink:label="loc_ameh_MinorityInterestPolicyTextBlock_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_ameh_MinorityInterestPolicyTextBlock_54" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_4792" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_4792" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_56" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_106" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_106" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_106" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_110" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_3889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_106" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_3889" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_252" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_253" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_252" xlink:to="loc_us-gaap_StatementTable_253" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_253" xlink:to="loc_dei_LegalEntityAxis_254" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_254" xlink:to="loc_dei_EntityDomain_255" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_256" xlink:to="loc_us-gaap_ClassOfStockDomain_1361" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2841" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1361" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_2957" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1361" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_2957" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_253" xlink:to="loc_us-gaap_StatementLineItems_1360" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_257" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_258" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_258" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesIssued_259" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2842" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2842" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_260" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_261" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_263" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3684" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1360" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3684" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MergersAndAcquisitionsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4108" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4108" xlink:to="loc_us-gaap_StatementTable_4121" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4122" xlink:to="loc_us-gaap_ClassOfStockDomain_4123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4121" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4124" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4126" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4121" xlink:to="loc_us-gaap_StatementLineItems_4125" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4117" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombonationequityConsiderationTableTextBlock" xlink:label="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock_4118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_ameh_BusinessCombonationequityConsiderationTableTextBlock_4118" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4119" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4125" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4120" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_131" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_132" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4262" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4262" xlink:to="loc_us-gaap_StatementTable_4263" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4263" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4264" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4264" xlink:to="loc_us-gaap_ClassOfStockDomain_4265" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4263" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4266" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4271" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4270" xlink:to="loc_ameh_UniversalCareIncMember_4273" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4263" xlink:to="loc_us-gaap_StatementLineItems_4269" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_4267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4269" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_4267" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_134" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_134" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_135" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfMedicalLiabilitiesAbstract" xlink:label="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3994" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesTableTextBlockTableTextBlock" xlink:label="loc_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock_3995" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3994" xlink:to="loc_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock_3995" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_145" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_145" xlink:to="loc_us-gaap_StatementTable_4320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4321" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4321" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4321" xlink:to="loc_us-gaap_ClassOfStockDomain_4322" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4323" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4335" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4331" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4335" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementAxis" xlink:label="loc_ameh_AmendmentAgreementAxis_4326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_ameh_AmendmentAgreementAxis_4326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmendmentAgreementDomain" xlink:label="loc_ameh_AmendmentAgreementDomain_4341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AmendmentAgreementAxis_4326" xlink:to="loc_ameh_AmendmentAgreementDomain_4341" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityAmendmentAgreementApcMember" xlink:label="loc_ameh_ExclusivityAmendmentAgreementApcMember_4345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AmendmentAgreementDomain_4341" xlink:to="loc_ameh_ExclusivityAmendmentAgreementApcMember_4345" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4339" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4339" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4361" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractedPhysiciansAndOtherServicesMember" xlink:label="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4361" xlink:to="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4363" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4320" xlink:to="loc_us-gaap_StatementLineItems_4359" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4359" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_147" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4359" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_151" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RevenueRecognitionTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4883" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock_4884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4883" xlink:to="loc_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock_4884" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4885" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4883" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_413" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_413" xlink:to="loc_us-gaap_StatementTable_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_414" xlink:to="loc_dei_LegalEntityAxis_415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_415" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_414" xlink:to="loc_us-gaap_StatementLineItems_417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_RevenuesAbstract_1447" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationCapitationRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationCapitationRevenue_3694" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationCapitationRevenue_3694" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationOtherRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationOtherRevenue_3686" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationOtherRevenue_3686" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementFeesRevenue" xlink:label="loc_us-gaap_ManagementFeesRevenue_3687" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_ManagementFeesRevenue_3687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue_3858" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_HealthCareOrganizationPatientServiceRevenue_3858" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_3689" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_OtherSalesRevenueNet_3689" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_3860" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1447" xlink:to="loc_us-gaap_SalesRevenueNet_3860" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OperatingExpensesAbstract_419" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaap_CostOfServices_420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_CostOfServices_420" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_421" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_422" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_419" xlink:to="loc_us-gaap_OperatingExpenses_423" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OperatingIncomeLoss_424" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3690" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3690" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_InterestExpense_426" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3867" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3867" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_427" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_428" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_429" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_430" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_431" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_ProfitLoss_432" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_433" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_NetIncomeLoss_434" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareBasic_439" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareDiluted_440" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_443" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_EarningsPerShareAbstract_438" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_441" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_417" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_435" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EarningsPerShareTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3705" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3706" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3705" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3706" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3707" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3705" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3707" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesViesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4596" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_4597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4596" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_4597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1216" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessTable" xlink:label="loc_ameh_DescriptionOfBusinessTable_1217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1216" xlink:to="loc_ameh_DescriptionOfBusinessTable_1217" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_dei_LegalEntityAxis_1218" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1218" xlink:to="loc_dei_EntityDomain_1224" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InternationalCancerCenterIccMember" xlink:label="loc_ameh_InternationalCancerCenterIccMember_3817" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1224" xlink:to="loc_ameh_InternationalCancerCenterIccMember_3817" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_1223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_StatementScenarioAxis_1223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_1223" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_CreditFacilityAxis_2233" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2233" xlink:to="loc_us-gaap_CreditFacilityDomain_2448" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2447" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2447" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2774" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_DebtInstrumentAxis_2773" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3462" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2773" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3462" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3461" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3461" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3467" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3466" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3466" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3470" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3469" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3469" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3808" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApollomedMember" xlink:label="loc_ameh_ApollomedMember_3809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_ApollomedMember_3809" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_3814" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_3814" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3815" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3815" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterMember_4850" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3808" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterMember_4850" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DescriptionOfBusinessLineItems" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_3807" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_1217" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_3807" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2771" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2771" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3447" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_3788" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_3788" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3806" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_3807" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3806" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract" xlink:label="loc_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract_154" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationAbstract_154" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_dei_LegalEntityAxis_156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_156" xlink:to="loc_dei_EntityDomain_157" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaacoMember" xlink:label="loc_ameh_ApaacoMember_4812" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_157" xlink:to="loc_ameh_ApaacoMember_4812" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_MajorCustomersAxis_159" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_159" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_160" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_164" xlink:to="loc_us-gaap_RelatedPartyDomain_165" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_171" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_171" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_172" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_175" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_RangeAxis_179" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_179" xlink:to="loc_us-gaap_RangeMember_180" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_180" xlink:to="loc_us-gaap_MaximumMember_181" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_180" xlink:to="loc_us-gaap_MinimumMember_182" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FinancialInstrumentAxis_183" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_184" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_187" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_187" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_188" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_190" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_190" xlink:to="loc_us-gaap_EquityComponentDomain_191" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_193" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2903" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2902" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2902" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantLiabilityMember" xlink:label="loc_ameh_WarrantLiabilityMember_3145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2906" xlink:to="loc_ameh_WarrantLiabilityMember_3145" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2905" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2905" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2905" xlink:to="loc_us-gaap_SegmentDomain_3147" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3146" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3289" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3288" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3793" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3288" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3793" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3792" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3792" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4814" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3792" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4814" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_155" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_197" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_198" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_199" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_SharePrice_201" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageForDownRoundFinancing" xlink:label="loc_ameh_PercentageForDownRoundFinancing_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_PercentageForDownRoundFinancing_202" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_3135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_CashUninsuredAmount_3135" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashInterestRate" xlink:label="loc_ameh_RestrictedCashInterestRate_3639" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_RestrictedCashInterestRate_3639" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_3910" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_RestrictedCash_3910" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseInRestrictedCash_3911" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_IncreaseInRestrictedCash_3911" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3915" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3915" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_3940" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_3940" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSignificantInfluenceDescription" xlink:label="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription_3955" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_EquityMethodInvestmentSignificantInfluenceDescription_3955" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EstimatedRevenuePercentage" xlink:label="loc_ameh_EstimatedRevenuePercentage_4811" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_4813" xlink:to="loc_ameh_EstimatedRevenuePercentage_4811" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2401" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueTable" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2401" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2403" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" xlink:to="loc_us-gaap_SalesRevenueNetMember_2407" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2406" xlink:to="loc_us-gaap_AccountsReceivableMember_2408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" xlink:to="loc_us-gaap_MajorCustomersAxis_2405" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_2405" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2410" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerAMember" xlink:label="loc_ameh_CustomerAMember_2411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerAMember_2411" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerBMember" xlink:label="loc_ameh_CustomerBMember_2412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerBMember_2412" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CustomerCMember" xlink:label="loc_ameh_CustomerCMember_2413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_CustomerCMember_2413" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorDMember" xlink:label="loc_ameh_PayorDMember_2599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_PayorDMember_2599" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PayorEMember" xlink:label="loc_ameh_PayorEMember_2600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2410" xlink:to="loc_ameh_PayorEMember_2600" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsReceivableAndNetRevenueLineItems" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_2402" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_2409" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2404" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4771" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4772" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4771" xlink:to="loc_us-gaap_StatementTable_4772" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4773" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4773" xlink:to="loc_us-gaap_ClassOfStockDomain_4774" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_InvestmentTypeAxis_4778" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4779" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4778" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4779" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4780" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4780" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4782" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4782" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_4781" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4779" xlink:to="loc_us-gaap_EquitySecuritiesMember_4781" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4783" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4785" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4785" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4786" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4786" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4787" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4784" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4787" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4772" xlink:to="loc_us-gaap_StatementLineItems_4775" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4775" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4776" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4777" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3897" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3897" xlink:to="loc_us-gaap_StatementTable_3898" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3898" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3899" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3899" xlink:to="loc_us-gaap_ClassOfStockDomain_3900" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3901" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3898" xlink:to="loc_us-gaap_StatementLineItems_3901" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3902" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_3904" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_3904" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3906" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3901" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3906" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4116" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4116" xlink:to="loc_us-gaap_StatementTable_4207" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4208" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4208" xlink:to="loc_us-gaap_ClassOfStockDomain_4209" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_4245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4209" xlink:to="loc_us-gaap_CommonClassBMember_4245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4210" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4210" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApolloMedicalHoldingsIncMember" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_4213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_4213" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MaverickMedicalGroupIncMember" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_4247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4212" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_4247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4211" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantOneMember" xlink:label="loc_ameh_WarrantOneMember_4217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" xlink:to="loc_ameh_WarrantOneMember_4217" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantTwoMember" xlink:label="loc_ameh_WarrantTwoMember_4218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4216" xlink:to="loc_ameh_WarrantTwoMember_4218" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_DebtInstrumentAxis_4215" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4215" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4223" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ConvertiblePromissoryNoteMember" xlink:label="loc_ameh_ConvertiblePromissoryNoteMember_4224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4223" xlink:to="loc_ameh_ConvertiblePromissoryNoteMember_4224" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_dei_LegalEntityAxis_4222" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4222" xlink:to="loc_dei_EntityDomain_4230" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncMember" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_4231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4230" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_4231" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4229" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4229" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4233" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaAcoIncMember" xlink:label="loc_ameh_ApaAcoIncMember_4234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_4233" xlink:to="loc_ameh_ApaAcoIncMember_4234" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4232" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4232" xlink:to="loc_us-gaap_EquityComponentDomain_4238" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4238" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4239" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4238" xlink:to="loc_us-gaap_PreferredStockMember_4244" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_4237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_4237" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_4237" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4573" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4207" xlink:to="loc_us-gaap_StatementLineItems_4571" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare" xlink:label="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare_4214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare_4214" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4219" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4220" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4221" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4225" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4226" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationconsiderationDescription" xlink:label="loc_ameh_BusinessCombinationconsiderationDescription_4227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_BusinessCombinationconsiderationDescription_4227" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4228" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4235" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4236" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_4240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_4240" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_4241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_4241" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_4242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_4242" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_4243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_4243" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentsForAgreementTermination" xlink:label="loc_ameh_PaymentsForAgreementTermination_4246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_PaymentsForAgreementTermination_4246" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationAsset_4248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationAsset_4248" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseDeferredTaxAsset" xlink:label="loc_ameh_IncreaseDecreaseDeferredTaxAsset_4948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4571" xlink:to="loc_ameh_IncreaseDecreaseDeferredTaxAsset_4948" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4109" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4109" xlink:to="loc_us-gaap_StatementTable_4129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4130" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4130" xlink:to="loc_us-gaap_ClassOfStockDomain_4131" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_dei_LegalEntityAxis_4132" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4132" xlink:to="loc_dei_EntityDomain_4134" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncMember" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_4135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4134" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_4135" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4133" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4133" xlink:to="loc_us-gaap_EquityComponentDomain_4139" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4139" xlink:to="loc_us-gaap_PreferredStockMember_4140" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4139" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4141" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_4138" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_4143" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4144" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4129" xlink:to="loc_us-gaap_StatementLineItems_4142" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4136" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_4137" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4142" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4145" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4110" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4110" xlink:to="loc_us-gaap_StatementTable_4146" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4146" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4147" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4147" xlink:to="loc_us-gaap_ClassOfStockDomain_4148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4146" xlink:to="loc_us-gaap_StatementLineItems_4149" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4151" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4149" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4152" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4111" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4111" xlink:to="loc_us-gaap_StatementTable_4153" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4153" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4154" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4154" xlink:to="loc_us-gaap_ClassOfStockDomain_4155" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4153" xlink:to="loc_us-gaap_StatementLineItems_4156" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4159" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_4160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_4160" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_4161" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4162" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_4163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_4163" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4164" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent_4165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent_4165" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_4166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_4166" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_4157" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_4167" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4169" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities_4170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities_4170" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit_4171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit_4171" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable_4172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable_4172" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty_4173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty_4173" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4174" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_4168" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4175" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4176" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4156" xlink:to="loc_us-gaap_Goodwill_4177" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4112" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4112" xlink:to="loc_us-gaap_StatementTable_4178" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4178" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4179" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4179" xlink:to="loc_us-gaap_ClassOfStockDomain_4180" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4178" xlink:to="loc_us-gaap_StatementLineItems_4181" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4182" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4183" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic_4185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract_4184" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic_4185" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract_4187" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4186" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted" xlink:label="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted_4189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract_4188" xlink:to="loc_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted_4189" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract" xlink:label="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4181" xlink:to="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract_4190" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4191" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3026" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3027" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3026" xlink:to="loc_us-gaap_StatementTable_3027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3028" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3029" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3028" xlink:to="loc_us-gaap_ClassOfStockDomain_3029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3030" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_dei_LegalEntityAxis_3030" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3033" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3030" xlink:to="loc_dei_EntityDomain_3033" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3032" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3216" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3215" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3215" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3488" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3487" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExclusivityMember" xlink:label="loc_ameh_ExclusivityMember_4087" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4086" xlink:to="loc_ameh_ExclusivityMember_4087" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4079" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3027" xlink:to="loc_us-gaap_StatementLineItems_4079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition" xlink:label="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition_3031" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4079" xlink:to="loc_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition_3031" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_458" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_458" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_460" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareLicenseMember" xlink:label="loc_ameh_MedicareLicenseMember_1199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_MedicareLicenseMember_1199" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkRelationshipsMember" xlink:label="loc_ameh_NetworkRelationshipsMember_465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_NetworkRelationshipsMember_465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_us-gaap_TradeNamesMember_466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ManagementContractsMember" xlink:label="loc_ameh_ManagementContractsMember_4094" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_ManagementContractsMember_4094" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MemberRelationshipsMember" xlink:label="loc_ameh_MemberRelationshipsMember_4095" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_MemberRelationshipsMember_4095" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PatientManagementPlatformMember" xlink:label="loc_ameh_PatientManagementPlatformMember_4096" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_461" xlink:to="loc_ameh_PatientManagementPlatformMember_4096" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_467" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_467" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_3265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_3265" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_3266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3264" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_3266" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_RangeAxis_3263" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4098" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3263" xlink:to="loc_us-gaap_RangeMember_4098" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4099" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4098" xlink:to="loc_us-gaap_MaximumMember_4099" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4098" xlink:to="loc_us-gaap_MinimumMember_4100" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_459" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3173" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3191" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3184" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3195" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_3177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_3177" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4097" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3237" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_479" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_479" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_482" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_480" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_486" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_487" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_488" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2305" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4688" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_4688" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_483" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2306" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1010" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1011" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1010" xlink:to="loc_us-gaap_StatementTable_1011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1012" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_dei_LegalEntityAxis_1012" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1013" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1012" xlink:to="loc_dei_EntityDomain_1013" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1014" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_DebtInstrumentAxis_1014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1696" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1014" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1696" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1695" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1695" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1699" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1695" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1699" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1698" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1698" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1698" xlink:to="loc_us-gaap_ClassOfStockDomain_3115" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_3114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_3114" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_3932" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_3114" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_3932" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3931" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3931" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3935" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3931" xlink:to="loc_us-gaap_EquityComponentDomain_3935" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3934" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_AwardTypeAxis_3934" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3937" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1011" xlink:to="loc_us-gaap_StatementLineItems_3937" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1016" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_ProfitLoss_1016" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1018" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1018" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3271" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1020" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1020" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_3875" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_3875" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1023" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_1023" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3881" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3881" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3907" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3907" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1017" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1025" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1025" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3104" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1029" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1029" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1030" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1030" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInIncentivesPayable" xlink:label="loc_ameh_IncreaseDecreaseInIncentivesPayable_4851" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInIncentivesPayable_4851" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInMedicalLiabilities" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_1031" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_1031" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1024" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3884" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1032" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1015" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1032" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3887" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3887" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_3891" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_3891" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_3892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_3892" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProceedsFromSaleOfCostMethodInvestments" xlink:label="loc_ameh_ProceedsFromSaleOfCostMethodInvestments_3893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_ameh_ProceedsFromSaleOfCostMethodInvestments_3893" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1035" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1035" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1036" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1033" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1036" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3916" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_3916" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_3917" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_PaymentsOfDividends_3917" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1040" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_1040" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3920" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3920" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1709" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1709" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1044" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1037" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1044" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4941" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4941" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4935" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4935" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4936" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4936" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1050" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" xlink:to="loc_us-gaap_IncomeTaxesPaid_1050" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1049" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1048" xlink:to="loc_us-gaap_InterestPaidNet_1049" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CashlessExerciseOfStockOptions" xlink:label="loc_ameh_CashlessExerciseOfStockOptions_4855" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CashlessExerciseOfStockOptions_4855" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_3313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_us-gaap_StockIssued1_3313" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DeferredTaxLiabilityAdjustmentToGoodwill" xlink:label="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill_4856" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_DeferredTaxLiabilityAdjustmentToGoodwill_4856" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable_4857" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable_4857" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities" xlink:label="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities_4858" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities_4858" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2976" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1051" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2976" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3937" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4860" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4860" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4861" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4861" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4862" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_RestrictedCashCurrent_4862" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4863" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_4859" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4863" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4325" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4325" xlink:to="loc_us-gaap_StatementTable_4327" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4328" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4328" xlink:to="loc_us-gaap_ClassOfStockDomain_4329" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_VotingCommonStockTwoMember" xlink:label="loc_ameh_VotingCommonStockTwoMember_4764" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4329" xlink:to="loc_ameh_VotingCommonStockTwoMember_4764" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_4330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_OwnershipAxis_4330" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipAxis_4330" xlink:to="loc_us-gaap_OwnershipDomain_4333" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcLsmaMember" xlink:label="loc_ameh_ApcLsmaMember_4334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_4333" xlink:to="loc_ameh_ApcLsmaMember_4334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_4350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_4333" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_4350" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4332" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4332" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4338" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_4338" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4340" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4337" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4347" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4349" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_UniversalCareIncMember_4354" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DiagnosticMedicalGroupMember" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_4423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_4423" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4346" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4454" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeAxis" xlink:label="loc_ameh_ContractTypeAxis_4344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_ameh_ContractTypeAxis_4344" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractTypeDomain" xlink:label="loc_ameh_ContractTypeDomain_4378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_4344" xlink:to="loc_ameh_ContractTypeDomain_4378" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AncillaryServiceContractMember" xlink:label="loc_ameh_AncillaryServiceContractMember_4379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_4378" xlink:to="loc_ameh_AncillaryServiceContractMember_4379" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4327" xlink:to="loc_us-gaap_StatementLineItems_4377" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4356" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_4357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_4357" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4362" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_EquityMethodInvestments_4365" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4366" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_4370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsForFees_4370" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4372" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaap_PaymentsForAdvanceToAffiliate_4373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_PaymentsForAdvanceToAffiliate_4373" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_4375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_4375" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4376" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_4385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_4385" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoansReceivableInterestRate" xlink:label="loc_ameh_LoansReceivableInterestRate_4414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4377" xlink:to="loc_ameh_LoansReceivableInterestRate_4414" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4274" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4274" xlink:to="loc_us-gaap_StatementTable_4275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4276" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4275" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4276" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4276" xlink:to="loc_us-gaap_ClassOfStockDomain_4277" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4275" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4278" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4281" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4280" xlink:to="loc_ameh_UniversalCareIncMember_4300" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4275" xlink:to="loc_us-gaap_StatementLineItems_4279" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents_4283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents_4283" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables_4284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables_4284" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets_4285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets_4285" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables_4286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables_4286" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash_4287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash_4287" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets_4301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets_4301" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment_4302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment_4302" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract_4282" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4288" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_4290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_4290" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities_4303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities_4303" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_4291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_4291" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity_4292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract_4289" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity_4292" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4279" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_4293" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_4293" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_4295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_4295" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes_4296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes_4296" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit" xlink:label="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit_4297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit_4297" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_4298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4294" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_4298" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4307" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4307" xlink:to="loc_us-gaap_StatementTable_4308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4308" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4309" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4309" xlink:to="loc_us-gaap_ClassOfStockDomain_4310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4308" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4311" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_4315" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_UniversalCareIncMember_4315" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LasalleMedicalAssociatesIpaMember" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4316" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DiagnosticMedicalGroupMember" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_4317" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_4317" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4318" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_4318" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_4314" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_4319" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4312" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4308" xlink:to="loc_us-gaap_StatementLineItems_4312" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4312" xlink:to="loc_us-gaap_EquityMethodInvestments_4313" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LoanReceivableAbstract" xlink:label="loc_ameh_LoanReceivableAbstract_3960" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LoanReceivableAbstract_3960" xlink:to="loc_us-gaap_StatementTable_3961" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3962" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3962" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3963" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3962" xlink:to="loc_us-gaap_ClassOfStockDomain_3963" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3978" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3964" xlink:to="loc_us-gaap_RelatedPartyDomain_3978" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DrJayLoanMember" xlink:label="loc_ameh_DrJayLoanMember_3979" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3978" xlink:to="loc_ameh_DrJayLoanMember_3979" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3977" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_dei_LegalEntityAxis_3977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3981" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3977" xlink:to="loc_dei_EntityDomain_3981" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcMember" xlink:label="loc_ameh_ApcMember_3982" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3981" xlink:to="loc_ameh_ApcMember_3982" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NmmBusinessLoanAgreementMember" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_3983" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3981" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_3983" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3980" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3961" xlink:to="loc_us-gaap_StatementLineItems_3980" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_3966" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_LoansReceivableNet_3966" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_3967" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_LineOfCredit_3967" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_3968" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_3968" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3969" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3969" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_3970" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_3970" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_3971" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_3971" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ExtendableAmountOnCreditFacility" xlink:label="loc_ameh_ExtendableAmountOnCreditFacility_3973" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_ExtendableAmountOnCreditFacility_3973" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_TermOfManagementServiceAgreement" xlink:label="loc_ameh_TermOfManagementServiceAgreement_3975" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_TermOfManagementServiceAgreement_3975" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PercentageOfManagingResponsibleOfHealthPlanship" xlink:label="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship_3976" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3980" xlink:to="loc_ameh_PercentageOfManagingResponsibleOfHealthPlanship_3976" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_491" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_491" xlink:to="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" xlink:to="loc_dei_LegalEntityAxis_493" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_493" xlink:to="loc_dei_EntityDomain_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AccountPayableAndAccruedLiabilitiesLineItems" xlink:label="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsPayableAndAccruedLiabilitiesTable_492" xlink:to="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_3948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccountsPayableCurrent_3948" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SpecialtyCapitationPayableCurrent" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_3949" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_3949" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SubcontractorIpaRiskPoolPayable" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable_3950" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_ameh_SubcontractorIpaRiskPoolPayable_3950" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_501" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3952" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3952" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_498" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_498" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountPayableAndAccruedLiabilitiesLineItems_495" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_502" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfMedicalLiabilitiesAbstract" xlink:label="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3985" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3986" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureOfMedicalLiabilitiesAbstract_3985" xlink:to="loc_us-gaap_StatementTable_3986" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3987" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3986" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3988" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3987" xlink:to="loc_us-gaap_ClassOfStockDomain_3988" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3989" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3986" xlink:to="loc_us-gaap_StatementLineItems_3989" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_3996" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_3996" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesAddedFromMerger" xlink:label="loc_ameh_MedicalLiabilitiesAddedFromMerger_4705" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_MedicalLiabilitiesAddedFromMerger_4705" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_4944" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_4944" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationExpensesNet" xlink:label="loc_us-gaap_HealthCareOrganizationExpensesNet_4846" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_HealthCareOrganizationExpensesNet_4846" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods" xlink:label="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_4945" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods_4945" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdjustmentsForMedicalLiabilities" xlink:label="loc_ameh_AdjustmentsForMedicalLiabilities_4001" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_AdjustmentsForMedicalLiabilities_4001" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_4002" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3989" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_4002" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract" xlink:label="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract_4008" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4009" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract_4008" xlink:to="loc_us-gaap_StatementTable_4009" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4010" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4010" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4011" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4010" xlink:to="loc_us-gaap_ClassOfStockDomain_4011" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4012" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_dei_LegalEntityAxis_4012" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4014" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4012" xlink:to="loc_dei_EntityDomain_4014" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IccMember" xlink:label="loc_ameh_IccMember_4015" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_IccMember_4015" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcMember" xlink:label="loc_ameh_ApcMember_4016" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApcMember_4016" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NmmBusinessLoanAgreementMember" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_4017" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_4017" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcBusinessLoanAgreementMember" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_4018" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_4018" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApaacoMember" xlink:label="loc_ameh_ApaacoMember_4021" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4014" xlink:to="loc_ameh_ApaacoMember_4021" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4013" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4013" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4013" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4025" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4024" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_DebtInstrumentAxis_4024" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4031" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4024" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4031" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4027" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_InvestmentTypeAxis_4027" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4084" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4027" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4084" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4085" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4084" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4085" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4083" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4083" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4083" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4809" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4810" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4809" xlink:to="loc_us-gaap_SubsequentEventMember_4810" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4009" xlink:to="loc_us-gaap_StatementLineItems_4808" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4042" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4042" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4043" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4043" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4044" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4044" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_4060" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_4060" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4065" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4065" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_4066" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_4066" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_4067" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_4067" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_4068" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCredit_4068" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4069" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4069" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_4078" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDescription_4078" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_4093" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_4093" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_4713" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_4713" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_4873" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeStart1_4873" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_4874" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4808" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateRangeEnd1_4874" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4390" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4390" xlink:to="loc_us-gaap_StatementTable_4491" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4492" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4492" xlink:to="loc_us-gaap_ClassOfStockDomain_4493" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4494" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4496" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4494" xlink:to="loc_us-gaap_EquityComponentDomain_4496" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4495" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NetworkMedicalManagementIncNmmMember" xlink:label="loc_ameh_NetworkMedicalManagementIncNmmMember_4505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_NetworkMedicalManagementIncNmmMember_4505" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmehMember" xlink:label="loc_ameh_AmehMember_4506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_AmehMember_4506" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4504" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4655" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4503" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4503" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4534" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_4533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_TitleOfIndividualAxis_4533" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_4533" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FormerShareholdersOfNmmMember" xlink:label="loc_ameh_FormerShareholdersOfNmmMember_4723" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_4540" xlink:to="loc_ameh_FormerShareholdersOfNmmMember_4723" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4538" xlink:to="loc_us-gaap_RelatedPartyDomain_4543" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4542" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4546" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4545" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4626" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4625" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_PlanNameAxis_4625" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4625" xlink:to="loc_us-gaap_PlanNameDomain_4674" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_AwardTypeAxis_4673" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4673" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_4700" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4678" xlink:to="loc_us-gaap_StockCompensationPlanMember_4700" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_dei_LegalEntityAxis_4677" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4708" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4677" xlink:to="loc_dei_EntityDomain_4708" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_4707" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_VestingAxis_4707" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_4718" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_4707" xlink:to="loc_us-gaap_VestingDomain_4718" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4716" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4716" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4730" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4716" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4730" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_4729" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_RangeAxis_4729" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4823" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_4729" xlink:to="loc_us-gaap_RangeMember_4823" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4824" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4823" xlink:to="loc_us-gaap_MinimumMember_4824" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4825" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4823" xlink:to="loc_us-gaap_MaximumMember_4825" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4822" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4832" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4491" xlink:to="loc_us-gaap_StatementLineItems_4831" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4512" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_4515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_4515" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_4528" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_4528" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4603" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4698" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4698" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_4699" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_4699" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4711" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4728" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_SharesOutstanding_4728" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4836" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4836" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4899" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod_4903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod_4903" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet_4905" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet_4905" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4909" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4909" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod_4917" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod_4917" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_4919" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_4919" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice" xlink:label="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice_4921" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4831" xlink:to="loc_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice_4921" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4386" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4386" xlink:to="loc_us-gaap_StatementTable_4391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4392" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4392" xlink:to="loc_us-gaap_ClassOfStockDomain_4393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_4394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_4394" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_4396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_4394" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_4396" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_4395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_OwnershipAxis_4395" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_4400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipAxis_4395" xlink:to="loc_us-gaap_OwnershipDomain_4400" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AlliedPacificOfCaliforniaMember" xlink:label="loc_ameh_AlliedPacificOfCaliforniaMember_4401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_4400" xlink:to="loc_ameh_AlliedPacificOfCaliforniaMember_4401" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_4399" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_4521" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4523" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4520" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4391" xlink:to="loc_us-gaap_StatementLineItems_4520" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4403" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4405" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4539" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4407" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4408" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4417" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4410" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4411" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4549" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4413" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4415" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_4409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4416" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4419" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_4418" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4563" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4520" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4552" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4562" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4561" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_4425" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4553" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4565" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4565" xlink:to="loc_us-gaap_StatementTable_4566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4566" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4567" xlink:to="loc_us-gaap_ClassOfStockDomain_4568" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4566" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4569" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4569" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4577" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ContractedPhysiciansAndOtherServicesMember" xlink:label="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4578" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4577" xlink:to="loc_ameh_ContractedPhysiciansAndOtherServicesMember_4578" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4566" xlink:to="loc_us-gaap_StatementLineItems_4576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4576" xlink:to="loc_us-gaap_ShareBasedCompensation_4574" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfWarrantDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4389" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4456" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4389" xlink:to="loc_us-gaap_StatementTable_4456" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4456" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4457" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4457" xlink:to="loc_us-gaap_ClassOfStockDomain_4458" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4459" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4456" xlink:to="loc_us-gaap_StatementLineItems_4459" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_SharesAbstract" xlink:label="loc_ameh_SharesAbstract_4460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_SharesAbstract_4460" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4461" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsGranted" xlink:label="loc_ameh_NumberOfWarrantsGranted_4463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_NumberOfWarrantsGranted_4463" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_NumberOfWarrantsExercised" xlink:label="loc_ameh_NumberOfWarrantsExercised_4464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_NumberOfWarrantsExercised_4464" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_4465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_4465" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesAbstract_4460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4466" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageexercisePriceAbstract" xlink:label="loc_ameh_WeightedaverageexercisePriceAbstract_4467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_WeightedaverageexercisePriceAbstract_4467" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4468" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4468" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod_4470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod_4470" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod_4471" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod_4471" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod_4472" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod_4472" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageexercisePriceAbstract_4467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4473" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_4478" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm_4479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm_4479" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm_4480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm_4480" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_4481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_4474" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_4481" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AggregateintrinsicvalueAbstract" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_4482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4459" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_4482" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4484" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_4486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_4486" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_4487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_4487" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4488" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4489" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_4482" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_4489" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/WarrantsDetail">
    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DisclosureWarrantsAbstract" xlink:label="loc_ameh_DisclosureWarrantsAbstract_985" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_986" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DisclosureWarrantsAbstract_985" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_986" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_987" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_dei_LegalEntityAxis_987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_988" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_988" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_989" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeOneMember" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_993" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_993" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeTwoMember" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_994" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_994" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeThreeMember" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_995" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_995" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFourMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_996" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_996" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_WarrantExercisePriceRangeFiveMember" xlink:label="loc_ameh_WarrantExercisePriceRangeFiveMember_997" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_990" xlink:to="loc_ameh_WarrantExercisePriceRangeFiveMember_997" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1003" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_us-gaap_RangeAxis_1003" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3054" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1003" xlink:to="loc_us-gaap_RangeMember_3054" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_986" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_1005" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_1005" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1006" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1006" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisable" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_1007" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_1007" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights_1008" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3053" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights_1008" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1157" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesTable" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_1158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1157" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_1158" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_dei_LegalEntityAxis_1159" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1159" xlink:to="loc_dei_EntityDomain_1161" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1160" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1855" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesAxis" xlink:label="loc_ameh_ProfessionalFeesAxis_2537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_ameh_ProfessionalFeesAxis_2537" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ProfessionalFeesDomain" xlink:label="loc_ameh_ProfessionalFeesDomain_2548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ProfessionalFeesAxis_2537" xlink:to="loc_ameh_ProfessionalFeesDomain_2548" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1854" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1854" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1854" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1921" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2547" xlink:to="loc_us-gaap_RelatedPartyDomain_2602" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2601" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2860" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2859" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_RangeAxis_2859" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2866" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2859" xlink:to="loc_us-gaap_RangeMember_2866" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_2865" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_3152" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_3151" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_3332" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_3331" xlink:to="loc_us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain_3343" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_CreditFacilityAxis_3342" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3500" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3342" xlink:to="loc_us-gaap_CreditFacilityDomain_3500" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3499" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3499" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3499" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3510" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3509" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4691" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3509" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4691" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4692" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4691" xlink:to="loc_us-gaap_SubsequentEventMember_4692" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommitmentsAndContingenciesLineItems" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_4690" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_1158" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_4690" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_4689" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_4690" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_4689" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1686" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1687" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1686" xlink:to="loc_us-gaap_StatementTable_1687" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1688" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_DebtInstrumentAxis_1688" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1689" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1688" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1689" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1690" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_dei_LegalEntityAxis_1690" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1692" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1690" xlink:to="loc_dei_EntityDomain_1692" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1691" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1691" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1691" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2983" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementAxis" xlink:label="loc_ameh_AgreementAxis_2982" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_ameh_AgreementAxis_2982" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AgreementDomain" xlink:label="loc_ameh_AgreementDomain_3120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AgreementAxis_2982" xlink:to="loc_ameh_AgreementDomain_3120" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3119" xlink:to="loc_us-gaap_RelatedPartyDomain_3123" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RobMikitarianMember" xlink:label="loc_ameh_RobMikitarianMember_3124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_RobMikitarianMember_3124" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_UniversalCareIncMember" xlink:label="loc_ameh_UniversalCareIncMember_3764" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_UniversalCareIncMember_3764" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_3771" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_3771" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalPropertyPartnersMember" xlink:label="loc_ameh_MedicalPropertyPartnersMember_3778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_MedicalPropertyPartnersMember_3778" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalInvestmentGroupLlcMember" xlink:label="loc_ameh_MedicalInvestmentGroupLlcMember_3779" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_MedicalInvestmentGroupLlcMember_3779" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ApcShareholdersMember" xlink:label="loc_ameh_ApcShareholdersMember_3780" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_ApcShareholdersMember_3780" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ShareholdersAndOfficersMember" xlink:label="loc_ameh_ShareholdersAndOfficersMember_3781" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3123" xlink:to="loc_ameh_ShareholdersAndOfficersMember_3781" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaap_ReceivableTypeDomain_3132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3122" xlink:to="loc_us-gaap_ReceivableTypeDomain_3132" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableMember" xlink:label="loc_us-gaap_NotesReceivableMember_3133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_3132" xlink:to="loc_us-gaap_NotesReceivableMember_3133" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3131" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3131" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3241" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3240" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3240" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3479" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3478" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3769" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3478" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3769" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_ServiceMember" xlink:label="loc_ameh_ServiceMember_3770" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3769" xlink:to="loc_ameh_ServiceMember_3770" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_3768" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_3768" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_3768" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3773" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LmaMember" xlink:label="loc_ameh_LmaMember_3774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_LmaMember_3774" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PmiocMember" xlink:label="loc_ameh_PmiocMember_3775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_PmiocMember_3775" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AmgIncMember" xlink:label="loc_ameh_AmgIncMember_3776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_AmgIncMember_3776" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_DmgMember" xlink:label="loc_ameh_DmgMember_3777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3773" xlink:to="loc_ameh_DmgMember_3777" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3772" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1687" xlink:to="loc_us-gaap_StatementLineItems_3772" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3128" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3129" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_3130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_3130" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3486" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_PaymentMadeToRelatedParty" xlink:label="loc_ameh_PaymentMadeToRelatedParty_3766" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_ameh_PaymentMadeToRelatedParty_3766" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3767" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3772" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3767" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4924" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4925" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4924" xlink:to="loc_us-gaap_StatementTable_4925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4926" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4925" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4927" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4926" xlink:to="loc_us-gaap_ClassOfStockDomain_4927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4925" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4952" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4928" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_4953" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4952" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_4953" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4925" xlink:to="loc_us-gaap_StatementLineItems_4951" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaap_EquityFairValueAdjustment_4929" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_EquityFairValueAdjustment_4929" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_4930" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_4930" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent_4931" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent_4931" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4932" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4932" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AllinclusivePopulationbasedPaymentsToBeReceived" xlink:label="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived_4934" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_ameh_AllinclusivePopulationbasedPaymentsToBeReceived_4934" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4954" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4951" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4954" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DescriptionOfBusiness">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1138" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1138" xlink:to="loc_us-gaap_NatureOfOperations_1139" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4887" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4888" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4887" xlink:to="loc_us-gaap_StatementTable_4888" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4888" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4889" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4890" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4889" xlink:to="loc_us-gaap_ClassOfStockDomain_4890" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4888" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4895" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4891" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4895" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_4896" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4895" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_4896" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_4897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4895" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_4897" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4888" xlink:to="loc_us-gaap_StatementLineItems_4894" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4892" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4892" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4893" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4898" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4900" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MezzanineEquityAbstract" xlink:label="loc_ameh_MezzanineEquityAbstract_4901" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_ameh_MezzanineEquityAbstract_4901" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4904" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_4901" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4904" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4894" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4908" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4906" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4908" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/DisaggregationOfRevenueDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4886" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4910" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4886" xlink:to="loc_us-gaap_StatementTable_4910" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4911" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4910" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4911" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4912" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4911" xlink:to="loc_us-gaap_ClassOfStockDomain_4912" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_4913" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4910" xlink:to="loc_us-gaap_MajorCustomersAxis_4913" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_4915" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_4913" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_4915" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_CommercialMember" xlink:label="loc_ameh_CommercialMember_4916" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_CommercialMember_4916" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicareMember" xlink:label="loc_ameh_MedicareMember_4920" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_MedicareMember_4920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicaidMember" xlink:label="loc_ameh_MedicaidMember_4922" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_MedicaidMember_4922" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OtherThirdPartiesMember" xlink:label="loc_ameh_OtherThirdPartiesMember_4923" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_4915" xlink:to="loc_ameh_OtherThirdPartiesMember_4923" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4914" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4910" xlink:to="loc_us-gaap_StatementLineItems_4914" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_4918" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4914" xlink:to="loc_us-gaap_SalesRevenueNet_4918" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2092" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2097" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2092" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2097" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2098" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_RangeAxis_2098" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2099" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2098" xlink:to="loc_us-gaap_RangeMember_2099" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_dei_LegalEntityAxis_2100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2100" xlink:to="loc_dei_EntityDomain_2121" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2120" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2120" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_StatementScenarioAxis_2585" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_4047" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2585" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_4047" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_4048" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_4047" xlink:to="loc_us-gaap_ScenarioPlanMember_4048" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2097" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2130" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome" xlink:label="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome_4717" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome_4717" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate_4722" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate_4722" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate" xlink:label="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate_4724" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate_4724" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4725" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4046" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_4725" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3741" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3742" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3741" xlink:to="loc_us-gaap_StatementTable_3742" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3743" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3742" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3743" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3744" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3743" xlink:to="loc_us-gaap_ClassOfStockDomain_3744" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3742" xlink:to="loc_us-gaap_StatementLineItems_3745" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares" xlink:label="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares_3746" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3745" xlink:to="loc_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares_3746" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3703" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3708" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3703" xlink:to="loc_us-gaap_StatementTable_3708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3709" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3708" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3710" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3709" xlink:to="loc_us-gaap_ClassOfStockDomain_3710" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3708" xlink:to="loc_us-gaap_StatementLineItems_3711" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3712" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_EarningsPerShareBasic_3712" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3714" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3714" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3716" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3716" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3717" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3711" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3717" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3718" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3719" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3718" xlink:to="loc_us-gaap_StatementTable_3719" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3720" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3720" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3721" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3720" xlink:to="loc_us-gaap_ClassOfStockDomain_3721" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3722" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3722" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3724" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3722" xlink:to="loc_us-gaap_EquityComponentDomain_3724" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3725" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3724" xlink:to="loc_us-gaap_CommonStockMember_3725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_3737" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3724" xlink:to="loc_us-gaap_WarrantMember_3737" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3723" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4744" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4743" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3719" xlink:to="loc_us-gaap_StatementLineItems_4743" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3738" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3738" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3739" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_3739" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3740" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4743" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3740" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1141" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1141" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4679" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4680" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4679" xlink:to="loc_us-gaap_StatementTable_4680" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4681" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4680" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4681" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4682" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4681" xlink:to="loc_us-gaap_ClassOfStockDomain_4682" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4683" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4680" xlink:to="loc_us-gaap_StatementLineItems_4683" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_RestrictedCashAcquiredFromAcquisition" xlink:label="loc_ameh_RestrictedCashAcquiredFromAcquisition_4685" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4683" xlink:to="loc_ameh_RestrictedCashAcquiredFromAcquisition_4685" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4598" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4598" xlink:to="loc_us-gaap_StatementTable_4599" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4599" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4600" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4600" xlink:to="loc_us-gaap_ClassOfStockDomain_4601" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4599" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_4602" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4608" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4609" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4599" xlink:to="loc_us-gaap_StatementLineItems_4607" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_4604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_AssetsAbstract_4604" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4605" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4606" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4606" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_RestrictedCashCurrent_4610" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryCashCurrent" xlink:label="loc_ameh_FiduciaryCashCurrent_4614" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_ameh_FiduciaryCashCurrent_4614" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4617" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4618" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4618" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4619" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4605" xlink:to="loc_us-gaap_AssetsCurrent_4620" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_4622" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_4622" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4627" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4627" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4630" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4630" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_Goodwill_4632" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_4633" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansReceivableNet" xlink:label="loc_us-gaap_LoansReceivableNet_4634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_LoansReceivableNet_4634" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_4635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_EquityMethodInvestments_4635" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="loc_us-gaap_CostMethodInvestments_4636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_CostMethodInvestments_4636" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4828" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4828" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4829" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4829" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_4830" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_4622" xlink:to="loc_us-gaap_AssetsNoncurrent_4830" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4641" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4604" xlink:to="loc_us-gaap_Assets_4641" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4644" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4648" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_4650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_4650" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_FiduciaryAccountsPayableCurrent" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_4652" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_4652" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_MedicalLiabilitiesCurrent" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_4654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_4654" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_TaxesPayableCurrent_4656" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueFromAffiliateCurrent" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_4657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_4657" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_4658" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_4659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_4659" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4662" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4644" xlink:to="loc_us-gaap_LiabilitiesCurrent_4662" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4665" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ameh-20180331.xsd#ameh_LiabilityForUnissuedEquitySharesNoncurrent" xlink:label="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_4666" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_ameh_LiabilityForUnissuedEquitySharesNoncurrent_4666" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_4667" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_4667" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_4664" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4670" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4607" xlink:to="loc_us-gaap_Liabilities_4671" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1076" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1077" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1076" xlink:to="loc_us-gaap_StatementTable_1077" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1078" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1078" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1079" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1078" xlink:to="loc_us-gaap_ClassOfStockDomain_1079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1080" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1081" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1080" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1081" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1082" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1081" xlink:to="loc_us-gaap_SubsequentEventMember_1082" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1083" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_DebtInstrumentAxis_1083" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1084" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1083" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1084" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1089" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1089" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1090" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1089" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1090" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1092" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_CreditFacilityAxis_1092" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1093" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1092" xlink:to="loc_us-gaap_CreditFacilityDomain_1093" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1106" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1106" xlink:to="loc_us-gaap_EquityComponentDomain_1107" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1110" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1111" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_dei_LegalEntityAxis_1116" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1116" xlink:to="loc_dei_EntityDomain_1653" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralAxis" xlink:label="loc_us-gaap_CollateralAxis_1651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_CollateralAxis_1651" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollateralDomain" xlink:label="loc_us-gaap_CollateralDomain_4868" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_1651" xlink:to="loc_us-gaap_CollateralDomain_4868" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateMember" xlink:label="loc_us-gaap_RealEstateMember_4869" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_4868" xlink:to="loc_us-gaap_RealEstateMember_4869" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_4872" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4871" xlink:to="loc_us-gaap_BuildingMember_4872" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4870" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1077" xlink:to="loc_us-gaap_SubsequentEventLineItems_4870" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1847" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1847" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_4864" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_Dividends_4864" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_4865" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_4865" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_4866" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4870" xlink:to="loc_us-gaap_AreaOfLand_4866" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788826176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 09, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,334,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790190480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,731,761<span></span>
</td>
<td class="nump">$ 99,749,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term</a></td>
<td class="nump">18,028,116<span></span>
</td>
<td class="nump">18,005,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Fiduciary cash</a></td>
<td class="nump">1,386,474<span></span>
</td>
<td class="nump">2,017,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">1,138,477<span></span>
</td>
<td class="nump">1,143,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">52,805,123<span></span>
</td>
<td class="nump">20,117,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,525,437<span></span>
</td>
<td class="nump">3,126,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">180,615,388<span></span>
</td>
<td class="nump">144,159,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="nump">13,700,034<span></span>
</td>
<td class="nump">13,814,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">99,138,657<span></span>
</td>
<td class="nump">103,533,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">188,933,191<span></span>
</td>
<td class="nump">189,847,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Loans receivable - related parties</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loan receivable</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities - equity method</a></td>
<td class="nump">21,875,500<span></span>
</td>
<td class="nump">21,903,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">745,293<span></span>
</td>
<td class="nump">745,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,585,850<span></span>
</td>
<td class="nump">1,632,406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">340,978,525<span></span>
</td>
<td class="nump">346,476,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">521,593,913<span></span>
</td>
<td class="nump">490,635,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Lines of credit</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,110,530<span></span>
</td>
<td class="nump">13,279,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncentivePayableCurrent', window );">Incentives payable</a></td>
<td class="nump">14,900,000<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,386,474<span></span>
</td>
<td class="nump">2,017,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="nump">69,110,826<span></span>
</td>
<td class="nump">63,972,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">7,614,669<span></span>
</td>
<td class="nump">3,198,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loan, short-term</a></td>
<td class="nump">394,783<span></span>
</td>
<td class="nump">510,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td>
<td class="nump">99,480<span></span>
</td>
<td class="nump">98,738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">110,616,762<span></span>
</td>
<td class="nump">109,601,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">30,055,819<span></span>
</td>
<td class="nump">24,916,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LiabilityForUnissuedEquitySharesNoncurrent', window );">Liability for unissued equity shares</a></td>
<td class="nump">1,185,025<span></span>
</td>
<td class="nump">1,185,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DividendPayableNoncurrent', window );">Dividends payable</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current portion</a></td>
<td class="nump">593,852<span></span>
</td>
<td class="nump">619,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">49,834,696<span></span>
</td>
<td class="nump">44,720,624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">160,451,458<span></span>
</td>
<td class="nump">154,322,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Pacific of California IPA (&#8220;APC&#8221;)</a></td>
<td class="nump">190,654,312<span></span>
</td>
<td class="nump">172,129,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001; 100,000,000 shares authorized, 32,652,295 and 32,304,876 shares outstanding, excluding 1,682,110 shares held by APC, at March 31, 2018 and December 31, 2017, respectively (see Note 10)</a></td>
<td class="nump">32,653<span></span>
</td>
<td class="nump">32,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">160,736,190<span></span>
</td>
<td class="nump">158,181,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">4,897,454<span></span>
</td>
<td class="nump">1,734,531<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent</a></td>
<td class="nump">165,666,297<span></span>
</td>
<td class="nump">159,948,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">4,821,846<span></span>
</td>
<td class="nump">4,235,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">170,488,143<span></span>
</td>
<td class="nump">164,183,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and stockholders&#8217; equity</a></td>
<td class="nump">521,593,913<span></span>
</td>
<td class="nump">490,635,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DividendPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the noncurrent portion of the liabilities (due after one year or beyond the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DividendPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Incentives to be paid and reflects the noncurrent portion of the liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LiabilityForUnissuedEquitySharesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for unissued equity shares classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LiabilityForUnissuedEquitySharesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788800528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">32,652,295<span></span>
</td>
<td class="nump">32,304,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="nump">1,682,110<span></span>
</td>
<td class="nump">1,682,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790154240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationCapitationRevenue', window );">Capitation, net</a></td>
<td class="nump">$ 85,905,284<span></span>
</td>
<td class="nump">$ 64,716,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationOtherRevenue', window );">Risk pool settlements and incentives</a></td>
<td class="nump">17,986,736<span></span>
</td>
<td class="nump">11,137,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeesRevenue', window );">Management fee income</a></td>
<td class="nump">12,074,572<span></span>
</td>
<td class="nump">6,537,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Fee-for-service, net</a></td>
<td class="nump">7,748,109<span></span>
</td>
<td class="nump">2,663,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other income</a></td>
<td class="nump">452,026<span></span>
</td>
<td class="nump">281,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
<td class="nump">124,166,727<span></span>
</td>
<td class="nump">85,336,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of services</a></td>
<td class="nump">84,670,608<span></span>
</td>
<td class="nump">59,607,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">11,735,898<span></span>
</td>
<td class="nump">5,211,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,058,512<span></span>
</td>
<td class="nump">4,836,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">101,465,018<span></span>
</td>
<td class="nump">69,655,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">22,701,709<span></span>
</td>
<td class="nump">15,680,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="num">(28,024)<span></span>
</td>
<td class="nump">2,227,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(85,001)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">269,818<span></span>
</td>
<td class="nump">182,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,522,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">87,993<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">244,786<span></span>
</td>
<td class="nump">3,932,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before provision for income taxes</a></td>
<td class="nump">22,946,495<span></span>
</td>
<td class="nump">19,613,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">7,228,840<span></span>
</td>
<td class="nump">7,889,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">15,717,655<span></span>
</td>
<td class="nump">11,723,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">13,557,200<span></span>
</td>
<td class="nump">7,374,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 2,160,455<span></span>
</td>
<td class="nump">$ 4,349,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">32,421,467<span></span>
</td>
<td class="nump">25,067,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">38,098,373<span></span>
</td>
<td class="nump">28,445,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationCapitationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized based on fees charged on a per capita basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8200-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationCapitationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of health care revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052803&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68054470&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, comprised of base and incentive revenue derived from the management of joint ventures, managing third-party properties, or another entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789467168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 15,717,655<span></span>
</td>
<td class="nump">$ 11,723,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,058,512<span></span>
</td>
<td class="nump">4,836,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">41,782<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">833,944<span></span>
</td>
<td class="nump">321,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss from investment in equity securities</a></td>
<td class="nump">8,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,522,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss (income) from equity method investments</a></td>
<td class="nump">28,024<span></span>
</td>
<td class="num">(2,227,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax</a></td>
<td class="nump">2,807,407<span></span>
</td>
<td class="nump">2,109,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable, net</a></td>
<td class="num">(21,087,819)<span></span>
</td>
<td class="nump">14,410,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(398,571)<span></span>
</td>
<td class="num">(428,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(59,444)<span></span>
</td>
<td class="num">(54,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,169,363)<span></span>
</td>
<td class="num">(2,350,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInIncentivesPayable', window );">Incentives payable</a></td>
<td class="num">(6,600,000)<span></span>
</td>
<td class="num">(9,721,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">5,138,508<span></span>
</td>
<td class="num">(257,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">4,416,174<span></span>
</td>
<td class="nump">4,267,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,735,359<span></span>
</td>
<td class="nump">21,105,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(3,932)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Advances to related parties - loans receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividends received from equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromSaleOfCostMethodInvestments', window );">Proceeds on sale of investments - cost method</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(485,121)<span></span>
</td>
<td class="num">(318,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(489,053)<span></span>
</td>
<td class="num">(4,295,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of bank loan</a></td>
<td class="num">(140,608)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(8,750,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Change in noncontrolling interest capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
<td class="num">(24,407)<span></span>
</td>
<td class="num">(30,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="nump">1,923,784<span></span>
</td>
<td class="nump">425,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(241,231)<span></span>
</td>
<td class="num">(8,383,455)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,005,075<span></span>
</td>
<td class="nump">8,427,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">118,500,095<span></span>
</td>
<td class="nump">54,925,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">122,505,170<span></span>
</td>
<td class="nump">63,352,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,511,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">73,610<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashlessExerciseOfStockOptions', window );">Cashless exercise of stock options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Reclassification of stock options exercised to liability for unissued common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">425,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilityAdjustmentToGoodwill', window );">Deferred tax liability adjustment to goodwill</a></td>
<td class="nump">914,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable', window );">Cumulative effect adjustment for ASC 606 included in accounts receivable</a></td>
<td class="nump">11,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities', window );">Cumulative effect adjustment for ASC 606 included in deferred tax liabilities</a></td>
<td class="nump">3,246,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Reclassification of fiduciary cash to payable</a></td>
<td class="nump">630,963<span></span>
</td>
<td class="nump">32,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">103,731,761<span></span>
</td>
<td class="nump">63,251,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term - letters of credit</a></td>
<td class="nump">745,293<span></span>
</td>
<td class="nump">101,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term - distributions to former NMM shareholders</a></td>
<td class="nump">18,028,116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 122,505,170<span></span>
</td>
<td class="nump">$ 63,352,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents cashless exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the cumulative effect adjustment included in accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CumulativeEffectAdjustmentIncludedInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the cumulative effect adjustment included in deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilityAdjustmentToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the deferred tax liability adjustment to goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilityAdjustmentToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInIncentivesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in incentives payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInIncentivesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromSaleOfCostMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of cost method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromSaleOfCostMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780211408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 1.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Description of Business</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Overview</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the &#8220;Merger Agreement&#8221;) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (&#8220;NMM&#8221;), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the &#8220;Merger&#8221;). The Merger closed and became effective on December 8, 2017 (the &#8220;Closing&#8221;) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM&#8217;s historical results of operations replaced ApolloMed&#8217;s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed&#8217;s board of directors approved a change in ApolloMed&#8217;s fiscal year end from March 31 to December 31, to correspond with NMM&#8217;s fiscal year end prior to the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (&#8220;HMOs&#8221;), with a small portion of the Company&#8217;s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (&#8220;AMM&#8221;), APA ACO, Inc. (&#8220;APAACO&#8221;) and Apollo Care Connect, Inc. (&#8220;Apollo Care Connect&#8221;), and their consolidated entities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">NMM was formed in 1994 as a management service organization (&#8220;MSO&#8221;) for the purposes of providing management services to medical companies and independent practice associations (&#8220;IPAs&#8221;). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;) was incorporated on August&#160;17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations (&#8220;HMOs&#8221;) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On July&#160;1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (&#8220;VIE&#8221;) as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation of the APC Joint Planning Board; therefore APC is consolidated by NMM. As of March 31, 2018 and December 31, 2017, APC had an ownership interest of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.90</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.95</font>% in ApolloMed, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed on March&#160;25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">625,000</font> for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 41.59</font>% ownership in CDSC. Due to capital stock changes in 2016, APC&#8217;s ownership percentage in CDSC&#8217;s capital stock changed to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43.80</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43.43</font>% on May&#160;31, 2016 and July&#160;31, 2016, respectively. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC also holds a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% ownership interest in Pacific Ambulatory Surgery Center, LLC (&#8220;PASC&#8221;), a multi-specialty outpatient surgery center.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC-LSMA was formed on October&#160;15, 2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes: The IPA line of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center (&#8220;ICC&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November&#160;15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% of the aggregate issued and outstanding shares of capital stock of ICC for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> in cash. Certain requirements to complete the investment transaction was completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to receive benefits that could potentially be significant to ICC. The results of operations of ICC from October 31, 2017 to December 31, 2017 were de minimis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% owned subsidiary of APC, was formed on June&#160;4, 2014, for the purpose of holding the investment in Universal Care, Inc. (&#8220;UCI&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APAACO, jointly owned by NMM and AMM, participates in the next generation accountable care organization model (&#8220;NGACO Model&#8221;) of the Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (&#8220;ACOs&#8221;) that participated in the Medicare Shared Savings Program (&#8220;MSSP&#8221;), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an &#8220;all or nothing&#8221; basis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (&#8220;ApolloMed ACO&#8221;) to participate in the MSSP.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On November&#160;11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (&#8220;APCN-ACO&#8221;) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January&#160;8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On December&#160;18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (&#8220;AP-ACO&#8221;) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December&#160;20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As the Company is transitioning to the NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. Effective on December 31, 2017, APCN-ACO&#8217;s MSSP participation agreement with CMS was terminated. Effective on December 31, 2016, AP-ACO&#8217;s MSSP participation agreement with CMS was terminated. Effective on December 31, 2017, ApolloMed ACO&#8217;s MSSP participation agreement with CMS was terminated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of Maverick Medical Group, Inc. (&#8220;MMG&#8221;). MMG has historically been included in the consolidated financial statements filed by ApolloMed.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (&#8220;AMH&#8221;), a hospitalist company, Southern California Heart Centers (&#8220;SCHC&#8221;), Bay Area Hospitalist Associates (&#8220;BAHA&#8221;), a medical corporation, ApolloMed Care Clinic (&#8220;ACC&#8221;) and AKM Medical Group, Inc. (&#8220;AKM&#8221;). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operates a hospitalist, intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several skilled nursing facilities. ACC and AKM are no longer active to any material extent.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ApolloMed also has a controlling interest in Apollo Palliative Services, LLC (&#8220;APS&#8221;), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (&#8220;BCHC&#8221;) and Holistic Care Home Health Agency, Inc. (&#8220;HCHHA&#8221;) and provides palliative care services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">ApolloMed also operated Pulmonary Critical Care Management, Inc. (&#8220;PCCM&#8221;) and Verdugo Medical Management, Inc. (&#8220;VMM&#8221;), which operated as physician practice management companies. PCCM and VMM are no longer active to any material extent.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946457696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>2.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Basis of Presentation and Summary of Significant Accounting Policies</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company&#8217;s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Principles of Consolidation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM&#8217;s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM&#8217;s consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM&#8217;s consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">All material intercompany balances and transactions have been eliminated in consolidation.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Business Combinations</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reportable Segments</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company&#8217;s reported revenue, net income, cash flows or total assets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)&#8217;s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">135.0</font> million. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk&#160;exposure.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Restricted Cash</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.05</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.10</font>%. Restricted cash also consists of cash held as collateral to secure standby letters of credits as required by certain contracts. As of March 31, 2018 and December 31, 2017, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,028,116</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,005,661</font> included in restricted cash short-term, respectively, in the accompanying condensed consolidated balance sheets. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000,000</font> of such restricted cash was related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), will be held in an escrow account for distribution to former NMM shareholders (see Note 17).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Receivables</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Capitation and claims receivable relate to the health plan&#8217;s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) ASC 606 (see Note 13). Other receivables include fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December&#160;31, 2017, the Company recorded an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">763,205</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">407,953</font>, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentrations of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company had major payors that contributed the following percentage of net revenue:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"> <div>For&#160;The&#160;Three&#160;Months<br/> Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>24.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>10.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160; &#160;* Less than 10% <font style="BACKGROUND-COLOR: transparent">of total net revenues</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent">The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;March<br/> 31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;December<br/> 31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>25.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>23.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor E</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>38.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>30.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value Measurements of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables &#150; long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>FASB ASC 820, <i>Fair Value Measurement</i> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">This hierarchy prioritizes the inputs into three broad levels as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;1</i> &#151;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;2</i> &#151;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;3</i> &#151;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The carrying amounts and fair values of the Company&#8217;s financial instruments as of March 31, 2018 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2017 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;* <i>Included in cash and cash equivalents</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Derivative<br/> Assets<br/> (Warrants)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,338,886</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Change in fair value of warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,522,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,861,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The fair value of the warrant derivative asset of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.9</font> million at March&#160;31, 2017 was estimated using the Black-Scholes valuation model, using the following inputs: term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.54</font> &#150; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.00</font> years, risk free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.62</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.71</font>%, no dividends, volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 62.3</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 62.4</font>%, share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.00</font> per share based on the trading price of ApolloMed&#8217;s common stock adjusted for a marketability discount, and a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% probability of redemption of the warrant shares issued along with the shares of ApolloMed&#8217;s convertible preferred stock issued in the financing.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible Assets and Long-Lived Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2018 and 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Goodwill and Indefinite-Lived Intangible Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under the ASC 350, <i>Intangibles &#150; Goodwill and Other</i> (&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At least annually, at the Company&#8217;s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March&#160;31, 2018 and 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Investments in Other Entities - Equity Method</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate.</font> Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. No impairment loss was recorded on equity method investments for the three months ended March&#160;31, 2018 and 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Medical Liabilities</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO&#8217;s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the revenue less actual claims processed for or paid to in-network providers (after taking into account the average discount negotiated with the in-network providers). The Company plans to use the traditional lag models as the claims history matures. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (&#8220;ASU&#8221;)&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company&#8217;s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Share-Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on performance of services in the future.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 <i>Equity-Based Payments to Non-Employees</i>. As such the fair value of such shares is periodically re-measured using an appropriate valuation model and income or expense is recognized over the vesting period.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basic and Diluted Earnings Per Share</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b):</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> a)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">The income of the legal acquiree (NMM) attributable to holders of the Company&#8217;s common stock in such period.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> b)</font></div> </td> <td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">The legal acquiree&#8217;s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Noncontrolling Interests</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company&#8217;s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Mezzanine Equity</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; (&#8220;ASU 2014-09&#8221;). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2016, the FASB issued ASU No. 2016-01, &#8220;Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#8221; (&#8220;ASU 2016-01&#8221;). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) &#150; Classification of Certain Cash Receipts and Cash Payments&#8221; (&#8220;ASU 2016-15&#8221;). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In December 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows (Topic 230) &#150; Restricted Cash&#8221; (&#8220;ASU 2016-18&#8221;). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2017, the FASB issued ASU No. 2017-01, &#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business&#8221; (&#8220;ASU 2017-01&#8221;). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles &#150; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#8221; (&#8220;ASU 2017-04&#8221;). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: rgb(46,46,46); font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception&#8221; (&#8220;ASU 2017-11&#8221;). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946574400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions of non-controlling interest in BAHA</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>3.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Mergers and Acquisitions</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On December 8, 2017, (the &#8220;Effective Time&#8221;) the merger (the &#8220;Merger&#8221;) of ApolloMed&#8217;s wholly-owned subsidiary, Apollo Acquisition Corp., with and into Network Medical Management, Inc. as the surviving entity was completed, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017), by and among the Company, Merger Sub, NMM and Kenneth Sim, M.D., as the NMM shareholders&#8217; representative. As a result of the Merger, NMM now is a wholly-owned subsidiary of ApolloMed and former NMM shareholders own a majority of the issued and outstanding common stock of the Company. Both companies are considered to be a business under the guidance outlined in ASC 805, Business Combinations. The combined company operates under the Apollo Medical Holdings name. NMM is the larger entity in terms of assets, revenues and earnings. In addition, as of the closing of the Merger, the majority of the board of directors of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed is considered to be the legal acquirer (and accounting acquiree) whereas NMM is considered to be the accounting acquirer (and legal acquiree) and, accordingly, the merger transaction is a reverse acquisition. Accordingly, as of the Effective Time, NMM&#8217;s historical results of operations replaced ApolloMed&#8217;s historical results of operations for all periods prior to the Merger, and the results of operations of both companies will be included in the Company&#8217;s financial statements for all periods following the Merger. As of the Effective Time, the Company&#8217;s board of directors approved a change in the Company&#8217;s fiscal year end from March 31 to December 31, to correspond with NMM&#8217;s fiscal year end prior to the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of NMM common stock converted into the right to receive (i) such number of fully paid and nonassessable shares of ApolloMed&#8217;s common stock that resulted in the NMM shareholders having a right to receive an aggregate number of shares of ApolloMed&#8217;s common stock that represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 82</font>% of the total issued and outstanding shares of ApolloMed common stock immediately following the Effective Time, with no NMM dissenting shareholder interests as of the Effective Time (the &#8220;exchange ratio&#8221;), plus (ii) an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,566,666</font> ApolloMed&#8217;s common stock, with no NMM dissenting shareholder interests as of the Effective Time, and (iii) common stock warrants to purchase a pro-rata portion of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 850,000</font> shares of common stock of ApolloMed, exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.00</font> per share and warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 900,000</font> shares of common stock of ApolloMed at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share. At the Effective Time, pre-Merger ApolloMed stockholders held their existing shares of ApolloMed&#8217;s common stock. At the Effective Time, ApolloMed held back 10% of the total number of shares of ApolloMed&#8217;s common stock issuable to pre-Merger NMM shareholders in the Merger to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. Separately, indemnification of pre-Merger NMM shareholders under the Merger Agreement was made by the issuance by ApolloMed to pre-Merger NMM shareholders of new additional shares of common stock (capped at the same number of shares of ApolloMed&#8217;s common stock as are subject to the holdback for the indemnification of ApolloMed). These holdback shares will be held for a period of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger agreement, by NMM. Half of these shares will be issued on the first and second anniversary of the Effective Time respectively.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For purposes of calculating the exchange ratio, (A) the aggregate number of shares of ApolloMed common stock held by the NMM shareholders immediately following the Effective Time excluded (i) any shares of ApolloMed common stock owned by NMM shareholders immediately prior to the Effective Time, (ii) the Series A warrant and Series B warrant issued by ApolloMed to NMM to purchase ApolloMed common stock (the &#8220;ApolloMed Warrants&#8221;) and (iii) any shares of ApolloMed common stock issued or issuable to NMM shareholders pursuant to the exercise of the ApolloMed Warrants, and (B) the total number of issued and outstanding shares of ApolloMed common stock immediately following the Effective Time excluded <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 520,081</font> shares of ApolloMed common stock issued or issuable under a Convertible Promissory Note to Alliance Apex, LLC (&#8220;Alliance&#8221;) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.99</font> million and accrued interest pursuant to the Securities Purchase Agreement between ApolloMed and Alliance dated as of March 30, 2017.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In addition, the fair value of NMM&#8217;s <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% interest in APAACO, an entity that was owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% by ApolloMed and 50% by NMM, was remeasured at fair value as of the Effective Time and added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,129,000</font>.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total estimated purchase consideration consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Equity consideration (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">61,092,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of ApolloMed preferred stock held by NMM (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,118,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of NMM&#8217;s noncontrolling interest in APAACO (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,129,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of the outstanding ApolloMed stock options (4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">187,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Total estimated purchase consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">85,526,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (1)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Equity consideration</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0px 0in -0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,109,205</font> shares of ApolloMed common stock.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The equity consideration, which represents a portion of the consideration deemed transferred to the pre-Merger ApolloMed stockholders in the Merger, is calculated based on the number of shares of the combined company that the pre-Merger ApolloMed stockholders would own as of the closing of the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders <sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,109,205</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Multiplied by the price per share of ApolloMed&#8217;s common stock <sup style="font-style:normal">(2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Equity consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">61,092,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> (1)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> (2)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> Represents the closing price of ApolloMed&#8217;s common stock on December 8, 2017.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (2)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of ApolloMed&#8217;s preferred shares held by NMM</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.01in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger.&#160; As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed.&#160; The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,118,000</font>.&#160;The valuation methodology was based on an Option Pricing Method (&#8220;OPM&#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company.&#160; OPM assumptions included an expected term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> years, volatility rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37.9</font>%, and a risk-free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.8</font>%.&#160; The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,745,000</font> and the fair value of the conversion option was determined to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,373,000</font> or an aggregate total fair value of $19,118,000.</div> <i>&#160;</i></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (3)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of NMM&#8217;s 50% share of APA ACO Inc.</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (4)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of the ApolloMed outstanding stock options</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see &#8220;MMG Transaction&#8221; below), with the excess recorded as goodwill:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">36,367,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Accounts receivable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,261,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Other receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,211,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">249,193</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Property, plant and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,114,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">745,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Fair value of intangible assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14,984,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,301,972</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">217,241</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">66,452,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Accounts payable and accrued liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,632,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Medical liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">39,353,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Line of credit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Convertible note payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,376,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Convertible note payable - related party</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,921,938</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Noncontrolling interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,142,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Total liabilities assumed and noncontrolling interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">66,451,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Net liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(913,468)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85,525,840</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Goodwill is not deductible for tax purposes. During the three months ended March 31, 2018, the deferred tax assets balance was increased by approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.9</font> million with an offset to goodwill as a result of the allocation of transaction costs related to the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Merger from</font> ApolloMed to NMM.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The purchase consideration and purchase price allocation are preliminary and subject to change as more information becomes available, which will be finalized as soon as practicable within the measurement period of no later than one year following the Effective Time of the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>MMG Transaction</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of MMG. MMG has historically been included in the consolidated financial statements filed by ApolloMed. APC-LSMA <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">agreed to</font> pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font> in consideration for all the shares of MMG. As the transaction is between related parties, the purchase consideration of MMG reflected in the purchase price allocation was determined to be the fair value of MMG. MMG and AMM terminated the existing Management Services Agreement between them (the &#8220;MMG Management Agreement&#8221;) and APC-LSMA paid AMM $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> as a termination payment on the Effective Time. APC-LSMA is consolidated by APC which in turn is consolidated by NMM, and as a result, the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> amount is eliminated upon consolidation.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <i>Pro Forma Combined Historical Results</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three&#160;Months<br/> Ended<br/> March&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Net revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">98,467,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Net loss attributable to Apollo Medical Holdings, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(351,982)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Weighted average common shares outstanding:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,601,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Earnings per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Weighted average common shares outstanding:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,601,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Earnings per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The pro forma information has been prepared for comparative purposes only and does not purport to be indicative of what would have occurred had the acquisition actually been made at such date, nor is it necessarily indicative of future operating results.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946523024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>4.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Intangible Assets, Net</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>At March&#160;31, 2018, the Company&#8217;s intangible assets, net, consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Useful</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Net</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Accumulated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Indefinite Lived Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Medicare license</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Amortized Intangible Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Network relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11-15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,883,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(39,179,025)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,703,975</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Management contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,832,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,646,843)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,185,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Member relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,696,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(357,292)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,338,708</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Patient management platform</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,060,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(137,333)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,922,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Tradename/trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,011,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(16,850)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>994,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>144,476,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(45,337,343)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>99,138,657</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At December&#160;31, 2017, the Company&#8217;s intangible assets, net, consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Useful</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Net</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Accumulated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Indefinite Lived Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Medicare license</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Amortized Intangible Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Network relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11-15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,883,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(35,842,508)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>74,040,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Management contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,832,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,014,886)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,817,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Member relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,696,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(46,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,649,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Patient management platform</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,060,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34,336)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,025,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Tradename/trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,011,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,212)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,006,788</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>144,476,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(40,942,442)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>103,533,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,394,901</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,374,841</font>, (excluding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">106,000</font> amortization expense for exclusivity incentives) for the three months ended March&#160;31, 2018 and 2017, respectively.</div> &#160;</div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future amortization expense is estimated to be as follows for the years ending December&#160;31:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2018 (remaining nine months)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,262,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,480,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,671,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,961,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,448,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,323,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>97,145,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946574400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Other Entities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>5.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Investments in Other Entities</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Equity Method Investments</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>LaSalle Medical Associates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">LaSalle Medical Associates (&#8220;LMA&#8221;) was founded by Dr. Albert Arteaga in 1996 and currently operates four neighborhood medical centers employing more than 120 dedicated healthcare professionals, treating children, adults and seniors in San Bernardino County. LMA&#8217;s patients are primarily served by Medi-Cal and they also accept Blue Cross, Blue Shield, Molina, Care 1<sup style="font-style:normal">st</sup>, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high quality care to more than 245,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended March&#160;31, 2018 and 2017, APC recorded (loss) income from this investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(352,792)</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,311,738</font>, respectively, in the accompanying consolidated statements of income. The investment balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,099,975</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,452,767</font> at March 31, 2018 and December&#160;31, 2017, respectively.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>LMA&#8217;s IPA line of business summarized balance sheets at March 31, 2018 and December&#160;31, 2017 and summarized statements of income for the three months ended March&#160;31, 2018 and 2017 are as follows (unaudited):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Balance Sheets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,064,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,065,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,005,144</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,433,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,173,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,565,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Loan receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>664,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>662,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,157,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,975,936</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Liabilities and Stockholders&#8217; Equity</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,946,133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,353,337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Stockholders&#8217; equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,211,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,622,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total liabilities and stockholders&#8217; equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,157,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,975,936</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Statements of Income</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>52,983,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>49,753,004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,002,458</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,506,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,018,667)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,246,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Pacific Medical Imaging and Oncology Center, Inc.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography at their facilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,200,000</font> for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% ownership in PMIOC.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million for the three months ended March&#160;31, 2018 and 2017, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. During the three months ended March&#160;31, 2018 and 2017, APC recorded (loss) income from this investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(26,025)</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,080</font> respectively, in the accompanying consolidated statements of income and has an investment balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,374,668</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,400,693</font> at March 31, 2018 and December&#160;31, 2017, respectively.</div> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Universal Care, Inc.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">UCI is a privately held health plan that has been in operation since 1985 in order to help its members through the complexities of the healthcare system. UCI holds a license under the California Knox-Keene Health Care Services Plan Act (&#8220;Knox-Keene Act&#8221;) to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On August&#160;10, 2015, UCAP, an entity solely owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% by APC with APC&#8217;s executives, Dr.&#160;Thomas Lam, Dr. Pen Lee and Dr. Kenneth Sim, as designated managers of UCAP, purchased from UCI <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of UCI class A-2 voting common stock (comprising <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48.9</font>% of the total outstanding UCI shares, but <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% of UCI&#8217;s voting common stock) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font>. APC accounts for its investment in UCI under the equity method of accounting as APC has the ability to exercise significant influence, but not control over UCI&#8217;s operations. During the three months ended March&#160;31, 2018 and 2017, the Company recorded (loss) income from this investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(20,202)</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">523,301</font>, respectively, in the accompanying consolidated statements of income and has an investment balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,589,253</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,609,455</font> at March 31, 2018 and December&#160;31, 2017, respectively.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In 2015, the Company also advanced $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> to UCI for working capital purposes. The subordinated loan accrues interest at the prime rate plus <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1</font>%, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.75</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.50</font>% as of March 31, 2018 and December&#160;31, 2017, respectively, with interest to be paid monthly. Pursuant to the stock purchase agreement, the principal repayment schedule is based on certain contingent criteria, and accordingly, the entire note receivable has been classified as non-current loans receivable - related parties on the consolidated balance sheets in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> as of March 31, 2018 and December 31, 2017.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>UCI&#8217;s balance sheets at March 31, 2018 and December&#160;31, 2017 and statements of income for the three months ended March&#160;31, 2018 and 2017 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Balance Sheets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,595,206</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,872,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,862,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,618,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,870,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,021,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,259,507</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,754,470</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,770,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,576,621</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,357,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,844,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Liabilities and Stockholders&#8217; Deficit</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>64,984,078</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,421,532</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,044,340</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,051,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Stockholders&#8217; deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,670,533)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,629,219)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total liabilities and stockholders&#8217; deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,357,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,844,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Statements of Income Operations</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,665,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>46,540,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,154,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,757,246</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Income before provision for income taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>510,487</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,783,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Provision for income taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>713,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(41,313)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,070,146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Diagnostic Medical Group</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On May&#160;14, 2016, David C.P. Chen M.D., Inc., a California professional corporation doing business as Diagnostic Medical Group (&#8220;DMG&#8221;), David C.P. Chen M.D., individually (collectively &#8220;Seller&#8221;) and APC-LSMA, a designated shareholder professional corporation formed on October&#160;15, 2012, which is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% owned by Dr. Thomas Lam (CEO of APC) and is controlled and consolidated by APC who is the primary beneficiary of this VIE, entered into a share purchase agreement whereby APC-LSMA acquired a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% ownership interest in DMG for total cash consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,600,000</font>.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. APC recorded income from this investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">329,042</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">361,644</font> for the three months ended March 31, 2018 and 2017, respectively, in the accompanying consolidated statements of operations. The investment balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,176,453</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,847,411</font> at March 31, 2018 and December&#160;31, 2017, respectively.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Pacific Ambulatory Surgery Center, LLC</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">PASC, a California limited liability company, is a multi-specialty outpatient surgery center that is certified to participate in the Medicare program and is accredited by the Accreditation Association for Ambulatory Health Care. PASC has entered into agreements with organizations such as healthcare service plans, independent physician practice associations, medical groups and other purchasers of healthcare services for the arrangement of the provision of outpatient surgery center services to subscribers or enrollees of such health plans. On November&#160;15, 2016, PASC and APC, entered into a membership interest purchase agreement whereby PASC sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% of its aggregate issued and outstanding membership interests to APC for total consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">800,000</font>.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In connection with the membership interest purchase agreement, PASC entered into a management services agreement with NMM, which requires the payment of management fees computed at predetermined percentage (as defined) of PASC revenues. The term of the management services agreement commenced on the effective date and extend for a period of 60 months thereafter, and may&#160;be extended in writing at the sole option of NMM for an additional period of 60 months following the expiration of the initial term and is automatically renewed for additional consecutive terms of three years unless terminated by either party. PASC shall not be permitted to terminate the management services agreement for any reason during the initial term and, if extended, the extended term.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC accounts for its investment in PASC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PASC&#8217;s operations. APC recorded income (loss) from this investment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,953</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(20,501)</font> for the three months ended March 31, 2018 and 2017, respectively, in the accompanying consolidated statements of income and has an investment balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">635,151</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">593,198</font> at March 31, 2018 and December&#160;31, 2017, respectively.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Equity Method Investment Summary</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Investments in other entities &#150; equity method consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Universal Care, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,589,253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,609,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>LaSalle Medical Associates &#150; IPA Line of Business</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,099,975</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,452,767</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Diagnostic Medical Group</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,176,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,847,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Pacific Medical Imaging &#38; Oncology Center, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,374,668</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,400,693</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Pacific Ambulatory Surgery Center, LLC</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>635,151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,875,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,903,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780046544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableAbstract', window );"><strong>Loan Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 6.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b>Loan Receivable</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On October&#160;9, 2017, NMM and APC-LSMA entered into an agreement with Accountable Health Care IPA (&#8220;Accountable&#8221;), a California professional medical corporation, Signal Health Solutions, Inc. (&#8220;Signal&#8221;), a California corporation and George M. Jayatilaka, M.D. (&#8220;Dr.&#160;Jay&#8221;), individually, whereby concurrent with the execution of the agreement, APC-LSMA extended a line of credit to Dr. Jay in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font> (&#8220;Dr. Jay Loan&#8221;) to fund the working capital needs of Accountable ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> of which was funded by APC on behalf of APC-LSMA and the other $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> was funded by NMM to Dr. Jay). Interest on the Dr. Jay Loan accrues at a rate that is equal to the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">prime rate plus 1%</font> (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.75</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.50</font>% as of March 31, 2018 and December 31, 2017, respectively) and payable in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The Dr. Jay Loan will not be subordinated. The Dr. Jay Loan shall at all times be secured by a first-lien security interest in shares of Accountable owned by Dr. Jay. The outstanding balance as of both March 31, 2018 and December 31, 2017 was $10,000,000.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Concurrently with the funding of the Dr. Jay Loan, Dr. Jay will loan to Accountable the entire proceeds of the Dr. Jay Loan at the same interest rate and maturity date as the Dr. Jay Loan (&#8220;Dr.&#160;Jay-Accountable Subordinated Loan&#8221;). Repayment of the Dr. Jay-Accountable Subordinated Loan will be subordinated to Accountable&#8217;s creditors in a manner acceptable to the California Department of Managed Health Care (&#8220;DMHC&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountable&#8217;s capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountable&#8217;s then-current valuation.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Subsequent to the funding of the Dr. Jay Loan, to the extent needed by Accountable for working capital needs as determined by APC-LSMA, APC-LSMA will extend an additional line of credit in the principal amount up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,000,000</font>. The funding mechanism, interest rate and maturity date of such additional line of credit shall be the same as the Dr. Jay Loan and additional collateral security in Accountable&#8217;s issued and outstanding shares will be required.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As a condition of funding the Dr. Jay Loan, Accountable entered into a management service agreement with NMM on October&#160;27, 2017, to commence on the termination of the Accountable&#8217;s existing management agreement with MedPoint Management to be effective on December&#160;1, 2017 and have a term of ten (10) years from its effective date. NMM will be responsible for managing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of all health plan membership assigned and delegated to Accountable, and all hospital risk pools. The management service agreement requires the payment of IPA management fees as set forth therein.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Concurrent with the initial funding of the Dr. Jay Loan, the Accountable Board of Directors shall be automatically reconstituted to be comprised of two directors, which will comprise of Dr. Jay and a director appointed by APC-LSMA. Dr. Jay and APC-LSMA will have two and one votes as a director, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Based on management&#8217;s assessment, Accountable is a variable interest entity, however, the Company does not have the power to the direct the activities of Accountable that most significantly impact its economic performance and as such, the Company is not the primary beneficiary of Accountable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for note receivable and management services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779576656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>7.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Accounts Payable and Accrued Expenses</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s accounts payable and accrued expenses consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,356,677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,786,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Specialty capitation payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>547,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Subcontractor IPA risk pool payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,472,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,348,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,727,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,004,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>710,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accrued compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,543,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,343,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,110,530</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,279,620</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780046544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DisclosureOfMedicalLiabilitiesAbstract', window );"><strong>Disclosure of Medical Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>8.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Medical Liabilities</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s medical liabilities consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Balance, beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63,972,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,957,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Medical liabilities assumed from Merger</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,353,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Claims paid for previous period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(28,633,287)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(23,075,516)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Incurred health care costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,634,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121,846,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Claims paid for current period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(10,805,984)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(92,476,160)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Adjustments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(56,478)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(633,386)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Balance, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,110,826</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63,972,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DisclosureOfMedicalLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DisclosureOfMedicalLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946401632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loan, Lines of Credit and Loan Payable &#150; Related Party<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract', window );"><strong>Disclosure of Bank Loan, Lines of Credit and Loan Payable - Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock', window );">Bank Loan Lines Of Credit And Loan Payable Related Party</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 9.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b>Bank Loan, Lines of Credit and Loan Payable &#150; Related Party</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Bank Loans</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In December 2010, ICC borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,600,000</font> loan from a financial institution. The loan bears interest based on the Wall Street Journal &#8220;prime rate&#8221; or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.75</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.50</font>% per annum as of March 31, 2018 and December 31, 2017, respectively. The loan is collateralized by one if its shareholders and the medical equipment ICC owns. The loan matures on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> December 31, 2018</font>. As of March 31, 2018 and December 31, 2017, the balance outstanding was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">394,783</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">510,391</font>, respectively, and is classified as current liabilities. As of March 31, 2018 and December&#160;31, 2017, ICC was in compliance with all affirmative and negative covenants contained in the loan agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Lines of Credit</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April&#160;2012, NMM entered into a promissory note agreement with a bank, which was amended on April&#160;9, 2016 and April 7, 2017 (as amended, the &#8220;NMM Business Loan Agreement&#8221;). The NMM Business Loan Agreement was amended on April 7, 2017 to increase the loan availability from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000,000</font>. The interest rate is based on the Wall Street Journal <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#8220;prime rate&#8221; plus 0.125%</font></font> or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.875</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.675</font>% as of March&#160;31, 2018 and December 31, 2017, respectively. As of December&#160;31, 2017, the Company was not in compliance with certain financial debt covenant requirements contained in the loan agreement for which NMM obtained a waiver through March 31, 2018. As of March 31, 2018, NMM was in compliance with such financial debt covenant requirements.&#160;The loan is personally guaranteed by 14 former shareholders of NMM, 13 of which are also members of former NMM&#8217;s board of directors, and a Trust held by NMM&#8217;s CEO, each of which guarantees is capped at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>. The loan is collateralized by substantially all assets of NMM. In October 2017, NMM borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font> on this line of credit to provide to Accountable Health Care IPA (see Note 6). The line of credit was amended on April 18, 2018 to extend the maturity date from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 22, 2018</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 22, 2018</font>. The amount outstanding as of both March 31, 2018 and December 31, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font></font>. As of both March 31, 2018 and December 31, 2017, availability under this line of credit was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,300,671</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April&#160;2012, APC entered into a promissory note agreement with a bank, which was amended on April&#160;22, 2016 and April 7, 2017 (as amended, the &#8220;APC Business Loan Agreement&#8221;). The APC Business Loan Agreement modifies certain terms of the promissory note agreement in order to (i) increase the original loan availability amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font>, (ii)&#160;extend the maturity date under the promissory note agreement to April&#160;22, 2018, and (iii) add six additional guarantees. The interest rate is based on the Wall Street Journal &#8220;prime rate&#8221; plus 0.125% or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.875</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.675</font>% as of March&#160;31, 2018 and December 31, 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company was not in compliance with certain financial debt covenant requirements contained in the loan agreement for which APC obtained a waiver from the bank through June 30, 2018. The loan is personally guaranteed by 14 shareholders of APC, 13 of which are also members of APC&#8217;s board of directors, and a Trust held by NMM&#8217;s CEO, each of which guarantees is capped at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font>. The loan is also collateralized by substantially all assets of APC. No amounts were drawn on this line during the three months ended March 31, 2018 and no amounts were outstanding as of March 31, 2018 and December&#160;31, 2017. As of both March 31, 2018 and December 31, 2017, availability under this line of credit was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,694,984</font></font>. The line of credit was amended on April 18, 2018 to extend the maturity date from April 22, 2018 to June 22, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Standby Letters of Credit</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 3, 2017, APAACO established an irrevocable standby letter of credit with a financial institution (through the NMM Business Loan Agreement) for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,699,329</font> for the benefit of CMS. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.</font> APAACO may continue to draw from the letter of credit for one year following the bank&#8217;s notification of non-renewal.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC established irrevocable standby letters of credit with a financial institution for a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">305,016</font> for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for bank loan, lines of credit and loan payable - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BankLoanLinesOfCreditAndLoanPayableRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DisclosureOfBankLoanLinesOfCreditAndLoanPayableRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609776768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>10.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Mezzanine and Stockholders&#8217; Equity</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">All the historical NMM share and per share information has been adjusted to reflect the exchange ratio from the Merger (see Note 3).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><u>Mezzanine</u></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>APC</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i><u>Stockholders&#8217; Equity</u></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As of the date of this Quarterly Report on Form 10-Q, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,970</font> shares, which are net of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,039,749</font> holdback shares and&#160;are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants.&#160; Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares on the Effective Date of the Merger.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 21, 2018, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37,593</font> shares of the Company&#8217;s common stock to the Company&#8217;s Chief Operating Officer for prior services rendered. The stock price on the date of issuance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16.80</font>, which resulted in the Company recording $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">631,562</font> of share-based compensation expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>Options</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s outstanding stock options consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,141,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">30,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(129,536)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">15.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> During the quarter ended March 31, 2018, stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 54,536</font> shares of the Company&#8217;s common stock, which resulted in the Company issuing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43,201</font> net shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the quarter ended March 31, 2018, stock options were exercised for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75,000</font> shares of the Company&#8217;s common stock, which resulted in proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">479,000</font>. The exercise price ranged from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.10</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Outstanding stock options granted to primary care physicians to purchase shares of APC&#8217;s common stock consisted of the following:</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of common stock as of March 31, 2018.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC&#8217;s common stock, recognized over their respective vesting periods, consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both"> Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both">Contracted physicians and other services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">202,382</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">321,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The remaining unrecognized share-based compensation expense of stock option awards granted to primary care physicians to purchase shares of APC&#8217;s common stock as of March 31, 2018 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,214,292</font>, which is expected to be recognized over the remaining term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.50</font> years.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>Warrants</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s outstanding warrants consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants outstanding at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,648,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(191,625)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.96</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(11,250)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Exercise&#160;Price&#160;Per</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Per</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">24,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">24,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,116,111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">2.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,116,111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,455,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,455,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50 &#150;11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the quarter ended March 31, 2018, common stock warrants were exercised for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 191,625</font> shares of the Company&#8217;s common stock, which resulted in proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million. The exercise price ranged from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share.</div> </div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>Treasury Stock</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">APC owns <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,682,110</font> shares of ApolloMed&#8217;s common stock as of March 31, 2018, which are legally issued and outstanding but excluded from shares of common stock outstanding in the condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790214336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 11.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Commitments and Contingencies</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Regulatory Matters</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As risk-bearing organizations, APC and MMG are required to follow regulations of the DMHC, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At March 31, 2018 and December 31, 2017, APC was in compliance with these regulations. At March 31, 2018 and December 31, 2017, MMG was not in compliance with these regulations. As a result, the California DMHC required MMG to develop and implement a corrective action plan (&#8220;CAP&#8221;) for such deficiency. The Company has been in communication with the DMHC regarding MMG&#8217;s business plans that, if implemented, could result in a significant reduction in the health plan enrollment assigned to MMG. MMG received confirmation from substantially all of MMG&#8217;s direct-contracted health plans, that they have moved membership out of MMG effective May 1, 2018. MMG is currently working with DMHC on providing a CAP plan.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Litigation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On or about March 23, 2018 and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#8220;Prospect&#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services (&#8220;JAMS&#8221;), arising out of MMG&#8217;s purported business plans, seeking damages in excess of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#8217;s current and future economic relationships with its health plans and their members. MMG, ApolloMed and AMM each disputes the allegations and intends to vigorously defend itself in this matter. At this time, it is too early in the process to assess the probability of the outcome of this matter and/or amount of loss, if any.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946574400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 12.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Related Party Transactions</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On November&#160;16, 2015, APC entered into a subordinated note receivable agreement with UCI, a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48.9</font>% owned equity method investee (see Note 5), in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,000</font>, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, NMM received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million, respectively, in management fees from LMA, which is accounted for under the equity method based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font>&#160;million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% equity ownership interest held by APC (see Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.7</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font>&#160;million, respectively, to AMG, Inc. for services as a provider. AMG, Inc. shares common ownership with certain board members of APC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In September 2015, ApolloMed entered into a note receivable with Rob Mikitarian, a minority owner in APS, in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font>. The note accrues interest at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% per annum and currently due on demand. As of March 31, 2018 and December 31, 2017, the balance of the note was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> and is included in other receivables in the accompanying consolidated balance sheets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In addition, affiliates wholly-owned by the Company&#8217;s officers, including Dr. Lam and Dr. Hosseinion, are reported in the accompanying consolidated statement of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related party transactions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font>&#160;million, respectively, to DMG for provider services, which is accounted for under the equity method based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% equity ownership interest held by APC (see Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, NMM paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font>&#160;million to Medical Property Partners (&#8220;MPP&#8221;) for office lease. MPP shares common ownership with certain board members of NMM.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,000</font></font> to Tag-2 Medical Investment Group, LLC (&#8220;Tag-2&#8221;) for office lease. Tag-2 shares common ownership with certain board members of APC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">During the three months ended March&#160;31, 2018 and 2017, APC paid an aggregate of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.2</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.8</font> million, respectively, to shareholders of APC for provider services, which include approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.3</font>&#160;million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.4</font> million, respectively, to shareholders who are also officers of APC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For loans receivable from related parties, see Note 6.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780143328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>13.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Revenue Recognition</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At the adoption of Topic 606, the majority of what was previously classified as the provision for bad debts in the consolidated statements of income is now reflected as implicit price concessions and, therefore, included as a reduction to revenues starting in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in operating expenses in the condensed consolidated statements of income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In addition, the cumulative effect of initially applying the new revenue standard is required to be presented as an adjustment to the opening balance of retained earnings. This cumulative effect amount was determined to be related to the full risk pool arrangements of APC, a variable interest entity (see Note 1). Therefore, the cumulative net effect of initially applying Topic 606 in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,208,000</font>, which is comprised of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,600,000</font> of additional revenue, offset by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,392,000</font> in related management fee expense, has been presented as an adjustment to the opening balance of the mezzanine equity, &#8220;Noncontrolling interest in Allied Pacific of California IPA.&#8221; Consequently, as a result of APC recording additional receivables, NMM recorded a corresponding entry of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,392,000</font> to retained earnings to record the related management fee income. These adjustments were offset by an aggregate adjustment to deferred tax liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,246,098</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The adoption of this ASU did not have a significant impact on the Company&#8217;s revenue, when comparing the amount of revenue recognized for the three months ended March 31, 2018 to the revenue that would have been recognized under the prior revenue standard ASC 605, such that comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The cumulative effect of changes made to the Company&#8217;s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance&#160;at<br/> December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Adjustments<br/> due&#160;to&#160;Topic&#160;606</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance&#160;at<br/> January&#160;1,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Current Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">20,117,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">31,717,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Liabilities, Mezzanine Equity and Stockholders&#8217; Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Noncurrent Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Deferred tax liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,916,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,246,098</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28,162,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Mezzanine equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Noncontrolling interest in Allied Pacific of California IPA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">172,129,744</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,351,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">179,481,178</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Stockholders&#8217; Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Retained earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,734,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,002,468</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,736,999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company operates as one reportable segment, the healthcare delivery segment. The Company disaggregates revenue from contracts by service type and by payor.&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.</font> The condensed consolidated statements of income presents disaggregated revenue by service type. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents disaggregated revenue generated by each payor type:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Commercial</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">105,350,102</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">83,848,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Medicare</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">18,541,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,453,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Medicaid</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">176,350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Other third parties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">99,160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">124,166,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85,336,062</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third party payors (e.g., hospitals); and (v) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 8.75pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursements are often subject to interpretation that could result in payments that differ from the Company&#8217;s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 2.9pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under the new revenue standard, the Company has elected to apply the following practical expedients and optional exemptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within general and administrative expenses.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#8217;s services completed to date.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed, and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">Use a portfolio approach for the fee-for-service (FFS) revenue stream to group contracts with similar characteristics and analyze historical cash collections trends.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">No adjustment is made for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 21.55pt; MARGIN: 0pt 2.9pt 0pt 5pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i><u>Nature of Services and Revenue Streams</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;) revenue, management fee income, MSSP surplus revenue and FFS revenue. Revenue is recorded in the period in which services are rendered. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Capitation, net</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under either provider service agreements (each, a &#8220;PSA&#8221;) or capitated arrangements directly made with various managed care providers including HMOs. Capitation revenue under the PSAs and HMO contracts is prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment model,&#8221; which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 6.65pt 0pt 2pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Per member per month (PMPM) managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes per member per month fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Risk Pool Settlements and Incentives</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC and APAACO enter into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC and APAACO is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC and APAACO generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for IBNR completion factor and constraint percentages were used by management in applying the most likely method.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under capitated arrangements with certain HMOs, APC and APAACO participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC and APAACO is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished. Risk pool settlements under arrangements with HMOs are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR, risk adjustment factors, stop loss provisions, etc., an estimate cannot be developed. Due to these limitations, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> APAACO</font> cannot determine the amount of surplus or deficit that will probably not be reversed in the future and therefore this shared risk pool revenue is considered to be fully constrained.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed the quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for efforts it takes to improve the quality of services and for efficient and effective use of pharmacy supplemental benefits provided to the HMO&#8217;s members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. Incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. As the Company does not have sufficient insight from the health plans on the amount and timing of the incentive payments, this revenue is considered to be fully constrained and is only recorded when such payments are received.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Generally for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e. the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>NGACO AIPBP Revenue</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under the NGACO Model, CMS grants the Company a pool of patients to manage (direct care and pay providers) based on a budget established with CMS. The Company is responsible for managing medical costs for these patients. The patients will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed or paid by CMS and the Company&#8217;s profits or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the surplus or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency or lack thereof, respectively, in managing how the patients assigned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s profits or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. In accordance with the guidance in ASC 606-10-55-36 through 55-40 on principal versus agent considerations, the Company records such revenues in the gross amount of consideration.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company also has arrangements for billing and payment services with the medical providers within the NGACO network. The Company retains certain defined percentages of the payments made to the providers in exchange for using the Company&#8217;s billing and payment services. The revenue for this service is earned as payments are made to medical providers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APAACO and CMS entered into a Next Generation ACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with a term of two performance years through December 31, 2018. CMS may offer to renew the Participation Agreement for additional terms of two performance years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For each performance year, the Company shall submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For each performance year, CMS shall pay the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies owed. If CMS owes the Company shared savings or other monies owed, CMS shall pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company shall pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As it relates specifically to the Company&#8217;s Participation Agreement with CMS, the Company recognizes capitation revenue in the month in which the Company is obligated to provide services. Also, because the Company&#8217;s arrangement with CMS is new (became effective in 2017), numerous factors create uncertainty regarding the risk pool settlement and incentive amounts that the Company is entitled to receive and limited historical data exists to develop reasonable and reliable estimates. As a result, the Company recognizes revenue from risk pool settlements and incentives under the arrangement with CMS in the period in which amounts are estimable and collection is reasonably assured. The Company will continue to evaluate and assess the reliability and reasonableness of data available to it in order develop future estimates, and will recognize risk pool settlements and incentives revenue based on such estimates only to the extent it is probable that a significant reversal of cumulative revenue will not occur in future periods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In October 2017, CMS notified the Company that it would not be renewed for participation in the AIPBP payment mechanism of the NGACO Model for performance year 2018 due to certain alleged deficiencies in performance. The Company submitted a reconsideration request. In December 2017, the Company received the official decision on its reconsideration request that CMS reversed the prior decision against the Company&#8217;s continued participation in the AIPBP mechanism. As a result, the Company is eligible for receiving monthly AIPBP payments currently at a rate of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.3</font> million per month from CMS starting February 2018. The Company, however, will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Management Fee Income</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. Such variable supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. The Company&#8217;s MSA revenue also includes revenue sharing payments from the Company&#8217;s partners based on their non-medical services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the respective contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Medicare Shared Savings Program Surplus Revenue</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company participates in the MSSP, which is sponsored by CMS. The goal of the MSSP is to improve the quality of patient care and outcomes through a more efficient and coordinated approach among providers. The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants&#8217; cost savings benchmark. Revenues earned by the Company are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and will be contingent on various factors, including achievement of the minimum savings rate as determined by MSSP for the relevant period. Such payments are earned and made on an &#8220;all or nothing&#8221; basis. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined solely by CMS, which are subject to significant estimation risk. Accordingly, they are not recognized as revenue until the amounts are estimable and collection is reasonably assured, which is generally when notice is received from CMS that cash payments are to be imminently received.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Fee-for-Service Revenue</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems as well as an estimate of the revenue associated with medical services.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i><u>Contract Assets</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets comprise accounts receivable. Generally, the Company does not have material amounts of other contract assets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i><u>Contract Liabilities (Deferred Revenue</u>)</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, which is generally uncommon. The Company&#8217;s contract liability balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">710,106</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> as of March 31, 2018 and December 31, 2017, respectively, and is presented within the &#8220;Accounts Payable and Accrued Expenses&#8221; line item of the condensed consolidated balance sheets. None of the amounts accrued as of December 31, 2017 was recognized as revenue for the three months ended March 31, 2018.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780057440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 14.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Income Taxes</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On December 22, 2017, the U.S. government enacted comprehensive tax legislation known as the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;). The TCJA establishes new tax laws that will take effect in 2018, including, but not limited to (1) a reduction of the U.S. federal corporate tax rate from a maximum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%; (2) elimination of the corporate alternative minimum tax; (3) a new limitation on deductible interest expense; (4) limitations on the deductibility of certain executive compensation; (5) changes to the bonus depreciation rules for fixed asset additions; and (6) limitations on net operating losses generated after December 31, 2017, to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of taxable income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">ASC 740, Income Taxes, generally requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA&#8217;s provisions, the SEC staff issued Staff Accounting Bulletin 118 (&#8220;SAB 118&#8221;), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the TCJA is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the TCJA.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At March 31, 2018 and December 31, 2017, the Company did not complete its accounting for the tax effects of enactment of the TCJA; however, the Company has made a reasonable estimate of the effects of the TCJA&#8217;s change in the federal rate and revalued its deferred tax assets based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. The Company recorded a decrease in its deferred tax assets and deferred tax liabilities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16.3</font> million, respectively, with a corresponding net adjustment to deferred income tax benefit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.7</font> million,&#160;for the year ended December 31, 2017. The Company&#8217;s provisional estimates are expected to be adjusted during the measurement period defined under SAB 118, based upon ongoing analysis of data and tax positions along with the new guidance from regulators and interpretations of the TCJA. The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on the differences between the Company&#8217;s financial statements and tax bases of assets and liabilities using enacted tax rates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. If and when this occurs, the income tax provision (benefit) will be adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the Company&#8217;s overall effective tax rate from quarter to quarter.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2018, due to overall cumulative losses incurred, prior to the merger with NMM, in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these assets is uncertain. The Company&#8217;s effective tax rate for the three months ended March 31, 2018 differed from the U.S. federal statutory rate primarily due to state income taxes. As of March 31, 2018, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2013 through December 31, 2016 and for the years ended December 31, 2014 through December 31, 2016, respectively. The Company currently does not anticipate material unrecognized tax benefits within the next 12 months.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780046544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>15.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Earnings Per Share</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Basic net income per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted net income per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Pursuant to the Merger Agreement, ApolloMed held back 10% of the shares of its common stock that were issuable to NMM shareholders (&#8220;Holdback Shares&#8221;) to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback Shares are excluded from the computation of basic earnings per share, but included in diluted earnings per share. As of both March 31, 2018 and 2017, APC held <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,682,110</font></font> shares of ApolloMed&#8217;s and NMM&#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 10).</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Below is a summary of the earnings per share computations:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Earnings per share &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Earnings per share &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,421,467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,067,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,098,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,445,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Below is a summary of the shares included in the diluted earnings per share computations:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,421,467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,067,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>10% shares held back pursuant to indemnification clause</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,039,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,785,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>835,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>592,365</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,801,367</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>38,098,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,445,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946602768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">VIE Assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>16.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="BACKGROUND-COLOR: transparent; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Variable Interest Entities (VIEs)</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s VIEs include APC and other immaterial entities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against the Company&#8217;s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on the Company&#8217;s general assets; rather, they represent claims against the specific assets of the VIE.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company evaluates its relationships with its VIEs on an ongoing basis to ensure that it continues to be the primary beneficiary.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investments in other entities &#150; cost method and amounts due to affiliate, which are eliminated upon consolidation with the NMM, are included in the accompanying consolidated balance sheets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,024,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,686,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted cash &#150; short-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,028,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,005,661</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Fiduciary cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,386,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,017,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investment in marketable securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,844,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,183,483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,960,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,821,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>119,304,721</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,771,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Noncurrent assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Land, property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,201,045</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,167,689</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,670,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,841,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,012,316</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,012,316</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loans receivable &#150; related parties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loan receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investments in other entities &#150; equity method</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,875,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,903,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investments in other entities &#150; cost method</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,320,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,320,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted cash &#150; long-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>745,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>745,235</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,155,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,371,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total noncurrent assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,980,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>179,362,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>295,284,826</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>272,133,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accounts payable and accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,505,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,625,610</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Incentives payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,900,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Fiduciary accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,386,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,017,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Medical liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,212,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,186,240</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Income taxes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,229,058</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,463,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Amount due to affiliate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,061,953</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,889,717</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Bank loan, short-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>394,783</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>510,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Capital lease obligations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>99,480</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>98,738</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>76,788,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>79,291,673</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Noncurrent liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Deferred tax liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,406,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,970,766</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Liability for unissued equity shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,185,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,185,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Capital lease obligations, net of current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,852</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>619,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total noncurrent liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,185,695</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,774,792</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>105,974,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>102,066,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000,000</font> of restricted cash is related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), was held for distribution to former NMM shareholders.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653075088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> 17.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b> Subsequent Events</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In April 2018, NMM distributed approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font> to former NMM shareholders, which was previously classified as restricted cash and dividends payable as of March 31, 2018, with $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,000,000</font> of restricted cash resulting from the Merger continuing to be held for distribution.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In April 2018, APC acquired a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% membership interest in a joint venture limited liability company. The joint venture entered into an agreement, effective as of April 10, 2018, to purchase real property of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 109,000</font> square feet including a building containing approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 89,000</font> rentable square feet situated in the City of Los Angeles, and provided a securing deposit into an escrow account. The transaction is expected to close on May 31, 2018.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789770912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Basis of Presentation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company&#8217;s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>Principles of Consolidation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM&#8217;s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM&#8217;s consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM&#8217;s consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA and ICC.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">All material intercompany balances and transactions have been eliminated in consolidation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Business Combinations</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Reportable Segments</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company&#8217;s reported revenue, net income, cash flows or total assets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Cash and Cash Equivalents</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)&#8217;s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">135.0</font> million. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk&#160;exposure.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Restricted Cash</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.05</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.10</font>%. Restricted cash also consists of cash held as collateral to secure standby letters of credits as required by certain contracts. As of March 31, 2018 and December 31, 2017, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,028,116</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,005,661</font> included in restricted cash short-term, respectively, in the accompanying condensed consolidated balance sheets. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000,000</font> of such restricted cash was related to an amount that, as a result of the Merger between ApolloMed and NMM (see Note 3), will be held in an escrow account for distribution to former NMM shareholders (see Note 17).</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Receivables</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Receivables</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Capitation and claims receivable relate to the health plan&#8217;s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) ASC 606 (see Note 13). Other receivables include fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December&#160;31, 2017, the Company recorded an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">763,205</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">407,953</font>, respectively.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risks</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Concentrations of Risks</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company had major payors that contributed the following percentage of net revenue:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"> <div>For&#160;The&#160;Three&#160;Months<br/> Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>24.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>10.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160; &#160;* Less than 10% <font style="BACKGROUND-COLOR: transparent">of total net revenues</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent">The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;March<br/> 31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;December<br/> 31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>25.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>23.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor E</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>38.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>30.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong>Fair Value Measurements of Financial Instruments</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables &#150; long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">FASB ASC 820, <i>Fair Value Measurement</i> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">This hierarchy prioritizes the inputs into three broad levels as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;1</i> &#151;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;2</i> &#151;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>Level&#160;3</i> &#151;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The carrying amounts and fair values of the Company&#8217;s financial instruments as of March 31, 2018 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2017 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;* <i>Included in cash and cash equivalents</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Derivative<br/> Assets<br/> (Warrants)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,338,886</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Change in fair value of warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,522,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,861,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The fair value of the warrant derivative asset of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.9</font> million at March&#160;31, 2017 was estimated using the Black-Scholes valuation model, using the following inputs: term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.54</font> &#150; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.00</font> years, risk free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.62</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.71</font>%, no dividends, volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 62.3</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 62.4</font>%, share price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.00</font> per share based on the trading price of ApolloMed&#8217;s common stock adjusted for a marketability discount, and a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% probability of redemption of the warrant shares issued along with the shares of ApolloMed&#8217;s convertible preferred stock issued in the financing.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Intangible Assets and Long-Lived Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2018 and 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Goodwill and Indefinite-Lived Intangible Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under the ASC 350, <i>Intangibles &#150; Goodwill and Other</i> (&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At least annually, at the Company&#8217;s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March&#160;31, 2018 and 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Investments in Other Entities - Equity Method</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate.</font> Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. No impairment loss was recorded on equity method investments for the three months ended March&#160;31, 2018 and 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Medical Liabilities</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO&#8217;s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the revenue less actual claims processed for or paid to in-network providers (after taking into account the average discount negotiated with the in-network providers). The Company plans to use the traditional lag models as the claims history matures. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Revenue Recognition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (&#8220;ASU&#8221;)&#160;2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company&#8217;s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Share-Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on performance of services in the future.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 <i>Equity-Based Payments to Non-Employees</i>. As such the fair value of such shares is periodically re-measured using an appropriate valuation model and income or expense is recognized over the vesting period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Basic and Diluted Earnings Per Share</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b):</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> a)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">The income of the legal acquiree (NMM) attributable to holders of the Company&#8217;s common stock in such period.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> b)</font></div> </td> <td style="TEXT-ALIGN: justify; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">The legal acquiree&#8217;s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyTextBlock', window );">Non-controlling Interests</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Noncontrolling Interests</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company&#8217;s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>Mezzanine Equity</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>Recent Accounting Pronouncements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221; (&#8220;ASU 2014-09&#8221;). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2016, the FASB issued ASU No. 2016-01, &#8220;Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&#8221; (&#8220;ASU 2016-01&#8221;). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2016, the FASB issued ASU No. 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) &#150; Classification of Certain Cash Receipts and Cash Payments&#8221; (&#8220;ASU 2016-15&#8221;). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In December 2016, the FASB issued ASU No. 2016-18, &#8220;Statement of Cash Flows (Topic 230) &#150; Restricted Cash&#8221; (&#8220;ASU 2016-18&#8221;). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18.</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2017, the FASB issued ASU No. 2017-01, &#8220;Business Combinations (Topic 805): Clarifying the Definition of a Business&#8221; (&#8220;ASU 2017-01&#8221;). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles &#150; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#8221; (&#8220;ASU 2017-04&#8221;). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: rgb(46,46,46); font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception&#8221; (&#8220;ASU 2017-11&#8221;). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company&#8217;s condensed consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.3A-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355119-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5144-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21459-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788868992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenue by Major Customers by Reporting Segments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company had major payors that contributed the following percentage of net revenue:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%" colspan="5"> <div>For&#160;The&#160;Three&#160;Months<br/> Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>24.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Payor C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="74%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>10.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>12.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160; &#160;* Less than 10% <font style="BACKGROUND-COLOR: transparent">of total net revenues</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent">The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="BACKGROUND-COLOR: transparent"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;March<br/> 31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>As&#160;of&#160;December<br/> 31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>25.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>23.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="70%"> <div>Payor E</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>38.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>30.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March 31, 2018 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,300,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">43,439,295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2017 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%" colspan="8"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Money market accounts*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">41,231,405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; certificates of deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Marketable securities &#150; equity securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">86,005</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42,374,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Derivative<br/> Assets<br/> (Warrants)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,338,886</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Change in fair value of warrant liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,522,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Balance at March 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,861,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776688480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Total estimated purchase consideration consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Equity consideration (1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">61,092,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of ApolloMed preferred stock held by NMM (2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19,118,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of NMM&#8217;s noncontrolling interest in APAACO (3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,129,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Estimated fair value of the outstanding ApolloMed stock options (4)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">187,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Total estimated purchase consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">85,526,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><i>&#160;</i></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (1)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Equity consideration</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0px 0in -0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,109,205</font> shares of ApolloMed common stock.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (2)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of ApolloMed&#8217;s preferred shares held by NMM</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.01in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger.&#160; As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed.&#160; The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,118,000</font>.&#160;The valuation methodology was based on an Option Pricing Method (&#8220;OPM&#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company.&#160; OPM assumptions included an expected term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> years, volatility rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37.9</font>%, and a risk-free rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.8</font>%.&#160; The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,745,000</font> and the fair value of the conversion option was determined to be $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,373,000</font> or an aggregate total fair value of $19,118,000.</div> <i>&#160;</i></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (3)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of NMM&#8217;s 50% share of APA ACO Inc.</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> (4)</i></font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 94%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Estimated fair value of the ApolloMed outstanding stock options</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombonationequityConsiderationTableTextBlock', window );">Business Combination, Equity consideration</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders <sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,109,205</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Multiplied by the price per share of ApolloMed&#8217;s common stock <sup style="font-style:normal">(2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Equity consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">61,092,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> (1)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> (2)</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 91%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> Represents the closing price of ApolloMed&#8217;s common stock on December 8, 2017.</font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see &#8220;MMG Transaction&#8221; below), with the excess recorded as goodwill:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">36,367,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Accounts receivable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,261,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Other receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,211,028</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">249,193</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Property, plant and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,114,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">745,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Fair value of intangible assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14,984,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,301,972</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">217,241</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">66,452,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Accounts payable and accrued liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,632,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Medical liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">39,353,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Line of credit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Convertible note payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,376,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Convertible note payable - related party</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9,921,938</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="82%"> <div style="CLEAR:both;CLEAR: both">Noncontrolling interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,142,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Total liabilities assumed and noncontrolling interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">66,451,586</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Net liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(913,468)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="82%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85,525,840</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Three&#160;Months<br/> Ended<br/> March&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Net revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">98,467,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Net loss attributable to Apollo Medical Holdings, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(351,982)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Weighted average common shares outstanding:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,601,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Earnings per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Weighted average common shares outstanding:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,601,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Earnings per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(0.01)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombonationequityConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity consideration in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombonationequityConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946485008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At March&#160;31, 2018, the Company&#8217;s intangible assets, net, consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Useful</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Net</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Accumulated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Indefinite Lived Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Medicare license</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Amortized Intangible Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Network relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11-15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,883,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(39,179,025)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,703,975</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Management contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,832,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,646,843)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,185,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Member relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,696,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(357,292)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,338,708</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Patient management platform</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,060,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(137,333)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,922,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Tradename/trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,011,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(16,850)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>994,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>144,476,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(45,337,343)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>99,138,657</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">At December&#160;31, 2017, the Company&#8217;s intangible assets, net, consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Useful</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Net</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Accumulated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amortization</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Indefinite Lived Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Medicare license</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,994,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Amortized Intangible Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Network relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11-15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,883,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(35,842,508)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>74,040,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Management contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,832,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,014,886)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,817,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Member relationships</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,696,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(46,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,649,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Patient management platform</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,060,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34,336)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,025,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>Tradename/trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,011,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(4,212)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,006,788</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>144,476,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(40,942,442)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>103,533,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Future amortization expense is estimated to be as follows for the years ending December&#160;31:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2018 (remaining nine months)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,262,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,480,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,671,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,961,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,448,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,323,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>97,145,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941223168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Investments in other entities &#150; equity method consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Universal Care, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,589,253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,609,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>LaSalle Medical Associates &#150; IPA Line of Business</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,099,975</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,452,767</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Diagnostic Medical Group</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,176,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,847,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Pacific Medical Imaging &#38; Oncology Center, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,374,668</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,400,693</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Pacific Ambulatory Surgery Center, LLC</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>635,151</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,875,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,903,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates IPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">LMA&#8217;s IPA line of business summarized balance sheets at March 31, 2018 and December&#160;31, 2017 and summarized statements of income for the three months ended March&#160;31, 2018 and 2017 are as follows (unaudited):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Balance Sheets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,064,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,065,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,005,144</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,433,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,173,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,565,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Loan receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Restricted cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>664,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>662,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,157,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,975,936</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Liabilities and Stockholders&#8217; Equity</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,946,133</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,353,337</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Stockholders&#8217; equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,211,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,622,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total liabilities and stockholders&#8217; equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,157,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,975,936</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Statements of Income</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>52,983,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>49,753,004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,002,458</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,506,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,018,667)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,246,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">UCI&#8217;s balance sheets at March 31, 2018 and December&#160;31, 2017 and statements of income for the three months ended March&#160;31, 2018 and 2017 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Balance Sheets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,595,206</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,872,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,862,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,618,760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,870,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,021,520</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,259,507</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,754,470</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,770,157</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,576,621</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,357,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,844,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Liabilities and Stockholders&#8217; Deficit</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>64,984,078</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,421,532</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Other liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,044,340</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,051,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Stockholders&#8217; deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,670,533)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,629,219)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Total liabilities and stockholders&#8217; deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,357,885</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,844,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Statements of Income Operations</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,665,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>46,540,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>72,154,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,757,246</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Income before provision for income taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>510,487</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,783,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Provision for income taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>713,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Net (loss) income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(41,313)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,070,146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719499424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s accounts payable and accrued expenses consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,356,677</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,786,381</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Specialty capitation payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>300,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>547,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Subcontractor IPA risk pool payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,472,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,348,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,727,238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,004,215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>710,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accrued compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,543,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,343,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,110,530</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>13,279,620</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6671688080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DisclosureOfMedicalLiabilitiesAbstract', window );"><strong>Disclosure of Medical Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s medical liabilities consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Balance, beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63,972,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,957,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Medical liabilities assumed from Merger</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>39,353,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Claims paid for previous period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(28,633,287)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(23,075,516)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Incurred health care costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,634,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121,846,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Claims paid for current period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(10,805,984)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(92,476,160)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Adjustments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(56,478)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(633,386)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Balance, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69,110,826</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>63,972,318</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DisclosureOfMedicalLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DisclosureOfMedicalLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790737568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Outstanding</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company&#8217;s outstanding warrants consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants outstanding at January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,648,541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">14.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(191,625)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7.55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.96</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(11,250)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrants outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Exercise&#160;Price&#160;Per</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Per</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">24,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">0.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">24,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,116,111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">2.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,116,111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,455,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">1,455,555</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">4.50 &#150;11.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3.69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">3,445,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div style="CLEAR:both;CLEAR: both">9.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember', window );">Contracted physicians and other services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC&#8217;s common stock, recognized over their respective vesting periods, consisted of the following: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both"> Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div style="CLEAR:both;CLEAR: both">Contracted physicians and other services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">202,382</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="2%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">321,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AmendmentAgreementAxis=ameh_ExclusivityAmendmentAgreementApcMember', window );">Exclusivity Amendment Agreement, APC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Outstanding stock options granted to primary care physicians to purchase shares of APC&#8217;s common stock consisted of the following: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options expired/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">853,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">508,864</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company&#8217;s outstanding stock options consisted of the following: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at January 1, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,141,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.79</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">19.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">30,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">9.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(129,536)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">15.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Options exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AmendmentAgreementAxis=ameh_ExclusivityAmendmentAgreementApcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AmendmentAgreementAxis=ameh_ExclusivityAmendmentAgreementApcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6677038032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock', window );">Schedule of Prospective Adoption of New Accounting Pronouncements</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The cumulative effect of changes made to the Company&#8217;s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance&#160;at<br/> December&#160;31,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Adjustments<br/> due&#160;to&#160;Topic&#160;606</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance&#160;at<br/> January&#160;1,&#160;2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Current Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">20,117,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">11,600,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">31,717,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Liabilities, Mezzanine Equity and Stockholders&#8217; Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Noncurrent Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Deferred tax liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">24,916,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,246,098</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">28,162,696</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Mezzanine equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Noncontrolling interest in Allied Pacific of California IPA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">172,129,744</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,351,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">179,481,178</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="63%"> <div style="CLEAR:both;CLEAR: both">Stockholders&#8217; Equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div style="CLEAR:both;CLEAR: both">Retained earnings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,734,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,002,468</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,736,999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The following table presents disaggregated revenue generated by each payor type:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March&#160;31,&#160;2018<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March&#160;31,&#160;2017<br/> (unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Commercial</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">105,350,102</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">83,848,918</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Medicare</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">18,541,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,453,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Medicaid</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">176,350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Other third parties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">99,160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div style="CLEAR:both;CLEAR: both">Revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">124,166,727</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">85,336,062</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the comparison between amounts disclosed under previous guidance and new guidance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946374160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Below is a summary of the earnings per share computations:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Earnings per share &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.07</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Earnings per share &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,421,467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,067,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,098,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,445,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted Average Number of Shares</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Below is a summary of the shares included in the diluted earnings per share computations:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,421,467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,067,954</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>10% shares held back pursuant to indemnification clause</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,039,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,785,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>835,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>592,365</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,801,367</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares of common stock outstanding &#150; diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>38,098,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,445,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946373728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investments in other entities &#150; cost method and amounts due to affiliate, which are eliminated upon consolidation with the NMM, are included in the accompanying consolidated balance sheets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March&#160;31,<br/> 2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December&#160;31,<br/> 2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>58,024,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>54,686,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted cash &#150; short-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,028,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,005,661</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Fiduciary cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,386,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,017,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investment in marketable securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,061,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,057,090</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Receivables, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,844,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,183,483</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,960,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,821,328</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>119,304,721</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,771,369</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Noncurrent assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Land, property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,201,045</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,167,689</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>67,670,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,841,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,012,316</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,012,316</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loans receivable &#150; related parties</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Loan receivable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investments in other entities &#150; equity method</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,875,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,903,524</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Investments in other entities &#150; cost method</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,320,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,320,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Restricted cash &#150; long-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>745,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>745,235</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,155,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,371,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total noncurrent assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,980,105</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>179,362,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>295,284,826</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>272,133,704</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accounts payable and accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,505,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,625,610</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Incentives payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,900,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Fiduciary accounts payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,386,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,017,437</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Medical liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,212,116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,186,240</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Income taxes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,229,058</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,463,540</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Amount due to affiliate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,061,953</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,889,717</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Bank loan, short-term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>394,783</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>510,391</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Capital lease obligations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>99,480</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>98,738</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>76,788,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>79,291,673</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Noncurrent liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Deferred tax liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27,406,818</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,970,766</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Liability for unissued equity shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,185,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,185,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Capital lease obligations, net of current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>593,852</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>619,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total noncurrent liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29,185,695</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,774,792</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div>Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>105,974,606</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>102,066,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=d3e5747-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=SL6228884-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=d3e5728-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=SL6759159-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790341808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 15, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jun. 04, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Initial Fixed Term Of Amended and Restated Management and Administrative Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ApollomedMember', window );">ApolloMed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember', window );">Concourse Diagnostic Surgery Center, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.43%<span></span>
</td>
<td class="nump">43.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_PacificAmbulatorySurgeryCenterMember', window );">Pacific Ambulatory Surgery Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_InternationalCancerCenterIccMember', window );">International Cancer Center ICC&#8221; [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ApollomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_ApollomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_PacificAmbulatorySurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_PacificAmbulatorySurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_InternationalCancerCenterIccMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_InternationalCancerCenterIccMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790102128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">18,028,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,005,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseInRestrictedCash', window );">Increase in Restricted Cash</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for Doubtful Accounts Receivable, Current</a></td>
<td class="nump">$ 763,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSignificantInfluenceDescription', window );">Equity Method Investment, Significant Influence Description</a></td>
<td class="text">Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investees board of directors, are considered in determining whether the equity method of accounting is appropriate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ameh_WarrantLiabilityMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageForDownRoundFinancing', window );">Percentage For Down round financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative Asset, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RestrictedCashInterestRate', window );">Restricted Cash Interest Rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RestrictedCashInterestRate', window );">Restricted Cash Interest Rate</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApaacoMember', window );">APA ACO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EstimatedRevenuePercentage', window );">Estimated Revenue Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSignificantInfluenceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of significant influence based on common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSignificantInfluenceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EstimatedRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated revenue percentage from the program of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EstimatedRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageForDownRoundFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage for Down round financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageForDownRoundFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RestrictedCashInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of restricted cash interest amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RestrictedCashInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ameh_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ameh_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788997488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Percentage of Net Revenue and Total Accounts Receivable (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Payor A [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Payor B [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Payor C [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Payor D [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Payor D [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">23.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Payor E [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">38.20%<span></span>
</td>
<td class="nump">30.50%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 10% of total net revenues</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789066544">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Carrying Amounts and Fair Values of Company's Financial Instruments (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 43,439,295<span></span>
</td>
<td class="nump">$ 42,374,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,439,295<span></span>
</td>
<td class="nump">42,374,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,300,818<span></span>
</td>
<td class="nump">41,231,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,300,818<span></span>
</td>
<td class="nump">41,231,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,061,022<span></span>
</td>
<td class="nump">1,057,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,061,022<span></span>
</td>
<td class="nump">1,057,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,455<span></span>
</td>
<td class="nump">86,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,455<span></span>
</td>
<td class="nump">86,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6671688080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarizes activity of Level 3 inputs measured on a recurring basis (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning Balance</a></td>
<td class="nump">$ 5,338,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease', window );">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)</a></td>
<td class="nump">1,522,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending Balance</a></td>
<td class="nump">$ 6,861,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787126704">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2017</div></th>
<th class="th"><div>Mar. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.88<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,109,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForAgreementTermination', window );">Payments for Agreement Termination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseDeferredTaxAsset', window );">Increase Decrease Deferred Tax Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ApaAcoIncMember', window );">APA ACO, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForAgreementTermination', window );">Payments for Agreement Termination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. [Member] | APA ACO, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember', window );">Apollo Medical Holdings, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare', window );">Business Combination, Step Acquisition, Equity Interest in Acquire, Number of Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,566,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationconsiderationDescription', window );">Business Combination, Consideration Description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,109,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair Value Assumptions, Expected Term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember', window );">Apollo Medical Holdings, Inc [Member] | Convertible Promissory Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember', window );">Apollo Medical Holdings, Inc [Member] | Warrant One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember', window );">Apollo Medical Holdings, Inc [Member] | Warrant Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_MaverickMedicalGroupIncMember', window );">Maverick Medical Group, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Business Combination, Contingent Consideration, Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Apollo Medical Holdings, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Estimated fair value of ApolloMed&#8217;s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (&#8220;OPM&#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Estimated fair value of NMM&#8217;s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationStepAcquisitionEquityInterestInAcquireeNumberOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationconsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationconsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase decrease in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForAgreementTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments made due to termination of agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForAgreementTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6411-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_ApaAcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_ApaAcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789566832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Estimated Purchase Consideration (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration</a></td>
<td class="nump">$ 61,092,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total estimated purchase consideration</a></td>
<td class="nump">85,526,383<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="nump">187,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="nump">19,118,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</a></td>
<td class="nump">$ 5,129,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Estimated fair value of the ApolloMed outstanding stock options The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Estimated fair value of ApolloMed&#8217;s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (&#8220;OPM&#8221;) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Estimated fair value of NMM&#8217;s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM&#8217;s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM&#8217;s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780012608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders | shares</a></td>
<td class="nump">6,109,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Multiplied by the price per share of ApolloMed&#8217;s common stock | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration | $</a></td>
<td class="nump">$ 61,092,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents the closing price of ApolloMed&#8217;s common stock on December 8, 2017.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790939360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assumption of Identifiable Assets Acquired and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,367,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">7,261,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other receivables</a></td>
<td class="nump">3,211,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">249,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,114,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">745,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Fair value of intangible assets acquired</a></td>
<td class="nump">14,984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent', window );">Deferred tax assets</a></td>
<td class="nump">2,301,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">217,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">66,452,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">8,632,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">39,353,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit', window );">Line of credit</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable', window );">Convertible note payable, net</a></td>
<td class="nump">5,376,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty', window );">Convertible note payable - related party</a></td>
<td class="nump">9,921,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interest</a></td>
<td class="nump">3,142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed and noncontrolling interest</a></td>
<td class="nump">66,451,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net liabilities assumed</a></td>
<td class="num">(913,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 188,933,191<span></span>
</td>
<td class="nump">$ 189,847,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of medical liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible note payable due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible note payable to related party due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of line of credit due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776694656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pro Forma Combined Historical Results (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues | $</a></td>
<td class="nump">$ 98,467,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss attributable to Apollo Medical Holdings, Inc. | $</a></td>
<td class="num">$ (351,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic', window );">Basic | shares</a></td>
<td class="nump">33,601,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">basic | $ / shares</a></td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted', window );">diluted | shares</a></td>
<td class="nump">33,601,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">diluted | $ / shares</a></td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaEarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaEarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proforma basic net weighted average outstanding for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proforma diluted net weighted average outstanding for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946464944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition', window );">Finite Lived Intangible Assets Accumulated Amortization Addition</a></td>
<td class="nump">$ 4,394,901<span></span>
</td>
<td class="nump">$ 4,374,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ExclusivityMember', window );">Exclusivity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition', window );">Finite Lived Intangible Assets Accumulated Amortization Addition</a></td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets accumulated amortization addition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ExclusivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ExclusivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791742096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of intangible assets (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (45,337,343)<span></span>
</td>
<td class="num">$ (40,942,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">99,138,657<span></span>
</td>
<td class="nump">103,533,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">144,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,533,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember', window );">Medicare License | Indefinite-lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">1,994,000<span></span>
</td>
<td class="nump">1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill', window );">Indefinite Lived Assets, Gross, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (39,179,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,842,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">70,703,975<span></span>
</td>
<td class="nump">$ 74,040,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 109,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (16,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">994,150<span></span>
</td>
<td class="nump">1,006,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (5,646,843)<span></span>
</td>
<td class="num">(5,014,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">17,185,157<span></span>
</td>
<td class="nump">$ 17,817,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (357,292)<span></span>
</td>
<td class="num">(46,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">6,338,708<span></span>
</td>
<td class="nump">$ 6,649,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 6,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Life (Yrs)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (137,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">1,922,667<span></span>
</td>
<td class="nump">$ 2,025,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross, Total, Ending Balance</a></td>
<td class="nump">$ 2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791794800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of future amortization expense (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018 (remaining nine months)</a></td>
<td class="nump">$ 12,262,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">14,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">12,671,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">10,961,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">9,448,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">37,323,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 97,145,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793129200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 15, 2016</div></th>
<th class="th"><div>Aug. 10, 2015</div></th>
<th class="th"><div>Jul. 01, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Oct. 15, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,024)<span></span>
</td>
<td class="nump">$ 2,227,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,875,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,903,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Due from Related Parties, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates IPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,099,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,452,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging and Oncology Center, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,025)<span></span>
</td>
<td class="nump">51,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,374,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging and Oncology Center, Inc [Member] | Ancillary Service Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,589,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,609,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Payments for Advance to Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Loans Receivable, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Due from Related Parties, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoansReceivableInterestRate', window );">Loans Receivable, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,176,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,847,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember', window );">Pacific Ambulatory Surgery Center, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member] | LaSalle Medical Associates IPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,792)<span></span>
</td>
<td class="nump">1,311,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,099,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,452,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member] | Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,202)<span></span>
</td>
<td class="nump">523,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,589,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,609,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member] | Diagnostic Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,042<span></span>
</td>
<td class="nump">361,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,176,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,847,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member] | Pacific Ambulatory Surgery Center, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,953<span></span>
</td>
<td class="num">$ (20,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 593,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_ApcLsmaMember', window );">APC LSMA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_ApcLsmaMember', window );">APC LSMA [Member] | LaSalle Medical Associates IPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_ApcLsmaMember', window );">APC LSMA [Member] | Allied Pacific of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC [Member] | Allied Pacific of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember', window );">Voting Common Stock A Two [Member] | Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsPurchaseOfShares', window );">Equity Method Investments, Purchase of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock', window );">Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember', window );">Voting Common Stock A Two [Member] | Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member] | Ancillary Service Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of investment in Voting common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased from equity method investment entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoansReceivableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate for the loans receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoansReceivableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage points (also referred to as 'margin') added to the reference rate as stated in the loan agreement and used to compute the variable rate on the loans receivable. For instance, the loan agreement might state that the interest rate the borrower is obligated to pay is the London Interbank Offered Rate (LIBOR) plus three quarters (3/4) of a percentage point adjusted quarterly (each three months). LIBOR in this example is the index or reference rate, 3/4 percentage point is the margin, the reference rate plus the margin is the fully indexed rate. This element would be used to report separately the margin.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_AlliedPacificOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777715440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Summarized Balance Sheets and Statements of Income) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates IPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents', window );">Equity Method Investment, Summarized Financial Information, Cash and Cash Equivalents</a></td>
<td class="nump">$ 22,064,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,065,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables', window );">Equity Method Investment, Summarized Financial Information, Receivables</a></td>
<td class="nump">3,005,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,433,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets', window );">Equity Method Investment, Summarized Financial Information, Other current assets</a></td>
<td class="nump">2,173,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,565,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables', window );">Equity Method Investment, Summarized Financial Information, Loan Receivables</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash', window );">Equity Method Investment, Summarized Financial Information, Restricted Cash</a></td>
<td class="nump">664,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets', window );">Equity Method Investment, Summarized Financial Information, Assets</a></td>
<td class="nump">29,157,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,975,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Liabilities and Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities', window );">Equity Method Investment, Summarized Financial Information, Current Liabilities</a></td>
<td class="nump">23,946,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,353,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Equity Method Investment Summarized Financial Information, Stockholders' deficit</a></td>
<td class="nump">5,211,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,622,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity', window );">Equity Method Investment, Summarized Financial Information, Total liabilities and stockholders' deficit</a></td>
<td class="nump">29,157,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,975,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Equity Method Investment, Summarized Financial Information, Revenue</a></td>
<td class="nump">52,983,791<span></span>
</td>
<td class="nump">$ 49,753,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales', window );">Equity Method Investment, Summarized Financial Information, Expenses</a></td>
<td class="nump">54,002,458<span></span>
</td>
<td class="nump">44,506,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Equity Method Investment, Summarized Financial Information, Net (loss) income</a></td>
<td class="num">(1,018,667)<span></span>
</td>
<td class="nump">5,246,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents', window );">Equity Method Investment, Summarized Financial Information, Cash and Cash Equivalents</a></td>
<td class="nump">22,595,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,872,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables', window );">Equity Method Investment, Summarized Financial Information, Receivables</a></td>
<td class="nump">23,862,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,618,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets', window );">Equity Method Investment, Summarized Financial Information, Other current assets</a></td>
<td class="nump">18,870,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,021,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets', window );">Equity Method Investment, Summarized Financial Information, Other Assets</a></td>
<td class="nump">2,259,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,754,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment', window );">Equity Method Investment, Summarized Financial Information, Property And Equipment</a></td>
<td class="nump">1,770,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,576,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets', window );">Equity Method Investment, Summarized Financial Information, Assets</a></td>
<td class="nump">69,357,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,844,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Liabilities and Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities', window );">Equity Method Investment, Summarized Financial Information, Current Liabilities</a></td>
<td class="nump">64,984,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,421,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities', window );">Equity Method Investment, Summarized Financial Information, Other Liabilities</a></td>
<td class="nump">10,044,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,051,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Equity Method Investment Summarized Financial Information, Stockholders' deficit</a></td>
<td class="num">(5,670,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,629,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity', window );">Equity Method Investment, Summarized Financial Information, Total liabilities and stockholders' deficit</a></td>
<td class="nump">69,357,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,844,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Equity Method Investment, Summarized Financial Information, Revenue</a></td>
<td class="nump">72,665,437<span></span>
</td>
<td class="nump">46,540,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales', window );">Equity Method Investment, Summarized Financial Information, Expenses</a></td>
<td class="nump">72,154,950<span></span>
</td>
<td class="nump">44,757,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes', window );">Equity Method Investment, Summarized Financial Information, Income before provision for income taxes</a></td>
<td class="nump">510,487<span></span>
</td>
<td class="nump">1,783,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit', window );">Equity Method Investment, Summarized Financial Information, Provision for income taxes</a></td>
<td class="nump">551,800<span></span>
</td>
<td class="nump">713,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Equity Method Investment, Summarized Financial Information, Net (loss) income</a></td>
<td class="num">$ (41,313)<span></span>
</td>
<td class="nump">$ 1,070,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income (loss) before income taxes reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes (benefit) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxesBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loan receivables reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationLoanReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other current assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property and equipment reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSummarizedFinancialInformationRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost of sales reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.g)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities and equity reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from sale of goods and services reduced by sales returns, allowances, and discounts reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946695968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Other Entities (Equity Method) (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 21,875,500<span></span>
</td>
<td class="nump">$ 21,903,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">8,589,253<span></span>
</td>
<td class="nump">8,609,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates - IPA Line of Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">9,099,975<span></span>
</td>
<td class="nump">9,452,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">2,176,453<span></span>
</td>
<td class="nump">1,847,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging and Oncology Center, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">1,374,668<span></span>
</td>
<td class="nump">1,400,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember', window );">Pacific Ambulatory Surgery Center, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 635,151<span></span>
</td>
<td class="nump">$ 593,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941336128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loans Receivable, Net</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ExtendableAmountOnCreditFacility', window );">Extendable Amount On Credit Facility</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TermOfManagementServiceAgreement', window );">Term Of Management Service Agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfManagingResponsibleOfHealthPlanship', window );">Percentage Of Managing Responsible Of Health Plan ship</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcMember', window );">APC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember', window );">NMM Business Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember', window );">Dr. Jay Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loans Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Debt Instrument, Interest Rate, Basis for Effective Rate</a></td>
<td class="text">prime rate plus 1%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, Payment Terms</a></td>
<td class="text">Interest on the Dr. Jay Loan accrues at a rate that is equal to the prime rate plus 1% (5.75% and 5.50% as of March 31, 2018 and December 31, 2017, respectively) and payable in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Debt Instrument, Convertible, Terms of Conversion Feature</a></td>
<td class="text">At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountables capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountables then-current valuation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ExtendableAmountOnCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of extendable amount on credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ExtendableAmountOnCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfManagingResponsibleOfHealthPlanship">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of managing responsible of health plan membership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfManagingResponsibleOfHealthPlanship</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TermOfManagementServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of management service agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TermOfManagementServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946349872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountPayableAndAccruedLiabilitiesLineItems', window );"><strong>Account Payable And Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 3,356,677<span></span>
</td>
<td class="nump">$ 3,786,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Specialty capitation payable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">547,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIpaRiskPoolPayable', window );">Subcontractor IPA risk pool payable</a></td>
<td class="nump">1,472,985<span></span>
</td>
<td class="nump">1,348,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,727,238<span></span>
</td>
<td class="nump">3,004,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">710,106<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,543,524<span></span>
</td>
<td class="nump">4,343,341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 12,110,530<span></span>
</td>
<td class="nump">$ 13,279,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountPayableAndAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountPayableAndAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIpaRiskPoolPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of subcontractor IPA risk pool payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIpaRiskPoolPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6671505792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Balance, beginning of period</a></td>
<td class="nump">$ 63,972,318<span></span>
</td>
<td class="nump">$ 18,957,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesAddedFromMerger', window );">Medical liabilities assumed from Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,353,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod', window );">Claims paid for previous period</a></td>
<td class="num">(28,633,287)<span></span>
</td>
<td class="num">(23,075,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationExpensesNet', window );">Incurred health care costs</a></td>
<td class="nump">44,634,257<span></span>
</td>
<td class="nump">121,846,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods', window );">Claims paid for current period</a></td>
<td class="num">(10,805,984)<span></span>
</td>
<td class="num">(92,476,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdjustmentsForMedicalLiabilities', window );">Adjustments</a></td>
<td class="num">(56,478)<span></span>
</td>
<td class="num">(633,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Balance, end of period</a></td>
<td class="nump">$ 69,110,826<span></span>
</td>
<td class="nump">$ 63,972,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdjustmentsForMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of adjustments for medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdjustmentsForMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesAddedFromMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of medical liabilities derived from merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesAddedFromMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of health care costs, net of recoveries of stop-loss insurance. Costs of services rendered (including costs of services rendered but not yet reported).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized for asserted and unasserted malpractice claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asserted and unasserted malpractice claims that were originally recognized in a prior period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredInPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791405120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loan, Lines of Credit and Loan Payable - Related Party - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 18, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Apr. 07, 2017</div></th>
<th class="th"><div>Mar. 03, 2017</div></th>
<th class="th"><div>Apr. 22, 2016</div></th>
<th class="th"><div>Apr. 21, 2016</div></th>
<th class="th"><div>Apr. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term Bank Loans and Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,783<span></span>
</td>
<td class="nump">$ 510,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt Instrument, Maturity Date Range, Start</a></td>
<td class="text">Apr. 22,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Debt Instrument, Maturity Date Range, End</a></td>
<td class="text">Jun. 22,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_IccMember', window );">ICC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term Bank Loans and Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,783<span></span>
</td>
<td class="nump">$ 510,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcMember', window );">APC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of Credit Facility, Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Line of Credit Facility, Interest Rate Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime rate plus 0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcMember', window );">APC [Member] | Standby Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember', window );">NMM Business Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of Credit Facility, Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.675%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties', window );">Line of Credit Facility, Guarantee Given by Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcBusinessLoanAgreementMember', window );">APC Business Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of Credit Facility, Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.675%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,694,984<span></span>
</td>
<td class="nump">$ 9,694,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Line of Credit Facility, Interest Rate Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime rate plus 0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties', window );">Line of Credit Facility, Guarantee Given by Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApaacoMember', window );">APAACO [Member] | Standby Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,699,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of Credit Facility, Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 22,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of Credit Facility, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of guarantee given by related parties for line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_IccMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_IccMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NmmBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790427520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders&#8217; Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 16.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,682,110<span></span>
</td>
<td class="nump">1,682,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">37,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="nump">$ 631,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet', window );">Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, warrants, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Warrant Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Warrant, Exercisable, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Warrant, Exercisable, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Share based Compensation Arrangement By Share based Payment Award Options Grant Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember', window );">Former Shareholders of NMM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementIncNmmMember', window );">Network Medical Management, Inc 'NMM' [Member] | Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,214,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AmehMember', window );">AMEH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,039,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,682,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of gross cashless options exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of net cashless options exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price of warrants exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of warrant exercise during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementIncNmmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementIncNmmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmehMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmehMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlliedPacificOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlliedPacificOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789885392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">1,141,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(129,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">1,041,504<span></span>
</td>
<td class="nump">1,141,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">1,041,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance</a></td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">6.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance</a></td>
<td class="nump">4.09<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Beginning Balance</a></td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning Balance</a></td>
<td class="nump">$ 19.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">11.86<span></span>
</td>
<td class="nump">$ 19.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 11.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnershipAxis=ameh_AlliedPacificOfCaliforniaMember', window );">Allied Pacific of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">853,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">853,800<span></span>
</td>
<td class="nump">853,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">853,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance</a></td>
<td class="nump">$ 0.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance</a></td>
<td class="nump">0.167<span></span>
</td>
<td class="nump">$ 0.167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Beginning Balance</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning Balance</a></td>
<td class="nump">$ 508,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">508,864<span></span>
</td>
<td class="nump">$ 508,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 508,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=ameh_AlliedPacificOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=ameh_AlliedPacificOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780212672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Share-based Compensation Expense Related to Common Stock Option Awards Granted (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember', window );">Contracted physicians and other services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 202,382<span></span>
</td>
<td class="nump">$ 321,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ameh_ContractedPhysiciansAndOtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789601152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Warrant (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesAbstract', window );"><strong>Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants, Outstanding</a></td>
<td class="nump">3,648,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Number Of Warrants Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Number Of Warrants Exercised</a></td>
<td class="num">(191,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Class Of Warrant Or Right Cancelled In Period</a></td>
<td class="num">(11,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants, Outstanding</a></td>
<td class="nump">3,445,666<span></span>
</td>
<td class="nump">3,648,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageexercisePriceAbstract', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod', window );">Class Of Warrants Or Right, Exercise Price Of Warrants Grant In Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod', window );">Class Of Warrants Or Right, Exercise Price Of Warrants Exercised In Period</a></td>
<td class="nump">7.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod', window );">Class Of Warrants Or Right, Exercise Price Of Warrants Forfeited In Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 9.88<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm', window );">Class Of Warrant Or Rights Exercised Weighted Average Remaining Contractual Term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm', window );">Class Of Warrant Or Rights Forfeited Weighted Average Remaining Contractual Term</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 8 months 8 days<span></span>
</td>
<td class="text">3 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 14.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</a></td>
<td class="nump">9.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 14.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights exercised Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights forfeited Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageexercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageexercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787210288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One 4.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants outstanding</a></td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price per share | $ / shares</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two 9.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants outstanding</a></td>
<td class="nump">1,116,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 6 months 11 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="nump">1,116,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price per share | $ / shares</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three 10.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants outstanding</a></td>
<td class="nump">1,455,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="nump">1,455,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price per share | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four 11.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants outstanding</a></td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price per share | $ / shares</a></td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFiveMember', window );">Warrant Exercise Price Range Five 4.50-11.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants outstanding</a></td>
<td class="nump">3,445,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="nump">3,445,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price per share | $ / shares</a></td>
<td class="nump">$ 9.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Exercisable Weighted Average Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=ameh_WarrantExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777560864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791149472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_LmaMember', window );">LMA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_PmiocMember', window );">PMIOC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=ameh_DmgMember', window );">DMG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ameh_ServiceMember', window );">Service [Member] | PMIOC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ameh_ServiceMember', window );">Service [Member] | AMG, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_RobMikitarianMember', window );">Rob Mikitarian [Member] | Notes Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and Other Receivables, Net, Current</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and Other Receivables, Net, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center [Member] | Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember', window );">Medical Property Partners [Member] | Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalInvestmentGroupLlcMember', window );">Medical Investment Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">Shareholders And Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payment Made To Related Party</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ameh_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ameh_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_RobMikitarianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_RobMikitarianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalInvestmentGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalInvestmentGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777415936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative Effect on Retained Earnings, Net of Tax</a></td>
<td class="nump">$ 1,392,000<span></span>
</td>
<td class="nump">1,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent', window );">Fresh-Start Adjustment, Increase (Decrease), Deferred Income Tax Liabilities, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,246,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AllinclusivePopulationbasedPaymentsToBeReceived', window );">All-Inclusive Population-Based Payments to be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, Net, Current, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,805,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,117,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, Net, Current, Total</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AllinclusivePopulationbasedPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of All-Inclusive Population-Based payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AllinclusivePopulationbasedPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fresh-start adjustment to noncurrent deferred income tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 740<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6918596&amp;loc=d3e57478-112775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778096416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Prospective Adoption of New Accounting Pronouncements (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 02, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 52,805,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,117,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">30,055,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,916,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Pacific of California IPA</a></td>
<td class="nump">190,654,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,129,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">$ 4,897,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,734,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,246,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Pacific of California IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,351,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember', window );">Adjustments for New Accounting Principle, Early Adoption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,717,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,162,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Pacific of California IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,481,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,736,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946486304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregation of Revenue (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 124,166,727<span></span>
</td>
<td class="nump">$ 85,336,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">105,350,102<span></span>
</td>
<td class="nump">83,848,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">18,541,115<span></span>
</td>
<td class="nump">1,453,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">176,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 99,160<span></span>
</td>
<td class="nump">$ 33,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776986048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome', window );">Operating Loss Carryforwards, Limitation Rate on Taxable Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate', window );">Increase Decrease in Deferred Tax Assets Due To Change in Enacted Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate', window );">Increase Decrease in Deferred Tax Liabilities Due To Change in Enacted Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease in deferred tax assets due to change in enacted tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease in deferred tax liabilities due to change in enacted tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage represents the limitation of using the net operating loss carry forwards on taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_OperatingLossCarryforwardsLimitationRateOnTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780166896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares</a></td>
<td class="nump">1,682,110<span></span>
</td>
<td class="nump">1,682,110<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946888144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">32,421,467<span></span>
</td>
<td class="nump">25,067,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">38,098,373<span></span>
</td>
<td class="nump">28,445,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946465472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Shares Included in Diluted Earnings Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">32,421,467<span></span>
</td>
<td class="nump">25,067,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">38,098,373<span></span>
</td>
<td class="nump">28,445,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">835,790<span></span>
</td>
<td class="nump">592,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">3,039,749<span></span>
</td>
<td class="nump">2,785,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">1,801,367<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780139200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VIE Assets - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RestrictedCashAcquiredFromAcquisition', window );">Restricted Cash Acquired from Acquisition</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RestrictedCashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RestrictedCashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777389280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,731,761<span></span>
</td>
<td class="nump">$ 99,749,199<span></span>
</td>
<td class="nump">$ 63,251,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term</a></td>
<td class="nump">18,028,116<span></span>
</td>
<td class="nump">18,005,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">1,138,477<span></span>
</td>
<td class="nump">1,143,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">52,805,123<span></span>
</td>
<td class="nump">20,117,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,525,437<span></span>
</td>
<td class="nump">3,126,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">180,615,388<span></span>
</td>
<td class="nump">144,159,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="nump">13,700,034<span></span>
</td>
<td class="nump">13,814,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">99,138,657<span></span>
</td>
<td class="nump">103,533,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">188,933,191<span></span>
</td>
<td class="nump">189,847,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Loans receivable - related parties</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loan receivable</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities - equity method</a></td>
<td class="nump">21,875,500<span></span>
</td>
<td class="nump">21,903,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">745,293<span></span>
</td>
<td class="nump">745,235<span></span>
</td>
<td class="nump">$ 101,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,585,850<span></span>
</td>
<td class="nump">1,632,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">340,978,525<span></span>
</td>
<td class="nump">346,476,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">521,593,913<span></span>
</td>
<td class="nump">490,635,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,110,530<span></span>
</td>
<td class="nump">13,279,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,386,474<span></span>
</td>
<td class="nump">2,017,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="nump">69,110,826<span></span>
</td>
<td class="nump">63,972,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,957,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loan, short-term</a></td>
<td class="nump">394,783<span></span>
</td>
<td class="nump">510,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td>
<td class="nump">99,480<span></span>
</td>
<td class="nump">98,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">110,616,762<span></span>
</td>
<td class="nump">109,601,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">30,055,819<span></span>
</td>
<td class="nump">24,916,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LiabilityForUnissuedEquitySharesNoncurrent', window );">Liability for unissued equity shares</a></td>
<td class="nump">1,185,025<span></span>
</td>
<td class="nump">1,185,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current portion</a></td>
<td class="nump">593,852<span></span>
</td>
<td class="nump">619,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">49,834,696<span></span>
</td>
<td class="nump">44,720,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">160,451,458<span></span>
</td>
<td class="nump">154,322,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">58,024,188<span></span>
</td>
<td class="nump">54,686,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term</a></td>
<td class="nump">18,028,116<span></span>
</td>
<td class="nump">18,005,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashCurrent', window );">Fiduciary cash</a></td>
<td class="nump">1,386,474<span></span>
</td>
<td class="nump">2,017,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="nump">1,061,022<span></span>
</td>
<td class="nump">1,057,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="nump">38,844,184<span></span>
</td>
<td class="nump">15,183,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,960,737<span></span>
</td>
<td class="nump">1,821,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">119,304,721<span></span>
</td>
<td class="nump">92,771,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="nump">10,201,045<span></span>
</td>
<td class="nump">10,167,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">67,670,837<span></span>
</td>
<td class="nump">70,841,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">60,012,316<span></span>
</td>
<td class="nump">60,012,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Loans receivable - related parties</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableNet', window );">Loan receivable</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities - equity method</a></td>
<td class="nump">21,875,500<span></span>
</td>
<td class="nump">21,903,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMethodInvestments', window );">Investments in other entities - cost method</a></td>
<td class="nump">4,320,000<span></span>
</td>
<td class="nump">4,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">745,293<span></span>
</td>
<td class="nump">745,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,155,114<span></span>
</td>
<td class="nump">1,371,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">175,980,105<span></span>
</td>
<td class="nump">179,362,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">295,284,826<span></span>
</td>
<td class="nump">272,133,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,505,047<span></span>
</td>
<td class="nump">3,625,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrent', window );">Incentives payable</a></td>
<td class="nump">14,900,000<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,386,474<span></span>
</td>
<td class="nump">2,017,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="nump">25,212,116<span></span>
</td>
<td class="nump">25,186,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">3,229,058<span></span>
</td>
<td class="nump">1,463,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amount due to affiliate</a></td>
<td class="nump">28,061,953<span></span>
</td>
<td class="nump">24,889,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loan, short-term</a></td>
<td class="nump">394,783<span></span>
</td>
<td class="nump">510,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td>
<td class="nump">99,480<span></span>
</td>
<td class="nump">98,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">76,788,911<span></span>
</td>
<td class="nump">79,291,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">27,406,818<span></span>
</td>
<td class="nump">20,970,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LiabilityForUnissuedEquitySharesNoncurrent', window );">Liability for unissued equity shares</a></td>
<td class="nump">1,185,025<span></span>
</td>
<td class="nump">1,185,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current portion</a></td>
<td class="nump">593,852<span></span>
</td>
<td class="nump">619,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">29,185,695<span></span>
</td>
<td class="nump">22,774,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 105,974,606<span></span>
</td>
<td class="nump">$ 102,066,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fiduciary cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LiabilityForUnissuedEquitySharesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for unissued equity shares classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LiabilityForUnissuedEquitySharesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75027002&amp;loc=d3e40346-111594<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e40010-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e40019-112707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77891322&amp;loc=d3e41614-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778138192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>a</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | a</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Real Estate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | a</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_RealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_RealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MT**C"+SDP-IIHC^/70,WP 0C##9^%U#/Q%S]$YL[P"[),9HY-0Q#.2QR+NW
MX>UI]Y+7+8R+))W"]"L:06>/6W:=_+JX?]@_LK:N^*:H5@5?[?E:U!NQK-XG
MUQ]^-V';:W,P_]CX*M@V\.LNVB]02P,$%     @ M8.O3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " "U@Z],]P!.V&8"   5"   &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6VXZ;,!#]%<0'++X 258$*4E5M5(K15NU?782)Z UF-I.
MV/Y];<-2:IOF(=CFG#DS]HR'HN?B55:4JNBM8:W<QI52W7.2R'-%&R*?>$=;
M_>;*14.4GHI;(CM!R<62&I8@ /*D(74;EX5=.XJRX'?%ZI8>123O34/$[SUE
MO-_&,'Y?>*EOE3(+25ETY$:_4?6].PH]2R8KE[JAK:QY&PEZW<8[^'R J2%8
MQ(^:]G(VCDPH)\Y?S>3S91L#XQ%E]*R,":(?#WJ@C!E+VH]?H]%XTC3$^?C=
M^D<;O [F1"0]</:SOJAJ&Z_CZ$*OY,[4"^\_T3&@+([&Z+_0!V4:;CS1&F?.
MI/V/SG>I>#-:T:XTY&UXUJU]]L.;%(ZT, &-!#01,/@O 8\$/!$@ML$/GME0
M/Q!%RD+P/A+#:77$) 5\QGHSSV;1[IU]IZ.5>O51@B)Y&#,C8C\@T P!)T2B
M;4\"*"2P1QX=_2MP\!$X+("#$6!+QS-Z&J:G07IJZ>F,GCD;X"/RL$ 6%,@\
M^LH1\!'KL$ >%,@]^L81\!$0A!560865SX>.Q #)+*0=CAG A3#609&U+^)D
MRGZ Y'/(0JIL@A(;7R)U) *0+"P!0;B@@&\A=TL*>+L%P1JGZ4)BP87:A;Z4
MFULAS,*QP& ![R#R+;@)%L"@A0R#X2J&V+?@YE@(@Q94PL4._5I&V+F.1LS\
M<+#^I2#;.%K)[))MJ+C9?B2C,[^WMAG.5J>>MT/VDOX+'QKF5R)N=2NC$U?Z
MJK<7\I5S1;5#X$F[4ND>/4T8O2HS7.FQ&!K5,%&\&YMP,GT)E'\ 4$L#!!0
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M7$RM_RV\AS+*>R<QQ[XNV^%[L7]KN[J::HE6JN+[^'LZ#[_7\1^#4Q@?@%,
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M&9U_V=C_!M&!EY)<^1'J_ =;# F-"\=;?S;3F$V&PW[^06SYQN4?4$L#!!0
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ML?\UH@,O97/E1ZCU'VPV)-0N'&_\V8QC-AH.N^D'L?D;%Q]02P,$%     @
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M0N6">>=M,ZS9X#ALQQ?$IF><_P-02P,$%     @ M8.O3+$ P/2V 0  T@,
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M9SN.V6AXTTT_B,W?N/@+4$L#!!0    ( +6#KTPXD/R1M0$  -(#   9
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MT?F;C?.O$1WX4I([OT*M?V"+HZ!VP?SH;3.MV>0X[.<7Q)9G7/P%4$L#!!0
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M]K]&=."E[*[\"+7^@RV&@MJ%X[4_FVG,)L-A/_\@MGSCX@]02P,$%     @
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M#YTYJ83D5)M0UD3U$FCIBC@C41#L"*=MY^>IRYUEGHI!L[:#L_34P#F5?T[
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M[]P*(;E:MNZ=^G_<J[-./RCX5NK;2-W7[8:_'4AQZ XS3G^BFO\#4$L#!!0
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M!8C\Q8(1)8!1YLL60TH @<R:J=>C:#J?4)%T?QY?&$$"&&34]H5$S.,'DTH
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M7:;FNAG.C(8;K<[C>5AT.Y1;_@]02P,$%     @ M8.O3.&PT"2@ @  -0D
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M9I+8!&Y9$#0+,OC3NRQR/ !% ] A )LG()PJ1A,QF#2#"<UH)C@/9,I0$/-
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MGJ4TW'K&#W:2"GN4CAW!S\8U4]M6_7G2=XQLAK,R&@_L_"]02P,$%     @
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MJ]:/24C]D??1>M+,M&?H"<,(&S(SFR%'PE,I'/.@8!Y3:MF'E!@Q;(8.B3E
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M*=6^&QZS_KF9KD.GETZ?S55O?+MO7OT'4$L#!!0    ( +6#KTR970P[W@$
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MKAM[5V'X@V%D-^XUF?Y<LK]02P,$%     @ M8.O3%%%7^TA P  & T  !D
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M 3,H "+ #!Y,U-/VWE6B##OPH0-?._"O''C&2G680&/*;AU"/PY\PD0!) H
MD6\0!1,B%U.$D"($%(%!$4XH/E%"X=RJ1Y H D2A010!(F+!3$(QY(EO*$X\
M+8[O!V%HQ+,!N(^*F," $K#=(NR 7'PRW4E./D7FT>Q R2C89!'-E(AF)(#
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M5C]#\D_&&Y7::N'V1MT;W,6E8S]AMEE0ZA 58;,@9!:CJA[(-HM>+(YT"7L
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MDGH8J3'O[H%N(EG37W%@N&>SOU!+ P04    " "U@Z],5;T'/2<#  #0#
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M4(T?1HU*.0CCO"RR\[P_).Z&KO)[^P["V+[)A$?TC:JF$QJ=I+'W[V^IEM*
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M#=IF=>1<,:TP?M#:SOK]FA8-.RHSU>TV$$,3'Q:*]^,#%4VO9/D74$L#!!0
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MV,7&& ^H)[O#0>CPF2R&A,:'[0/N;1J69'@SS.^ +8^Q_ -02P,$%     @
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M./6$ 4P@!]  )E"%XJP'*M_+>@@CF"R"BS-3'9SM8T!#]7/A]%D$)C!; IL
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M?/4F.GEUVCCQ=.4NS*P+JDE5I?L& IPGU5T$BXI6^$?ZCT-VGVS@\<:#7U)
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M:7G$''W,Y4+26<4B*R$*; GO#TB5GRXN&!?$T-)ASWW^MG#:!V05$:@#@)_
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M^-E*' EQ2]X&LAJX3H"(X39XV97>P1<("@SZV]LRO268&Z<>H)U/6J;XFU8
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M8K^T+R >_M21G^'WHTD^<:2=66 +W&W+^:V,R:O>K)@CFOFQI>\EUFB!W&Y
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MV\:/HP&0>FN>@M^Y["RT@  )60 K&(Q&^*%/!@_@]JTSB<5V0E:F\6B,O -
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M&$.A9P75:])TDZ3JGEU)YYN+'WT2?_L*T,(*W[-Q]F2%G%!SW;7T6 K?E4&
MK')R2GU-,:>.M7[3JJ!S&[YV@TMCXO3-H:E"RVX# /142!>)!K:14;8/'/;
MSF"SAJ8?:UR<5#3>G>0\_?I^TMRJ2J#,6;CN*I [Q,<I"!Y)%98PVH ,(".,
M@Q@/H]$4=DTJTV"&/L010&$^GL7CP<#)Q,OM-=KCL"GJU0&]1EX2_OCQ/+I<
M7IW7L J]:_O4=C5<:8(8R1/4K^6,*B "YWRD\D#:I5AF8,5;<E"YZ#;G!F/P
MM=8$\JW,'5-U+5@ETF7%WET?[+>4;Z0TA5@6]**:O1IYH4>;I",,Q5#7(8,9
M?5'>)KD8G+QP;>47D1A(Z*/KD.[08XIF.>U1[,HXNE %'"UV)@FJ55699@TJ
M!'.B5',V7^#,M'YVXJ>C4YA,TWD.;BC8-2;644&XDG/4K41+>S;R$'6ZBSX!
MYMK<::!0!%"YW7%=N/<]?KV3^XBH3V.1^Q)N\5SN,#L^\[3F]WS>T+*^^K*\
M$=7W/_6KD1R;EF)GKI0V@LB,0I*[[2.ZPP8KKED]W&X$/TJ()[YA#"6PTO+4
M1\DA-E0:7$[U^$JU8+B+ /9I\[ZS]+=]*DU#$^.A!M%*'/U[9[;DY %I1L?O
ML2+\@ W D )R$!2*J9'/!<? *BZ@XB+H71V5<*K0_YU^VV6E*QA&#FIIC$L0
MT(M_ #4TV8O;&62C]$&<D68RZI&Z.DB-)M?V#UW!7,SWD'/W5CH1[:\E71LH
MND,H _"BS48:VYIB0QAAIZ\^XUQ\K2JL36S+6=9W2/6F%-323$<!+R7.GV9A
MM/+_*SP,9WXV$Q/1J)N7C5%8'9%F,T'O]'2$GCE02A:C&+3/3A,T<+,M5=%\
M4KINU8Y?&=7IE5&>CABOI5#;A\NE"SYR";UMYM1.D>L8NZZ;L/XYV>Y^Z#!B
MM9D"GLGVZU 6+6U"(BU]6*"W9SAN>"_(UNKUN"=^?K%+8MJ+ZD-\]N+?0EV:
MFIWN[$0AL<_KE%TBT&@\:TK PW3%;/PS7A+NEK>=D\$+K'%TA?+M1J>X*K"?
M(O%_.C"=B9_JF,0*P+C%'U,03  A>]&?DT?X>I-\33@3W\ON)?WH![22>NPX
M+1;6%$W3=*D@$NK)L>&B'KA*G5 X#,+N,'&5)_?M!^#F@W1G>]B^LC:,2<M?
MZ NA%,>4VU(._FB,$N=NV=*4C/W2!PYDDF7K*A!Y8O>)PBTVB$\8Y6-P@+8.
MU+&4*IE8M+!E),?\J'2?2ARELMDMEN\AZZR8EAKOUT[HS*[AZG!-2=S$F?!I
M7T+I2VI$#C/H\?==+%ME?PEW[C-#Z #%=T7249Z6XFG2N*B:.>X-!@4YTLV^
M\'5PG;PR^?[<=.+9$V.DCE %]68V'3;7S%U94>@(FE,&JF>N/9.:!^]05G@F
M:YQI*CR>^ZMK:K+G;Q11[1JI2/XU18A&0*_ATRN/JRT!V V<)RID<E[:X&_#
M[D(8L3OYN<"Q0(F;&"B2W4["CQ,_#Y?=R?) 9CH.^/\BF'-<*K;Q?A+(]D((
MP%UZ7!O8<=@SI8*N>&T/+Y/VS!/$/[IGEYN+Q8*H(K!$.)KEH-R&T2;D/);3
MSHG2D#K@% 7C[C# I+LL<GPH9-=(<!?=%<2-Y@YSE]+T=.VJ2>L>6P[5;.1)
M1:I%C[)&F^',12(53GU1[45%;,."VL[-90>8V6NS@NAT2?$0)DJ'@Q&]AF13
MX :F3(Y4071:6(JYO/U3O10HO5*&3*!J<<T5WRP*JS54+N*:%HHK'O0M#_,<
M[%F7JP:/Z+76H'CC:E#P-<.*-#6M"16D?;8_^!R:H-S*_J'PE2R"<&A]C.:1
MY7!Y:7W>-",RZ-L+G@Y1F<G 0\&FCYS:W5* NQDU-CU0-UB&1V^R/W2'$+YZ
M;HBL9*)R;0(=SV9G2XRM0["@2N@<<3&LCE;MX#&7%<;+DS F6)OS;X42!9#6
M+8C[M0+;4DN-L <.I-B"<&X[LQ-<V=Q4[SWOR&1+E]_:](VP5I=R<6E2+I:2
M<J&&\_I+\FSE'TXVQVN+'9G$>$B>)_K/>M&S5OT,9U0]W^15-(I'DVD\G<WH
M[]D<L\\'T94S8C*!UBXG]-)(Q510T4;]&;((=0W"!4#-@1J [@K,4))W0!&;
M8;S#!)6S\1SS3="9X+4&,AJ!?@@T<3B:4]C+F#)27#:.-BJ=@<P\Z$\C#6!1
M,*QL_5[,A6$]#=T_L,GQ@,/;!@/T[E#LZ"@>SA;Q=-B,1%-EL_NH_F0BFZDJ
M6>.%%VMX\U[K,$\>JG@DX[ (HEB<7H%&BVE+\6A <8SS>#$!Q7HZ:4TCTJP:
M+L+#B2EG-KGHG--@26*ZH5ZIZ7U6'"K71'Z(>4H V/GL%#[ *:+J/)B>HIXG
MD>TL%J^X=AB65!V#KCZ"PT9W(VK;8TQCG33F4CZA4\%!8O&PQ7P,4RV&%)\Y
MF )O6IJRD2> W./9')[ 98TP^-3!2]J7>4@M"#OFPVD(MD:EP23_*EP([1U<
M;I9E#KR6)%WJ/77]9#CT%VM\/AY'I9>,?A8.?(0BN5%ET,]NT&5]T&-K[4#=
M1>]%RVX#BA^@JK?XZ<?1A_/S"%2WLG@@)_W8^;3&J V/41NN7PR@(8LQ.B[)
MC3E:#!KKPL9@P$$VXCA#F:4FT8$*C/T8T%A$R7 UP2H!D3H/,^]]S4$>>B$%
M"8E>TS<B\]D2A<S?1$7$93CS&8'-5:8*2PD?>;!]+3HS-\8I4^VW3G8 R?]B
M"RC=_\ X,?1_RCJ]:4*+'Y.%HM\;#"=_A".9T\%,9Q,*I*X;-@3P0SDJ;A*H
MG_QCP"C0?C<;U \+3:J_^V') EYR6KB.9YW6D0>U*:=OPFNL]NF1?=GX(ZPY
M%9QJ 6IE1FI1XWBM 6KHXUW\$;>?'O#*!85><.]QD&\_ION]..CD3GUVQ395
MM9'T=9 UX>YGU1WEW$49T/+[@A,(*QEM0Z,9#4[.+:PUC7([E12R 59'[L(I
M,8]7E%  C&S(%9@:<Y'_A:/;FI2$8OZX:DVH2S@#("ZUP%XP6M>X[I1!R?Z,
MS12N])YV$Y'B)9$X2B1%RWB$V(0A;AM  O89B^O7 B5PS;CJ'XL^C/ H$TH[
M4CLT>RCL"74?3_7<\V$?F^M1!M)E'S- IDU9ZY=?$DI#.!XV7'_//OF_U!M"
M7;Z[N>"S1^_@<X,^RFC/6V^TE$134R32U33C=%Y7FJ<UU["K]U98^<YCD<AK
M)U6:,AQ&IW:U>,1+ML2B.W;+'DNMM.[?&IXJX1&SD>A;$HYGLGUMG0MT=QMW
MFT2&.OV1HG5O'BEU.$4%#]%=GF4S@VPZK!O?D1I.IMFMVQDB.>RG*%']XT%[
M1P^FT6.>''#_SLUKJ1$ )6P">##%%D[][-]CH8.+61]U$Q")9^.%IW;#("?<
M:ZJ48CR:Q9/%*!I,>_,^R)48GC^,KM+4EXC 6I92LRZJM'1KBB4[),^T42SO
ML*/D'U\!KU9T0H/3?!2 3M"+/LM#5WR^+K76_;%T%<#T46MO!'6^UE #ZS",
M!Y@,AM>\MT#_Q&Q!!6MZH$SJ(+<X/\)#V$EO. &2>.9^U^V@;#]<@)8&POJT
M-QC (X-)KS]R#P)0;E**?CF3_^M89TUWPB4"]/MC%"%[_04L<XJR_F#0FT_K
MRV U^X5CF/H!V@NYO71 >%Q4[,=OOU[I$/,RB/2[ P_B6XC;\W4V3BHBSF(V
MPH$F8X1H!+HPK.!W6BABYXR3N<8S+D$S[ VTA.?OAU]S4#_GY( %\7(*:B)*
M_:^B27\>SZ?C!H+5L<(ON/D+<OWU=[\6HYH+H[34^L*.H]03@_QT9ZN:9MB6
M+L?<>*YJ$E; $U<;B)-2N@K(R/Z!NAK>I19],K&P[8^4TPGH#I=>"E?>"PL,
MO&U!((GC%?,0XK8&A-E8+Q<U@HD]H'3/AQ3,-XB'6#V1.)8F+!YRM-_>YI3)
M:IL#!>8?DQ9I$5A*XCA$P:@[,2%RF)U?G*V&:AQ6ES["XTGPD))!Z1F#,69*
M\\%J<=+G7 _W[-'[@5'=T_$\GI"-:X%W8]2;C2EM%6FL&Z5^/]P/EO(N!O&4
MTLA[$R3/B]YB:A^LWY>3 :62G=:'/'YO1O%X/*$:P+C@.7S1FR+#F/;ZLS:(
M2-$'_?>M(O(E(7+M(_9'<NOXXC#'?>7[)WTVBU0</9#][<:-RBYE>OP56QJ&
MG%#=[TW=W_++HD>I=8/!%/X; "VD4!;]R+_V^9GQ9$+5DX"'3,Q'^9D*(FMY
MY#'")JR5+/.Q(86_\B E6#8@_&R*'^"U$TM:*+^@"J#U&+>A>_NII"HPC])6
M#>5 *GD(#\_)_EJ7RD%<VF8F>?=<VVRO6NRN1Q]^5KV)+ME^T(N.#_XEO=70
MH8N$=:&/R0,_6?)OS(8P&BSW-75;8GA-.*OO2,P64<H4JA?P(<D7%KMW3<2]
ME F"8I;>N\XVTN6(1\I\X3+TA5$_-M;J-FTKERA#:@/[($4!<0J,YB6[<DD^
M<2!-W,$!8\[$3TT!;,6&"XEO-JE^BP96USGFH2SR6XK!QQ93&=68T@4@6*GN
M'A5$])UKL,Y)W-@-1>2V[F&5Y!+JH< 3?9J/A71SM%IC'QSMG>0@BW3\(45(
M54'HGUFC]B!PC9 P?+6*$49PIEDJ5:>I^#-G2G@%33 !?W<9S8(6%17F1,?)
MV76:E QM$W<=N\P^K$"4^(Y3Q,4X.B& @WI-+]Z?V[9-2 WA.+@7QXVVRZW[
MXT&/T1(1F \DFII&L?STZ:T/J4+A]&Q?G$F%3%9**>M9[?>/ G/3(&M7NN[;
M8L7 =0)>?WJ+""@QP:0"^NE)!/;U.0 D8@_)S[ 4UH/I:AR=2!H$EV, J0$C
M8JF@I'3/QA)[; ^YN<DV%,AX&K,),X@2\I$8%06CU!@9;K2EL@B>%2?1-C 7
M-ENE]J1>,"P>_4/"%_290_OZEG$C; E [K$(QZ;6U_>@>.[X;B MXH@";KO
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M5'D/+C-2R9Y5!6R_+$\0) H%P_P^.4(I^(9%?\AU@>7S-]B!^%:2D(6CNF;
M5%P1<.0Y',<4"?2YF+X#7P=BJ)\\.-OC)4->7!,D"*QS^Q!ZIO[-9H4A,HNI
M*-^H&D1:Y3<6C=:^?YAZ57D[QL_:FLCFP=-1EZ;GC842?GXE1NI+*1MX)9YA
MC8QZRNJ&]2V4\B!110-5X4L.,I[=%O^GO7=K;B.YUD2?Y_R*>E#/)G<4853A
MWHYP!$5);7E$24=4VV>'8QY LBAA-PAP $)J.OK'S[IFKJS,*A1(J>T3X7"T
M!0)565EY6;DNW_K6W$%,B!!CT8;WC! T<,:B]N[#<G/.O@AQH%=K7Y; L;.
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M$M"B:?@2AR0LK^W6P6 Z'Y&UV[(SY4/6>@DLH%@E8_2^0."2 L8K<QO7-,?
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MJ6NE$?;>R*L&MS.:@I^.9ET2#E[M*7+"3_89 (YWWI=;8,LOZ#?7N& 930J
MQ\)HGY!0FQWL2ZT^!(TP^;SC(^4%O!(=92G5'4F!B!)U%!YJ'NY+)TJERTL<
M*>' ,]0+3;6[M+2>F^0ZYYDMR4;J$]9;Q%)LJ2*0K >3BYY-;!Y("Y51-(G
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M=RI,3E:V4.?$%PH09\_[(0*.K5<?\PU*GM";KRJ'-5-?FM(37KOL5!ED>9B
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M+J]4.@K=\KX..KG8W9*[$'ZSU"D6H(A<]%3E[B-Q#1Q'J6%7GZMK+&:]OG'
MH,L'.!40".;AAU0"VP'O#JK9&0:K]]*@?V[F0#?LZC_^F_3]7X;T/<?PGE9D
MAU4)JH/CL^V^1+X'_7&B=OKOQ7W\;YKJ?]-4_S-IJIOW;IZ]A1$PM-&G7(1
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M+JR49R/'Q8:Q@-LY*.:.V+2["PJ4A(QN\X>.23B2> VE^B_L5D;7/E<[<1*
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M&%0\IU.UO^&@F(!55HZ.LTD_G_0'(*%'MD*]9ZJ >TN0GP.62$>C?#P<@WP
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M/ =QKI<I<X*UV:Y3@[8G",=IB6=]B9C]033/+W^]6NZV#"D_=0S<ITJ]S[4
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M#C&!D3B<X3[5L0>I:QZ!'#*P%@-JZ=20W89#F"'Q]+E/#>L4R;!XF5*>P&S
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MX9KGNP7Q+C8;&B"^J6@:VEJ_9?M?\3>0P4P\/4^65OG#=GO_I_\+4$L#!!0
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M=ZN6G40(>_L+CDG);%O>?]0M?@)02P,$%     @ M8.O3.QX9*;H!0  YBT
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M -CEO:;.[M9UD4/&^5>,?[88D])(P.R185V6>AO+#G180QQ7*U5E+QXYI9.
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MK[< O86OMP"]A:^W +V%KW< >@>^W@'H'?AZ!Z!W6."L!!V6\/4.0._ USL
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M?;WY/]AUZI\(-ZW(3[\!4$L#!!0    ( +6#KTSA'Z&^! (  #PI   3
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M<R\N<F5L<U!+ 0(4 Q0    ( +6#KTQF\PM@@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ M8.O3.GIY&[O
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ M8.O3)E<G",0!@  G"<  !,              ( !MP(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "U@Z],]P!.V&8"   5"
M&               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ M8.O3+.!ZQ[T!0  <!X  !@              ( !E L  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +6#KTQB6&+@E (
M #P*   8              "  ;X1  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "U@Z],FG5.FGX$  !C$P  &               @ &(
M%   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ M8.O3"AL
MP<;@!0  -AX  !@              ( !/!D  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( +6#KTQ[VQ$RL@$  -(#   8
M  "  5(?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "U
M@Z],F]9I'K<!  #2 P  &               @ $Z(0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ M8.O3()&[!.W 0  T@,  !@
M         ( !)R,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( +6#KTP@^'R6M@$  -(#   8              "  10E  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "U@Z],;:[7$K0!  #2 P
M&0              @ $ )P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( +6#KTQ:]^6FM $  -(#   9              "  >LH  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ M8.O3 <1ZB2V
M 0  T@,  !D              ( !UBH  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "U@Z],-HM_B+0!  #2 P  &0
M@ '#+   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +6#
MKTQXT?G/LP$  -(#   9              "  :XN  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ M8.O3+$ P/2V 0  T@,  !D
M         ( !F#   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "U@Z],S=%A>;4!  #2 P  &0              @ &%,@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +6#KTPXD/R1M0$  -(#
M   9              "  7$T  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ M8.O3!G*K6>S 0  T@,  !D              ( !738
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "U@Z],']\&
M![0!  #2 P  &0              @ %'.   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( +6#KTS!P)F,M $  -(#   9
M  "  3(Z  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MM8.O3,)>:-VS 0  T@,  !D              ( !'3P  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "U@Z],ZWZ./;0!  #2 P  &0
M            @ $'/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( +6#KTS\;6S/S@(  $P,   9              "  ?(_  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ M8.O3+2/*.// 0
MG 0  !D              ( !]T(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "U@Z],U^,21=4!  # !   &0              @ ']
M1   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +6#KTR%
MG6"PQ0$  #<$   9              "  0E'  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ M8.O3#:-"T;7 0  W00  !D
M     ( !!4D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +6#KTR3=- HQ0$  #<$   9              "
M 0U3  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ M8.O
M3(MP%92S 0  T@,  !D              ( !"54  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "U@Z],_17%Y=<"  #W"P  &0
M        @ 'S5@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( +6#KTSKE%J?/P,  (X.   9              "  0%:  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ M8.O3$\]C4\G P  70T
M !D              ( !=UT  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "U@Z],HQ_0O/8#  "X%0  &0              @ '58
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +6#KTQI72%Y
MVP$  &D$   9              "  0)E  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ M8.O3*); N0#!   H!,  !D
M ( !%&<  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "U
M@Z],X;#0)* "   U"0  &0              @ %.:P  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +6#KTP(5<<Q0 (  -T&   9
M          "  25N  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ M8.O3*PPR=8, P  H@L  !D              ( !G'   'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "U@Z],5)RM>S4"  "P
M!@  &0              @ '?<P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    ( +6#KTQZY+0I\ $  -($   9              "  4MV
M  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ M8.O3'$G
M]KN*!0  ^QX  !D              ( !<G@  'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    " "U@Z], M94% D"  #>!0  &0
M    @ $S?@  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M +6#KTP)LV[$.04  &D<   9              "  7.   !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ M8.O3%ATVB?,!   OQ4  !D
M             ( !XX4  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "U@Z],\C7<HEH"  "\!P  &0              @ 'FB@  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +6#KTQS"@^G@@(
M &0)   9              "  7>-  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ M8.O3.$4MC1; @  / <  !D              ( !
M,)   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "U@Z],
MV<Y%=WD"  "D!P  &0              @ '"D@  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( +6#KTR,,G95Z@,  %L3   9
M      "  7*5  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ M8.O3*V =\I* P  O@T  !D              ( !DYD  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "U@Z],:8Q?CU@$  ![%@
M&0              @ $4G0  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( +6#KTR970P[W@$  &@$   9              "  :.A  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ M8.O3%%%7^TA
M P  & T  !D              ( !N*,  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "U@Z],W-0!1B\#  "R#@  &0
M@ $0IP  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( +6#
MKTR]/P,&R@$  !4$   9              "  7:J  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ M8.O3 E)-.YX P  2A   !D
M         ( !=ZP  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " "U@Z],U5D/DTX"  !S!P  &0              @ $FL   >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +6#KTQ5O0<])P,  - ,
M   9              "  :NR  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ M8.O3$<0/D-> @  ;P<  !D              ( !";8
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "U@Z],I,P*
MGCD"  #5!@  &0              @ &>N   >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( +6#KTQ&<T7>T $  "D$   9
M  "  0Z[  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MM8.O3 J,K7LG @  XP4  !D              ( !%;T  'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "U@Z],Q&J1$& "   Q!P  &0
M            @ %SOP  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( +6#KTPM'WO9M $  )@#   9              "  0K"  !X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ M8.O3&:TW-Z9!P
MYR@  !D              ( !]<,  'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " "U@Z],8JZ'HT<"  !@!P  &0              @ '%
MRP  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( +6#KTSJ
M<9D^V<P   H6 P 4              "  4/.  !X;"]S:&%R9613=')I;F=S
M+GAM;%!+ 0(4 Q0    ( +6#KTQ,(C?K90(  .$-   -              "
M 4Z; 0!X;"]S='EL97,N>&UL4$L! A0#%     @ M8.O3.QX9*;H!0  YBT
M  \              ( !WIT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M +6#KTR:MP@[2P(  !<J   :              "  ?.C 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +6#KTSA'Z&^! (  #PI   3
M              "  7:F 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !/
- $\ FQ4  *NH 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>271</ContextCount>
  <ElementCount>383</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>101</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Mergers and Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MergersAndAcquisitions</Role>
      <ShortName>Mergers and Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Investments in Other Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsInOtherEntities</Role>
      <ShortName>Investments in Other Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Loan Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivable</Role>
      <ShortName>Loan Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Bank Loan, Lines of Credit and Loan Payable  Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedParty</Role>
      <ShortName>Bank Loan, Lines of Credit and Loan Payable  Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Mezzanine and Stockholders’ Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineAndStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders’ Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVies</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Mergers and Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MergersAndAcquisitionsTables</Role>
      <ShortName>Mergers and Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MergersAndAcquisitions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Investments in Other Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables</Role>
      <ShortName>Investments in Other Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsInOtherEntities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Mezzanine and Stockholders’ Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineAndStockholdersEquityTables</Role>
      <ShortName>Mezzanine and Stockholders’ Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MezzanineAndStockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RevenueRecognition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesViesTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - Percentage of Net Revenue and Total Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/PercentageOfNetRevenueAndTotalAccountsReceivableDetail</Role>
      <ShortName>Percentage of Net Revenue and Total Accounts Receivable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - Carrying Amounts and Fair Values of Company's Financial Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CarryingAmountsAndFairValuesOfCompanysFinancialInstrumentsDetail</Role>
      <ShortName>Carrying Amounts and Fair Values of Company's Financial Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - Summarizes activity of Level 3 inputs measured on a recurring basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SummarizesActivityOfLevel3InputsMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Summarizes activity of Level 3 inputs measured on a recurring basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - Mergers and Acquisitions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MergersAndAcquisitionsAdditionalInformationDetail</Role>
      <ShortName>Mergers and Acquisitions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - Total Estimated Purchase Consideration (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/TotalEstimatedPurchaseConsiderationDetail</Role>
      <ShortName>Total Estimated Purchase Consideration (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CalculatedBasedOnNumberOfSharesOfCombinedCompanyPremergerDetail</Role>
      <ShortName>Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - Assumption of Identifiable Assets Acquired and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AssumptionOfIdentifiableAssetsAcquiredAndLiabilitiesDetail</Role>
      <ShortName>Assumption of Identifiable Assets Acquired and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - Pro Forma Combined Historical Results (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ProFormaCombinedHistoricalResultsDetail</Role>
      <ShortName>Pro Forma Combined Historical Results (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - Schedule of intangible assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ScheduleOfIntangibleAssetsDetail</Role>
      <ShortName>Schedule of intangible assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - Schedule of future amortization expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ScheduleOfFutureAmortizationExpenseDetail</Role>
      <ShortName>Schedule of future amortization expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>147 - Disclosure - Investments in Other Entities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsInOtherEntitiesAdditionalInformationDetail</Role>
      <ShortName>Investments in Other Entities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>148 - Disclosure - Investments in Other Entities (Summarized Balance Sheets and Statements of Income) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsInOtherEntitiesSummarizedBalanceSheetsAndStatementsOfIncomeDetail</Role>
      <ShortName>Investments in Other Entities (Summarized Balance Sheets and Statements of Income) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>149 - Disclosure - Investments in Other Entities (Equity Method) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsInOtherEntitiesEquityMethodDetail</Role>
      <ShortName>Investments in Other Entities (Equity Method) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsInOtherEntitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>150 - Disclosure - Loan Receivable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableAdditionalInformationDetail</Role>
      <ShortName>Loan Receivable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>151 - Disclosure - Accounts payable and accrued expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts payable and accrued expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>152 - Disclosure - Medical Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesDetail</Role>
      <ShortName>Medical Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilitiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>153 - Disclosure - Bank Loan, Lines of Credit and Loan Payable - Related Party - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BankLoanLinesOfCreditAndLoanPayableRelatedPartyAdditionalInformationDetail</Role>
      <ShortName>Bank Loan, Lines of Credit and Loan Payable - Related Party - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>154 - Disclosure - Mezzanine and Stockholders’ Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineAndStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Mezzanine and Stockholders’ Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>155 - Disclosure - Schedule of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ScheduleOfStockOptionsActivityDetail</Role>
      <ShortName>Schedule of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>156 - Disclosure - Summary of Share-based Compensation Expense Related to Common Stock Option Awards Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SummaryOfSharebasedCompensationExpenseRelatedToCommonStockOptionAwardsGrantedDetail</Role>
      <ShortName>Summary of Share-based Compensation Expense Related to Common Stock Option Awards Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>157 - Disclosure - Summary of Warrant (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SummaryOfWarrantDetail</Role>
      <ShortName>Summary of Warrant (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>158 - Disclosure - Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/WarrantsDetail</Role>
      <ShortName>Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>159 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>160 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>161 - Disclosure - Revenue Recognition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RevenueRecognitionAdditionalInformationDetail</Role>
      <ShortName>Revenue Recognition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>162 - Disclosure - Schedule of Prospective Adoption of New Accounting Pronouncements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsDetail</Role>
      <ShortName>Schedule of Prospective Adoption of New Accounting Pronouncements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>163 - Disclosure - Disaggregation of Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DisaggregationOfRevenueDetail</Role>
      <ShortName>Disaggregation of Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>164 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>165 - Disclosure - Earnings Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>166 - Disclosure - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasicNetIncomeLossPerShareIsCalculatedUsingWeightedAverageNumberOfSharesDetail</Role>
      <ShortName>Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>167 - Disclosure - Summary of Shares Included in Diluted Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SummaryOfSharesIncludedInDilutedEarningsPerShareDetail</Role>
      <ShortName>Summary of Shares Included in Diluted Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>168 - Disclosure - VIE Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VieAssetsAdditionalInformationDetail</Role>
      <ShortName>VIE Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>169 - Disclosure - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetail</Role>
      <ShortName>Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>170 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ameh-20180331.xml</File>
    <File>ameh-20180331.xsd</File>
    <File>ameh-20180331_cal.xml</File>
    <File>ameh-20180331_def.xml</File>
    <File>ameh-20180331_lab.xml</File>
    <File>ameh-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001144204-18-028920-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-028920-xbrl.zip
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MB0E"6?X5QH&>_22/;3S!JRBP^W]J7,I0DNOP,NRD*2E1*"E1GF0ADI*'U7.
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MHB$KDK9OMJMZ#&6SQ[%/@J!BI6?NZC'<^_'/JIE,*-X,FYWL8W0>\@/TBX/
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M U;LK&D9^J=)A\"*T'TPE+(-Q9)^8D7-S9C@<5K**Z9HLG<I^^=FGY!6["3
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MC(+Q$PRSH<MXQ*N%!T*1O9'1L=L-C5\Z=?5MU_N$!T*2TP9#T55=4AK>R"Y
MLK8#NDD%O$#X0Q3]^Z/UHUL"RM[.J**@&$UBC@P4CH#P4027L]71#5E3FIS\
M[Q]B\JX+Y**9'79)=GF[(%4T&M6KV^;^<( >150YVR-=E-4] 7K8N]J'@9/3
MS?M<$66QX1Z] ]>S#X0E[ZZ(+HA-K7\-,*NE4:M/HA+UAN-UY<@Q+3$2"UN[
M()RDXCYZ)$G;1\5ORDN#NNDH33'XT;;F+O:BTFN@O_K>:KDGF>#<,]=*<HYY
MC';U#M%!L65O7&3)%)13N4ET4%S9VQA9$S5%Z=U]HH,BR"G-)>J:THM;10<%
MC;,),10=F]A#WBT2Q2=1C8UB(QCCY\:+9VC=Z/GKAY4_1WY<;2!WR:A%1%D7
M/5JSS<4/\AJH]1U:]C;$.)U;P4<"F-//&T\ K4![;=N/A3"G-I<DJ#V\-GPL
M,#F9:+(JJFW9KGT:_&/!QTE(,V71W&.!H.U220<'@)--=CCY.18 G/2OPTG
M88)%G'[@>R\\<,2JD JG6_C>>X-2O!]R@\-I(W[(7>&!9)SC)+=:+:);W0T4
M3A/RNEU<Z_!^2!GG-"FONXG/W4C_@MCW-S[Z?[?6\ S-)'6C>_WHX_<!R=@/
MNEC3WQ2PQ';MMDM ;1.[Q8[M8JPO?3P=;$;&RWAI3I%]@[>*#G'6BHC<L><W
M34%MZKXL%A>K /\Z"(#G,=[-DK(D%4EFNSP[D?P1/8?7;A#Z*QB?+EA :J5,
MF4<?E#5H56Y41O2%JC*Q.P_9$]X?(7*G(&CCA;=RPSLW@@B3 7ETS&3,',$<
MER29D$K#9FC<D'XWN[5<4G3S*PJ6&$7[&=3.9V0YX<N]@]%]L9=5HAHYTG4&
MUE')R#J$Y,7L#\__ALWFI;=8(BP'=+[B^K*LXL5FP>1HYA3&E_&B5BA566'P
M5N@MQ9AS?U+%$B\IC>@=3R8@2\&]M0;)VIE$3M=?658U3:>,;O%X=:DJFVA>
MYUS=T&1#K$H5D>.')8*#80RDM;3#Z+)?7<S8YDVF%SUWV*9$ED+(,6^*+J>W
MGG<D<O4\B:N">3[V!K_:P;=[SW/B1W; D=,X5=$ETTB*"G%&;49A*8B<6A"R
M8LBZMAN%E,SZ*VRC?&^&O0$,N>5\0BC871HY)V<Z_@_=3IX];E,J2Y%D;V"A
MGXDDJG6I_(AF"'\QC3./=\>0;5AT41 %C?8[BH:K2U0I9)S6CFJN"A.3*"*A
M\6:&NC# )TK+$L5IEB@:IJHK6K)H2P?,D#6>_G,5[V(^>?[V,^4'"F70<7H0
MGFNR+!O)NN4-WP:M#$>,T]3O7-44N!.[.ZG;7X^G4S2%LXA;! '*&K2RC8I0
M.NVYD5NADS7_G#P74U:Q\[4SN<E2BUQ>" 3=^7/+M?\5W1#[ 5X;"K:VVI60
MY27":[(BJ90CQJ6A+:)9,/-:2XL&IIO>L>U,=7:+AP>.-T\,C24\74\JQ@ X
M;<N4?*Y9&35[VEQ7YX.5MA!MG)5F&^?DR8<7SP\?D;^XL-QO)&PS=J=?O! %
M%=R_'1CB[)Q,K!.IN"^7*O8$W5KARL=T?"ROOIK-#ZC,AT;:LHK&N2B=RV+9
M!-#CLT)+2:3@UOIA+U:+"\_WO>]0]]9:XF\* Q?*DTQJ_4H-0T^<ME0%(;T=
MZ&Z=9T%O(]S&Z1@E[9UG>F&.0[PH;6]ZY4Z92ZPARS)#D:B1(C%H3;(#V;L%
M3=MCJ<6@:1&W7]'"LET\LU5$LS6F.%7%\7Y*TT7V-)43GJW26_#HKRO+MS!O
MZ%<;;S8R85U>/8^&?'/K=%"QE]TI;UT126)Z0Z )UVPW1>J4[I6D5EAF[\CW
M;V_JZ-Z&++-J;.]1]^[,<?:TK0''S'8\,<?:'CFNJ;H;,LWVI$S-A#I8753=
M#?FN="C<%=4M/^'_QB)N61.OC,<GO&%RI\_K&Q1B,0R2$>G3T,TA?=)$(P<,
M.ZBB::8I2V8GM#N-2ND.J U(./$;R+/5VD&$M%F[L (TI8_=QCX6M3F1[HOU
MYB?Q7;/Q=\N?WBW)F?;=*@R 7SS$EQ5PR-275XNEXZT1(OU'HC?0N"0QW!)2
M_K##EVL\U*L]75G.%EG!Q1K@O)L5OF8;9-J'+&M9)RJBH CT3KMEN-J>CT^>
M/T,VWD^CX-J-K$&E+7VG9D;CSTR+<U( V1%625?G0J^P2@1%5 6E1ZOD5["D
M/5X@!G]2Y.S^H%W$MN8#0+D.@A6:?ESY>-JBGT4]/"G$@JL?R)_8>(C^85ZE
MPZEDJC)EF'>'I6U!CU],L@K[I7@R_8<.I7BVX-JC(?@#V?,7[,"/7Y%OS5$B
M O>^/6'W?^K4+.5V<T]+Y#^1E^9:A,GO374O!H(%X\ZS%^RD!:O/8 _T6[Z9
M4^E,FN^E76:R/4A;G\T"Q^^TIE2N,J7";LYTRZ!V1L%V=0Z5BLM2>2^8W5>P
MG&%_AXLB4RCC^F.))OC/1P\^.KE)58\RJ<W0;5W])F\_4>6K59QC[3U]O>FP
MJ!;.Z3-?PI[Y_O.U&^(=3V!/?K><%1+[LS89AXT21 3?&UINNO8"V!X-8W:D
M_LP,XTRT9&;V@=<1)Z:KFT!&MAI,C/G>V$7#M3HQ#=9FN5U,SQ^3]O 81$B_
MDWIGI4SL_=^K?^JWDO&Q/:U6 [FV)Z_$UZ'T;47*Q/[-J;B/.6T/T.,>05:J
M=L,H7YKI(%<2ES14V6@S^-[%\Y#&.,H'/>0[ROE%8XR4W3 Z^G%#W=/GQD!5
M.,L_Y1/CQOA5.''OG5+;[>RK,805#LK;AK 7QU6-@36J!%)D2)<4Z?HX70V!
M'OB,J3'\YA$.$8YX*-1^5++A#*CYSG0'F8'F8<2NG<PUGH9*1]W#:5K+AE7-
M=[WKN_X_WA%8XYFH=)[<_DSLX=RJ$X&0PZ@MY=TO]^*?VNT;"P7M$$MO##&G
M$JU@&-I^LF,[<S+1IL!RFO<=%<W#GXTVAI-]>;(0SB,>:%:JGI^H$4S!RQH/
M8$<5#TAW] ?DOV*M'V3OVT E>E+; >B]\2;%H7.5TWQ/ED1)EGFRUXC1K/+?
M'Z.<XDJ")!O2KHRFAR 19<4/??&B<K!3(C7!HQ=:#OT]=+;XXH5_(DS;Q)N[
MT->,?:,:A=\]_UM<Q8;4:"3,8RR^+!8T.LGM/=(H*[ 39)Y(:)2F :HYT@\2
M4@NO:JF<=GBB)"I2IJ'POC#*5H!K(UI>T8A7$N1&$(NI!W-PYC*H1C&VN]D?
MED_B$^1%U8X"<AQ5.$-*KH*6#,HD;*=3BAQI%8YESD53U"2UA,"MPP7RJTO'
M"H+T1W?^5X#_TG(GR''0=)?#@AR]%8Y(SD514A,\JQ&25VV%3V6V&1L XF\#
MIEW/<5$U(=!\;U"U#&M1Q9B6@/T*(GH-IJI21AQ51ZT^<?5Y3*6W 9]ZQ<G4
MWZMJ'5:W:*S/;AQ?:L1NI?A\W6G=(I"O5;*BT*(5R_%M8K,D_,E2*[4HJ<!@
M*@![8TX2^,SM2D4%QM+9WA]C(I^Q7:FHP-CN&5$U6,,JY5[^T[B%M)]6::F@
M7S*2GK:IJQXVR+%2K=!F?5)VT)A!>UPQRCH0VVYJE50DCZ(*S!6<*S1GCQT&
M8T]:=8(J<$=)>'.N&.$HDKV?EA&O2TLE7Y-ZS0ZT5\A)D!5%U32-XU12PY<5
MNT_B$IL^)E#0M+S"LO@D:D"SRNPM5+.7ALIIG;15]JX2%RUWBMTG^ZQB6N2$
M1C&HFT4[MW*->F-$>^M;:XH>/9J>:@<;TU?8=6UZ#67:QM4#X2D.JU1X>ALS
M3@,F2=K49RKEO!$^N1:AG<.'TY5"V0&?1/#B:NU0:YI5B:M$A&X6E7I4YMA@
M%.(Z5PNJ'I?2V)29['S78X;A*!%FU+K,--!MC6=(82@O"927Q.T!MU_==;^P
MO4D5QIHM.(9#12:7+AEW")5T(+89'A>PK>[$=KOR7!F!'$NL;E.-^ZJW88P7
M\YSGL9^I97AE,+7ZH27Z4'PSCMN ;Z.62%=O#B"8<1UT]8F4A=]XMYDSF-@'
M)C])RLA_LEWLAI"N9\DSX%<D?R='-D]?O>=;^YL=6K[=2C<\E=.:2]SJ_]*T
M-\'5;(;PT*^(J0OZB*3(LZ>"7 8D!Z"6-H/T<6YO4.44=%4;;#!;T.@?%_/=
M[12K:QKH*5$[M(*NQP8CT$;8.(#GE)V-.#OAWO>6"#\##X(Y/\(NCM73#;"1
M#PW->#DAIT4OGC.M#4F.1XX':4H']S/VP"0CL8L(N;2;5]'"5-(L@IZ;S;"4
MML0MQW.4#B"WV2G=)[,<=U&MH;_NL.*Q0FPG;[P@N+1\?SWS?))>=&,OXJZ7
M8.3OW$?K1Y2^![ED.W?%4E5657NRUTG:N=4D:6MGE[@ET=?XM_ 09$:Y4 L[
MR@X*/R$\498#N7&KT//7F1^72W?*)99N[/-@[\'+IRZEZ7;)#[8G5.5Z8!+=
MXKPY0]FF?=A03FUG!:]\0!/HM83-YM6/B;.*^[Q!(M4J OQN=F7Y< 888"^/
MR'AT?WCW\TBU0I:3J!F2*":2W JA6RV-LV><4;K21Q@%Q5>CZ2.:M,-@Q?S,
MQ<)S27);H41$6WD@VG/AMD^!9%3(MY(%V=05*EQ?DZ7](I-/T6V,3(7,+DDW
M5%DR.HY,5F;B@[6ZJ%2I6F\(HDQ?P.DD*EEY:8C*;A7C.XG'3@5E&FK*BW7Q
M"PJ0K7*M759UL^OP9L6M,_!6J.2NFI*LJ:W#>VD%+]AOA?^!!?9J.61MA<01
MPT_R;_K\#K&4Z*('B1&1#?GZWL?$^^L+Y*(9W%CPUS2RA<]@:"[6).\ +KDD
MH!8WTE$YO3%50Y 4,9,E6X71EM"A;I4=!QV-'37%6V-#DW6A(3I?,6V^#?=2
MX+DJ8;TCH<%IVXEEQ1#I5CJ%C-7D_OBRP(E0&H*@:II8D7OBH7^RIRM":<?G
MG9T_*,J&INA*O.LHXJD&T\>?;G;7**!,D?4*3"?B<&OYWU (1&U,6(?GG)U^
M* J:*$C432P&=XV .+X<\)J$JKI NVL[ )$<8FP.+RJ>ZAP)"?;=5]DP%.PJ
M*-N'-$7\-</B^%+!Z2BJBH:LT$W%=\'BWD=+RY[&C>R3(ZYQ$*"PRQJ#[4F*
MIB;H,K6-KL!E*\ <759TSM&[(8F9J$L-8+HN&YPVI:)HRH*BTU';)NP>?\;9
MKJ(IZ;HH:V9%;M-C3L=R0Z@3@C<62]B#8@W2Q;GF>(L"IDU05%K>R_EKAL7Q
M!8'M1(J"J.D:G3J^"Q:8+,N=VYC 2'SP3Z*8"MYG_NIYT^^VXW11/MB>)09$
M%PS:4%3ALQULCB\O;&<3 Z.(IM 0FR[+!MO%U 1!E&0ZPK [C\>?8[;K6)W'
MCT6)YU\\=])=-X 3;,Q?(^)PV!B0H\N"P8DO-@2$9/5E=AP=%(I\TT,>!MM,
MU6'[^%//]A%KL%V<Z1YT<<K9+J(D&KJJTLR7L%8;@>///B>ZB*V\K$K<:PQ;
M"$ MHUY( -L)5&0I*_V%?-5D_OB3S_;RZC$?^7]=G&JV3R>9JF0HAJ3E=\-5
M&3S^=+(=.DF71%G6Z<;*)0S&(<)[:PT$X=T?_L1?H>D-)M!V.GY@P&I;!=%A
M55 %1=\.B%;@ME6@CBXN)MOGDS5)U<2"JPXU@+I!5@!IC_@KN&<2O:"[(F1R
MHH2*F?>)&/PUP^+X4L)V#R4Q?Q6Y"A;9L\J<8'58+FJ=/Q>SUPR*XXM%K5/I
M"E#$5VIZ86I,MO,HJ9(HD3P4-F=U^3^^$+#]1TD5#4U2A*K\)QKDT?J!>J ,
M.*?0DF0**G6:5L!5+<://^N<(V=%DU5%V(GQ.)PTGLW(18@NSSJGPK(A:**I
MREN1LCQKM1$X]O1K^;XU>004PS!U4=\9@8<7SP^A+-V%Y7Y+K@&3.\&Q['1/
M&K1\\YB\#C 5W<@4%N>PV (FQY</3CQ1%&13;(#)I;6T0VQ&P,V\>W;L.:&G
MNUZ"EN^ODC^$-Q4CD[C+8J\I&,>7#K;?:!JZ;-0%HP\^H\;I*J)K.M:?(K5
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M1TGKB(YPPY-X]/APK"RGE\@"2&X>MZTT5_(A)AZ.-./SM>&XK#^<_>;"*6Y
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M*#=T A>4TJ.'WUQ"!^EX%I5*7<!QAY7-OW[_\'[TZSB;@QZEN&9@6KD47T6
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MJ*#IUEH 0O*+P1B1&G989%8DAAPW<=B.2K3E_V3O%O;,WI^0ZW)0-_=^XTW
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ML_>FS6UCUZ+H]U3E/Z!RTA4K!;%)S7:?G"I9MCNZ1[;\;'?ZW4\ID-B4$(,
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M3>%*N!-I![;U;4]5W+$'HS69B/5,YGC%*AI$$D"=^2QM:!Q/X<M==VAG)[>
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MY=3<Z5)'=-G,UPU7I)1EV*.@?I&:$_,-6?%F#F.GX#-=Y84T;88BYRGC$$0
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M8-3UJ:DBCP4$Q4R%N;Y9N_-_4NG/JMU]1K7*W<)I6#;-*O.^I):\/I[:X[J
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M7>01\#MQ)5)J1L\A[:5OI?*8G?%_6>EZ9CI.]/,,K]/L>&!15B48#7XY95A
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M#_T>^KT(Y%7*5M0B]9TJNT1Q?3.FUC5CVC\,^Z_[K0<(CPX>'=97#O=HX-'
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M!HAIT12M&9,A#%1B/.4F/81(17"2PP5F<WL$=24FV\FZ9%@A+FK<##9XYXM
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MQE&!N%,M_B[.++6<2CLT+!=(J9$ +EC>%LL^D0("/)\QOID'GW(XQ<'N=M#
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MU5?#S$PE4-FB5/:8-_A.PD94YAE,@:$FW]%Z!2MIZ+K#V2E57I74>"A+*)^
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MGRR *L15(JZE9FC!RO6ER$#N+P+X%\BIJ =8DOXH*0#D !BS$7T14[]1 "$
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M^"&*$>A.00D;H)@G4CW'P%:!187!L)H%Z+L@1WB>A@&Z+ZS9A%AQ:;.O3>O
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MHV2,=ZH^DYG1Q!'DF->/WA]@_"6SB#@G-D0EC&BV/"M!&!"4BHQ3*!M'HU"
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M#VEU[K!$^0!)L2YLOI?.C<^BH-$>;SG>W73!<H,MQP"+R8BP\5V2DO50P5<
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MD'%,/L!!E%O+ E"$"$LU)U@0C]) ]A&'F4:9=@*:#WPA1[A)O'3[82K?0T"
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MKR_',T?SL*,X])LNRK=!1S-*]"C43C;]5U:PJF78Y'*H3 9'(18FA1'^/:H
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MGHA#YR_\ &C_&/]'@$.3B0>?1YBC!HK+B/, %1L_0:TH8Y7(W=&FDNH!\MC
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MAB2M(2_AUL7C=/$X73QN;\XZY2#4Q>-T\3B5[JJ40X$N'J=J)1KED*&E15T
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M[#GD@KN>PWQR-F4W7G CDS<O01ORPYM[<BI#,2CF/AQ+3'CS[6XB3E:VO9'
M7EV<79Z2.R:DSAO-PHAAVV\O()9A=/#?>(()%_ I9KV<PA#C, H\=DS2G\ZB
M\-9S88V@,<\B/N&!\&XY<3UV$X0PCT.\C)2 9=QZ#CR9"/D6QSP*QT<PP1&+
M8A)S9Q)(0LO'#L=C'@DR >%#_I/ U/%]<>#Y@")Q)@1 N/AZ]O/%UQ-*KCY]
M^_GT&R7X%R2.SUE$IDC97L I2?PX8B), I?"<#<>)BS_.(K8/>!U!.@C+@(!
MPH;'T;T\ ?E34S:=AC<1FTW@\QA1XT5D#$<G374^;AIU-)?Q-0&&LX#\3^+?
M+\7*=RDYN3H].K^^.)&4FQXDR;?EL8Y#PHB8L(B361(Y$R8X83<1EXEMY&X"
MCXWN%T-XP2T7R!#^L4L%P:3 7"CHF\N: C 66-PN)P(%:FF*GTAX%P!+F7@S
M9&T2.2N'5E.\PC  71:H>L) T+" G 3 @'T&O/HZE0CD% :,F ,<.KSAP*6C
M.66O":U;>3#FHB0,R(A/F#]&:8?3P8'A013Z/N<R[Q/%X<QG@<@>."9_!"Y,
M@)\_LA <:L:\?.GC;#0V@Z7\  D9<_]^MX?,..XL'Z\IK,T#^!"!.YZINWDF
M/-"(EW@"#(9,X>N) &RZ@/#UE!^">6!R<9CR0TG$Q8P[,2@3/B@$<N<=!X1V
M+.2X7BPR[B0Y5WZ:23+?C;2V",C]>!*Z$MGI[Z5:*^2(P/[DHVFQDGNYV3]X
MY'C %050'ZK$3(X^]A,>.* \C)(8*#0&RH&=#7V"!)1.7:AK GL[XZ!) 1+$
M,?F81#CGUIC E48<M#-\?,E#2<9@<\*@WA(N -2=[N^AU:.&U7V[O,D[)Z.N
M28W!BD@H$@'-M5'<Q^F,!?>(5=@'Z=>7:JM82M'.<(0+Q8T&3E% THC!(7;X
MSI%E4KO?H;W>H&1LF;0#,K0WM%?FB5."(DMTM+%YT*9S]I LW,VKADG4N:'X
M1P#8BP08"*>@6&G[N$' _G%Z1H"[,E 9O-M42D^X#PR%,S^>2$T >!*<.N0P
M(\Z1QRR8/P@1Y#'F<-"5GT=2-H4XQ$Q*L*D\EBB$HC !*Q?9&S(WG_](BV=E
M&D<ZG8-JN[@'A7P*:@>L#"MJX>)\T#4"D%D+X;<PU,F_@O#'T;]@:9S\GJX:
MJ317402Y0AA.0$<YS"689;PO_ B^FG]AOG^+ZT\!Y"A&&1DGOG^4*5!%O*1+
M=#(-2) [#Z>^N"ZL,O4VP6).W%N0L^R&DRO@1T[DS23Z/D;)#7R")O=4&]>U
M@:P),%S"F4ANX(/%-IF&E)E@8O]Q>G)%4:$ 30+U1M! D#.@<>GNUH UC54+
M-C7/T],$+Y:T3E!>G01%.2#B8W2\6/JW"4PFR#F;RB_(%3"J<Y[J1OC^7SP(
M0$\FUQX\  ^";008D3H5+!+.921940IW[CAP4_433_FN85YW#DB?1;8(X"H^
M$Z#"'UGD-HQ3-7 Z17Z+=0;)H?1%>M+-N%MWPN!XN.I02!ET+,L>ADD,*FB
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M;6M(C8ZUK*$BT]GM+#TX6IW.\BSR: ->XPDP(#*%CR<">!5B0-9[(K8IF?1
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MCZ[,]D&"MB$=JV"1>Y$:MI.AQ+3-"PJ4\DHAE8B3XW\GD>),Y!6+8,<M@$<
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M]O#KQ=7W#^2!"ZZ<4W:$=O&UB2^:?/&B:4GU+\UZ1M:-1AJU.Y1]UXMPM%.
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MM <IYXX(=7G?^W0D;^2]\00H,PC-0<8BY;D;,")A2KUQ3-UVU6I]G-V=\)@
M3>)*<!$RA_@]$L(O>[[K^H]PSX=MZ$6[OG_>MN4E;6R8+Y07F!5?"O_]_/3N
MG_+VK$.*S>)R[VM.]SHEWUR<?;V;N3Y1Z-P+)K\XN;JXZ%[?0C-MZ&TZ$J"R
M*_ D7R^NOG\@#UQPY=2S0]N+KTU\^.2+%XURJG_I$#.R;C1$J]TQ]KM>O:2=
M K0KSJ.?AD!%DG! $6!!];7J4C&(0*@@5%Y4UW<FH\>XYNU]\%[]NOO  MIG
MV4MGR1$K4^U>!]QF"#&$6%X0NV%#RCT( +(73R Z"R!-B:B;O7S'@F'V\[O_
M,!J(30Y!T4_9",?MPK';[P>L3\,9\)T#S#BD-W;VXK^I&Z&)V^X""NUTA='Y
M8<A?DM(II5//CI>J(7U*A@]4#]('\8'T0?H@?9 ^FJD'Z:-MHES^+?CIBH7Y
MVG=_4B^BP9C$>PU:&^#H4/:KZ""];BYH3P^NK!G->MMHU/$X8[VE+W"MY0&P
MH%-I-;2' !( _<'V_4&E5=B&,60"NH+""6#5*U7T!=IGF(5.Q$XRS+[\?WB0
MM^;2'T[H4.AN)#RC46_ID09( Z0!T@!I@#1 &B -"J>!)JFD'I.525VTXI+)
M$HP]Z"!]B>QF68;<WED=RVA6&YOLJT'HZ]3WVD"_S"/0K4H#!Z#UEAZ9L-_!
M,]( :: /#3J53F%5ODK !$W22#UF)-G3B ?,>=_S@Q[C.#>YGO2OVZFN&5RT
MTT\^*6FAPW;O+,NH-LS",E)D#[('!\*12D@EI!)2":E4N'Z02@=')4WR:CS.
M6?<!&!VD3SN_)#OV-3H94,<-^\B<$F$#F8/,T00<R!QD3CFP@\Q!YB!SRL4<
M31)B/2::YXHKX3G.>+9?P0K:TR'*FE&O-XPF'IB)I,(#,]^\DJZ-O@EIA+XI
MMVI133P7'?F$;NEM-&I6S,+*T9: 1NL>X[S\I3/*T.60W+C-4_'QS%<\\W53
MX]/*<K#SIC/+L,IZV>5'," 8$ P(!@0#@F$W8,@>NUM&591DZE +7:$-01N"
M8$ PH$-!**!=0##L% S=!Q;0/BNK)C#.1!.B+W TEA_!@&! ?X)(0+. 8-@!
M&,Z20MQ3I5P'W$8S@6'G:Q1'GH/1]",+$%/EE#_/P:YD/TU958%0R T*-VQ(
MN<>]?EEU@5A LX!0R!L*&"=L(_9\7?4S+;29(Z9N!S3 C&8]^0\;*5?3;=Z(
M%\3+B^HZ\;TPH'8847>JN0O>0VN#Z%E[[$UM\4&\(%XPCCG<D=F2U(8JG7K:
MAZ$?Q ?2!^F#]$'Z:*4>I,]!R(_T0?H@?9 ^FJD'Z:/M,(-F9\5LK^15Z0XL
M?CUIZI6&N8$V#J6.M [2Z^9I]Y0)U;H!SDE[-" 7D M;YX)9:2(3])8>F8!>
M ;F *0*F" 430)-\N@0C#[MF38XJ>3UK.I7BW,;:@N^EVT FZ,4$R["L)ORS
MM <$T@'IL/V,HM*H:8\%9 (R 1T#T@'I@!F#)DS0),_& 5J]1J<LLT#:E&!X
M2@?ID0H[BJ?JC8;1:#2T!P32 >FP@WD+$YF@M_3(!'0,2 >D Z8,.E%A%V6:
M#F\$ZW7ZV=,Q+LO"0:YMP 7I=)!T:C?,(I<G(J&04/M%J'JEV4$V(9N03>B>
M= 8,$NH@"87ITWZN$2A)$8D5K-)2.SNN(7$HXX,Z2(_,0>8@<Y YVFD'F;.W
MTB-SD#G('&2.=MI!YF@TFO#,0%4-.M+QHWLIREZ-Y*U;*>.5>LF'@P5/)C5,
MDF"M8>+@W5O'>O>60MM6T)Z.AM>,>KUA-)M-)!62"DF5$ZEP!03R"?F$3JH,
MF"D]J7:?/)692YU*NXTT6FN\XGVH3N:<?)SY3?)!:4S>!F\*'!9\.H)&)JU1
M;?U@F>8O'XFZY]BE8S\*/_3X$W,^'A&;N?(H2)M[??4[^7E$'2?Y/'E^,/G+
M2?]ZG_TSF/Z9MOCW]Y$X[E,Z^G!K#Y@3N>RJ=QOZ]E\#WX5FBK._(QZ.O_DA
M^TZ#@'JAN IN).+%'7L*O[APY^>??_KY)T)^7_(@>0[E%RJ8<^(/1\P3-.2^
MIQY_-9)_BJX=\@=XP9ULS^2)Q/:]$#[<L-ZGHVO3^@'_54VK?>>;M1^U^.\?
MZ9&ZS+D>C 6W.87'><Y5.&#!+0L>N,W$)1O>LR 2LEWGGNT/V6U(0S9D7GCA
MVZHUW2<NC@AW/AU]A8=QYT>K81Y]GL/+9??FCW/ &X 0_B4LCD%)[A24OP&4
M;R24C?B"0: -O$=B^"E%'-]+38!L4U40]B3_9B1@+K3+(:%/?*490A]IX C2
MESJ/OQ@%?$B#,;'A660TD5E]%07V )Y.A'R1('Z/=*]/8BBWJU;KHY"O'<)C
MA52^ >^S_;['_P=/]A]80$!I/("K8L1DCS#RP$0(\"(CD,)W0!SH$L&%; H\
M'&XG/=]U_4>XY\,*=LVP?DY3'^?IO;&6/T)CO/!8@#S'U/EO)$)I=CR67@\#
M%MJ#U!0=$>KROO?I2-[(>^.7:)^#9!D+>:$,I+IP_NWT3 IH<C" W\]/[_XI
M;S<S)BNV&,O]DCD=K4Z^N3C[>C=S?:+0N1=,?G%R=7'1O;Z%9MK0FW0D0&57
M8&2_7EQ]_T >N.#*W64'RQ=?FWBWR1<OVJM4_])79&3=V>XW'D(#[()<<:O^
M:I=$[@8!8U.$7@*H!V+Z^<QSF)/YFH(QF'ZL6<8&?OQPSNC9GT.CK3<=&BV=
MZCX I8I >8E*;P9*:Q^ HME<I@ZZVG16? .GAB?(E5#^DJPI*9UZS,/03Y$^
M6P?YD3Y(GU)YG[+N\<HS4)F.,V8'W:CG$%\.-1*1C#46-5A>@L5]Q<XYE>%H
M*VWFG')4UNNM<M6L&K5VM?Q,*FX, IF$3)(K(:J64:T5=O9)"7S27D_@;CCO
MNC"3*Y]S/_^<KIP'[JM)U"_CZ2W7="PO=>6\9?*6JR@4(41*(.9W)HG&G.X#
M"VB?W; AY1Y<3Z.KB+IW+!A6GYGZ;=WY5C69^FW].!N.7'_,6$:B[$SO*>NQ
M('BVT=]Y.#B'1CUP!]XZU54B@/@ROAN/0(M+'[,X6VP=?;YN_*=S:=5/,WVQ
M>\V5I?.ZKLOE"VW>X_95[X2ZO.<''J?9+KQZ]%@@!GRT1.%54+@%"D=MK[%*
MXLW:KBEM-_72]HE+A;CJ)4M2DA4IF>?.JJ8KKKPI .?DJQ^1R./QG?'JB2/B
M,)N#RQ.?CLZ_?3WZ7&O6VXVZ-=7 2Z]?J[EG3RRPN6#7 62/DR\GRVNL5\C0
MR,CPK]O3'R,6_%!=D!4%:-.IM!HO2/%2JU+1Z) -EC]A@_Y=QV[,B=P$6-;^
MT[ZL-L'JYMJ8%1**Q:[N]OL!Z].0G<-#N">X_6_J1NP5G=>:[;RY+K/JE6IC
MJ83K-^;E/CL7(F+.N7>M5ONL95B2!\S@Y49:@"N/96W+)?VO'TB'*J1'O0^[
MGA.O*;ME=A3PD#.QQ.JT7V9E%<)$<U7?SPJU6R7</?IO5T+G9258EM6$?]JJ
M02Y<>;,BFN8:BJ@WY/_IJHBO?A2\70_6RWIH-TR-:?&5/^0 A^H:+KM>;S2;
MS3SU(/Z0']+[W^;9=FA*FS* :UV^X"8WD4U+E>5A>)MU4%D58E[+.A2MY6.G
M&Z"W^G^L]H%H+1^CWE1*:U\>C-9R\0&M)/XO1&N)4&HT<"'0WYEASR-&SDBR
M [%S,<[Y1,4[%CP7^]K*)P[>K>BY&,E6+I'OC@7/P\ZU\HEU-Y5\SF*^,#A4
MG"ULU=8< 9-E8M94U.MDUTZM>=C:5GWM@<6UF5=VM>9CR=<=L57'IQV&9O-Q
M%,UU%6L=CF)S<42MM4U!N[U5O<Y,0XF5DSX9[7SU@R$+U&^2G<U7O6_#858O
M=SR4D^?3J>$E6E@CYK8@"NFTS+GY,K%B>DA-8]^P=!.O<PJ]X/7CG"7^\7I3
M?:#SK#Q?(L$])D37AMX5?/GT=6N-<+IFUCJM>B<CT8L-GA?QPA="IEEP&_/L
M\2D=0H>+6S^"GETR86+6,Q+6?]3,6,+;Z%ZPOR,&*'^ _\D*._>5A/>BL&WS
M^;F68\C#&_%BH:F@+S9[7LZ;>!_W-0W"\1W 5\@W^YXXY<)V?1$%K]OD/M=\
M*_>-Z;EM,IYL#I[;:+S^%N[D.9DWOW;C\6NW@:^Q*F=NY7-VH52R>WQQ35/H
MC]9;%9THRJQ4&]R;6>:4+O.1[4Y_/[^6:L7^\UG53I87W:M76-6*6D%T/UE+
M)-\R^?"ZU6+9+?2[:'S"+Z((1K(,VT2F%6O L)R!II)=>>2;_Z L_U1(JVD0
ML)<-0Y:](&I[!H"$>Z%/*!&17+''/04<SP]EM0V;\0=E]F@?XGFY0H4\\G!
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M=_!Z)0,XK2""QTW< PUS]4RU.;\T C50SXN&R@[841" 9D%F)V+2*3H,'ND
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M[(0],3M2[\X>!@O/:?Q&[('<LZM.=573\KX7"7@2(-/F<6N"2$Z!RQ13A;F
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MXY&66H;D?T<T@'>!0\B8EPE+R;O$TOPFT3<?+"L/F#1G\N9 Q8?*;<RZX.S
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M-:-EUK0'Q,%'$86./L11!'<PV-1:^L.QFL4.0K2:<A!">S@@&9 ,6R?#L?9
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MP2]_Z8PR=#E^-V[S5'P\\Q7/?-W4^+2R'.R\Z<PRK+)>=OD1# @&! ." <&
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M<^X''AZ_3I+X-F%C>GS$69B-Z&N0"> <8#*1.*,=3T+^G1Y*\\%_P*S%?,@
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M+<(L7\_/Q4NR\U$MS/4O^(YF$+GRM= :O"MX$22,S\?B*%L%B>KQ%UQ*F>$
M3AH>7RX"3P3&9V:U[H,PQ+,X IBZ4%5."?,)KJ31L@#0;(3S9')PC!]01&Y8
MG>L-/ UC^4$JFAE@=@6>QD^2^#!A&0.,IA3$P9G&\,(L@M[:2G:)[(X25#SD
MQ&C>'$)HS9AKIV)K-L9?(VR@4,N=L$6Z7/6D=3$1@&Z!92W&%J.FE=7N8:(O
MV'B29\7^#$CE<F5W%<K!IN9C,F&%SD!\J4KFGZ6\#AP+.&Q1ZDB9A$(;]YJ1
MS#5T?'M>^S>$%W;DT3Z=+VNQ1L.+=)MR8^B4Z3$-7=6X>2KR1@KEOV!/K3=
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MI*^FE3$7@)F" $8QJ?!4*@'#.5L#64546OR.A3E(09"1Q$RA:/4T"B:I=1^
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MMNQ.KV,WNRMLRJL_Y6JL@5?;*^V*IUD24-DEZ>!**GLZBI/L,./)>)]M,QW
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M?,(2T^9L\^#MD(A;KY?1MF%P_*?]%AL*-A1L*'C[=/2*SY1!1U=4]#[;:3J
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MP6_I.'N=4FP88'\9H&$[G8[=ZNQU_*JJ\]]E=!MG92 %^LG9Y^.K]X#G41W
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MO$[@Z91LI*V7L47[:<C5D.L6[>>6ZE.M4]+/6.3;UB2))SS)II0%A\W-)EA
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M"Q+5TA<N=6'DEM94SXE3$\#S,BXISJ/DX,5^'EGG = 2K/PV)C%?>"&I>#Q
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M;67#81 *:T+AJZ92BG7(':.H@W# 0'?F7IECMV2T5%0I8#3@C@R :BFR.G[
M?2U/2,D;^R_8"3 +*6I$(Y7O4;(Q[J^,OQ,P1\*/F3L1$0&H>:*;([9RJ3,.
MT"M8%DK7:6-'D#LZ*;?M]./7*Y5=30<F8#;$B2I9QJJ10+C>DIH B;@!>2JX
MKW(BA/N$M6_+<69T]]9 )H31DGAQ37:C1)@32=3:& _#,A&20!>0K$)TO-#:
MEY9_;5BR48EZXGD/KBZ-RQ!+7 G5O%DV]%L9:<LQ\!A1-*2(@Z+\E0Q%0A]9
M*8RQQ%Z&L_*)C!46T2M81:CJMY8N[<BZKJQFF1J45BXI,]*<2_7B0SIP)@2C
MM.#CJDJ<K8H2U8I"4C#8UD#ZBY71+3_&)E-Q5E7X; F$,MFZ5,;R9#7APUCI
MZ<K0V*8AB%(9*9O5OW64^AS$9(#.*J@%D'LB9(WK KU"(A7$<B!FS",*TKVA
MFMNH/&F0\CBF =Z6WBAU)A+J14:]A)+-4(P>"Y3,U*SC5]4##IMD,?.DX(95
MRP4+N3V@R6&>G'J8/%>)"3V\V^KJJK0]RJ!.4.T;(HKZR^U!ZZ':=*!P[H6)
M"*\.XSP!]$GK0NU;>;"/(U+?)<DS!:U35"K-A[B%0MNEE*=/U*]BT1$UJ:J%
MK*2+7*%;VF/:Q)/SZVI'@CSZ,XKOE0I.B[0&F "UM,S\J*2TR0=M4#3QA(16
MI0.!;8&0/T(J+"(H*K \P"8,=SR,)XCF3\5^PS+"8"RY& 9X*/W.^GE&!?UL
M_XR!@.'/<PWF1-:?0&@MV4VMISBHF"F94-8JMKN1O$-D1Y0D*7%J28@$]95;
M+MM1S,H;H+"YS:B< ZIB"8'V 2=K?%J:0MP8,=L#V6FIY7$W<<,/E7179_CU
M7@X4["R\J#*&*>5PY8@2= REJ5>8O7H^6;0D0<D%TH;.8-6YO^A[51R6J;-V
M+PGP;(B1_&%1.3TNGF1>'"XV0HC(Z1QZ'&>\F$_,4S74A!CS.8IMV>Y-/5S.
M5JQ=. %%\SV2L8%G30"%8^8M?(56J@YE:ZBE!"89:41&9G\*\RT8H\SBM;54
MFUGA(N2[4O3B-R)[%Z>6PK-85)J#$Z*J\0>PY"'&.(L,"RFM 1DU/U=&'86/
MM @NT#=_%M'3FHB7)Z@27:H=6*6GU -)#8O&.:I$Q5Y.=\^U#8IF@T5+M\<T
M7Q%#J#G4<:WN369#R_R$K(Y;B2!;2.5G"6$56"8#IFQ^,*+67]C-IQI9D/QL
M)/?V0/9;:<ZILB!0WS*;IF(,VY4T@$I@B9(?)NC;H"$1B5R.X@##9_5CDRH3
MROX91,)1A'D?DBW'908".46E*5664^(IA9(0/F:Y" =$6"/APJ&PY)/L8=55
MJ[H8]%4'7/9[(\]#G+5)CJ$@F,J'75+N66G\E95V,S+AI- <JF6=/"(44F)^
MJ6^"(WY4.SPD:_FM/><M\"(3MW )2I_Q.V;(%?FUL[6I^,A^&%L[ 8TZX9'9
MYI@YKO*\S8'.]D%6MCT3&WI.>7?DI][BJ7W=0F#">Z)")]F]&"2!B A;;T12
MJ55TZP.57";*O2W-( ;BU+_E6:VCJW*/ZSD!"P)8-!LE8RG;FGHB2:V1\F)I
M8J1BH;6<NC(5!$V:R6B:@JFC3@=$1]J9E-U*RI\(A "0N-4@60\CGMW'B3@L
MBO/L,!ZJK^K0%&Y&)7)&"T!T+TBN0P,?<.B%+!C+I59F*Q8T-PG81C)%HU9-
M(FRB<L;*P3RK[S.%?52&2G4#Z*1.:)W:7F0EILO]ITH,:A,PE?%&D<U<Z=5@
MDTK# PHUBH>9;YE0)\H26)@UO0@3A4(+R!"<B4D"S**% JI@Y5VI>!"8W=*V
M6-Q45X:G5:?5,D6XG!SAQDZ^J'TI)S< !7Y2V;PZ;<R\*0?G%+2B=$O1K+R8
M?5'^!\9P$=:XB&"#*5/;E86X>W A96"MDDY*AH,RD 1UBC-!)+?(HS- I+*2
MC2_S),TQ2%CWAN;/&BDX4QYV5O:J2I)%")4RG$/RD!4W$YQEY&C JS1*.5PR
MEL0\Y(W*@<,"022Q7G/:%O8#ENZ11]DO(3J+%'6*AS:QC'!6,0^ZNB58[I-5
MQ1(0O_3,9YQ&N?DR;VV.YN=ES1*!\ B]B ;"XO1ZIFZJ$'$>MD55F+&+5K"5
MELO5H'"E-3'NKSR:&$Q+%PVM7*K#JKQ&Y(8&/*Z##F!4%*.0*PLJ_(6H+BQA
M&1X%LUEM-.(_FY&.Y"!+ ;D@X$B38Q)R!LL*2,$49Z5DX-8(GAKBSW:S+?UA
M\NTEW17N!OU^FP>^S)NKMMEOMP^;G4*.P:>6(_9(E9JA>0T+!HT;975K.IT'
MM5 $10&+='5N$XP=+^E5L\,V^*Y!5M7\%,JDCD+5PR.4@=72256B7K!Y09'*
MXJD7-TB"$>;A$K-&'.$IAD5&BD0KH2*%0%5,*A% &1_54U]99 3>HL@\IW67
M,:P':RH70"566-P_0'H@*+K+H=51)LC70D=J87/(,$RQ-9#)DSRD"]2AM=-V
M!O-^SRP1;B)Y7;@]UF61PT#?%Q;)&Z3 :IW=XN=JM7?R%%QEQ /;U (]XAQ3
MB?E/8,A0YG?3M:V&X_:.:.%X1T1,-Q.0L8.-J7$ERY99K?4"RJ4K%I;.;<AY
M:R#[(@O!YS:QKN_!C@83691@(<$@!:&M)TLF5?K7;*K,AYDC6"F1P4Q\1^?+
M8/Q]@%4!-46L&L4OKR?Y4!ZZ\&B$JY.16I&E(6X_PE]][HGLGH3?,F&'W\4A
MS(NV( $^<YE3)2915SET%XOHMTQPHOF"KP[$H:\:%=U7NL %#+DH%[IBJE9;
M72Q6>8B:Q%D<&S[9&L@>X!.D$<$?&%"IA3H66^</$GR9?U0V7\09R/::T.%F
MS67_4$;(JT&)\N7J@G"0 ?8:*D92EY:)FV"$SW./'1<+EU[::$L4PY'UI<AV
M$5EM?E'N.HLJ,4DFG 9YPQEM&Z,^&B+M LLA:Y=T+)E8X)T\]R!-<ZKQ*H]L
M$HX]X6;]7GQ IDRKK2A$DY1R.'?*[N I4=$LOI'^;'%U1_&6#.?%$9:LQ/=X
MJG(Z%"&W>Y[.BM"9P>=>?H26Z-1'FLU-1YP)E=6K>.J"WESMTA5^QZ)L 6+H
M2(MC(2F==MEH&O,)=:9Z\L:?UML5$,!R_16<+8)SMG*4S9VY+=(^B!'2.X]A
MXNEPSP$Q9$%8Q$8KGC;(<%[HO:?M!(+E\S%%-6$=G H6YU94W7)Q,H==!_&^
M+BKMY6FFXD1Y) )W+"2&8O)H#.>JW(D%:Q3H+FJ/?3XHK_S!D\':K5VXSI#)
MFZ 67JTE@@S2]+-K4</?CZZ/P+[$]-QJ!==-0L=]4V)J3*@@![(<'%=4[:J3
M45(>NP/<*QCDK^)-N05$.?66%D:!;@UD50MK-I\;=U2<]HG$&$E'-0NM/$RJ
M/"G(<::D,Q:)P11-INLI@'0IHP9UHLP;K+KZ192T=FLF]96@TQA@EO^(ALY2
M[L]H%0S!RJ,53#(&3I8FZDQP?=&!$[(]"ECKF)ZF/S]63IVJ!Q&E'*X<>*B6
M$1P\N817FT=4FGO,](%9T&-$P32'"\-A6P/9,67"+2O-71;H6N;P+SXIJ82X
MYYO)O4JOF^,PC>TBCWG9JA>=OU'"!V#W#;X\YI6D/EA*PW&[;^WREC65%>V!
MKLIX+6N\=" +RWHFD;[>'J]04"0M9J"MUARK(R5QT F>-!:VE>V#J?$();00
M.\J<:@N5:1PQ=4(JVWCPVIV1I3FU=+MJUZ4^I>E?Q01?C.W%S?:J!0%BB6KE
M%8U/DE""-:4SVJ(C7^U,3CK79!)P[--/UDYQ::6R]@ AHBV10)#"5X2/@"XA
MQ-;,BX#JRS#-+RGP+#.\"[0*^:U.]M7])T]!G$)U<<Q'#D^II1:4C+QV.<3<
M!8I&CF\-9&!N7X!PPI M2BUAX\#6BJ8<-44N*VGNZ0+:HG(!A*#LDC2I"?>:
MI347>%A@=8DQ9KUXC"$K?T@=RX"6X;=%41*/O$!8=I67Z^Q==G-BXM2SDKA'
MM]>FHIE($;T6J)@1;B+I!+^,Z<2<;O^4<< XDM=$+QQ<X XQ6U1ZB.!D0*>U
M<@QVBX=/V5(UI.23_Q"F"PP_(*A14ZCD U%)A[")ME#"M*SM6JH\.92>*"D2
MY7)B7.>[RA+YQVN6W'2/FO5RFS$>D8D[YU1'&97] U9P0F;J%SY(<HS BH.'
M"@7@'?;WB'I;RBXNE&15Y-/AN+SP"2UE<>H@BXE5!ZV'PQ2UB[FE5QLG4Q5H
M*G+J9[(_*A[*DLW$@=_!3E6=E%V31&4WZ;JPW<T\3 7L>5F$_H5S+)^(QR;_
M= LA.U_47YIZ$8($HN DM:2BL%J1<2C#CT7:IL7\NR %D6'7VGUEV)R">G+4
M[\,L$X=@L8=/;LV*19F7QZE=[1Y1C+2@\2C6@Z-120#(V+FJ5*RWM$Y)0: X
M] \I^V@4Y]@'(Q$V[DP>1:5V'5%6N<S$QN^4<3\,OO-ZRT:[TF*#&CZ4R7SU
M= E<K.K_538NJR:5B&(!BM-+)TUU!,.EIP+W&"Q7R5L8RA1Y9]7+5U MT2^%
M%A_ UH_&+/E3V/:4/%<T*P-;/;45*BO99\P;!9PT<5EWER68(S:/([DI!5BU
MXK$B2VJFEFJ^A95TJ<KZHZI/5<F;E-5,M!?UPE05^\G%'1&%QRT24FAMD@"+
M:Q-+;Z\\VZ=M4]F&91;E\A3 \^OC,NVWTNFM!%$53!:&3%'WM3"E$$@JFNVR
M&BSFK=W3OCLKF&NQ8"'1TAEW5R5344.,C-\F+)O+.D[5/>EU85JWT$,1TJ7\
M'.H;<D<)R)C?.LEGSTG%TV4.-X5/B=P%8]F"'RMM:A8UK,3OR"EZY HZ8J.H
MN)]C*1,L[EDI<OCI$GF,>?B+X[H(;JW**A<M!4# J%C;,^<5UQ$4#3(QOJ)*
MX2JW3^/!KIA\/@A(:TXKBQ83/9!9O!0#Y4V!,U4&ZH;7M#B*AI75!JU4"AC1
ML360G=2<>5(>"[FQVA856%%R636L/-L"4[0GK=4H%%JG8A;53"+9-UREG(N"
M'Z&]!5T3FU7%7:T\Y([Z\ =X.]01/%$R:+$6>6GG; ;_0A%7KEO%#*K)J])W
MKK5&\W,^<XHM%KOLLL_E!0L+]V#,N:SQ4KT(I,E2JW&E$_.Z!"D$2'&O:>5@
M0^TAWL(JPJ9^V6(&NY3>!1D*IN)J4Q*3HE1(F5>+I(G,TA)'?F(9\DK4MV+Z
M"=A"7%6M/>'^57$/;!%=D <!1M9L#63+U-$CZI\Z'&!G:LESU,D6U"Q8\Y0=
M^];&#+"1*HZ>*J=#U7D Q<)CP-1/,<J+!50[OR=\#/8'I4 NYF15\%1CQ(<O
MX'WV#;NU?A$%'-)J4 4J]2BHS'$+59P[GLAT8ZYN<*:#H._">Y37.%>L)PE.
MI5!F80OF$CU+;GD^VEV:WF'(BOB=RGR2[=VN9<;=I6AF CZZ*,LRE>5;"]G&
M87A1BA->;*=L1O1=,!,H3HHD7&%[W<:L*!RFF_""A_H:S=5%@UN+4<ZR_(.)
M-IGU?D=>3!6,(B:DKDQFX[B:6"260TM N7J?6K56G/+<1!384K?_-"N26\%>
M4AT.Q1TB<13)HW\ZS"D;1<Y%2&',RMT^JMK^LM+^:'899<:T4FM%VR1?!B+#
MHN8UGEEIT8A1!1%F1I=M1.\*"W-V]MJ52]61BVAC<5=A41<V$_REVFZ5@*)"
MD\/YT%\E=*<2<\K:Y>(2G9E*ZGH9;)FD2O:U6$\ETV' Y0'<K>QUHX[.BN:
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MQ_GKV/*+%/9'$6G%;JVW013)[#'9:N'YV[]>B,>![Z,7OS;VUF!#'P'O'R^
M*L'+VQ>#=7G\Z=/IU]]4!*2M8EGK!W6!H.HT[7ZW83=?Y&4:2C64NC9*=7MV
MO]VU6YVV]ENY0DK51*&NU@,^7W#Z0!<8JRJ[<Y[<\F13=/!DX+=38NE@-ZY;
M=+TBS M$UZ'V6VDHU5 J_MWLV\UVTVZW'.WW=/>5[.O94XN4[$G(@G&EZ^\$
MRU>PQ8%Q7'4 3R>1]0+X3B[.+JZ*.-JJQ-6;1L_N-)MVH]=]J_V.&H+5F6!7
M1:!-V^FV[;;;V6L"U42CKM9M/8WH-A)?-JH75?M45;;/QI0.X.DDF[2V_ULM
MT*<MN]%^2:J)(5E#LNLG6;?AVKU6QVYV-Q88UH%F-=&PZ_59BWN<C<NJ 7@Z
MB2Q]75;7L7M.V^[W6GOM$>@ WI83[(H(M-^P6]V.#2#N-8%JHE!7Z[(>4WT4
ME1'OL_'TTAH#S79X_0AX'8&V6@?A3;L# JVW,6%F"-P0^&H)'(] FKW-19AU
MH'!-U/5J_=\MLJWWQ'70I6AB0YZ%-C43AKAUVEU#W%N\^[NOI'_,''MR.1"/
M_,T7 NE@FSUJ?#>!J_PXIW8BFNWV*U5@/!/P;3V,Z_1M%P/<C8ZA=T/O>T#O
M&R^?6Q.]T[>KZ4'V9(NA[,IGS;^C5ASJVD?P!?T :ZT$3R,/+RCCG[CZK^C\
M>L.^4ZOJ%S0/;!U8>12(-WZ__G1@^=P+@ #37PX.VP>_]HEGY<H?FUZM5;5+
M/,%&RM@F$7LC7P7IGY<\P2_8+7>?LM1OEWC]QZ=S:HF3ISCF.=Y4KOHMIL??
M@_3;-0MY*CLS?N59]>FY!7R<?E17$>*[,[AH5W QR1->14;SX%?GR'7Z93/(
MAZ![!4QT*YCHKAL3G4<QT>BN#1-UFE @?UP;,KJ/(\/9$%FL'QF]QY#1:&T:
M&2=K0T;_4<IP5R\PFC4V:33K;'*\+F3TG3ED?$^#]U$0_G*0)3E\?+<R(->V
MXWWW^4#FXUQ<F_MY..1>=A%=<;STAON?68*-0E)8T<40=.A#\@_^;BQ0W_W&
M<O7M'/SJ-OL-4M\O6,PL'*I)]55Q-0$\>B*3[VH+/TXOHG+!W^2+,/AUQB*?
M)7[Z^P3[4\.O+:=?W8Q**L*7. %3LGSW,HFC&&\&IE\7[$SS84R  >O44/$0
M/+.PS]#/T_14/ ;ZPVN/'B;.&3 >L,<0#*?=;#NNTRCAF%G;:RQ=73K]K(6W
M'UYXK]UR7;>]AG4'_K/6W7EXW=T.('REJ[[ :SIN\#+)2[Q+FZ?/6G[WP>7W
M^T#WK[SZ&:7[,C+O/;CL7K/7 EG;6^G*7T3E_8>II=5N=IWF&I;]+"+O.\Z#
MRUXMA?P(??<=]\&5-YNMEOOPZO_Y?PX/O\1Q]C7.N'4M;_J&X0X/%7!A$/WY
M?@B/1/#(&7RPOM-728P1@U&63=Z_>W=_?W_T?9"$1W%R^PZ4:O,=_OP.'SR0
MSV?3"3P/Z* [$ Y^Q<'5\.#*RZ=&"8+R?R6 #=>IOPX/LBQ.U)<A&_"0OOWF
MEL;%[**?L6#U"DPP#F%X#&OPZ/#WZ_HR$I[&.1AC,^OX\A66\>LIW7LO+AJA
M:TCHWF#\@_\W!UT:HHK^Y[O:$I>L_#CQ:O.RQ#NP9-3&+984RYGE9^S_4N!$
M? 7O/0*]?.(=7B9X6&)A%J7+-ZKUU(UJ+M^H'P2WN3YP&T^FR];*P&VM$5SW
MJ>"V5P9N>XW@/IF8.RL#M[-&<+M/!;>[,G"[ZP.W^63>[:T,W-X:P6T^%=S^
MRL#MKP_<=N^IX*)MH87) );:9WGYM6\-69!88"3D=!75\01OD &C]G^*>\D2
M=9]=.@+S/+5&//2MP=3Z>GY._V3%7SBUXOLHI<M:Z99Z\71U3+H,!KX[K@Z:
MX2U+:+'('S_._JAN0\.;KY@'%@W^,DD"O.Y*7-PL>L\=6<=8AYADZC(<\;6X
MIO$'UR!NIAYSEN9T(WI611M=*Z9L,%9?@U>[7C=+6)3*<6'MQ:+$G6[UG<"W
M?V"MPU#<>Z:&"@/ G"^6(5[@D8<7]'BB@).NW06<XJUQ9#_&T1VX '1G_(3>
MHI71[<X)CX='UFEDL=O;A-\"&=D_L-Q[&$\,3D@9<.L?+N8L]/#J-X$9_%4L
M?<RS4>S'87P[)8(H[AQFD74AUGF9!'A<"-N/CUIO_D?<ZG9Q>?X_XKZVMY*@
MQ$7A..L(;PW%R[OIF'*2#\+  WJ&[?+I#C>\=T^N%I#DT2W(N"9U/?B#@%<>
M6 !\>0.==-X*RF&3(,-KY[,D]^C"Y?KE@4<60"1Z,!+<:84&(XM_QWOO$#:>
MT+5T#6O*&5[$?!=CQ)%N!TSP\F[XK=D]ZO\DKL=C="GXX1"OD%,_NT>]GY91
MZ&*R*NZB^P'$P.;Z'%>/X="",!IVM]5&PBA&F%_3/.DN'@P+U)LT5HQWOI?4
M# \@YNLC5XER!<Z4,Z_$RN_6H,7Z3]9B#4VT6&.Y%@.U5.BOMO.3T$6DBBZ/
MK>.3"Y!=WA$*BED=8N,3^ !2#*@S&!G?!VU7*A D//P2)CFJS13%$5W!"0^B
M8 BP93Q/,Q06<E2\N'C >?2 +DD+*@[C%(?!T+RZN9+YOB#?IZL6')'A/9AY
MF$G4P"=8(/!M.J)U9BD%"D @!, X(N!?633\142+P\8#/)ZP))@UY;Y(0KP0
M.[S85LFI;=MM](E3___FKF U@1B(_DKH6:D;=%E+$4I/!4_M%VPUUA3=%&-J
M/[\SF<3=2%QR<(,7T8#99&?FS9M)X!GM,7<M-:G+NU['9J=.+CW8UT4;=1*M
M-?O"=<-[ZFS1@Y2N]UY_$Q_H<F<47*3N3N!(2,M !L %'L$%G@\7RO1^6$_C
M(2LN3*_C0L@$E3EJ/ )#CZ*DHUPF14\6/7-T_]G.%\XA.PF90N9*M*(\L)4I
M)Z5>( 3LY>.559,9A53*PQ#>VI2OV*^++'CJMVFHR6IG;IV5K0TF.@@-2+UC
M\2<UGNNQU19>N1BKS=@'^<]!H; @<BRMU4K67CF7=&M/>()H5PIKD!CG;&,L
M7T%"A63I("QIQY 9(D*FD0C)V*HJD\O=HJ=YDS5"RH?%NW JR#I(-L1NHW5@
MP(+ARUF:N")EXB%,6T9,F[%/52:WY8J>SDU6TU8 ?I3+0\!YVZ-^+(0NE#5G
MD5AK>KIY@)4BWA@=631P"'&!-ENU@_E(9UPVKES#P9 \@_>4HV(R'_')+-H%
MZ'K2$%Y31;PF7_^KG"<# K^3AA"LXQ(0&F-C&^S66I!(Y_[3UE KJD)AL#XF
M^,Q)&? 38-3(=SW:!'V: 3R!1XHJGJ^HLG>P$CWA3HHJ6,=B*33Z ,1T 54.
MVLA6PXTX>JGY 0X3>83G\GP\U]XD2S35C0[8HCN^#6^!984&6L(/&']^Q"GD
M$W[:'?P#4$L#!!0    ( +6#KTS'N\NC2QL  (%) 0 1    86UE:"TR,#$X
M,#,S,2YX<V3M7>MOXSB2_[[ _@^Z++"8!=:=I#.],]T[O0OG->-#$@=)IG>!
MPV'!2+3-;8GTD%(2S^'^]RM2E"59(O6PDV%R^M(=VV3Q5P^^BL7B#W]_BD+O
M 7-!&/V\=_CN8,_#U&<!H?//>S_?G8^^W_/^_K??_^Z'_QB-O!\QQ1S%./#N
M5]XIBM$=1_Y7D=7W#M\=OOOHR3\^C"[1:O3^X/![[[\.CCZ]/_CT_OO_]O[G
M^O)_O;/;.V_D/3X^O@N 0JPHO/-9Y(U&LAWA+W"$O!CQ.8ZO4(3%$OGX\]XB
MCI>?]O=E/;1D8<@B'+RC.-Z7C1P<'1T"\!!'F,;GC$>G>(:2,/Z\]TN"0C(C
M.-CS@%,J/@'%12MJJGBIY./1.\;G4.3@</^?EQ>W"FE&-R3T:ZGTTST/L_)'
M^_+G>R1P5ES^&L3K"L7"'_;3']=%0PO=?UX X2)18BE,J(@1]7,0%=":Q<./
M'S_NJU^SHHD8S1%:K@O/D+A71?4/4G#?C0X.1VO1??)90F.^*O,HL/]NSA[V
M]8]UU1+.P01-]?2O-14#3.KKP ^R^+?EXOC)7]27E[_4T"?T 8NXODKZFZQT
M5*Y$$?%%?1WU4TT[@OCU%> '6?RP7!P4$*^66-2J1OU2UT:\Y(9&X)>:5@*\
MY-B7?=]H7Q_W$?<Y"S$@\.,1?EJ&B**8\=4Y?%X+A%&:1/5$@ICO2\3[4&@$
MI3 G_KI><R5= 481S_L!4<I@>(%A27V6WRR7A,Z8_@A?2/O^) '?075/_O'S
MS<0R-BC>3IF?R%%F3(,S&I-X-0&:/%(M[7D$Q&,ML6X]:S_ ,T*)PGEX< @C
M8U:]^">0\E):7H'8#_N;%'[_NTWRB<#!E/Y-_0T:%$!-U97#AJZOB]CKYHUT
MK>FCT$]"8Z.ZVGY)&062_;1TPFB *;0!?P@6DD!:[C$*Y>AWN\ X%JFN6I2S
M:^P]J.D61(JURDZF5Z=G5[=GI_*OV^G%Y'1\!Q^.QQ?CJY,S[_:GL[.[VT%Q
M6RCN&L$$$"]P3 !@6RV6*]E5>M1'I=XWI2;^-*BXFXK7 A?3V006H!&VJ+:F
ML%VEW[93Z>T=_'=Y=@7JG)Y[DZN3Z>79H$B;(FM5<H+$XCQDC_D8VU#,KKP/
M5>695'8ROOW).[^8_F,88BTK&"Q\3I:RT>GL.!&$8J%55?^373U_D0L5(OR0
MB81C^2$GXK&9EY$9-&+4R#$2!#K$=8%C6/'=)E&$^&HZNR5S"GM8'\&:TE<;
M)]B=7T.7\@G6BMN*@EV_WVWJ5[4E-5MLS4.P1-7MR=\*+7IYDU[6YF ,1F.X
MQ'R.N0#UC?U?$B(4<JUFPV]V!7Z_J4!-1:FL2&=0BE$I$V"3SLE]B,="P'KR
M"L>I1NI^L*OCXZ8Z<A)>2N//'E 9E&%1AG2VJ%7$A$YAR<W5WG@]&%I^MZKF
M\*"JFC4ECU!/T?(R8H.&C!JZ8(C>8!^3!P1FG6IEXSN[)@XW-2%K>WGU0?9&
MV>O9%K:\*RDI-5?X/,'!V=-2[J1T)VDN9M?0^TT-900]35%/+XJFEQ$=]&:9
M]P/I.;@@Z)Z$A=&LYGN[9HZJ\[VBX!5(#'JP+,;I5SG:7,A="^Q2.4A/^G+E
M=]JT;W H-[/7B,>K;/W=K9)=@]]6E]STJQH"_^RI%N0*.VU#]3(U.&;=[H]_
M./QP\%=/-^>I]@9U6[K=K[\B"D*5^Z68^5\7+ Q@=7P&Z^),NPUE[,K\4.V.
MFEJZ9RK0^^,?OG]_^-U?O93NH#2+YRF*2+HN Y6<,+6YQ#3?#]L*V-55<6<4
M2"F%E8@-.C+JJ#C>W7%$!?(+.UGCKW;M5)P1I6'.*U(:5&-1S0.F"<Q(/ING
ML#.E5+ZWJZ/B6M 4O *)00^6C:P\N[A#3_G.-?_"+OD:+X*LZJFZ@\B-(C]#
M'*;>N;C&_':!N-Z;5KZU"O]]Q4^0U?> @*<H#"HPJN +XD2N5"<TQL!UG/E3
MOJQG;VL)NVHJCH.,EI<16_MOO&^^3,[$<%)KUM1M<B_P+PEP>_8@US^I=BK?
MVC52<13D];V4P*"!9SD9VMT)4;N3HO<5Q\,N3HJ\;[*_AI[Z/'9R)X?''5B)
MIF.WD1K7QBYL)&U[L)"NQXI%W5M+V+5:X^.H/V(<--7KK+&H)O//=AU5'!OU
MYXZ#AK8Y@"PKJJ&475\55X?U,')0VPY.QHK::UO8KL2*@Z35*=F@S#['9>6Y
MS/"K75T5KTK-T=F@G&T/5<J*:E'2JK2CBC>F[0'+H,D^KN*B]HR_VC56<=+4
MN(T'Y71W9A958_C-KIB*KZ;JV!STLIV'LZBC%N7L^JIX7!J]G8/Z>@;(CX-
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M:4Z@/8^2,)2A]%E9 1M4:#21O_[(6;+,&B% /MT>RW7OO]JA-+ XH3)S(7G
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MUS3KT;9Z<C!+N""35A8N'3H<9-<2O_%4,HI(>E(D;U; .@FF3DQ]G9%%<NC
M(R'M4#Z3,UQ-EZ]IF?RR#)O.L@KY?+(T[C\F2+EW\8_D =/C52$GB=N1U7V8
M,<AENE0W+>E<Q@J?P.2YFC$NA0^6##:>QO\#H2F]0T_I29L,B/WM<[OW!FY\
M*P6T !9XBM/_)_04SS",U0'43P/Y3Q-\QTX6TFPG](RJ0!/XL7@>ZN" O"UC
MIBF8\4A[_/036M.92^NA!GQ]K*!P+\$14^@Z<.R$/8/H*J$;+B4&L($S!>(
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M3;>2PSPW0Y<\_[ O_ 6.D&+__P!02P,$%     @ M8.O3!5O8ZA2#   \+L
M !4   !A;65H+3(P,3@P,S,Q7V-A;"YX;6SM76UOX[@1_EZ@_\'-?78<)[WN
M;K#;@[.)KP&2=6![^X*B.-#2."8BBRXE.<D6_>\=RJ^R)9*R'7OH],/ALC*'
MFH?/D)PAA]3G7UZ&064,,N(B_')2/ST[J4#H"9^'CU].OG>;U8\GE5_^_/O?
M??Y#M5KY%4*0+ :_TGNM7+.8=27SGJ*9?*5^6C_]5%%__%R]9Z_5\[/ZQ\H_
MSRXNS\\NSS_^J_*?A_O_5FXZW4JU\OS\?.IC#7%:PZDGAI5J5;TGX.%3CT50
M0<7"Z,O)((Y'E[6:*O_2D\&ID(^U\[.SB]JLX,FDY.5+Q#.EGR]F9>NUO]_?
M=;P!#%F5AU',0F\AI:K)DZM_^O2IEOZ*12-^&:7R=\)C<=I41KTJA274OZJS
M8E7UJ%H_KU[43U\B_P3;H%+Y+$4 ;>A74@4NX]<1?#F)^' 4*,739P,)_2\G
M; B#M)G/+B;R/]V&B.^1]P)H1!'$T3>(3RJJNN_MVXS6;"2"0 S!/PTAKJD2
MM5S9&FJTI4X-SQ-)&$</[)6IRD,?G\@$_)N7$8011-8:6M2T WUOL0<,H<M>
M2FB6D=F!#E]%Z"M$/OX1B8#[JM]=L4 9;V< R(ZU:C95O97&'>SB, 2DK-6?
M--%V:N?5MP/=U>C@)P&T^LTD3B0TAD+&_$?:UZ>F=0TQXX&U]B5JW$</*ZF]
M=7V[L9M<>K^R:- ,Q',I0S?5M -][\'G'@ON..OQ@,>\Q""1)SK7"'_PDB U
MD#M\?T8S>(D!>X,_TTW5MJO^D\XX^/Y >)EW!FJN$S+;'--7IA-:GT6]=%9+
MHNHC8R.<W>H?:A#$T>R):K@/U;/Z='+[:?KX-YQ8)B^_$U$T>T' >A"DK_VM
MH-RLJ?:K[(,4?1X;-%TNM*3F$J<-F=6826]6'_ZY1FC699B6J$7)<)C65N5(
MXTR^+\50VW#3]XIBG9,(7R]&JFJ&W5I('R3Z@^@./@-_',3X]Z':?P&DB3C1
MF&,>)NB?MD;*&46%HROH"PE+,_ ]#X7D\2LZ-" ABG'\RM9R\^\$?[Z'>"#P
MES$62?N$AN"]:D' @M:M?M5\]MHBA.USBC=\M!K2<DL3X/L O6S5H'*;AC#Q
M'19 U(8QA FDH5(AZ6LE"1"N,=M58M;4)TS*'-8B(C3WQ?7HT0UB<@#D4W.^
M1$WU8-Q\%5'<ZG= CKFG)6:U("565NUJE9-5W0GWE<EZ7J"B.W_(0Q[%"N(8
MIA U!!DE76+,",;<IPY&X36,)'@\;0_\.X"TF1')TG*#AD<[<9?(M$.4S^@%
M!4:_B5!D9P!S=]3($.".@&NI:2#"G7NW,2OE:--H]/K@T\6P<6;:YMZ]5M)-
MPE9 4'94%S8TP3937DM2D8B;;!6A(3QS_LIXJ$:$%D[\DH]3'^XV1&\N24<#
MC%P?),3L1>?76E?A(JOVZ/)9_B,%EEOQ .0F3I))T$5&39CR>?R9 H]S;V^J
M[!5&87VN'V(+) @P9[M<GJ,]Y8DPLX_4B&/)>TFL=H2[ JW.0U<>6RE([<XX
M0VY0%P%BK7;2-H!FSSJ"KZWL#;_AEK%A _T F\7JY>H_Y>2/6: T:F,32NZA
MENH'# ZS#Y9*/N!$IV("3P)3&1>3_]^\>$'BIZL)WH"%C]!&K#?]/G@Z ]ZW
M(@?K\DIU'-#&',WGZO5[!*CW? &FX:';,,U=T/5UZTH(=/+#F%C.*&+=:(0#
M6T?S)4H:O:/)%.]EO7A[0K=92":Q>KB(]M3^;:N/;8'HX]>'@(6Q&K]&:G:W
M"H;U%1P%W;9@S>L?A_/6&T%:.?IN R;ABJ6Y?T,5;2RGG6H8MZW@*!BW!4MX
M+>1[B+Y&P'^ OS!?NZT!H^114&Q$:5X?.>0B=-:CO UG6=EM\ "]SUZ@WS6P
M$3\*FNV@YG/]IRVY7L\/5T]R5'J0,&)\GD"/GD2Z>/<UD1)M<7+@)H?.K6IS
MFMVMD.>3_8%HQTX1+)JDR!;*5N T_67!YC/^D2CCA0=L,F=#-AC<]14>J478
M@<^WD$\4'+EWMW6YPWAML[W,^AF5D>&]I/CLHM]OD?-3WY>CAT]0$33'V7!D
M[]7EB#K-G#W, M*V7$BSYBSO8*8M:;I#G<?$6A[. MI(I -=0Q\P)O#+)QH8
M)9VFUQIE ;DD5KYR?4#E\2TE$1</OQO5<A2DET)<8  DTH<*FF+B"6RY39U;
M"0'Z26]3YS8:X>TQM/+48>R*AH>M).&>R2=(LW8ZX"729#N6\@3,IGQ76=O<
MML-JWO<^7*"U@-!,0O].A(\QR.&=8"$^:D.@-H(>F+0FW:*6(Z/> C'E5$9L
M P_ U\2.UUPU4NA'+7FM#@&J)#YU.JD-<2)#E04WXK'"I<MJV=4[CL-X=M<>
M;W+NH" ^7%9[D@V@#O7:+,N4$W>:XW)0"6^BKTUNF=0/=*EL<F7*5.(T[9L
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MP@:#<P+A;CKZ%S,G 840UL()@JS_YR^<W&3YKVE<%'Q!-1URT^1!TO,4PQY
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MT>@D6R3K>OR69!/&ZA5'OQ9+66H);0-0"0156+<LR!!1J,%:62TD)*_'446
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M?H 1T5TRO_Q7@SLV"I)KCH?OP,4;5\%3'*QWAV@[@IHDH]"<!.CH4C(5!MW
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MY5C=C(N)QEF_1FO [=(SZ&I*TH>&4.HS<[E8<JT#9HW6<"&(AE-"GR1#DM?
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M'B\.B!R;9:4<P 6!JR][8)YU54WM-K--'5S-[G _!Q_3I^%Z\-00;&G 2R0
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MB%7NE*N0%IX/_>(B3R5[6PH G=K[^21[^QD0^K4".]X?UE>(L1VVI>[A!)7
MU*=Y_=0!<F0<4+HB,JN^$(Q8?_A;5BXMS#YSD$L^]78=@G8(K& -KR5OA!49
M"=Y\.L+8K\\AS,(JKQU8ET&2L.AB,GNNF#UH'&FMWS.X*HFF]Y",#3N@D4'B
MS6\D1'7]P0=]7+"'/ [9YQ\_H71,AX:J/] -@0J -@:$)E1D&'CS1,%29QI8
M ZNJ68@-BQ:1.=/T1+=%4;%(QK]91Z - G=[#8EOA1&YE.W-:Z4$T1M#.=^-
MN)YU 1H@6LUE$Y:;Z!!^[:=Y6UJVAAG?!/'WS'+M%&$>UP(8K/FQ+@ 5@;L"
M&Z[K%>@0SKQ7&D.W(C.;TL_AO^ U:NQ(9G\U6\NW> %HC\#=ALW7]NVQ(R/'
MF]-MBN2>E:\9MU#O' THIO\]Y=;K-7Y;;&*4ITL:?8#W9/=F;5-X",7>2SN8
MNRT^"RS*)G,;W8/F=F^BMX@<&3/>PJ$^!:RKRM5R%=<?;RSD"QGP<$K&@ZHI
M'!/MWB9>$Q7"HS>GGDSLW[*$C]F$#]!'KHJ6C#8[ 2WLWG[<&!_"LC>'G0C
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M= <*(IL/0&)(-\!*S*>R*J\0F;K0ITDWH @:#NH-:)28 #,U$//,^!H/M"8
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M,DM-%M("\!$XCVQ)F!P40IJ_]'BO65Y"F9>+(/U6^YSY(NAK5GZ..0E]RK:
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MC 3/GB9=XD..PYA>W).?$TPSI B2G9Z\$G72 [>N4YI4<0W0.F ;U  R1>N
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M=I>W/_FR;!P#>VLFX-ZLGA%1' ;)?0[O"\L3G.%2G!?R150 V>X?(:> [V9
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MH@'HVC[PE.B8! K%&EHQ.*\L@CY-'?6 T@A$7:N6<JM2-=$PJ,EZZ%UBC=@
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M/A _T9K;;,Y2E][0J'@\-MA!0Y81C/E6+/4@OPH@B]G-]S&1\]J>B-P=<!Y
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MXR*N@E_O9*B8B\K)B,U&]73T.P! %,+( ;XI09J%Z<TUVF89SAVH$%/FR*Z
M361'@P;3?\7!*<*[_>!20YS)2)T2%/.F50G'GJXO9D.QR(@4$@A$^.@?G!%!
M$TC;%] )[-NS@5-YU[)A) N[.-,&+>$^]*GAWNV9?A%<;)T&S@US*<9:TG)2
MF77D@NJ<_96R.$J;:XZONRL:L9:BNZ-J8(SSL2*6LI[?!K4!.W1W<\J^=OEX
M^J;:#ECNT_#@I><+')/0V0_)CZ,]8*8"<D,7\S"5Y^(""&I <:#US+PME@L#
MY/9W1O^A+V%PHG OO>SU\I2F.!Y]+V%XK-F>1"/K[?)2-0S!.%0,M/C*B_*Z
MH>6+S<:)D@M^P$>R! R]#^&96^^0G.(<0H)]"Q/;K0]Y;-[J%27F<7.V \H'
MOI)5"7SU]C#C>K^SRBZ#P)\1_-T95WJ(K%UM/$Y3@ZYODN5W.']-@IOXC5@$
M$%D>'XR,-^_,CJR[UV*6C$-L(&J,M'G517;IC;_"/<V$J+X4X3)F_(Q\0.U
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M%NK= )?@'X/MY7&:L\=S<+;;7^%CDH6Y4 :XL\RWFN?BT$LO-T;#,50QWH'
M4&%/>GW-93?$8,>)?YW"_%RG,X1,-3;!?*^'L97WSFSHP$9&RB$FXI._UQA
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M?_A?__.__[?_^+]^^NF'+RQFJ9^SX(?WV0\W?NZ_I?[@CVS1_H?.SYV?+WZ
M/YS\].C/?CH^ZIS_\+^/NO\X/OK'\?G_^>'_?7[\_WZX?7W[X:<?OG[]^G/
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M]B=A2<U< A*J-7OPNJ<7)$XY"*=B!3 #9RG"Q[UA4@R[<.-458CUQO"6$XF
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M]D0412L2!3;1075!Y5:(->%B.29Q<T$9TR%X!X_C] &L\&L2?T*"/-?>9RZ
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M!WBP8!474NSHV7V635D@4QNSCD"$M(+4]/2E$DI$49IEK50B+Q^,W$M%YEV
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ME2NIU8VY'^!Z-0K$Z-1^7)]JU*:"<YF1* UBKGJW?AIS)-DS2PMX^RY?TOY
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M9E^,#6'9.&": LM\#'S! W#R1W:WO@2ID;CQVV%9A UAV3RDV3G+"[D\)?&
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MV^@;#C^-=3T8*YYML3DN]^1NB2S;6%X6RS8PG1M[23[H4K@A+UN%J]IS@CS
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M9T_B%+5+BI2\C=&WHH*,Q8+_9VZ?":WBJ)%":44%&,L%_\^Z- ZV4N*TR=Y
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MV8FP_/N[))UOULJ;E79'('!:02$6#M 82D11FF9CQ:U+%O1$W \78*..$?N
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M-0$XZ)@KIIQ.:2. 2\)F;L*C#B+'&=ER E?)+U_29#IYB!1KJ:(90"9Q1JU
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M     &%M96@M,C Q.# S,S$N>&UL4$L! A0#%     @ M8.O3,>[RZ-+&P
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M,#$X,#,S,5]L86(N>&UL4$L! A0#%     @ M8.O3.T5$/2?AP  _2 ) !4
M             ( !1&$# &%M96@M,C Q.# S,S%?<')E+GAM;%!+!08
..!@ & (H!   6Z0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
